Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
lesiones hepáticas is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, metastásicas is a MORFOLOGIA_NEOPLASIA, lesiones hepáticas is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA
151_task0
Sentence: Anamnesis Paciente de 56 años, sin antecedentes de interés. Ingresa en nuestro hospital de forma urgente el 10/1/2015 por un cuadro de dolor epigástrico de alta intensidad seguido de pérdida de consciencia de varios minutos de duración con cortejo vegetativo acompañante, habiéndose detectado en el Servicio de Urgencias la existencia de lesiones hepáticas sugestivas de metástasis y una trombosis parcial de la vena cava inferior mediante ecografía abdominal, realizada tras el hallazgo de una elevación de las enzimas hepáticas en la analítica sanguínea realizada. Exploración física . Pruebas complementarias . Diagnóstico Durante su estancia en planta de hospitalización a cargo de Medicina Interna, y estando pendiente de la realización de una TC de abdomen para completar el estudio, el paciente presentó oligoanuria y pesadez abdominal. Se solicitó una analítica el 12/1/2015, en la que se objetivó una insuficiencia renal aguda con creatinina de 63 mg/dL y filtrado glomerular de 9 mL/min, por lo que se realizó una TC de forma urgente, detectándose una lesión en segmentos I y IV hepáticos de unos 85 x 46 mm en el plano axial, sugestiva de neoplasia de vía biliar, acompañada de múltiples lesiones redondeadas metastásicas en ambos lóbulos hepáticos y trombosis de la rama portal izquierda, trombosis de vena cava inferior que se extiende hasta ambas venas renales, y adenopatías interaortoesofágicas y retroperitoneales. El caso fue valorado por Nefrología, y se decidió su inclusión en programa de hemodiálisis. Tratamiento Tras la detección por ecografía de la trombosis parcial de vena cava inferior se había iniciado anticoagulación con HBPM, pero al objetivar el deterioro de la función renal se sustituyó por HNF. Este tratamiento se interrumpió el 15/1/2015 para la realización de una biopsia de alguna de las lesiones hepáticas que permitiese confirmar el diagnóstico de sospecha, como finalmente se hizo, pero antes de que se pudiese reiniciar nuevamente el estado general del paciente empeoró de forma aguda, asociando hipotensión arterial, taquicardia y síntomas vegetativos. Tras comprobar en la analítica sanguínea una caída brusca del hematocríto de casi 10 puntos, quedando finalmente una hemoglobina de 85 g/dL, se solicitó una angio-TC que demostró la existencia de hemorragia activa en el lóbulo hepático derecho, que había provocado un hemoperitoneo de volumen importante. Desestimándose llevar a cabo más medidas agresivas por la presencia de una neoplasia avanzada no curable, y únicamente con soporte transfusional y fluidoterapia, se recuperó la estabilidad hemodinámica. Por trombosis del catéter de hemodiálisis y de vena femoral acontencida el 20/1/2015 se decidió suspender esta técnica, acordándose finalmente con el paciente y la familia realizar medidas de soporte y control sintomático; en este momento la función renal era de 265 mg/dL con filtrado glomerular de 25 mL/min. Progresivamente el estado general fue mejorando y, teniendo ya el diagnóstico anatomopatológico, se consideró que se podía plantear la posibilidad de tratamiento quimioterápico con intención paliativa. El 23/1/2015 se reinició anticoagulación con HBPM a dosis ajustadas según función renal, y se administró el primer ciclo de gemcitabina y oxaliplatino, con buena tolerancia al mismo. Evolución En los sucesivos controles analíticos la función renal mejoró, alcanzando un filtrado glomerular mayor de 60 mL/min el 26/01/2015 que persiste en el momento actual, aunque el día 30/01/2015 se detectó una trombopenia grado III con 67.000 plaquetas/mm3. Valorando si esta alteración podía tratarse de toxicidad medular secundaria a la quimioterapia o estar en relación con el tratamiento con heparina de bajo peso molecular, se realizó una determinación sérica de anticuerpos anti-heparina/F4pl, cuya positividad confirmó el segundo mecanismo. Se sustituyó entonces la heparina por fondaparinux, consiguiendo una recuperación de las cifras de plaquetas, que alcanzaron las 289.000/mm3 el 6/2/2015, y habiendo resuelto los principales problemas que justificaban mantener el ingreso, se indicó alta hospitalaria. En el momento actual el paciente continúa en tratamiento quimioterápico con gemcitabina y oxaliplatino, habiendo recibido hasta la fecha 3 ciclos sin incidencias. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Paciente de 56 años, sin antecedentes de interés. Ingresa en nuestro hospital de forma urgente el 10/1/2015 por un cuadro de dolor epigástrico de alta intensidad seguido de pérdida de consciencia de varios minutos de duración con cortejo vegetativo acompañante, habiéndose detectado en el Servicio de Urgencias la existencia de lesiones hepáticas sugestivas de metástasis y una trombosis parcial de la vena cava inferior mediante ecografía abdominal, realizada tras el hallazgo de una elevación de las enzimas hepáticas en la analítica sanguínea realizada. Exploración física . Pruebas complementarias . Diagnóstico Durante su estancia en planta de hospitalización a cargo de Medicina Interna, y estando pendiente de la realización de una TC de abdomen para completar el estudio, el paciente presentó oligoanuria y pesadez abdominal. Se solicitó una analítica el 12/1/2015, en la que se objetivó una insuficiencia renal aguda con creatinina de 63 mg/dL y filtrado glomerular de 9 mL/min, por lo que se realizó una TC de forma urgente, detectándose una lesión en segmentos I y IV hepáticos de unos 85 x 46 mm en el plano axial, sugestiva de neoplasia de vía biliar, acompañada de múltiples lesiones redondeadas metastásicas en ambos lóbulos hepáticos y trombosis de la rama portal izquierda, trombosis de vena cava inferior que se extiende hasta ambas venas renales, y adenopatías interaortoesofágicas y retroperitoneales. El caso fue valorado por Nefrología, y se decidió su inclusión en programa de hemodiálisis. Tratamiento Tras la detección por ecografía de la trombosis parcial de vena cava inferior se había iniciado anticoagulación con HBPM, pero al objetivar el deterioro de la función renal se sustituyó por HNF. Este tratamiento se interrumpió el 15/1/2015 para la realización de una biopsia de alguna de las lesiones hepáticas que permitiese confirmar el diagnóstico de sospecha, como finalmente se hizo, pero antes de que se pudiese reiniciar nuevamente el estado general del paciente empeoró de forma aguda, asociando hipotensión arterial, taquicardia y síntomas vegetativos. Tras comprobar en la analítica sanguínea una caída brusca del hematocríto de casi 10 puntos, quedando finalmente una hemoglobina de 85 g/dL, se solicitó una angio-TC que demostró la existencia de hemorragia activa en el lóbulo hepático derecho, que había provocado un hemoperitoneo de volumen importante. Desestimándose llevar a cabo más medidas agresivas por la presencia de una neoplasia avanzada no curable, y únicamente con soporte transfusional y fluidoterapia, se recuperó la estabilidad hemodinámica. Por trombosis del catéter de hemodiálisis y de vena femoral acontencida el 20/1/2015 se decidió suspender esta técnica, acordándose finalmente con el paciente y la familia realizar medidas de soporte y control sintomático; en este momento la función renal era de 265 mg/dL con filtrado glomerular de 25 mL/min. Progresivamente el estado general fue mejorando y, teniendo ya el diagnóstico anatomopatológico, se consideró que se podía plantear la posibilidad de tratamiento quimioterápico con intención paliativa. El 23/1/2015 se reinició anticoagulación con HBPM a dosis ajustadas según función renal, y se administró el primer ciclo de gemcitabina y oxaliplatino, con buena tolerancia al mismo. Evolución En los sucesivos controles analíticos la función renal mejoró, alcanzando un filtrado glomerular mayor de 60 mL/min el 26/01/2015 que persiste en el momento actual, aunque el día 30/01/2015 se detectó una trombopenia grado III con 67.000 plaquetas/mm3. Valorando si esta alteración podía tratarse de toxicidad medular secundaria a la quimioterapia o estar en relación con el tratamiento con heparina de bajo peso molecular, se realizó una determinación sérica de anticuerpos anti-heparina/F4pl, cuya positividad confirmó el segundo mecanismo. Se sustituyó entonces la heparina por fondaparinux, consiguiendo una recuperación de las cifras de plaquetas, que alcanzaron las 289.000/mm3 el 6/2/2015, y habiendo resuelto los principales problemas que justificaban mantener el ingreso, se indicó alta hospitalaria. En el momento actual el paciente continúa en tratamiento quimioterápico con gemcitabina y oxaliplatino, habiendo recibido hasta la fecha 3 ciclos sin incidencias.
[ "Anamnesis", "\n", "Paciente", "de", "56", "años", ",", "sin", "antecedentes", "de", "interés", ".", "Ingresa", "en", "nuestro", "hospital", "de", "forma", "urgente", "el", "10/1/2015", "por", "un", "cuadro", "de", "dolor", "epigástrico", "de", "alta", "intensidad", "seguido", "de", "pérdida", "de", "consciencia", "de", "varios", "minutos", "de", "duración", "con", "cortejo", "vegetativo", "acompañante", ",", "habiéndose", "detectado", "en", "el", "Servicio", "de", "Urgencias", "la", "existencia", "de", "lesiones", "hepáticas", "sugestivas", "de", "metástasis", "y", "una", "trombosis", "parcial", "de", "la", "vena", "cava", "inferior", "mediante", "ecografía", "abdominal", ",", "realizada", "tras", "el", "hallazgo", "de", "una", "elevación", "de", "las", "enzimas", "hepáticas", "en", "la", "analítica", "sanguínea", "realizada", ".", "\n\n", "Exploración", "física", "\n", ".", "\n\n", "Pruebas", "complementarias", "\n", ".", "\n\n", "Diagnóstico", "\n", "Durante", "su", "estancia", "en", "planta", "de", "hospitalización", "a", "cargo", "de", "Medicina", "Interna", ",", "y", "estando", "pendiente", "de", "la", "realización", "de", "una", "TC", "de", "abdomen", "para", "completar", "el", "estudio", ",", "el", "paciente", "presentó", "oligoanuria", "y", "pesadez", "abdominal", ".", "Se", "solicitó", "una", "analítica", "el", "12/1/2015", ",", "en", "la", "que", "se", "objetivó", "una", "insuficiencia", "renal", "aguda", "con", "creatinina", "de", "63", "mg", "/", "dL", "y", "filtrado", "glomerular", "de", "9", "mL", "/", "min", ",", "por", "lo", "que", "se", "realizó", "una", "TC", "de", "forma", "urgente", ",", "detectándose", "una", "lesión", "en", "segmentos", "I", "y", "IV", "hepáticos", "de", "unos", "85", "x", "46", "mm", "en", "el", "plano", "axial", ",", "sugestiva", "de", "neoplasia", "de", "vía", "biliar", ",", "acompañada", "de", "múltiples", "lesiones", "redondeadas", "metastásicas", "en", "ambos", "lóbulos", "hepáticos", "y", "trombosis", "de", "la", "rama", "portal", "izquierda", ",", "trombosis", "de", "vena", "cava", "inferior", "que", "se", "extiende", "hasta", "ambas", "venas", "renales", ",", "y", "adenopatías", "interaortoesofágicas", "y", "retroperitoneales", ".", "El", "caso", "fue", "valorado", "por", "Nefrología", ",", "y", "se", "decidió", "su", "inclusión", "en", "programa", "de", "hemodiálisis", ".", "\n\n", "Tratamiento", "\n", "Tras", "la", "detección", "por", "ecografía", "de", "la", "trombosis", "parcial", "de", "vena", "cava", "inferior", "se", "había", "iniciado", "anticoagulación", "con", "HBPM", ",", "pero", "al", "objetivar", "el", "deterioro", "de", "la", "función", "renal", "se", "sustituyó", "por", "HNF", ".", "Este", "tratamiento", "se", "interrumpió", "el", "15/1/2015", "para", "la", "realización", "de", "una", "biopsia", "de", "alguna", "de", "las", "lesiones", "hepáticas", "que", "permitiese", "confirmar", "el", "diagnóstico", "de", "sospecha", ",", "como", "finalmente", "se", "hizo", ",", "pero", "antes", "de", "que", "se", "pudiese", "reiniciar", "nuevamente", "el", "estado", "general", "del", "paciente", "empeoró", "de", "forma", "aguda", ",", "asociando", "hipotensión", "arterial", ",", "taquicardia", "y", "síntomas", "vegetativos", ".", "Tras", "comprobar", "en", "la", "analítica", "sanguínea", "una", "caída", "brusca", "del", "hematocríto", "de", "casi", "10", "puntos", ",", "quedando", "finalmente", "una", "hemoglobina", "de", "85", "g", "/", "dL", ",", "se", "solicitó", "una", "angio", "-", "TC", "que", "demostró", "la", "existencia", "de", "hemorragia", "activa", "en", "el", "lóbulo", "hepático", "derecho", ",", "que", "había", "provocado", "un", "hemoperitoneo", "de", "volumen", "importante", ".", "\n\n", "Desestimándose", "llevar", "a", "cabo", "más", "medidas", "agresivas", "por", "la", "presencia", "de", "una", "neoplasia", "avanzada", "no", "curable", ",", "y", "únicamente", "con", "soporte", "transfusional", "y", "fluidoterapia", ",", "se", "recuperó", "la", "estabilidad", "hemodinámica", ".", "Por", "trombosis", "del", "catéter", "de", "hemodiálisis", "y", "de", "vena", "femoral", "acontencida", "el", "20/1/2015", "se", "decidió", "suspender", "esta", "técnica", ",", "acordándose", "finalmente", "con", "el", "paciente", "y", "la", "familia", "realizar", "medidas", "de", "soporte", "y", "control", "sintomático", ";", "en", "este", "momento", "la", "función", "renal", "era", "de", "265", "mg", "/", "dL", "con", "filtrado", "glomerular", "de", "25", "mL", "/", "min", ".", "Progresivamente", "el", "estado", "general", "fue", "mejorando", "y", ",", "teniendo", "ya", "el", "diagnóstico", "anatomopatológico", ",", "se", "consideró", "que", "se", "podía", "plantear", "la", "posibilidad", "de", "tratamiento", "quimioterápico", "con", "intención", "paliativa", ".", "El", "23/1/2015", "se", "reinició", "anticoagulación", "con", "HBPM", "a", "dosis", "ajustadas", "según", "función", "renal", ",", "y", "se", "administró", "el", "primer", "ciclo", "de", "gemcitabina", "y", "oxaliplatino", ",", "con", "buena", "tolerancia", "al", "mismo", ".", "\n\n", "Evolución", "\n", "En", "los", "sucesivos", "controles", "analíticos", "la", "función", "renal", "mejoró", ",", "alcanzando", "un", "filtrado", "glomerular", "mayor", "de", "60", "mL", "/", "min", "el", "26/01/2015", "que", "persiste", "en", "el", "momento", "actual", ",", "aunque", "el", "día", "30/01/2015", "se", "detectó", "una", "trombopenia", "grado", "III", "con", "67.000", "plaquetas", "/", "mm3", ".", "Valorando", "si", "esta", "alteración", "podía", "tratarse", "de", "toxicidad", "medular", "secundaria", "a", "la", "quimioterapia", "o", "estar", "en", "relación", "con", "el", "tratamiento", "con", "heparina", "de", "bajo", "peso", "molecular", ",", "se", "realizó", "una", "determinación", "sérica", "de", "anticuerpos", "anti", "-", "heparina", "/", "F4pl", ",", "cuya", "positividad", "confirmó", "el", "segundo", "mecanismo", ".", "Se", "sustituyó", "entonces", "la", "heparina", "por", "fondaparinux", ",", "consiguiendo", "una", "recuperación", "de", "las", "cifras", "de", "plaquetas", ",", "que", "alcanzaron", "las", "289.000", "/", "mm3", "el", "6/2/2015", ",", "y", "habiendo", "resuelto", "los", "principales", "problemas", "que", "justificaban", "mantener", "el", "ingreso", ",", "se", "indicó", "alta", "hospitalaria", ".", "En", "el", "momento", "actual", "el", "paciente", "continúa", "en", "tratamiento", "quimioterápico", "con", "gemcitabina", "y", "oxaliplatino", ",", "habiendo", "recibido", "hasta", "la", "fecha", "3", "ciclos", "sin", "incidencias", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
lesiones hepáticas is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, metastásicas is a MORFOLOGIA_NEOPLASIA, lesiones hepáticas is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA
151_task1
Sentence: Anamnesis Paciente de 56 años, sin antecedentes de interés. Ingresa en nuestro hospital de forma urgente el 10/1/2015 por un cuadro de dolor epigástrico de alta intensidad seguido de pérdida de consciencia de varios minutos de duración con cortejo vegetativo acompañante, habiéndose detectado en el Servicio de Urgencias la existencia de lesiones hepáticas sugestivas de metástasis y una trombosis parcial de la vena cava inferior mediante ecografía abdominal, realizada tras el hallazgo de una elevación de las enzimas hepáticas en la analítica sanguínea realizada. Exploración física . Pruebas complementarias . Diagnóstico Durante su estancia en planta de hospitalización a cargo de Medicina Interna, y estando pendiente de la realización de una TC de abdomen para completar el estudio, el paciente presentó oligoanuria y pesadez abdominal. Se solicitó una analítica el 12/1/2015, en la que se objetivó una insuficiencia renal aguda con creatinina de 63 mg/dL y filtrado glomerular de 9 mL/min, por lo que se realizó una TC de forma urgente, detectándose una lesión en segmentos I y IV hepáticos de unos 85 x 46 mm en el plano axial, sugestiva de neoplasia de vía biliar, acompañada de múltiples lesiones redondeadas metastásicas en ambos lóbulos hepáticos y trombosis de la rama portal izquierda, trombosis de vena cava inferior que se extiende hasta ambas venas renales, y adenopatías interaortoesofágicas y retroperitoneales. El caso fue valorado por Nefrología, y se decidió su inclusión en programa de hemodiálisis. Tratamiento Tras la detección por ecografía de la trombosis parcial de vena cava inferior se había iniciado anticoagulación con HBPM, pero al objetivar el deterioro de la función renal se sustituyó por HNF. Este tratamiento se interrumpió el 15/1/2015 para la realización de una biopsia de alguna de las lesiones hepáticas que permitiese confirmar el diagnóstico de sospecha, como finalmente se hizo, pero antes de que se pudiese reiniciar nuevamente el estado general del paciente empeoró de forma aguda, asociando hipotensión arterial, taquicardia y síntomas vegetativos. Tras comprobar en la analítica sanguínea una caída brusca del hematocríto de casi 10 puntos, quedando finalmente una hemoglobina de 85 g/dL, se solicitó una angio-TC que demostró la existencia de hemorragia activa en el lóbulo hepático derecho, que había provocado un hemoperitoneo de volumen importante. Desestimándose llevar a cabo más medidas agresivas por la presencia de una neoplasia avanzada no curable, y únicamente con soporte transfusional y fluidoterapia, se recuperó la estabilidad hemodinámica. Por trombosis del catéter de hemodiálisis y de vena femoral acontencida el 20/1/2015 se decidió suspender esta técnica, acordándose finalmente con el paciente y la familia realizar medidas de soporte y control sintomático; en este momento la función renal era de 265 mg/dL con filtrado glomerular de 25 mL/min. Progresivamente el estado general fue mejorando y, teniendo ya el diagnóstico anatomopatológico, se consideró que se podía plantear la posibilidad de tratamiento quimioterápico con intención paliativa. El 23/1/2015 se reinició anticoagulación con HBPM a dosis ajustadas según función renal, y se administró el primer ciclo de gemcitabina y oxaliplatino, con buena tolerancia al mismo. Evolución En los sucesivos controles analíticos la función renal mejoró, alcanzando un filtrado glomerular mayor de 60 mL/min el 26/01/2015 que persiste en el momento actual, aunque el día 30/01/2015 se detectó una trombopenia grado III con 67.000 plaquetas/mm3. Valorando si esta alteración podía tratarse de toxicidad medular secundaria a la quimioterapia o estar en relación con el tratamiento con heparina de bajo peso molecular, se realizó una determinación sérica de anticuerpos anti-heparina/F4pl, cuya positividad confirmó el segundo mecanismo. Se sustituyó entonces la heparina por fondaparinux, consiguiendo una recuperación de las cifras de plaquetas, que alcanzaron las 289.000/mm3 el 6/2/2015, y habiendo resuelto los principales problemas que justificaban mantener el ingreso, se indicó alta hospitalaria. En el momento actual el paciente continúa en tratamiento quimioterápico con gemcitabina y oxaliplatino, habiendo recibido hasta la fecha 3 ciclos sin incidencias. Instructions: please typing these entity words according to sentence: lesiones hepáticas, metástasis, neoplasia, metastásicas, lesiones hepáticas, neoplasia Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Paciente de 56 años, sin antecedentes de interés. Ingresa en nuestro hospital de forma urgente el 10/1/2015 por un cuadro de dolor epigástrico de alta intensidad seguido de pérdida de consciencia de varios minutos de duración con cortejo vegetativo acompañante, habiéndose detectado en el Servicio de Urgencias la existencia de lesiones hepáticas sugestivas de metástasis y una trombosis parcial de la vena cava inferior mediante ecografía abdominal, realizada tras el hallazgo de una elevación de las enzimas hepáticas en la analítica sanguínea realizada. Exploración física . Pruebas complementarias . Diagnóstico Durante su estancia en planta de hospitalización a cargo de Medicina Interna, y estando pendiente de la realización de una TC de abdomen para completar el estudio, el paciente presentó oligoanuria y pesadez abdominal. Se solicitó una analítica el 12/1/2015, en la que se objetivó una insuficiencia renal aguda con creatinina de 63 mg/dL y filtrado glomerular de 9 mL/min, por lo que se realizó una TC de forma urgente, detectándose una lesión en segmentos I y IV hepáticos de unos 85 x 46 mm en el plano axial, sugestiva de neoplasia de vía biliar, acompañada de múltiples lesiones redondeadas metastásicas en ambos lóbulos hepáticos y trombosis de la rama portal izquierda, trombosis de vena cava inferior que se extiende hasta ambas venas renales, y adenopatías interaortoesofágicas y retroperitoneales. El caso fue valorado por Nefrología, y se decidió su inclusión en programa de hemodiálisis. Tratamiento Tras la detección por ecografía de la trombosis parcial de vena cava inferior se había iniciado anticoagulación con HBPM, pero al objetivar el deterioro de la función renal se sustituyó por HNF. Este tratamiento se interrumpió el 15/1/2015 para la realización de una biopsia de alguna de las lesiones hepáticas que permitiese confirmar el diagnóstico de sospecha, como finalmente se hizo, pero antes de que se pudiese reiniciar nuevamente el estado general del paciente empeoró de forma aguda, asociando hipotensión arterial, taquicardia y síntomas vegetativos. Tras comprobar en la analítica sanguínea una caída brusca del hematocríto de casi 10 puntos, quedando finalmente una hemoglobina de 85 g/dL, se solicitó una angio-TC que demostró la existencia de hemorragia activa en el lóbulo hepático derecho, que había provocado un hemoperitoneo de volumen importante. Desestimándose llevar a cabo más medidas agresivas por la presencia de una neoplasia avanzada no curable, y únicamente con soporte transfusional y fluidoterapia, se recuperó la estabilidad hemodinámica. Por trombosis del catéter de hemodiálisis y de vena femoral acontencida el 20/1/2015 se decidió suspender esta técnica, acordándose finalmente con el paciente y la familia realizar medidas de soporte y control sintomático; en este momento la función renal era de 265 mg/dL con filtrado glomerular de 25 mL/min. Progresivamente el estado general fue mejorando y, teniendo ya el diagnóstico anatomopatológico, se consideró que se podía plantear la posibilidad de tratamiento quimioterápico con intención paliativa. El 23/1/2015 se reinició anticoagulación con HBPM a dosis ajustadas según función renal, y se administró el primer ciclo de gemcitabina y oxaliplatino, con buena tolerancia al mismo. Evolución En los sucesivos controles analíticos la función renal mejoró, alcanzando un filtrado glomerular mayor de 60 mL/min el 26/01/2015 que persiste en el momento actual, aunque el día 30/01/2015 se detectó una trombopenia grado III con 67.000 plaquetas/mm3. Valorando si esta alteración podía tratarse de toxicidad medular secundaria a la quimioterapia o estar en relación con el tratamiento con heparina de bajo peso molecular, se realizó una determinación sérica de anticuerpos anti-heparina/F4pl, cuya positividad confirmó el segundo mecanismo. Se sustituyó entonces la heparina por fondaparinux, consiguiendo una recuperación de las cifras de plaquetas, que alcanzaron las 289.000/mm3 el 6/2/2015, y habiendo resuelto los principales problemas que justificaban mantener el ingreso, se indicó alta hospitalaria. En el momento actual el paciente continúa en tratamiento quimioterápico con gemcitabina y oxaliplatino, habiendo recibido hasta la fecha 3 ciclos sin incidencias.
[ "Anamnesis", "\n", "Paciente", "de", "56", "años", ",", "sin", "antecedentes", "de", "interés", ".", "Ingresa", "en", "nuestro", "hospital", "de", "forma", "urgente", "el", "10/1/2015", "por", "un", "cuadro", "de", "dolor", "epigástrico", "de", "alta", "intensidad", "seguido", "de", "pérdida", "de", "consciencia", "de", "varios", "minutos", "de", "duración", "con", "cortejo", "vegetativo", "acompañante", ",", "habiéndose", "detectado", "en", "el", "Servicio", "de", "Urgencias", "la", "existencia", "de", "lesiones", "hepáticas", "sugestivas", "de", "metástasis", "y", "una", "trombosis", "parcial", "de", "la", "vena", "cava", "inferior", "mediante", "ecografía", "abdominal", ",", "realizada", "tras", "el", "hallazgo", "de", "una", "elevación", "de", "las", "enzimas", "hepáticas", "en", "la", "analítica", "sanguínea", "realizada", ".", "\n\n", "Exploración", "física", "\n", ".", "\n\n", "Pruebas", "complementarias", "\n", ".", "\n\n", "Diagnóstico", "\n", "Durante", "su", "estancia", "en", "planta", "de", "hospitalización", "a", "cargo", "de", "Medicina", "Interna", ",", "y", "estando", "pendiente", "de", "la", "realización", "de", "una", "TC", "de", "abdomen", "para", "completar", "el", "estudio", ",", "el", "paciente", "presentó", "oligoanuria", "y", "pesadez", "abdominal", ".", "Se", "solicitó", "una", "analítica", "el", "12/1/2015", ",", "en", "la", "que", "se", "objetivó", "una", "insuficiencia", "renal", "aguda", "con", "creatinina", "de", "63", "mg", "/", "dL", "y", "filtrado", "glomerular", "de", "9", "mL", "/", "min", ",", "por", "lo", "que", "se", "realizó", "una", "TC", "de", "forma", "urgente", ",", "detectándose", "una", "lesión", "en", "segmentos", "I", "y", "IV", "hepáticos", "de", "unos", "85", "x", "46", "mm", "en", "el", "plano", "axial", ",", "sugestiva", "de", "neoplasia", "de", "vía", "biliar", ",", "acompañada", "de", "múltiples", "lesiones", "redondeadas", "metastásicas", "en", "ambos", "lóbulos", "hepáticos", "y", "trombosis", "de", "la", "rama", "portal", "izquierda", ",", "trombosis", "de", "vena", "cava", "inferior", "que", "se", "extiende", "hasta", "ambas", "venas", "renales", ",", "y", "adenopatías", "interaortoesofágicas", "y", "retroperitoneales", ".", "El", "caso", "fue", "valorado", "por", "Nefrología", ",", "y", "se", "decidió", "su", "inclusión", "en", "programa", "de", "hemodiálisis", ".", "\n\n", "Tratamiento", "\n", "Tras", "la", "detección", "por", "ecografía", "de", "la", "trombosis", "parcial", "de", "vena", "cava", "inferior", "se", "había", "iniciado", "anticoagulación", "con", "HBPM", ",", "pero", "al", "objetivar", "el", "deterioro", "de", "la", "función", "renal", "se", "sustituyó", "por", "HNF", ".", "Este", "tratamiento", "se", "interrumpió", "el", "15/1/2015", "para", "la", "realización", "de", "una", "biopsia", "de", "alguna", "de", "las", "lesiones", "hepáticas", "que", "permitiese", "confirmar", "el", "diagnóstico", "de", "sospecha", ",", "como", "finalmente", "se", "hizo", ",", "pero", "antes", "de", "que", "se", "pudiese", "reiniciar", "nuevamente", "el", "estado", "general", "del", "paciente", "empeoró", "de", "forma", "aguda", ",", "asociando", "hipotensión", "arterial", ",", "taquicardia", "y", "síntomas", "vegetativos", ".", "Tras", "comprobar", "en", "la", "analítica", "sanguínea", "una", "caída", "brusca", "del", "hematocríto", "de", "casi", "10", "puntos", ",", "quedando", "finalmente", "una", "hemoglobina", "de", "85", "g", "/", "dL", ",", "se", "solicitó", "una", "angio", "-", "TC", "que", "demostró", "la", "existencia", "de", "hemorragia", "activa", "en", "el", "lóbulo", "hepático", "derecho", ",", "que", "había", "provocado", "un", "hemoperitoneo", "de", "volumen", "importante", ".", "\n\n", "Desestimándose", "llevar", "a", "cabo", "más", "medidas", "agresivas", "por", "la", "presencia", "de", "una", "neoplasia", "avanzada", "no", "curable", ",", "y", "únicamente", "con", "soporte", "transfusional", "y", "fluidoterapia", ",", "se", "recuperó", "la", "estabilidad", "hemodinámica", ".", "Por", "trombosis", "del", "catéter", "de", "hemodiálisis", "y", "de", "vena", "femoral", "acontencida", "el", "20/1/2015", "se", "decidió", "suspender", "esta", "técnica", ",", "acordándose", "finalmente", "con", "el", "paciente", "y", "la", "familia", "realizar", "medidas", "de", "soporte", "y", "control", "sintomático", ";", "en", "este", "momento", "la", "función", "renal", "era", "de", "265", "mg", "/", "dL", "con", "filtrado", "glomerular", "de", "25", "mL", "/", "min", ".", "Progresivamente", "el", "estado", "general", "fue", "mejorando", "y", ",", "teniendo", "ya", "el", "diagnóstico", "anatomopatológico", ",", "se", "consideró", "que", "se", "podía", "plantear", "la", "posibilidad", "de", "tratamiento", "quimioterápico", "con", "intención", "paliativa", ".", "El", "23/1/2015", "se", "reinició", "anticoagulación", "con", "HBPM", "a", "dosis", "ajustadas", "según", "función", "renal", ",", "y", "se", "administró", "el", "primer", "ciclo", "de", "gemcitabina", "y", "oxaliplatino", ",", "con", "buena", "tolerancia", "al", "mismo", ".", "\n\n", "Evolución", "\n", "En", "los", "sucesivos", "controles", "analíticos", "la", "función", "renal", "mejoró", ",", "alcanzando", "un", "filtrado", "glomerular", "mayor", "de", "60", "mL", "/", "min", "el", "26/01/2015", "que", "persiste", "en", "el", "momento", "actual", ",", "aunque", "el", "día", "30/01/2015", "se", "detectó", "una", "trombopenia", "grado", "III", "con", "67.000", "plaquetas", "/", "mm3", ".", "Valorando", "si", "esta", "alteración", "podía", "tratarse", "de", "toxicidad", "medular", "secundaria", "a", "la", "quimioterapia", "o", "estar", "en", "relación", "con", "el", "tratamiento", "con", "heparina", "de", "bajo", "peso", "molecular", ",", "se", "realizó", "una", "determinación", "sérica", "de", "anticuerpos", "anti", "-", "heparina", "/", "F4pl", ",", "cuya", "positividad", "confirmó", "el", "segundo", "mecanismo", ".", "Se", "sustituyó", "entonces", "la", "heparina", "por", "fondaparinux", ",", "consiguiendo", "una", "recuperación", "de", "las", "cifras", "de", "plaquetas", ",", "que", "alcanzaron", "las", "289.000", "/", "mm3", "el", "6/2/2015", ",", "y", "habiendo", "resuelto", "los", "principales", "problemas", "que", "justificaban", "mantener", "el", "ingreso", ",", "se", "indicó", "alta", "hospitalaria", ".", "En", "el", "momento", "actual", "el", "paciente", "continúa", "en", "tratamiento", "quimioterápico", "con", "gemcitabina", "y", "oxaliplatino", ",", "habiendo", "recibido", "hasta", "la", "fecha", "3", "ciclos", "sin", "incidencias", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
lesiones hepáticas, metástasis, neoplasia, metastásicas, lesiones hepáticas, neoplasia
151_task2
Sentence: Anamnesis Paciente de 56 años, sin antecedentes de interés. Ingresa en nuestro hospital de forma urgente el 10/1/2015 por un cuadro de dolor epigástrico de alta intensidad seguido de pérdida de consciencia de varios minutos de duración con cortejo vegetativo acompañante, habiéndose detectado en el Servicio de Urgencias la existencia de lesiones hepáticas sugestivas de metástasis y una trombosis parcial de la vena cava inferior mediante ecografía abdominal, realizada tras el hallazgo de una elevación de las enzimas hepáticas en la analítica sanguínea realizada. Exploración física . Pruebas complementarias . Diagnóstico Durante su estancia en planta de hospitalización a cargo de Medicina Interna, y estando pendiente de la realización de una TC de abdomen para completar el estudio, el paciente presentó oligoanuria y pesadez abdominal. Se solicitó una analítica el 12/1/2015, en la que se objetivó una insuficiencia renal aguda con creatinina de 63 mg/dL y filtrado glomerular de 9 mL/min, por lo que se realizó una TC de forma urgente, detectándose una lesión en segmentos I y IV hepáticos de unos 85 x 46 mm en el plano axial, sugestiva de neoplasia de vía biliar, acompañada de múltiples lesiones redondeadas metastásicas en ambos lóbulos hepáticos y trombosis de la rama portal izquierda, trombosis de vena cava inferior que se extiende hasta ambas venas renales, y adenopatías interaortoesofágicas y retroperitoneales. El caso fue valorado por Nefrología, y se decidió su inclusión en programa de hemodiálisis. Tratamiento Tras la detección por ecografía de la trombosis parcial de vena cava inferior se había iniciado anticoagulación con HBPM, pero al objetivar el deterioro de la función renal se sustituyó por HNF. Este tratamiento se interrumpió el 15/1/2015 para la realización de una biopsia de alguna de las lesiones hepáticas que permitiese confirmar el diagnóstico de sospecha, como finalmente se hizo, pero antes de que se pudiese reiniciar nuevamente el estado general del paciente empeoró de forma aguda, asociando hipotensión arterial, taquicardia y síntomas vegetativos. Tras comprobar en la analítica sanguínea una caída brusca del hematocríto de casi 10 puntos, quedando finalmente una hemoglobina de 85 g/dL, se solicitó una angio-TC que demostró la existencia de hemorragia activa en el lóbulo hepático derecho, que había provocado un hemoperitoneo de volumen importante. Desestimándose llevar a cabo más medidas agresivas por la presencia de una neoplasia avanzada no curable, y únicamente con soporte transfusional y fluidoterapia, se recuperó la estabilidad hemodinámica. Por trombosis del catéter de hemodiálisis y de vena femoral acontencida el 20/1/2015 se decidió suspender esta técnica, acordándose finalmente con el paciente y la familia realizar medidas de soporte y control sintomático; en este momento la función renal era de 265 mg/dL con filtrado glomerular de 25 mL/min. Progresivamente el estado general fue mejorando y, teniendo ya el diagnóstico anatomopatológico, se consideró que se podía plantear la posibilidad de tratamiento quimioterápico con intención paliativa. El 23/1/2015 se reinició anticoagulación con HBPM a dosis ajustadas según función renal, y se administró el primer ciclo de gemcitabina y oxaliplatino, con buena tolerancia al mismo. Evolución En los sucesivos controles analíticos la función renal mejoró, alcanzando un filtrado glomerular mayor de 60 mL/min el 26/01/2015 que persiste en el momento actual, aunque el día 30/01/2015 se detectó una trombopenia grado III con 67.000 plaquetas/mm3. Valorando si esta alteración podía tratarse de toxicidad medular secundaria a la quimioterapia o estar en relación con el tratamiento con heparina de bajo peso molecular, se realizó una determinación sérica de anticuerpos anti-heparina/F4pl, cuya positividad confirmó el segundo mecanismo. Se sustituyó entonces la heparina por fondaparinux, consiguiendo una recuperación de las cifras de plaquetas, que alcanzaron las 289.000/mm3 el 6/2/2015, y habiendo resuelto los principales problemas que justificaban mantener el ingreso, se indicó alta hospitalaria. En el momento actual el paciente continúa en tratamiento quimioterápico con gemcitabina y oxaliplatino, habiendo recibido hasta la fecha 3 ciclos sin incidencias. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Paciente de 56 años, sin antecedentes de interés. Ingresa en nuestro hospital de forma urgente el 10/1/2015 por un cuadro de dolor epigástrico de alta intensidad seguido de pérdida de consciencia de varios minutos de duración con cortejo vegetativo acompañante, habiéndose detectado en el Servicio de Urgencias la existencia de lesiones hepáticas sugestivas de metástasis y una trombosis parcial de la vena cava inferior mediante ecografía abdominal, realizada tras el hallazgo de una elevación de las enzimas hepáticas en la analítica sanguínea realizada. Exploración física . Pruebas complementarias . Diagnóstico Durante su estancia en planta de hospitalización a cargo de Medicina Interna, y estando pendiente de la realización de una TC de abdomen para completar el estudio, el paciente presentó oligoanuria y pesadez abdominal. Se solicitó una analítica el 12/1/2015, en la que se objetivó una insuficiencia renal aguda con creatinina de 63 mg/dL y filtrado glomerular de 9 mL/min, por lo que se realizó una TC de forma urgente, detectándose una lesión en segmentos I y IV hepáticos de unos 85 x 46 mm en el plano axial, sugestiva de neoplasia de vía biliar, acompañada de múltiples lesiones redondeadas metastásicas en ambos lóbulos hepáticos y trombosis de la rama portal izquierda, trombosis de vena cava inferior que se extiende hasta ambas venas renales, y adenopatías interaortoesofágicas y retroperitoneales. El caso fue valorado por Nefrología, y se decidió su inclusión en programa de hemodiálisis. Tratamiento Tras la detección por ecografía de la trombosis parcial de vena cava inferior se había iniciado anticoagulación con HBPM, pero al objetivar el deterioro de la función renal se sustituyó por HNF. Este tratamiento se interrumpió el 15/1/2015 para la realización de una biopsia de alguna de las lesiones hepáticas que permitiese confirmar el diagnóstico de sospecha, como finalmente se hizo, pero antes de que se pudiese reiniciar nuevamente el estado general del paciente empeoró de forma aguda, asociando hipotensión arterial, taquicardia y síntomas vegetativos. Tras comprobar en la analítica sanguínea una caída brusca del hematocríto de casi 10 puntos, quedando finalmente una hemoglobina de 85 g/dL, se solicitó una angio-TC que demostró la existencia de hemorragia activa en el lóbulo hepático derecho, que había provocado un hemoperitoneo de volumen importante. Desestimándose llevar a cabo más medidas agresivas por la presencia de una neoplasia avanzada no curable, y únicamente con soporte transfusional y fluidoterapia, se recuperó la estabilidad hemodinámica. Por trombosis del catéter de hemodiálisis y de vena femoral acontencida el 20/1/2015 se decidió suspender esta técnica, acordándose finalmente con el paciente y la familia realizar medidas de soporte y control sintomático; en este momento la función renal era de 265 mg/dL con filtrado glomerular de 25 mL/min. Progresivamente el estado general fue mejorando y, teniendo ya el diagnóstico anatomopatológico, se consideró que se podía plantear la posibilidad de tratamiento quimioterápico con intención paliativa. El 23/1/2015 se reinició anticoagulación con HBPM a dosis ajustadas según función renal, y se administró el primer ciclo de gemcitabina y oxaliplatino, con buena tolerancia al mismo. Evolución En los sucesivos controles analíticos la función renal mejoró, alcanzando un filtrado glomerular mayor de 60 mL/min el 26/01/2015 que persiste en el momento actual, aunque el día 30/01/2015 se detectó una trombopenia grado III con 67.000 plaquetas/mm3. Valorando si esta alteración podía tratarse de toxicidad medular secundaria a la quimioterapia o estar en relación con el tratamiento con heparina de bajo peso molecular, se realizó una determinación sérica de anticuerpos anti-heparina/F4pl, cuya positividad confirmó el segundo mecanismo. Se sustituyó entonces la heparina por fondaparinux, consiguiendo una recuperación de las cifras de plaquetas, que alcanzaron las 289.000/mm3 el 6/2/2015, y habiendo resuelto los principales problemas que justificaban mantener el ingreso, se indicó alta hospitalaria. En el momento actual el paciente continúa en tratamiento quimioterápico con gemcitabina y oxaliplatino, habiendo recibido hasta la fecha 3 ciclos sin incidencias.
[ "Anamnesis", "\n", "Paciente", "de", "56", "años", ",", "sin", "antecedentes", "de", "interés", ".", "Ingresa", "en", "nuestro", "hospital", "de", "forma", "urgente", "el", "10/1/2015", "por", "un", "cuadro", "de", "dolor", "epigástrico", "de", "alta", "intensidad", "seguido", "de", "pérdida", "de", "consciencia", "de", "varios", "minutos", "de", "duración", "con", "cortejo", "vegetativo", "acompañante", ",", "habiéndose", "detectado", "en", "el", "Servicio", "de", "Urgencias", "la", "existencia", "de", "lesiones", "hepáticas", "sugestivas", "de", "metástasis", "y", "una", "trombosis", "parcial", "de", "la", "vena", "cava", "inferior", "mediante", "ecografía", "abdominal", ",", "realizada", "tras", "el", "hallazgo", "de", "una", "elevación", "de", "las", "enzimas", "hepáticas", "en", "la", "analítica", "sanguínea", "realizada", ".", "\n\n", "Exploración", "física", "\n", ".", "\n\n", "Pruebas", "complementarias", "\n", ".", "\n\n", "Diagnóstico", "\n", "Durante", "su", "estancia", "en", "planta", "de", "hospitalización", "a", "cargo", "de", "Medicina", "Interna", ",", "y", "estando", "pendiente", "de", "la", "realización", "de", "una", "TC", "de", "abdomen", "para", "completar", "el", "estudio", ",", "el", "paciente", "presentó", "oligoanuria", "y", "pesadez", "abdominal", ".", "Se", "solicitó", "una", "analítica", "el", "12/1/2015", ",", "en", "la", "que", "se", "objetivó", "una", "insuficiencia", "renal", "aguda", "con", "creatinina", "de", "63", "mg", "/", "dL", "y", "filtrado", "glomerular", "de", "9", "mL", "/", "min", ",", "por", "lo", "que", "se", "realizó", "una", "TC", "de", "forma", "urgente", ",", "detectándose", "una", "lesión", "en", "segmentos", "I", "y", "IV", "hepáticos", "de", "unos", "85", "x", "46", "mm", "en", "el", "plano", "axial", ",", "sugestiva", "de", "neoplasia", "de", "vía", "biliar", ",", "acompañada", "de", "múltiples", "lesiones", "redondeadas", "metastásicas", "en", "ambos", "lóbulos", "hepáticos", "y", "trombosis", "de", "la", "rama", "portal", "izquierda", ",", "trombosis", "de", "vena", "cava", "inferior", "que", "se", "extiende", "hasta", "ambas", "venas", "renales", ",", "y", "adenopatías", "interaortoesofágicas", "y", "retroperitoneales", ".", "El", "caso", "fue", "valorado", "por", "Nefrología", ",", "y", "se", "decidió", "su", "inclusión", "en", "programa", "de", "hemodiálisis", ".", "\n\n", "Tratamiento", "\n", "Tras", "la", "detección", "por", "ecografía", "de", "la", "trombosis", "parcial", "de", "vena", "cava", "inferior", "se", "había", "iniciado", "anticoagulación", "con", "HBPM", ",", "pero", "al", "objetivar", "el", "deterioro", "de", "la", "función", "renal", "se", "sustituyó", "por", "HNF", ".", "Este", "tratamiento", "se", "interrumpió", "el", "15/1/2015", "para", "la", "realización", "de", "una", "biopsia", "de", "alguna", "de", "las", "lesiones", "hepáticas", "que", "permitiese", "confirmar", "el", "diagnóstico", "de", "sospecha", ",", "como", "finalmente", "se", "hizo", ",", "pero", "antes", "de", "que", "se", "pudiese", "reiniciar", "nuevamente", "el", "estado", "general", "del", "paciente", "empeoró", "de", "forma", "aguda", ",", "asociando", "hipotensión", "arterial", ",", "taquicardia", "y", "síntomas", "vegetativos", ".", "Tras", "comprobar", "en", "la", "analítica", "sanguínea", "una", "caída", "brusca", "del", "hematocríto", "de", "casi", "10", "puntos", ",", "quedando", "finalmente", "una", "hemoglobina", "de", "85", "g", "/", "dL", ",", "se", "solicitó", "una", "angio", "-", "TC", "que", "demostró", "la", "existencia", "de", "hemorragia", "activa", "en", "el", "lóbulo", "hepático", "derecho", ",", "que", "había", "provocado", "un", "hemoperitoneo", "de", "volumen", "importante", ".", "\n\n", "Desestimándose", "llevar", "a", "cabo", "más", "medidas", "agresivas", "por", "la", "presencia", "de", "una", "neoplasia", "avanzada", "no", "curable", ",", "y", "únicamente", "con", "soporte", "transfusional", "y", "fluidoterapia", ",", "se", "recuperó", "la", "estabilidad", "hemodinámica", ".", "Por", "trombosis", "del", "catéter", "de", "hemodiálisis", "y", "de", "vena", "femoral", "acontencida", "el", "20/1/2015", "se", "decidió", "suspender", "esta", "técnica", ",", "acordándose", "finalmente", "con", "el", "paciente", "y", "la", "familia", "realizar", "medidas", "de", "soporte", "y", "control", "sintomático", ";", "en", "este", "momento", "la", "función", "renal", "era", "de", "265", "mg", "/", "dL", "con", "filtrado", "glomerular", "de", "25", "mL", "/", "min", ".", "Progresivamente", "el", "estado", "general", "fue", "mejorando", "y", ",", "teniendo", "ya", "el", "diagnóstico", "anatomopatológico", ",", "se", "consideró", "que", "se", "podía", "plantear", "la", "posibilidad", "de", "tratamiento", "quimioterápico", "con", "intención", "paliativa", ".", "El", "23/1/2015", "se", "reinició", "anticoagulación", "con", "HBPM", "a", "dosis", "ajustadas", "según", "función", "renal", ",", "y", "se", "administró", "el", "primer", "ciclo", "de", "gemcitabina", "y", "oxaliplatino", ",", "con", "buena", "tolerancia", "al", "mismo", ".", "\n\n", "Evolución", "\n", "En", "los", "sucesivos", "controles", "analíticos", "la", "función", "renal", "mejoró", ",", "alcanzando", "un", "filtrado", "glomerular", "mayor", "de", "60", "mL", "/", "min", "el", "26/01/2015", "que", "persiste", "en", "el", "momento", "actual", ",", "aunque", "el", "día", "30/01/2015", "se", "detectó", "una", "trombopenia", "grado", "III", "con", "67.000", "plaquetas", "/", "mm3", ".", "Valorando", "si", "esta", "alteración", "podía", "tratarse", "de", "toxicidad", "medular", "secundaria", "a", "la", "quimioterapia", "o", "estar", "en", "relación", "con", "el", "tratamiento", "con", "heparina", "de", "bajo", "peso", "molecular", ",", "se", "realizó", "una", "determinación", "sérica", "de", "anticuerpos", "anti", "-", "heparina", "/", "F4pl", ",", "cuya", "positividad", "confirmó", "el", "segundo", "mecanismo", ".", "Se", "sustituyó", "entonces", "la", "heparina", "por", "fondaparinux", ",", "consiguiendo", "una", "recuperación", "de", "las", "cifras", "de", "plaquetas", ",", "que", "alcanzaron", "las", "289.000", "/", "mm3", "el", "6/2/2015", ",", "y", "habiendo", "resuelto", "los", "principales", "problemas", "que", "justificaban", "mantener", "el", "ingreso", ",", "se", "indicó", "alta", "hospitalaria", ".", "En", "el", "momento", "actual", "el", "paciente", "continúa", "en", "tratamiento", "quimioterápico", "con", "gemcitabina", "y", "oxaliplatino", ",", "habiendo", "recibido", "hasta", "la", "fecha", "3", "ciclos", "sin", "incidencias", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
Objectives is an umlsterm, muscle tone is an umlsterm, rats is an umlsterm, intrathecal injection is an umlsterm, flupirtine is an umlsterm, analgetic is an umlsterm, muscle - relaxing is an umlsterm, patients is an umlsterm, spasticity is an umlsterm, flupirtine is an umlsterm, increased muscle tone is an umlsterm, patients is an umlsterm, spasticity is an umlsterm
DerSchmerz.90130324.eng.abstr_task0
Sentence: Objectives : A reduction of muscle tone in rats can be found after intraperitoneal or intrathecal injection of flupirtine in analgetic doses . However , a muscle-relaxing effect in patients with spasticity has not yet been shown . In this study we investigated whether flupirtine can reduce the increased muscle tone in patients with spasticity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
Objectives : A reduction of muscle tone in rats can be found after intraperitoneal or intrathecal injection of flupirtine in analgetic doses . However , a muscle-relaxing effect in patients with spasticity has not yet been shown . In this study we investigated whether flupirtine can reduce the increased muscle tone in patients with spasticity .
[ "Objectives", ":", "A", "reduction", "of", "muscle", "tone", "in", "rats", "can", "be", "found", "after", "intraperitoneal", "or", "intrathecal", "injection", "of", "flupirtine", "in", "analgetic", "doses", ".", "However", ",", "a", "muscle", "-", "relaxing", "effect", "in", "patients", "with", "spasticity", "has", "not", "yet", "been", "shown", ".", "In", "this", "study", "we", "investigated", "whether", "flupirtine", "can", "reduce", "the", "increased", "muscle", "tone", "in", "patients", "with", "spasticity", "." ]
[ "umlsterm" ]
Objectives is an umlsterm, muscle tone is an umlsterm, rats is an umlsterm, intrathecal injection is an umlsterm, flupirtine is an umlsterm, analgetic is an umlsterm, muscle - relaxing is an umlsterm, patients is an umlsterm, spasticity is an umlsterm, flupirtine is an umlsterm, increased muscle tone is an umlsterm, patients is an umlsterm, spasticity is an umlsterm
DerSchmerz.90130324.eng.abstr_task1
Sentence: Objectives : A reduction of muscle tone in rats can be found after intraperitoneal or intrathecal injection of flupirtine in analgetic doses . However , a muscle-relaxing effect in patients with spasticity has not yet been shown . In this study we investigated whether flupirtine can reduce the increased muscle tone in patients with spasticity . Instructions: please typing these entity words according to sentence: Objectives, muscle tone, rats, intrathecal injection, flupirtine, analgetic, muscle - relaxing, patients, spasticity, flupirtine, increased muscle tone, patients, spasticity Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
Objectives : A reduction of muscle tone in rats can be found after intraperitoneal or intrathecal injection of flupirtine in analgetic doses . However , a muscle-relaxing effect in patients with spasticity has not yet been shown . In this study we investigated whether flupirtine can reduce the increased muscle tone in patients with spasticity .
[ "Objectives", ":", "A", "reduction", "of", "muscle", "tone", "in", "rats", "can", "be", "found", "after", "intraperitoneal", "or", "intrathecal", "injection", "of", "flupirtine", "in", "analgetic", "doses", ".", "However", ",", "a", "muscle", "-", "relaxing", "effect", "in", "patients", "with", "spasticity", "has", "not", "yet", "been", "shown", ".", "In", "this", "study", "we", "investigated", "whether", "flupirtine", "can", "reduce", "the", "increased", "muscle", "tone", "in", "patients", "with", "spasticity", "." ]
[ "umlsterm" ]
Objectives, muscle tone, rats, intrathecal injection, flupirtine, analgetic, muscle - relaxing, patients, spasticity, flupirtine, increased muscle tone, patients, spasticity
DerSchmerz.90130324.eng.abstr_task2
Sentence: Objectives : A reduction of muscle tone in rats can be found after intraperitoneal or intrathecal injection of flupirtine in analgetic doses . However , a muscle-relaxing effect in patients with spasticity has not yet been shown . In this study we investigated whether flupirtine can reduce the increased muscle tone in patients with spasticity . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
Objectives : A reduction of muscle tone in rats can be found after intraperitoneal or intrathecal injection of flupirtine in analgetic doses . However , a muscle-relaxing effect in patients with spasticity has not yet been shown . In this study we investigated whether flupirtine can reduce the increased muscle tone in patients with spasticity .
[ "Objectives", ":", "A", "reduction", "of", "muscle", "tone", "in", "rats", "can", "be", "found", "after", "intraperitoneal", "or", "intrathecal", "injection", "of", "flupirtine", "in", "analgetic", "doses", ".", "However", ",", "a", "muscle", "-", "relaxing", "effect", "in", "patients", "with", "spasticity", "has", "not", "yet", "been", "shown", ".", "In", "this", "study", "we", "investigated", "whether", "flupirtine", "can", "reduce", "the", "increased", "muscle", "tone", "in", "patients", "with", "spasticity", "." ]
[ "umlsterm" ]
human is a Species, APP is a Genes/Proteins, regulated is a Relation_Trigger, miRNAs is a Non-Specific_miRNAs
1586_task0
Sentence: These results are the first to demonstrate that levels of human APP can be regulated by miRNAs. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Genes/Proteins, Relation_Trigger, Species, Non-Specific_miRNAs
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Species", "B-Genes/Proteins", "O", "O", "B-Relation_Trigger", "O", "B-Non-Specific_miRNAs", "O", "O" ]
These results are the first to demonstrate that levels of human APP can be regulated by miRNAs.
[ "These", "results", "are", "the", "first", "to", "demonstrate", "that", "levels", "of", "human", "APP", "can", "be", "regulated", "by", "miRNAs", ".", " " ]
[ "Relation_Trigger", "Diseases", "Specific_miRNAs", "Non-Specific_miRNAs", "Species", "Genes/Proteins" ]
human is a Species, APP is a Genes/Proteins, regulated is a Relation_Trigger, miRNAs is a Non-Specific_miRNAs
1586_task1
Sentence: These results are the first to demonstrate that levels of human APP can be regulated by miRNAs. Instructions: please typing these entity words according to sentence: human, APP, regulated, miRNAs Options: Genes/Proteins, Relation_Trigger, Species, Non-Specific_miRNAs
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Species", "B-Genes/Proteins", "O", "O", "B-Relation_Trigger", "O", "B-Non-Specific_miRNAs", "O", "O" ]
These results are the first to demonstrate that levels of human APP can be regulated by miRNAs.
[ "These", "results", "are", "the", "first", "to", "demonstrate", "that", "levels", "of", "human", "APP", "can", "be", "regulated", "by", "miRNAs", ".", " " ]
[ "Relation_Trigger", "Diseases", "Specific_miRNAs", "Non-Specific_miRNAs", "Species", "Genes/Proteins" ]
human, APP, regulated, miRNAs
1586_task2
Sentence: These results are the first to demonstrate that levels of human APP can be regulated by miRNAs. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Species", "B-Genes/Proteins", "O", "O", "B-Relation_Trigger", "O", "B-Non-Specific_miRNAs", "O", "O" ]
These results are the first to demonstrate that levels of human APP can be regulated by miRNAs.
[ "These", "results", "are", "the", "first", "to", "demonstrate", "that", "levels", "of", "human", "APP", "can", "be", "regulated", "by", "miRNAs", ".", " " ]
[ "Relation_Trigger", "Diseases", "Specific_miRNAs", "Non-Specific_miRNAs", "Species", "Genes/Proteins" ]
Metastasen is an umlsterm, Tumoren is an umlsterm, Skeletts is an umlsterm, Diagnostik is an umlsterm, Skelettmetastasen is an umlsterm, bildgebende is an umlsterm, Skelettabschnitte is an umlsterm, Roentgenaufnahmen is an umlsterm, Metastasen is an umlsterm, Skelettes is an umlsterm, Spezifitaet is an umlsterm, Computertomographie is an umlsterm, Magnetresonanztomographie is an umlsterm, Wirbelsaeulendiagnostik is an umlsterm, Biopsien is an umlsterm, Schichtorientierung is an umlsterm
DerOrthopaede.80270224.ger.abstr_task0
Sentence: Metastasen sind die haeufigsten malignen Tumoren des Skeletts . Fuer die Diagnostik von Skelettmetastasen stehen mehrere bildgebende Verfahren zur Verfuegung , welche je nach klinischer Ausgangssituation einzeln oder kombiniert zum Einsatz kommen . Konventionelle Aufnahmen werden gezielt zur Abklaerung auffaelliger Skelettabschnitte eingesetzt . Die Roentgenaufnahmen sind in bezug auf Metastasen nicht sehr sensitiv , koennen aber in vielen Faellen gutartige Veraenderungen als Ursache der Beschwerden nachweisen . Die Skelettszintigraphie eignet sich zum raschen Screening des gesamten Skelettes mit hoher Sensitivitaet , jedoch geringer Spezifitaet . Die Computertomographie ( CT ) und die Magnetresonanztomographie sind weiterfuehrende Verfahren , die sich insbesondere in der Wirbelsaeulendiagnostik als unverzichtbar erwiesen haben . Mit der CT sind darueber hinaus perkutane Biopsien einfach und sicher durchfuehrbar . Die MRT ist allen Verfahren an Sensitivitaet ueberlegen . Sie bietet darueber hinaus den Vorteil der beliebigen Schichtorientierung im Raum und der guten Darstellung der umgebenden Weichteile . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Metastasen sind die haeufigsten malignen Tumoren des Skeletts . Fuer die Diagnostik von Skelettmetastasen stehen mehrere bildgebende Verfahren zur Verfuegung , welche je nach klinischer Ausgangssituation einzeln oder kombiniert zum Einsatz kommen . Konventionelle Aufnahmen werden gezielt zur Abklaerung auffaelliger Skelettabschnitte eingesetzt . Die Roentgenaufnahmen sind in bezug auf Metastasen nicht sehr sensitiv , koennen aber in vielen Faellen gutartige Veraenderungen als Ursache der Beschwerden nachweisen . Die Skelettszintigraphie eignet sich zum raschen Screening des gesamten Skelettes mit hoher Sensitivitaet , jedoch geringer Spezifitaet . Die Computertomographie ( CT ) und die Magnetresonanztomographie sind weiterfuehrende Verfahren , die sich insbesondere in der Wirbelsaeulendiagnostik als unverzichtbar erwiesen haben . Mit der CT sind darueber hinaus perkutane Biopsien einfach und sicher durchfuehrbar . Die MRT ist allen Verfahren an Sensitivitaet ueberlegen . Sie bietet darueber hinaus den Vorteil der beliebigen Schichtorientierung im Raum und der guten Darstellung der umgebenden Weichteile .
[ "Metastasen", "sind", "die", "haeufigsten", "malignen", "Tumoren", "des", "Skeletts", ".", "Fuer", "die", "Diagnostik", "von", "Skelettmetastasen", "stehen", "mehrere", "bildgebende", "Verfahren", "zur", "Verfuegung", ",", "welche", "je", "nach", "klinischer", "Ausgangssituation", "einzeln", "oder", "kombiniert", "zum", "Einsatz", "kommen", ".", "Konventionelle", "Aufnahmen", "werden", "gezielt", "zur", "Abklaerung", "auffaelliger", "Skelettabschnitte", "eingesetzt", ".", "Die", "Roentgenaufnahmen", "sind", "in", "bezug", "auf", "Metastasen", "nicht", "sehr", "sensitiv", ",", "koennen", "aber", "in", "vielen", "Faellen", "gutartige", "Veraenderungen", "als", "Ursache", "der", "Beschwerden", "nachweisen", ".", "Die", "Skelettszintigraphie", "eignet", "sich", "zum", "raschen", "Screening", "des", "gesamten", "Skelettes", "mit", "hoher", "Sensitivitaet", ",", "jedoch", "geringer", "Spezifitaet", ".", "Die", "Computertomographie", "(", "CT", ")", "und", "die", "Magnetresonanztomographie", "sind", "weiterfuehrende", "Verfahren", ",", "die", "sich", "insbesondere", "in", "der", "Wirbelsaeulendiagnostik", "als", "unverzichtbar", "erwiesen", "haben", ".", "Mit", "der", "CT", "sind", "darueber", "hinaus", "perkutane", "Biopsien", "einfach", "und", "sicher", "durchfuehrbar", ".", "Die", "MRT", "ist", "allen", "Verfahren", "an", "Sensitivitaet", "ueberlegen", ".", "Sie", "bietet", "darueber", "hinaus", "den", "Vorteil", "der", "beliebigen", "Schichtorientierung", "im", "Raum", "und", "der", "guten", "Darstellung", "der", "umgebenden", "Weichteile", "." ]
[ "umlsterm" ]
Metastasen is an umlsterm, Tumoren is an umlsterm, Skeletts is an umlsterm, Diagnostik is an umlsterm, Skelettmetastasen is an umlsterm, bildgebende is an umlsterm, Skelettabschnitte is an umlsterm, Roentgenaufnahmen is an umlsterm, Metastasen is an umlsterm, Skelettes is an umlsterm, Spezifitaet is an umlsterm, Computertomographie is an umlsterm, Magnetresonanztomographie is an umlsterm, Wirbelsaeulendiagnostik is an umlsterm, Biopsien is an umlsterm, Schichtorientierung is an umlsterm
DerOrthopaede.80270224.ger.abstr_task1
Sentence: Metastasen sind die haeufigsten malignen Tumoren des Skeletts . Fuer die Diagnostik von Skelettmetastasen stehen mehrere bildgebende Verfahren zur Verfuegung , welche je nach klinischer Ausgangssituation einzeln oder kombiniert zum Einsatz kommen . Konventionelle Aufnahmen werden gezielt zur Abklaerung auffaelliger Skelettabschnitte eingesetzt . Die Roentgenaufnahmen sind in bezug auf Metastasen nicht sehr sensitiv , koennen aber in vielen Faellen gutartige Veraenderungen als Ursache der Beschwerden nachweisen . Die Skelettszintigraphie eignet sich zum raschen Screening des gesamten Skelettes mit hoher Sensitivitaet , jedoch geringer Spezifitaet . Die Computertomographie ( CT ) und die Magnetresonanztomographie sind weiterfuehrende Verfahren , die sich insbesondere in der Wirbelsaeulendiagnostik als unverzichtbar erwiesen haben . Mit der CT sind darueber hinaus perkutane Biopsien einfach und sicher durchfuehrbar . Die MRT ist allen Verfahren an Sensitivitaet ueberlegen . Sie bietet darueber hinaus den Vorteil der beliebigen Schichtorientierung im Raum und der guten Darstellung der umgebenden Weichteile . Instructions: please typing these entity words according to sentence: Metastasen, Tumoren, Skeletts, Diagnostik, Skelettmetastasen, bildgebende, Skelettabschnitte, Roentgenaufnahmen, Metastasen, Skelettes, Spezifitaet, Computertomographie, Magnetresonanztomographie, Wirbelsaeulendiagnostik, Biopsien, Schichtorientierung Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Metastasen sind die haeufigsten malignen Tumoren des Skeletts . Fuer die Diagnostik von Skelettmetastasen stehen mehrere bildgebende Verfahren zur Verfuegung , welche je nach klinischer Ausgangssituation einzeln oder kombiniert zum Einsatz kommen . Konventionelle Aufnahmen werden gezielt zur Abklaerung auffaelliger Skelettabschnitte eingesetzt . Die Roentgenaufnahmen sind in bezug auf Metastasen nicht sehr sensitiv , koennen aber in vielen Faellen gutartige Veraenderungen als Ursache der Beschwerden nachweisen . Die Skelettszintigraphie eignet sich zum raschen Screening des gesamten Skelettes mit hoher Sensitivitaet , jedoch geringer Spezifitaet . Die Computertomographie ( CT ) und die Magnetresonanztomographie sind weiterfuehrende Verfahren , die sich insbesondere in der Wirbelsaeulendiagnostik als unverzichtbar erwiesen haben . Mit der CT sind darueber hinaus perkutane Biopsien einfach und sicher durchfuehrbar . Die MRT ist allen Verfahren an Sensitivitaet ueberlegen . Sie bietet darueber hinaus den Vorteil der beliebigen Schichtorientierung im Raum und der guten Darstellung der umgebenden Weichteile .
[ "Metastasen", "sind", "die", "haeufigsten", "malignen", "Tumoren", "des", "Skeletts", ".", "Fuer", "die", "Diagnostik", "von", "Skelettmetastasen", "stehen", "mehrere", "bildgebende", "Verfahren", "zur", "Verfuegung", ",", "welche", "je", "nach", "klinischer", "Ausgangssituation", "einzeln", "oder", "kombiniert", "zum", "Einsatz", "kommen", ".", "Konventionelle", "Aufnahmen", "werden", "gezielt", "zur", "Abklaerung", "auffaelliger", "Skelettabschnitte", "eingesetzt", ".", "Die", "Roentgenaufnahmen", "sind", "in", "bezug", "auf", "Metastasen", "nicht", "sehr", "sensitiv", ",", "koennen", "aber", "in", "vielen", "Faellen", "gutartige", "Veraenderungen", "als", "Ursache", "der", "Beschwerden", "nachweisen", ".", "Die", "Skelettszintigraphie", "eignet", "sich", "zum", "raschen", "Screening", "des", "gesamten", "Skelettes", "mit", "hoher", "Sensitivitaet", ",", "jedoch", "geringer", "Spezifitaet", ".", "Die", "Computertomographie", "(", "CT", ")", "und", "die", "Magnetresonanztomographie", "sind", "weiterfuehrende", "Verfahren", ",", "die", "sich", "insbesondere", "in", "der", "Wirbelsaeulendiagnostik", "als", "unverzichtbar", "erwiesen", "haben", ".", "Mit", "der", "CT", "sind", "darueber", "hinaus", "perkutane", "Biopsien", "einfach", "und", "sicher", "durchfuehrbar", ".", "Die", "MRT", "ist", "allen", "Verfahren", "an", "Sensitivitaet", "ueberlegen", ".", "Sie", "bietet", "darueber", "hinaus", "den", "Vorteil", "der", "beliebigen", "Schichtorientierung", "im", "Raum", "und", "der", "guten", "Darstellung", "der", "umgebenden", "Weichteile", "." ]
[ "umlsterm" ]
Metastasen, Tumoren, Skeletts, Diagnostik, Skelettmetastasen, bildgebende, Skelettabschnitte, Roentgenaufnahmen, Metastasen, Skelettes, Spezifitaet, Computertomographie, Magnetresonanztomographie, Wirbelsaeulendiagnostik, Biopsien, Schichtorientierung
DerOrthopaede.80270224.ger.abstr_task2
Sentence: Metastasen sind die haeufigsten malignen Tumoren des Skeletts . Fuer die Diagnostik von Skelettmetastasen stehen mehrere bildgebende Verfahren zur Verfuegung , welche je nach klinischer Ausgangssituation einzeln oder kombiniert zum Einsatz kommen . Konventionelle Aufnahmen werden gezielt zur Abklaerung auffaelliger Skelettabschnitte eingesetzt . Die Roentgenaufnahmen sind in bezug auf Metastasen nicht sehr sensitiv , koennen aber in vielen Faellen gutartige Veraenderungen als Ursache der Beschwerden nachweisen . Die Skelettszintigraphie eignet sich zum raschen Screening des gesamten Skelettes mit hoher Sensitivitaet , jedoch geringer Spezifitaet . Die Computertomographie ( CT ) und die Magnetresonanztomographie sind weiterfuehrende Verfahren , die sich insbesondere in der Wirbelsaeulendiagnostik als unverzichtbar erwiesen haben . Mit der CT sind darueber hinaus perkutane Biopsien einfach und sicher durchfuehrbar . Die MRT ist allen Verfahren an Sensitivitaet ueberlegen . Sie bietet darueber hinaus den Vorteil der beliebigen Schichtorientierung im Raum und der guten Darstellung der umgebenden Weichteile . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Metastasen sind die haeufigsten malignen Tumoren des Skeletts . Fuer die Diagnostik von Skelettmetastasen stehen mehrere bildgebende Verfahren zur Verfuegung , welche je nach klinischer Ausgangssituation einzeln oder kombiniert zum Einsatz kommen . Konventionelle Aufnahmen werden gezielt zur Abklaerung auffaelliger Skelettabschnitte eingesetzt . Die Roentgenaufnahmen sind in bezug auf Metastasen nicht sehr sensitiv , koennen aber in vielen Faellen gutartige Veraenderungen als Ursache der Beschwerden nachweisen . Die Skelettszintigraphie eignet sich zum raschen Screening des gesamten Skelettes mit hoher Sensitivitaet , jedoch geringer Spezifitaet . Die Computertomographie ( CT ) und die Magnetresonanztomographie sind weiterfuehrende Verfahren , die sich insbesondere in der Wirbelsaeulendiagnostik als unverzichtbar erwiesen haben . Mit der CT sind darueber hinaus perkutane Biopsien einfach und sicher durchfuehrbar . Die MRT ist allen Verfahren an Sensitivitaet ueberlegen . Sie bietet darueber hinaus den Vorteil der beliebigen Schichtorientierung im Raum und der guten Darstellung der umgebenden Weichteile .
[ "Metastasen", "sind", "die", "haeufigsten", "malignen", "Tumoren", "des", "Skeletts", ".", "Fuer", "die", "Diagnostik", "von", "Skelettmetastasen", "stehen", "mehrere", "bildgebende", "Verfahren", "zur", "Verfuegung", ",", "welche", "je", "nach", "klinischer", "Ausgangssituation", "einzeln", "oder", "kombiniert", "zum", "Einsatz", "kommen", ".", "Konventionelle", "Aufnahmen", "werden", "gezielt", "zur", "Abklaerung", "auffaelliger", "Skelettabschnitte", "eingesetzt", ".", "Die", "Roentgenaufnahmen", "sind", "in", "bezug", "auf", "Metastasen", "nicht", "sehr", "sensitiv", ",", "koennen", "aber", "in", "vielen", "Faellen", "gutartige", "Veraenderungen", "als", "Ursache", "der", "Beschwerden", "nachweisen", ".", "Die", "Skelettszintigraphie", "eignet", "sich", "zum", "raschen", "Screening", "des", "gesamten", "Skelettes", "mit", "hoher", "Sensitivitaet", ",", "jedoch", "geringer", "Spezifitaet", ".", "Die", "Computertomographie", "(", "CT", ")", "und", "die", "Magnetresonanztomographie", "sind", "weiterfuehrende", "Verfahren", ",", "die", "sich", "insbesondere", "in", "der", "Wirbelsaeulendiagnostik", "als", "unverzichtbar", "erwiesen", "haben", ".", "Mit", "der", "CT", "sind", "darueber", "hinaus", "perkutane", "Biopsien", "einfach", "und", "sicher", "durchfuehrbar", ".", "Die", "MRT", "ist", "allen", "Verfahren", "an", "Sensitivitaet", "ueberlegen", ".", "Sie", "bietet", "darueber", "hinaus", "den", "Vorteil", "der", "beliebigen", "Schichtorientierung", "im", "Raum", "und", "der", "guten", "Darstellung", "der", "umgebenden", "Weichteile", "." ]
[ "umlsterm" ]
Age is a Person, ≥ 18 years is a Value, Age is a Person, ≥ 12 years is a Value, bone sarcomas is a Condition, Histologically is a Procedure, confirmed is a Value, unresectable , recurrent , and / or metastatic high grade is a Scope, soft - tissue or bone sarcoma is a Scope, soft tissue sarcomas ( leiomyosarcoma , poorly differentiated / de - differentiated liposarcoma , high grade pleomorphic undifferentiated sarcoma / MFH and synovial sarcoma ) , and bone sarcomas ( Ewing sarcoma , osteosarcoma , and chondrosarcoma [ de - differentiated or mesenchymal ] ) is a Scope, ECOG Performance Status is a Measurement, 0 or 1 is a Value, measurable disease is a Condition, CT / MRI scans is a Scope, Baseline is a Temporal, imaging is a Procedure, within 30 days of dosing is a Temporal, 1 - 3 is a Multiplier, prior is a Temporal, systemic therapies is a Procedure, metastatic setting is a Qualifier, Adequate organ function is a Condition, within 14 days of dosing is a Temporal, men and women of childbearing potential is a Scope, birth control is a Procedure, from providing signed consent is a Temporal, for 120 days after last study drug administration is a Temporal, Women is a Person, childbearing potential is a Condition, pre - menopausal is a Condition, women is a Person, women is a Person, within the first 2 years of the onset of menopause is a Temporal, Women of childbearing potential is a Scope, negative is a Value, pregnancy test is a Measurement, ≤ 72 hours prior to Day 1 is a Temporal, birth control is a Procedure, surgically sterile , barrier device ( condom , diaphragm ) , contraceptive coil , intrauterine device ( IUD ) , and abstinence is a Scope, Life expectancy is a Observation, > 12 weeks is a Value, central nervous system disease is a Condition, radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening , have no evidence of new or enlarging brain metastases , and are off steroids for at least 7 days before first dose of pembrolizumab is a Scope
NCT02301039_inc_task0
Sentence: Age ≥ 18 years (Age ≥ 12 years for patients with bone sarcomas). Histologically confirmed diagnosis of unresectable, recurrent, and/or metastatic high grade soft-tissue or bone sarcoma of one of the following subtypes: soft tissue sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]). ECOG Performance Status of 0 or 1. At least one site of measurable disease on CT/MRI scans as defined by RECIST 1.1. Baseline imaging must be performed within 30 days of dosing. At least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts. Patients may have received 1-3 prior systemic therapies in the metastatic setting. Adequate organ function within 14 days of dosing Must be willing to provide and have available archival tissue for PD-L1 testing. Written, voluntary informed consent. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative pregnancy test ≤ 72 hours prior to Day 1 of study. Effective methods of birth control include: surgically sterile, barrier device (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence. Life expectancy of >12 weeks. Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Observation, Multiplier, Procedure, Scope, Measurement
[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Procedure", "B-Value", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Procedure", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Temporal", "B-Procedure", "I-Procedure", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Person", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "B-Person", "O", "B-Person", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Value", "B-Measurement", "I-Measurement", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "I-Observation", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]
Age ≥ 18 years (Age ≥ 12 years for patients with bone sarcomas). Histologically confirmed diagnosis of unresectable, recurrent, and/or metastatic high grade soft-tissue or bone sarcoma of one of the following subtypes: soft tissue sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]). ECOG Performance Status of 0 or 1. At least one site of measurable disease on CT/MRI scans as defined by RECIST 1.1. Baseline imaging must be performed within 30 days of dosing. At least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts. Patients may have received 1-3 prior systemic therapies in the metastatic setting. Adequate organ function within 14 days of dosing Must be willing to provide and have available archival tissue for PD-L1 testing. Written, voluntary informed consent. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative pregnancy test ≤ 72 hours prior to Day 1 of study. Effective methods of birth control include: surgically sterile, barrier device (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence. Life expectancy of >12 weeks. Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab.
[ "Age", "≥", "18", "years", "(", "Age", "≥", "12", "years", "for", "patients", "with", "bone", "sarcomas", ")", ".", "\n", "Histologically", "confirmed", "diagnosis", "of", "unresectable", ",", "recurrent", ",", "and", "/", "or", "metastatic", "high", "grade", "soft", "-", "tissue", "or", "bone", "sarcoma", "of", "one", "of", "the", "following", "subtypes", ":", "soft", "tissue", "sarcomas", "(", "leiomyosarcoma", ",", "poorly", "differentiated", "/", "de", "-", "differentiated", "liposarcoma", ",", "high", "grade", "pleomorphic", "undifferentiated", "sarcoma", "/", "MFH", "and", "synovial", "sarcoma", ")", ",", "and", "bone", "sarcomas", "(", "Ewing", "sarcoma", ",", "osteosarcoma", ",", "and", "chondrosarcoma", "[", "de", "-", "differentiated", "or", "mesenchymal", "]", ")", ".", "\n", "ECOG", "Performance", "Status", "of", "0", "or", "1", ".", "\n", "At", "least", "one", "site", "of", "measurable", "disease", "on", "CT", "/", "MRI", "scans", "as", "defined", "by", "RECIST", "1.1", ".", "Baseline", "imaging", "must", "be", "performed", "within", "30", "days", "of", "dosing", ".", "\n", "At", "least", "one", "site", "of", "accessible", "disease", "for", "pre-", "and", "post", "-", "treatment", "core", "biopsies", "for", "at", "least", "20", "patients", "per", "arm", "on", "the", "expansion", "cohorts", ".", "\n", "Patients", "may", "have", "received", "1", "-", "3", "prior", "systemic", "therapies", "in", "the", "metastatic", "setting", ".", "\n", "Adequate", "organ", "function", "within", "14", "days", "of", "dosing", "\n", "Must", "be", "willing", "to", "provide", "and", "have", "available", "archival", "tissue", "for", "PD", "-", "L1", "testing", ".", "\n", "Written", ",", "voluntary", "informed", "consent", ".", "\n", "Fertile", "men", "and", "women", "of", "childbearing", "potential", "must", "agree", "to", "use", "an", "effective", "method", "of", "birth", "control", "from", "providing", "signed", "consent", "and", "for", "120", "days", "after", "last", "study", "drug", "administration", ".", "Women", "of", "childbearing", "potential", "include", "pre", "-", "menopausal", "women", "and", "women", "within", "the", "first", "2", "years", "of", "the", "onset", "of", "menopause", ".", "Women", "of", "childbearing", "potential", "must", "have", "a", "negative", "pregnancy", "test", "≤", "72", "hours", "prior", "to", "Day", "1", "of", "study", ".", "\n", "Effective", "methods", "of", "birth", "control", "include", ":", "surgically", "sterile", ",", "barrier", "device", "(", "condom", ",", "diaphragm", ")", ",", "contraceptive", "coil", ",", "intrauterine", "device", "(", "IUD", ")", ",", "and", "abstinence", ".", "\n", "Life", "expectancy", "of", ">", "12", "weeks", ".", "\n", "Patients", "with", "central", "nervous", "system", "disease", "are", "eligible", "for", "enrollment", "if", "they", "have", "received", "prior", "radiotherapy", "or", "surgery", "to", "sites", "of", "CNS", "metastatic", "disease", "and", "are", "without", "evidence", "of", "clinical", "progression", "for", "at", "least", "4", "weeks", "prior", "to", "screening", ",", "have", "no", "evidence", "of", "new", "or", "enlarging", "brain", "metastases", ",", "and", "are", "off", "steroids", "for", "at", "least", "7", "days", "before", "first", "dose", "of", "pembrolizumab", ".", "\n" ]
[ "Scope", "Temporal", "Reference_point", "Condition", "Device", "Measurement", "Qualifier", "Procedure", "Observation", "Drug", "Value", "Negation", "Person", "Multiplier" ]
Age is a Person, ≥ 18 years is a Value, Age is a Person, ≥ 12 years is a Value, bone sarcomas is a Condition, Histologically is a Procedure, confirmed is a Value, unresectable , recurrent , and / or metastatic high grade is a Scope, soft - tissue or bone sarcoma is a Scope, soft tissue sarcomas ( leiomyosarcoma , poorly differentiated / de - differentiated liposarcoma , high grade pleomorphic undifferentiated sarcoma / MFH and synovial sarcoma ) , and bone sarcomas ( Ewing sarcoma , osteosarcoma , and chondrosarcoma [ de - differentiated or mesenchymal ] ) is a Scope, ECOG Performance Status is a Measurement, 0 or 1 is a Value, measurable disease is a Condition, CT / MRI scans is a Scope, Baseline is a Temporal, imaging is a Procedure, within 30 days of dosing is a Temporal, 1 - 3 is a Multiplier, prior is a Temporal, systemic therapies is a Procedure, metastatic setting is a Qualifier, Adequate organ function is a Condition, within 14 days of dosing is a Temporal, men and women of childbearing potential is a Scope, birth control is a Procedure, from providing signed consent is a Temporal, for 120 days after last study drug administration is a Temporal, Women is a Person, childbearing potential is a Condition, pre - menopausal is a Condition, women is a Person, women is a Person, within the first 2 years of the onset of menopause is a Temporal, Women of childbearing potential is a Scope, negative is a Value, pregnancy test is a Measurement, ≤ 72 hours prior to Day 1 is a Temporal, birth control is a Procedure, surgically sterile , barrier device ( condom , diaphragm ) , contraceptive coil , intrauterine device ( IUD ) , and abstinence is a Scope, Life expectancy is a Observation, > 12 weeks is a Value, central nervous system disease is a Condition, radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening , have no evidence of new or enlarging brain metastases , and are off steroids for at least 7 days before first dose of pembrolizumab is a Scope
NCT02301039_inc_task1
Sentence: Age ≥ 18 years (Age ≥ 12 years for patients with bone sarcomas). Histologically confirmed diagnosis of unresectable, recurrent, and/or metastatic high grade soft-tissue or bone sarcoma of one of the following subtypes: soft tissue sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]). ECOG Performance Status of 0 or 1. At least one site of measurable disease on CT/MRI scans as defined by RECIST 1.1. Baseline imaging must be performed within 30 days of dosing. At least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts. Patients may have received 1-3 prior systemic therapies in the metastatic setting. Adequate organ function within 14 days of dosing Must be willing to provide and have available archival tissue for PD-L1 testing. Written, voluntary informed consent. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative pregnancy test ≤ 72 hours prior to Day 1 of study. Effective methods of birth control include: surgically sterile, barrier device (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence. Life expectancy of >12 weeks. Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab. Instructions: please typing these entity words according to sentence: Age, ≥ 18 years, Age, ≥ 12 years, bone sarcomas, Histologically, confirmed, unresectable , recurrent , and / or metastatic high grade, soft - tissue or bone sarcoma, soft tissue sarcomas ( leiomyosarcoma , poorly differentiated / de - differentiated liposarcoma , high grade pleomorphic undifferentiated sarcoma / MFH and synovial sarcoma ) , and bone sarcomas ( Ewing sarcoma , osteosarcoma , and chondrosarcoma [ de - differentiated or mesenchymal ] ), ECOG Performance Status, 0 or 1, measurable disease, CT / MRI scans, Baseline, imaging, within 30 days of dosing, 1 - 3, prior, systemic therapies, metastatic setting, Adequate organ function, within 14 days of dosing, men and women of childbearing potential, birth control, from providing signed consent, for 120 days after last study drug administration, Women, childbearing potential, pre - menopausal, women, women, within the first 2 years of the onset of menopause, Women of childbearing potential, negative, pregnancy test, ≤ 72 hours prior to Day 1, birth control, surgically sterile , barrier device ( condom , diaphragm ) , contraceptive coil , intrauterine device ( IUD ) , and abstinence, Life expectancy, > 12 weeks, central nervous system disease, radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening , have no evidence of new or enlarging brain metastases , and are off steroids for at least 7 days before first dose of pembrolizumab Options: Temporal, Condition, Qualifier, Value, Person, Observation, Multiplier, Procedure, Scope, Measurement
[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Procedure", "B-Value", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Procedure", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Temporal", "B-Procedure", "I-Procedure", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Person", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "B-Person", "O", "B-Person", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Value", "B-Measurement", "I-Measurement", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "I-Observation", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]
Age ≥ 18 years (Age ≥ 12 years for patients with bone sarcomas). Histologically confirmed diagnosis of unresectable, recurrent, and/or metastatic high grade soft-tissue or bone sarcoma of one of the following subtypes: soft tissue sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]). ECOG Performance Status of 0 or 1. At least one site of measurable disease on CT/MRI scans as defined by RECIST 1.1. Baseline imaging must be performed within 30 days of dosing. At least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts. Patients may have received 1-3 prior systemic therapies in the metastatic setting. Adequate organ function within 14 days of dosing Must be willing to provide and have available archival tissue for PD-L1 testing. Written, voluntary informed consent. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative pregnancy test ≤ 72 hours prior to Day 1 of study. Effective methods of birth control include: surgically sterile, barrier device (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence. Life expectancy of >12 weeks. Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab.
[ "Age", "≥", "18", "years", "(", "Age", "≥", "12", "years", "for", "patients", "with", "bone", "sarcomas", ")", ".", "\n", "Histologically", "confirmed", "diagnosis", "of", "unresectable", ",", "recurrent", ",", "and", "/", "or", "metastatic", "high", "grade", "soft", "-", "tissue", "or", "bone", "sarcoma", "of", "one", "of", "the", "following", "subtypes", ":", "soft", "tissue", "sarcomas", "(", "leiomyosarcoma", ",", "poorly", "differentiated", "/", "de", "-", "differentiated", "liposarcoma", ",", "high", "grade", "pleomorphic", "undifferentiated", "sarcoma", "/", "MFH", "and", "synovial", "sarcoma", ")", ",", "and", "bone", "sarcomas", "(", "Ewing", "sarcoma", ",", "osteosarcoma", ",", "and", "chondrosarcoma", "[", "de", "-", "differentiated", "or", "mesenchymal", "]", ")", ".", "\n", "ECOG", "Performance", "Status", "of", "0", "or", "1", ".", "\n", "At", "least", "one", "site", "of", "measurable", "disease", "on", "CT", "/", "MRI", "scans", "as", "defined", "by", "RECIST", "1.1", ".", "Baseline", "imaging", "must", "be", "performed", "within", "30", "days", "of", "dosing", ".", "\n", "At", "least", "one", "site", "of", "accessible", "disease", "for", "pre-", "and", "post", "-", "treatment", "core", "biopsies", "for", "at", "least", "20", "patients", "per", "arm", "on", "the", "expansion", "cohorts", ".", "\n", "Patients", "may", "have", "received", "1", "-", "3", "prior", "systemic", "therapies", "in", "the", "metastatic", "setting", ".", "\n", "Adequate", "organ", "function", "within", "14", "days", "of", "dosing", "\n", "Must", "be", "willing", "to", "provide", "and", "have", "available", "archival", "tissue", "for", "PD", "-", "L1", "testing", ".", "\n", "Written", ",", "voluntary", "informed", "consent", ".", "\n", "Fertile", "men", "and", "women", "of", "childbearing", "potential", "must", "agree", "to", "use", "an", "effective", "method", "of", "birth", "control", "from", "providing", "signed", "consent", "and", "for", "120", "days", "after", "last", "study", "drug", "administration", ".", "Women", "of", "childbearing", "potential", "include", "pre", "-", "menopausal", "women", "and", "women", "within", "the", "first", "2", "years", "of", "the", "onset", "of", "menopause", ".", "Women", "of", "childbearing", "potential", "must", "have", "a", "negative", "pregnancy", "test", "≤", "72", "hours", "prior", "to", "Day", "1", "of", "study", ".", "\n", "Effective", "methods", "of", "birth", "control", "include", ":", "surgically", "sterile", ",", "barrier", "device", "(", "condom", ",", "diaphragm", ")", ",", "contraceptive", "coil", ",", "intrauterine", "device", "(", "IUD", ")", ",", "and", "abstinence", ".", "\n", "Life", "expectancy", "of", ">", "12", "weeks", ".", "\n", "Patients", "with", "central", "nervous", "system", "disease", "are", "eligible", "for", "enrollment", "if", "they", "have", "received", "prior", "radiotherapy", "or", "surgery", "to", "sites", "of", "CNS", "metastatic", "disease", "and", "are", "without", "evidence", "of", "clinical", "progression", "for", "at", "least", "4", "weeks", "prior", "to", "screening", ",", "have", "no", "evidence", "of", "new", "or", "enlarging", "brain", "metastases", ",", "and", "are", "off", "steroids", "for", "at", "least", "7", "days", "before", "first", "dose", "of", "pembrolizumab", ".", "\n" ]
[ "Scope", "Temporal", "Reference_point", "Condition", "Device", "Measurement", "Qualifier", "Procedure", "Observation", "Drug", "Value", "Negation", "Person", "Multiplier" ]
Age, ≥ 18 years, Age, ≥ 12 years, bone sarcomas, Histologically, confirmed, unresectable , recurrent , and / or metastatic high grade, soft - tissue or bone sarcoma, soft tissue sarcomas ( leiomyosarcoma , poorly differentiated / de - differentiated liposarcoma , high grade pleomorphic undifferentiated sarcoma / MFH and synovial sarcoma ) , and bone sarcomas ( Ewing sarcoma , osteosarcoma , and chondrosarcoma [ de - differentiated or mesenchymal ] ), ECOG Performance Status, 0 or 1, measurable disease, CT / MRI scans, Baseline, imaging, within 30 days of dosing, 1 - 3, prior, systemic therapies, metastatic setting, Adequate organ function, within 14 days of dosing, men and women of childbearing potential, birth control, from providing signed consent, for 120 days after last study drug administration, Women, childbearing potential, pre - menopausal, women, women, within the first 2 years of the onset of menopause, Women of childbearing potential, negative, pregnancy test, ≤ 72 hours prior to Day 1, birth control, surgically sterile , barrier device ( condom , diaphragm ) , contraceptive coil , intrauterine device ( IUD ) , and abstinence, Life expectancy, > 12 weeks, central nervous system disease, radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening , have no evidence of new or enlarging brain metastases , and are off steroids for at least 7 days before first dose of pembrolizumab
NCT02301039_inc_task2
Sentence: Age ≥ 18 years (Age ≥ 12 years for patients with bone sarcomas). Histologically confirmed diagnosis of unresectable, recurrent, and/or metastatic high grade soft-tissue or bone sarcoma of one of the following subtypes: soft tissue sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]). ECOG Performance Status of 0 or 1. At least one site of measurable disease on CT/MRI scans as defined by RECIST 1.1. Baseline imaging must be performed within 30 days of dosing. At least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts. Patients may have received 1-3 prior systemic therapies in the metastatic setting. Adequate organ function within 14 days of dosing Must be willing to provide and have available archival tissue for PD-L1 testing. Written, voluntary informed consent. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative pregnancy test ≤ 72 hours prior to Day 1 of study. Effective methods of birth control include: surgically sterile, barrier device (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence. Life expectancy of >12 weeks. Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab. Instructions: please extract entity words from the input sentence
[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Procedure", "B-Value", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Temporal", "B-Procedure", "O", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "B-Temporal", "B-Procedure", "I-Procedure", "O", "O", "B-Qualifier", "I-Qualifier", "O", "O", "B-Condition", "I-Condition", "I-Condition", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Person", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "B-Person", "O", "B-Person", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Value", "B-Measurement", "I-Measurement", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Observation", "I-Observation", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]
Age ≥ 18 years (Age ≥ 12 years for patients with bone sarcomas). Histologically confirmed diagnosis of unresectable, recurrent, and/or metastatic high grade soft-tissue or bone sarcoma of one of the following subtypes: soft tissue sarcomas (leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH and synovial sarcoma), and bone sarcomas (Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]). ECOG Performance Status of 0 or 1. At least one site of measurable disease on CT/MRI scans as defined by RECIST 1.1. Baseline imaging must be performed within 30 days of dosing. At least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts. Patients may have received 1-3 prior systemic therapies in the metastatic setting. Adequate organ function within 14 days of dosing Must be willing to provide and have available archival tissue for PD-L1 testing. Written, voluntary informed consent. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative pregnancy test ≤ 72 hours prior to Day 1 of study. Effective methods of birth control include: surgically sterile, barrier device (condom, diaphragm), contraceptive coil, intrauterine device (IUD), and abstinence. Life expectancy of >12 weeks. Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least 4 weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least 7 days before first dose of pembrolizumab.
[ "Age", "≥", "18", "years", "(", "Age", "≥", "12", "years", "for", "patients", "with", "bone", "sarcomas", ")", ".", "\n", "Histologically", "confirmed", "diagnosis", "of", "unresectable", ",", "recurrent", ",", "and", "/", "or", "metastatic", "high", "grade", "soft", "-", "tissue", "or", "bone", "sarcoma", "of", "one", "of", "the", "following", "subtypes", ":", "soft", "tissue", "sarcomas", "(", "leiomyosarcoma", ",", "poorly", "differentiated", "/", "de", "-", "differentiated", "liposarcoma", ",", "high", "grade", "pleomorphic", "undifferentiated", "sarcoma", "/", "MFH", "and", "synovial", "sarcoma", ")", ",", "and", "bone", "sarcomas", "(", "Ewing", "sarcoma", ",", "osteosarcoma", ",", "and", "chondrosarcoma", "[", "de", "-", "differentiated", "or", "mesenchymal", "]", ")", ".", "\n", "ECOG", "Performance", "Status", "of", "0", "or", "1", ".", "\n", "At", "least", "one", "site", "of", "measurable", "disease", "on", "CT", "/", "MRI", "scans", "as", "defined", "by", "RECIST", "1.1", ".", "Baseline", "imaging", "must", "be", "performed", "within", "30", "days", "of", "dosing", ".", "\n", "At", "least", "one", "site", "of", "accessible", "disease", "for", "pre-", "and", "post", "-", "treatment", "core", "biopsies", "for", "at", "least", "20", "patients", "per", "arm", "on", "the", "expansion", "cohorts", ".", "\n", "Patients", "may", "have", "received", "1", "-", "3", "prior", "systemic", "therapies", "in", "the", "metastatic", "setting", ".", "\n", "Adequate", "organ", "function", "within", "14", "days", "of", "dosing", "\n", "Must", "be", "willing", "to", "provide", "and", "have", "available", "archival", "tissue", "for", "PD", "-", "L1", "testing", ".", "\n", "Written", ",", "voluntary", "informed", "consent", ".", "\n", "Fertile", "men", "and", "women", "of", "childbearing", "potential", "must", "agree", "to", "use", "an", "effective", "method", "of", "birth", "control", "from", "providing", "signed", "consent", "and", "for", "120", "days", "after", "last", "study", "drug", "administration", ".", "Women", "of", "childbearing", "potential", "include", "pre", "-", "menopausal", "women", "and", "women", "within", "the", "first", "2", "years", "of", "the", "onset", "of", "menopause", ".", "Women", "of", "childbearing", "potential", "must", "have", "a", "negative", "pregnancy", "test", "≤", "72", "hours", "prior", "to", "Day", "1", "of", "study", ".", "\n", "Effective", "methods", "of", "birth", "control", "include", ":", "surgically", "sterile", ",", "barrier", "device", "(", "condom", ",", "diaphragm", ")", ",", "contraceptive", "coil", ",", "intrauterine", "device", "(", "IUD", ")", ",", "and", "abstinence", ".", "\n", "Life", "expectancy", "of", ">", "12", "weeks", ".", "\n", "Patients", "with", "central", "nervous", "system", "disease", "are", "eligible", "for", "enrollment", "if", "they", "have", "received", "prior", "radiotherapy", "or", "surgery", "to", "sites", "of", "CNS", "metastatic", "disease", "and", "are", "without", "evidence", "of", "clinical", "progression", "for", "at", "least", "4", "weeks", "prior", "to", "screening", ",", "have", "no", "evidence", "of", "new", "or", "enlarging", "brain", "metastases", ",", "and", "are", "off", "steroids", "for", "at", "least", "7", "days", "before", "first", "dose", "of", "pembrolizumab", ".", "\n" ]
[ "Scope", "Temporal", "Reference_point", "Condition", "Device", "Measurement", "Qualifier", "Procedure", "Observation", "Drug", "Value", "Negation", "Person", "Multiplier" ]
Methode is an umlsterm, Kontrastmittel is an umlsterm, Kontrastmittel is an umlsterm, artefaktfrei is an umlsterm, Patienten is an umlsterm, Hals- is an umlsterm, Beurteilung is an umlsterm, Hals- is an umlsterm
DerRadiologe.70370089.ger.abstr_task0
Sentence: Es wurde eine Methode zur ueberlagerungsfreien Darstellung von Gefaessen mittels der CT-Angiographie ( CTA ) entwickelt und erprobt . Dazu wurde ein automatisierter , sog . " elastischer " digitaler Subtraktionsalgorithmus entwickelt , der es ermoeglicht , einen Spiral-CT-Datensatz ohne Kontrastmittel von einem solchen mit Kontrastmittel artefaktfrei zu subtrahieren . Der elastische " Subtraktionsalgorithmus " korrigiert stochastische transmissionsbedingte und durch Bewegung verursachte Inkongruenzen , zwischen den beiden zu subtrahierenden Datensaetzen und ist somit der einfachen digitalen Subtraktion ueberlegen . Bisher wurde die CT-Subtraktionsangiographie ( CTSA ) an 7 Patienten im Bereich der Hals- und intrakraniellen Gefaesse erprobt . Der elastische " Subtraktionsalgorithmus " war bei der Beurteilung von Bildqualitaet und -artefakten in allen Faellen und statistisch signifikant besser als die einfache digitale Subtraktion . Die elastische " CTSA " ermoeglicht eine automatisierte Trennung von ossaeren Strukturen und Gefaessen und erleichtert somit die ueberlagerungsfreie , raeumliche und selektive Darstellung der Hals- und intrakraniellen Gefaesse . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Es wurde eine Methode zur ueberlagerungsfreien Darstellung von Gefaessen mittels der CT-Angiographie ( CTA ) entwickelt und erprobt . Dazu wurde ein automatisierter , sog . " elastischer " digitaler Subtraktionsalgorithmus entwickelt , der es ermoeglicht , einen Spiral-CT-Datensatz ohne Kontrastmittel von einem solchen mit Kontrastmittel artefaktfrei zu subtrahieren . Der elastische " Subtraktionsalgorithmus " korrigiert stochastische transmissionsbedingte und durch Bewegung verursachte Inkongruenzen , zwischen den beiden zu subtrahierenden Datensaetzen und ist somit der einfachen digitalen Subtraktion ueberlegen . Bisher wurde die CT-Subtraktionsangiographie ( CTSA ) an 7 Patienten im Bereich der Hals- und intrakraniellen Gefaesse erprobt . Der elastische " Subtraktionsalgorithmus " war bei der Beurteilung von Bildqualitaet und -artefakten in allen Faellen und statistisch signifikant besser als die einfache digitale Subtraktion . Die elastische " CTSA " ermoeglicht eine automatisierte Trennung von ossaeren Strukturen und Gefaessen und erleichtert somit die ueberlagerungsfreie , raeumliche und selektive Darstellung der Hals- und intrakraniellen Gefaesse .
[ "Es", "wurde", "eine", "Methode", "zur", "ueberlagerungsfreien", "Darstellung", "von", "Gefaessen", "mittels", "der", "CT", "-", "Angiographie", "(", "CTA", ")", "entwickelt", "und", "erprobt", ".", "Dazu", "wurde", "ein", "automatisierter", ",", "sog", ".", "\"", "elastischer", "\"", "digitaler", "Subtraktionsalgorithmus", "entwickelt", ",", "der", "es", "ermoeglicht", ",", "einen", "Spiral", "-", "CT", "-", "Datensatz", "ohne", "Kontrastmittel", "von", "einem", "solchen", "mit", "Kontrastmittel", "artefaktfrei", "zu", "subtrahieren", ".", "Der", "elastische", "\"", "Subtraktionsalgorithmus", "\"", "korrigiert", "stochastische", "transmissionsbedingte", "und", "durch", "Bewegung", "verursachte", "Inkongruenzen", ",", "zwischen", "den", "beiden", "zu", "subtrahierenden", "Datensaetzen", "und", "ist", "somit", "der", "einfachen", "digitalen", "Subtraktion", "ueberlegen", ".", "Bisher", "wurde", "die", "CT", "-", "Subtraktionsangiographie", "(", "CTSA", ")", "an", "7", "Patienten", "im", "Bereich", "der", "Hals-", "und", "intrakraniellen", "Gefaesse", "erprobt", ".", "Der", "elastische", "\"", "Subtraktionsalgorithmus", "\"", "war", "bei", "der", "Beurteilung", "von", "Bildqualitaet", "und", "-artefakten", "in", "allen", "Faellen", "und", "statistisch", "signifikant", "besser", "als", "die", "einfache", "digitale", "Subtraktion", ".", "Die", "elastische", "\"", "CTSA", "\"", "ermoeglicht", "eine", "automatisierte", "Trennung", "von", "ossaeren", "Strukturen", "und", "Gefaessen", "und", "erleichtert", "somit", "die", "ueberlagerungsfreie", ",", "raeumliche", "und", "selektive", "Darstellung", "der", "Hals-", "und", "intrakraniellen", "Gefaesse", "." ]
[ "umlsterm" ]
Methode is an umlsterm, Kontrastmittel is an umlsterm, Kontrastmittel is an umlsterm, artefaktfrei is an umlsterm, Patienten is an umlsterm, Hals- is an umlsterm, Beurteilung is an umlsterm, Hals- is an umlsterm
DerRadiologe.70370089.ger.abstr_task1
Sentence: Es wurde eine Methode zur ueberlagerungsfreien Darstellung von Gefaessen mittels der CT-Angiographie ( CTA ) entwickelt und erprobt . Dazu wurde ein automatisierter , sog . " elastischer " digitaler Subtraktionsalgorithmus entwickelt , der es ermoeglicht , einen Spiral-CT-Datensatz ohne Kontrastmittel von einem solchen mit Kontrastmittel artefaktfrei zu subtrahieren . Der elastische " Subtraktionsalgorithmus " korrigiert stochastische transmissionsbedingte und durch Bewegung verursachte Inkongruenzen , zwischen den beiden zu subtrahierenden Datensaetzen und ist somit der einfachen digitalen Subtraktion ueberlegen . Bisher wurde die CT-Subtraktionsangiographie ( CTSA ) an 7 Patienten im Bereich der Hals- und intrakraniellen Gefaesse erprobt . Der elastische " Subtraktionsalgorithmus " war bei der Beurteilung von Bildqualitaet und -artefakten in allen Faellen und statistisch signifikant besser als die einfache digitale Subtraktion . Die elastische " CTSA " ermoeglicht eine automatisierte Trennung von ossaeren Strukturen und Gefaessen und erleichtert somit die ueberlagerungsfreie , raeumliche und selektive Darstellung der Hals- und intrakraniellen Gefaesse . Instructions: please typing these entity words according to sentence: Methode, Kontrastmittel, Kontrastmittel, artefaktfrei, Patienten, Hals-, Beurteilung, Hals- Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Es wurde eine Methode zur ueberlagerungsfreien Darstellung von Gefaessen mittels der CT-Angiographie ( CTA ) entwickelt und erprobt . Dazu wurde ein automatisierter , sog . " elastischer " digitaler Subtraktionsalgorithmus entwickelt , der es ermoeglicht , einen Spiral-CT-Datensatz ohne Kontrastmittel von einem solchen mit Kontrastmittel artefaktfrei zu subtrahieren . Der elastische " Subtraktionsalgorithmus " korrigiert stochastische transmissionsbedingte und durch Bewegung verursachte Inkongruenzen , zwischen den beiden zu subtrahierenden Datensaetzen und ist somit der einfachen digitalen Subtraktion ueberlegen . Bisher wurde die CT-Subtraktionsangiographie ( CTSA ) an 7 Patienten im Bereich der Hals- und intrakraniellen Gefaesse erprobt . Der elastische " Subtraktionsalgorithmus " war bei der Beurteilung von Bildqualitaet und -artefakten in allen Faellen und statistisch signifikant besser als die einfache digitale Subtraktion . Die elastische " CTSA " ermoeglicht eine automatisierte Trennung von ossaeren Strukturen und Gefaessen und erleichtert somit die ueberlagerungsfreie , raeumliche und selektive Darstellung der Hals- und intrakraniellen Gefaesse .
[ "Es", "wurde", "eine", "Methode", "zur", "ueberlagerungsfreien", "Darstellung", "von", "Gefaessen", "mittels", "der", "CT", "-", "Angiographie", "(", "CTA", ")", "entwickelt", "und", "erprobt", ".", "Dazu", "wurde", "ein", "automatisierter", ",", "sog", ".", "\"", "elastischer", "\"", "digitaler", "Subtraktionsalgorithmus", "entwickelt", ",", "der", "es", "ermoeglicht", ",", "einen", "Spiral", "-", "CT", "-", "Datensatz", "ohne", "Kontrastmittel", "von", "einem", "solchen", "mit", "Kontrastmittel", "artefaktfrei", "zu", "subtrahieren", ".", "Der", "elastische", "\"", "Subtraktionsalgorithmus", "\"", "korrigiert", "stochastische", "transmissionsbedingte", "und", "durch", "Bewegung", "verursachte", "Inkongruenzen", ",", "zwischen", "den", "beiden", "zu", "subtrahierenden", "Datensaetzen", "und", "ist", "somit", "der", "einfachen", "digitalen", "Subtraktion", "ueberlegen", ".", "Bisher", "wurde", "die", "CT", "-", "Subtraktionsangiographie", "(", "CTSA", ")", "an", "7", "Patienten", "im", "Bereich", "der", "Hals-", "und", "intrakraniellen", "Gefaesse", "erprobt", ".", "Der", "elastische", "\"", "Subtraktionsalgorithmus", "\"", "war", "bei", "der", "Beurteilung", "von", "Bildqualitaet", "und", "-artefakten", "in", "allen", "Faellen", "und", "statistisch", "signifikant", "besser", "als", "die", "einfache", "digitale", "Subtraktion", ".", "Die", "elastische", "\"", "CTSA", "\"", "ermoeglicht", "eine", "automatisierte", "Trennung", "von", "ossaeren", "Strukturen", "und", "Gefaessen", "und", "erleichtert", "somit", "die", "ueberlagerungsfreie", ",", "raeumliche", "und", "selektive", "Darstellung", "der", "Hals-", "und", "intrakraniellen", "Gefaesse", "." ]
[ "umlsterm" ]
Methode, Kontrastmittel, Kontrastmittel, artefaktfrei, Patienten, Hals-, Beurteilung, Hals-
DerRadiologe.70370089.ger.abstr_task2
Sentence: Es wurde eine Methode zur ueberlagerungsfreien Darstellung von Gefaessen mittels der CT-Angiographie ( CTA ) entwickelt und erprobt . Dazu wurde ein automatisierter , sog . " elastischer " digitaler Subtraktionsalgorithmus entwickelt , der es ermoeglicht , einen Spiral-CT-Datensatz ohne Kontrastmittel von einem solchen mit Kontrastmittel artefaktfrei zu subtrahieren . Der elastische " Subtraktionsalgorithmus " korrigiert stochastische transmissionsbedingte und durch Bewegung verursachte Inkongruenzen , zwischen den beiden zu subtrahierenden Datensaetzen und ist somit der einfachen digitalen Subtraktion ueberlegen . Bisher wurde die CT-Subtraktionsangiographie ( CTSA ) an 7 Patienten im Bereich der Hals- und intrakraniellen Gefaesse erprobt . Der elastische " Subtraktionsalgorithmus " war bei der Beurteilung von Bildqualitaet und -artefakten in allen Faellen und statistisch signifikant besser als die einfache digitale Subtraktion . Die elastische " CTSA " ermoeglicht eine automatisierte Trennung von ossaeren Strukturen und Gefaessen und erleichtert somit die ueberlagerungsfreie , raeumliche und selektive Darstellung der Hals- und intrakraniellen Gefaesse . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Es wurde eine Methode zur ueberlagerungsfreien Darstellung von Gefaessen mittels der CT-Angiographie ( CTA ) entwickelt und erprobt . Dazu wurde ein automatisierter , sog . " elastischer " digitaler Subtraktionsalgorithmus entwickelt , der es ermoeglicht , einen Spiral-CT-Datensatz ohne Kontrastmittel von einem solchen mit Kontrastmittel artefaktfrei zu subtrahieren . Der elastische " Subtraktionsalgorithmus " korrigiert stochastische transmissionsbedingte und durch Bewegung verursachte Inkongruenzen , zwischen den beiden zu subtrahierenden Datensaetzen und ist somit der einfachen digitalen Subtraktion ueberlegen . Bisher wurde die CT-Subtraktionsangiographie ( CTSA ) an 7 Patienten im Bereich der Hals- und intrakraniellen Gefaesse erprobt . Der elastische " Subtraktionsalgorithmus " war bei der Beurteilung von Bildqualitaet und -artefakten in allen Faellen und statistisch signifikant besser als die einfache digitale Subtraktion . Die elastische " CTSA " ermoeglicht eine automatisierte Trennung von ossaeren Strukturen und Gefaessen und erleichtert somit die ueberlagerungsfreie , raeumliche und selektive Darstellung der Hals- und intrakraniellen Gefaesse .
[ "Es", "wurde", "eine", "Methode", "zur", "ueberlagerungsfreien", "Darstellung", "von", "Gefaessen", "mittels", "der", "CT", "-", "Angiographie", "(", "CTA", ")", "entwickelt", "und", "erprobt", ".", "Dazu", "wurde", "ein", "automatisierter", ",", "sog", ".", "\"", "elastischer", "\"", "digitaler", "Subtraktionsalgorithmus", "entwickelt", ",", "der", "es", "ermoeglicht", ",", "einen", "Spiral", "-", "CT", "-", "Datensatz", "ohne", "Kontrastmittel", "von", "einem", "solchen", "mit", "Kontrastmittel", "artefaktfrei", "zu", "subtrahieren", ".", "Der", "elastische", "\"", "Subtraktionsalgorithmus", "\"", "korrigiert", "stochastische", "transmissionsbedingte", "und", "durch", "Bewegung", "verursachte", "Inkongruenzen", ",", "zwischen", "den", "beiden", "zu", "subtrahierenden", "Datensaetzen", "und", "ist", "somit", "der", "einfachen", "digitalen", "Subtraktion", "ueberlegen", ".", "Bisher", "wurde", "die", "CT", "-", "Subtraktionsangiographie", "(", "CTSA", ")", "an", "7", "Patienten", "im", "Bereich", "der", "Hals-", "und", "intrakraniellen", "Gefaesse", "erprobt", ".", "Der", "elastische", "\"", "Subtraktionsalgorithmus", "\"", "war", "bei", "der", "Beurteilung", "von", "Bildqualitaet", "und", "-artefakten", "in", "allen", "Faellen", "und", "statistisch", "signifikant", "besser", "als", "die", "einfache", "digitale", "Subtraktion", ".", "Die", "elastische", "\"", "CTSA", "\"", "ermoeglicht", "eine", "automatisierte", "Trennung", "von", "ossaeren", "Strukturen", "und", "Gefaessen", "und", "erleichtert", "somit", "die", "ueberlagerungsfreie", ",", "raeumliche", "und", "selektive", "Darstellung", "der", "Hals-", "und", "intrakraniellen", "Gefaesse", "." ]
[ "umlsterm" ]
Patienten is an umlsterm, Haemangiom is an umlsterm, Literatur is an umlsterm, Arterie is an umlsterm, Tumorresektion is an umlsterm, Patient is an umlsterm, Lokalrezidiv is an umlsterm
DerChirurg.90701494.ger.abstr_task0
Sentence: Zusammenfassung . Wir berichten ueber einen 37 jaehrigen Patienten mit einem epitheloiden Haemangiom des dritten Segmentes der A. poplitea sowie des T. tibiofibularis . Bisher wurde nach unseren Recherchen in der Literatur kein primaerer Befall einer Arterie dieser Groessenordnung beschrieben . Nach Tumorresektion und gefaesschirurgischer Rekonstruktion ist der Patient 1 Jahr postoperativ beschwerdefrei ohne Hinweis auf ein Lokalrezidiv . Im Rahmen dieses Artikels wird auf die klinischen und morphologischen Charakteristika dieser seltenen Erkrankung naeher eingegangen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Wir berichten ueber einen 37 jaehrigen Patienten mit einem epitheloiden Haemangiom des dritten Segmentes der A. poplitea sowie des T. tibiofibularis . Bisher wurde nach unseren Recherchen in der Literatur kein primaerer Befall einer Arterie dieser Groessenordnung beschrieben . Nach Tumorresektion und gefaesschirurgischer Rekonstruktion ist der Patient 1 Jahr postoperativ beschwerdefrei ohne Hinweis auf ein Lokalrezidiv . Im Rahmen dieses Artikels wird auf die klinischen und morphologischen Charakteristika dieser seltenen Erkrankung naeher eingegangen .
[ "Zusammenfassung", ".", "Wir", "berichten", "ueber", "einen", "37", "jaehrigen", "Patienten", "mit", "einem", "epitheloiden", "Haemangiom", "des", "dritten", "Segmentes", "der", "A.", "poplitea", "sowie", "des", "T.", "tibiofibularis", ".", "Bisher", "wurde", "nach", "unseren", "Recherchen", "in", "der", "Literatur", "kein", "primaerer", "Befall", "einer", "Arterie", "dieser", "Groessenordnung", "beschrieben", ".", "Nach", "Tumorresektion", "und", "gefaesschirurgischer", "Rekonstruktion", "ist", "der", "Patient", "1", "Jahr", "postoperativ", "beschwerdefrei", "ohne", "Hinweis", "auf", "ein", "Lokalrezidiv", ".", "Im", "Rahmen", "dieses", "Artikels", "wird", "auf", "die", "klinischen", "und", "morphologischen", "Charakteristika", "dieser", "seltenen", "Erkrankung", "naeher", "eingegangen", "." ]
[ "umlsterm" ]
Patienten is an umlsterm, Haemangiom is an umlsterm, Literatur is an umlsterm, Arterie is an umlsterm, Tumorresektion is an umlsterm, Patient is an umlsterm, Lokalrezidiv is an umlsterm
DerChirurg.90701494.ger.abstr_task1
Sentence: Zusammenfassung . Wir berichten ueber einen 37 jaehrigen Patienten mit einem epitheloiden Haemangiom des dritten Segmentes der A. poplitea sowie des T. tibiofibularis . Bisher wurde nach unseren Recherchen in der Literatur kein primaerer Befall einer Arterie dieser Groessenordnung beschrieben . Nach Tumorresektion und gefaesschirurgischer Rekonstruktion ist der Patient 1 Jahr postoperativ beschwerdefrei ohne Hinweis auf ein Lokalrezidiv . Im Rahmen dieses Artikels wird auf die klinischen und morphologischen Charakteristika dieser seltenen Erkrankung naeher eingegangen . Instructions: please typing these entity words according to sentence: Patienten, Haemangiom, Literatur, Arterie, Tumorresektion, Patient, Lokalrezidiv Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Wir berichten ueber einen 37 jaehrigen Patienten mit einem epitheloiden Haemangiom des dritten Segmentes der A. poplitea sowie des T. tibiofibularis . Bisher wurde nach unseren Recherchen in der Literatur kein primaerer Befall einer Arterie dieser Groessenordnung beschrieben . Nach Tumorresektion und gefaesschirurgischer Rekonstruktion ist der Patient 1 Jahr postoperativ beschwerdefrei ohne Hinweis auf ein Lokalrezidiv . Im Rahmen dieses Artikels wird auf die klinischen und morphologischen Charakteristika dieser seltenen Erkrankung naeher eingegangen .
[ "Zusammenfassung", ".", "Wir", "berichten", "ueber", "einen", "37", "jaehrigen", "Patienten", "mit", "einem", "epitheloiden", "Haemangiom", "des", "dritten", "Segmentes", "der", "A.", "poplitea", "sowie", "des", "T.", "tibiofibularis", ".", "Bisher", "wurde", "nach", "unseren", "Recherchen", "in", "der", "Literatur", "kein", "primaerer", "Befall", "einer", "Arterie", "dieser", "Groessenordnung", "beschrieben", ".", "Nach", "Tumorresektion", "und", "gefaesschirurgischer", "Rekonstruktion", "ist", "der", "Patient", "1", "Jahr", "postoperativ", "beschwerdefrei", "ohne", "Hinweis", "auf", "ein", "Lokalrezidiv", ".", "Im", "Rahmen", "dieses", "Artikels", "wird", "auf", "die", "klinischen", "und", "morphologischen", "Charakteristika", "dieser", "seltenen", "Erkrankung", "naeher", "eingegangen", "." ]
[ "umlsterm" ]
Patienten, Haemangiom, Literatur, Arterie, Tumorresektion, Patient, Lokalrezidiv
DerChirurg.90701494.ger.abstr_task2
Sentence: Zusammenfassung . Wir berichten ueber einen 37 jaehrigen Patienten mit einem epitheloiden Haemangiom des dritten Segmentes der A. poplitea sowie des T. tibiofibularis . Bisher wurde nach unseren Recherchen in der Literatur kein primaerer Befall einer Arterie dieser Groessenordnung beschrieben . Nach Tumorresektion und gefaesschirurgischer Rekonstruktion ist der Patient 1 Jahr postoperativ beschwerdefrei ohne Hinweis auf ein Lokalrezidiv . Im Rahmen dieses Artikels wird auf die klinischen und morphologischen Charakteristika dieser seltenen Erkrankung naeher eingegangen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Wir berichten ueber einen 37 jaehrigen Patienten mit einem epitheloiden Haemangiom des dritten Segmentes der A. poplitea sowie des T. tibiofibularis . Bisher wurde nach unseren Recherchen in der Literatur kein primaerer Befall einer Arterie dieser Groessenordnung beschrieben . Nach Tumorresektion und gefaesschirurgischer Rekonstruktion ist der Patient 1 Jahr postoperativ beschwerdefrei ohne Hinweis auf ein Lokalrezidiv . Im Rahmen dieses Artikels wird auf die klinischen und morphologischen Charakteristika dieser seltenen Erkrankung naeher eingegangen .
[ "Zusammenfassung", ".", "Wir", "berichten", "ueber", "einen", "37", "jaehrigen", "Patienten", "mit", "einem", "epitheloiden", "Haemangiom", "des", "dritten", "Segmentes", "der", "A.", "poplitea", "sowie", "des", "T.", "tibiofibularis", ".", "Bisher", "wurde", "nach", "unseren", "Recherchen", "in", "der", "Literatur", "kein", "primaerer", "Befall", "einer", "Arterie", "dieser", "Groessenordnung", "beschrieben", ".", "Nach", "Tumorresektion", "und", "gefaesschirurgischer", "Rekonstruktion", "ist", "der", "Patient", "1", "Jahr", "postoperativ", "beschwerdefrei", "ohne", "Hinweis", "auf", "ein", "Lokalrezidiv", ".", "Im", "Rahmen", "dieses", "Artikels", "wird", "auf", "die", "klinischen", "und", "morphologischen", "Charakteristika", "dieser", "seltenen", "Erkrankung", "naeher", "eingegangen", "." ]
[ "umlsterm" ]
Fallbericht is an umlsterm, Dermatose is an umlsterm, Augenbeteiligung is an umlsterm, Kindern is an umlsterm, lichtexponierten is an umlsterm, lichtreichen is an umlsterm, Jahreszeit is an umlsterm, Erwachsenenalter is an umlsterm
MonatsschriftKinderheilkunde.01480895.ger.abstr_task0
Sentence: Fallbericht . Anhand der Kasuistik eines 6-jaehrigen Jungen wird die Hydroa vacciniformis , eine seltene , durch UVA-Exposition ausgeloeste Dermatose mit moeglicher Augenbeteiligung bei Kindern , vorgestellt . In lichtexponierten Bereichen treten zu Beginn der lichtreichen Jahreszeit rezidivierend bis zum Erwachsenenalter akut zahlreiche haemorrhagische Blaeschen auf , die narbig abheilen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Fallbericht . Anhand der Kasuistik eines 6-jaehrigen Jungen wird die Hydroa vacciniformis , eine seltene , durch UVA-Exposition ausgeloeste Dermatose mit moeglicher Augenbeteiligung bei Kindern , vorgestellt . In lichtexponierten Bereichen treten zu Beginn der lichtreichen Jahreszeit rezidivierend bis zum Erwachsenenalter akut zahlreiche haemorrhagische Blaeschen auf , die narbig abheilen .
[ "Fallbericht", ".", "Anhand", "der", "Kasuistik", "eines", "6-jaehrigen", "Jungen", "wird", "die", "Hydroa", "vacciniformis", ",", "eine", "seltene", ",", "durch", "UVA", "-", "Exposition", "ausgeloeste", "Dermatose", "mit", "moeglicher", "Augenbeteiligung", "bei", "Kindern", ",", "vorgestellt", ".", "In", "lichtexponierten", "Bereichen", "treten", "zu", "Beginn", "der", "lichtreichen", "Jahreszeit", "rezidivierend", "bis", "zum", "Erwachsenenalter", "akut", "zahlreiche", "haemorrhagische", "Blaeschen", "auf", ",", "die", "narbig", "abheilen", "." ]
[ "umlsterm" ]
Fallbericht is an umlsterm, Dermatose is an umlsterm, Augenbeteiligung is an umlsterm, Kindern is an umlsterm, lichtexponierten is an umlsterm, lichtreichen is an umlsterm, Jahreszeit is an umlsterm, Erwachsenenalter is an umlsterm
MonatsschriftKinderheilkunde.01480895.ger.abstr_task1
Sentence: Fallbericht . Anhand der Kasuistik eines 6-jaehrigen Jungen wird die Hydroa vacciniformis , eine seltene , durch UVA-Exposition ausgeloeste Dermatose mit moeglicher Augenbeteiligung bei Kindern , vorgestellt . In lichtexponierten Bereichen treten zu Beginn der lichtreichen Jahreszeit rezidivierend bis zum Erwachsenenalter akut zahlreiche haemorrhagische Blaeschen auf , die narbig abheilen . Instructions: please typing these entity words according to sentence: Fallbericht, Dermatose, Augenbeteiligung, Kindern, lichtexponierten, lichtreichen, Jahreszeit, Erwachsenenalter Options: umlsterm
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Fallbericht . Anhand der Kasuistik eines 6-jaehrigen Jungen wird die Hydroa vacciniformis , eine seltene , durch UVA-Exposition ausgeloeste Dermatose mit moeglicher Augenbeteiligung bei Kindern , vorgestellt . In lichtexponierten Bereichen treten zu Beginn der lichtreichen Jahreszeit rezidivierend bis zum Erwachsenenalter akut zahlreiche haemorrhagische Blaeschen auf , die narbig abheilen .
[ "Fallbericht", ".", "Anhand", "der", "Kasuistik", "eines", "6-jaehrigen", "Jungen", "wird", "die", "Hydroa", "vacciniformis", ",", "eine", "seltene", ",", "durch", "UVA", "-", "Exposition", "ausgeloeste", "Dermatose", "mit", "moeglicher", "Augenbeteiligung", "bei", "Kindern", ",", "vorgestellt", ".", "In", "lichtexponierten", "Bereichen", "treten", "zu", "Beginn", "der", "lichtreichen", "Jahreszeit", "rezidivierend", "bis", "zum", "Erwachsenenalter", "akut", "zahlreiche", "haemorrhagische", "Blaeschen", "auf", ",", "die", "narbig", "abheilen", "." ]
[ "umlsterm" ]
Fallbericht, Dermatose, Augenbeteiligung, Kindern, lichtexponierten, lichtreichen, Jahreszeit, Erwachsenenalter
MonatsschriftKinderheilkunde.01480895.ger.abstr_task2
Sentence: Fallbericht . Anhand der Kasuistik eines 6-jaehrigen Jungen wird die Hydroa vacciniformis , eine seltene , durch UVA-Exposition ausgeloeste Dermatose mit moeglicher Augenbeteiligung bei Kindern , vorgestellt . In lichtexponierten Bereichen treten zu Beginn der lichtreichen Jahreszeit rezidivierend bis zum Erwachsenenalter akut zahlreiche haemorrhagische Blaeschen auf , die narbig abheilen . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Fallbericht . Anhand der Kasuistik eines 6-jaehrigen Jungen wird die Hydroa vacciniformis , eine seltene , durch UVA-Exposition ausgeloeste Dermatose mit moeglicher Augenbeteiligung bei Kindern , vorgestellt . In lichtexponierten Bereichen treten zu Beginn der lichtreichen Jahreszeit rezidivierend bis zum Erwachsenenalter akut zahlreiche haemorrhagische Blaeschen auf , die narbig abheilen .
[ "Fallbericht", ".", "Anhand", "der", "Kasuistik", "eines", "6-jaehrigen", "Jungen", "wird", "die", "Hydroa", "vacciniformis", ",", "eine", "seltene", ",", "durch", "UVA", "-", "Exposition", "ausgeloeste", "Dermatose", "mit", "moeglicher", "Augenbeteiligung", "bei", "Kindern", ",", "vorgestellt", ".", "In", "lichtexponierten", "Bereichen", "treten", "zu", "Beginn", "der", "lichtreichen", "Jahreszeit", "rezidivierend", "bis", "zum", "Erwachsenenalter", "akut", "zahlreiche", "haemorrhagische", "Blaeschen", "auf", ",", "die", "narbig", "abheilen", "." ]
[ "umlsterm" ]
Contraindication to neuraxial is a Scope, coagulopathy is a Condition, anticoagulant is a Drug, local infection is a Condition, sepsis is a Condition
NCT01991743_exc_task0
Sentence: Refusal Contraindication to neuraxial (coagulopathy, anticoagulant use, local infection, sepsis etc) .Rupture of membranes. Drop-out: Patients may choose to drop-out of the study at any time. The physicians involved in this study may choose to end a patient's involvement in the study at their discretion. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Condition, Drug
[ "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Drug", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Refusal Contraindication to neuraxial (coagulopathy, anticoagulant use, local infection, sepsis etc) .Rupture of membranes. Drop-out: Patients may choose to drop-out of the study at any time. The physicians involved in this study may choose to end a patient's involvement in the study at their discretion.
[ "Refusal", "\n", "Contraindication", "to", "neuraxial", "(", "coagulopathy", ",", "anticoagulant", "use", ",", "local", "infection", ",", "sepsis", "etc", ")", ".Rupture", "of", "membranes", ".", "\n", "Drop", "-", "out", ":", "Patients", "may", "choose", "to", "drop", "-", "out", "of", "the", "study", "at", "any", "time", ".", "The", "physicians", "involved", "in", "this", "study", "may", "choose", "to", "end", "a", "patient", "'s", "involvement", "in", "the", "study", "at", "their", "discretion", ".", "\n" ]
[ "Scope", "Condition", "Drug", "Procedure" ]
Contraindication to neuraxial is a Scope, coagulopathy is a Condition, anticoagulant is a Drug, local infection is a Condition, sepsis is a Condition
NCT01991743_exc_task1
Sentence: Refusal Contraindication to neuraxial (coagulopathy, anticoagulant use, local infection, sepsis etc) .Rupture of membranes. Drop-out: Patients may choose to drop-out of the study at any time. The physicians involved in this study may choose to end a patient's involvement in the study at their discretion. Instructions: please typing these entity words according to sentence: Contraindication to neuraxial, coagulopathy, anticoagulant, local infection, sepsis Options: Scope, Condition, Drug
[ "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Drug", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Refusal Contraindication to neuraxial (coagulopathy, anticoagulant use, local infection, sepsis etc) .Rupture of membranes. Drop-out: Patients may choose to drop-out of the study at any time. The physicians involved in this study may choose to end a patient's involvement in the study at their discretion.
[ "Refusal", "\n", "Contraindication", "to", "neuraxial", "(", "coagulopathy", ",", "anticoagulant", "use", ",", "local", "infection", ",", "sepsis", "etc", ")", ".Rupture", "of", "membranes", ".", "\n", "Drop", "-", "out", ":", "Patients", "may", "choose", "to", "drop", "-", "out", "of", "the", "study", "at", "any", "time", ".", "The", "physicians", "involved", "in", "this", "study", "may", "choose", "to", "end", "a", "patient", "'s", "involvement", "in", "the", "study", "at", "their", "discretion", ".", "\n" ]
[ "Scope", "Condition", "Drug", "Procedure" ]
Contraindication to neuraxial, coagulopathy, anticoagulant, local infection, sepsis
NCT01991743_exc_task2
Sentence: Refusal Contraindication to neuraxial (coagulopathy, anticoagulant use, local infection, sepsis etc) .Rupture of membranes. Drop-out: Patients may choose to drop-out of the study at any time. The physicians involved in this study may choose to end a patient's involvement in the study at their discretion. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Drug", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Refusal Contraindication to neuraxial (coagulopathy, anticoagulant use, local infection, sepsis etc) .Rupture of membranes. Drop-out: Patients may choose to drop-out of the study at any time. The physicians involved in this study may choose to end a patient's involvement in the study at their discretion.
[ "Refusal", "\n", "Contraindication", "to", "neuraxial", "(", "coagulopathy", ",", "anticoagulant", "use", ",", "local", "infection", ",", "sepsis", "etc", ")", ".Rupture", "of", "membranes", ".", "\n", "Drop", "-", "out", ":", "Patients", "may", "choose", "to", "drop", "-", "out", "of", "the", "study", "at", "any", "time", ".", "The", "physicians", "involved", "in", "this", "study", "may", "choose", "to", "end", "a", "patient", "'s", "involvement", "in", "the", "study", "at", "their", "discretion", ".", "\n" ]
[ "Scope", "Condition", "Drug", "Procedure" ]
thymocytes is a cell_type, transgenic mice is an other_artificial_source, catalytically inactive form is a protein_family_or_group, Ca2+/calmodulin - dependent protein kinase IV is a protein_molecule
62360_task0
Sentence: Defective survival and activation of thymocytes in transgenic mice expressing a catalytically inactive form of Ca2+/calmodulin-dependent protein kinase IV. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, protein_family_or_group, other_artificial_source, protein_molecule
[ "O", "O", "O", "O", "O", "B-cell_type", "O", "B-other_artificial_source", "I-other_artificial_source", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]
Defective survival and activation of thymocytes in transgenic mice expressing a catalytically inactive form of Ca2+/calmodulin-dependent protein kinase IV.
[ "Defective", "survival", "and", "activation", "of", "thymocytes", "in", "transgenic", "mice", "expressing", "a", "catalytically", "inactive", "form", "of", "Ca2+/calmodulin", "-", "dependent", "protein", "kinase", "IV", "." ]
[ "protein_molecule", "protein_family_or_group", "other_name", "DNA_family_or_group", "cell_type", "DNA_domain_or_region", "other_artificial_source", "other_organic_compound", "body_part", "nucleotide" ]
thymocytes is a cell_type, transgenic mice is an other_artificial_source, catalytically inactive form is a protein_family_or_group, Ca2+/calmodulin - dependent protein kinase IV is a protein_molecule
62360_task1
Sentence: Defective survival and activation of thymocytes in transgenic mice expressing a catalytically inactive form of Ca2+/calmodulin-dependent protein kinase IV. Instructions: please typing these entity words according to sentence: thymocytes, transgenic mice, catalytically inactive form, Ca2+/calmodulin - dependent protein kinase IV Options: cell_type, protein_family_or_group, other_artificial_source, protein_molecule
[ "O", "O", "O", "O", "O", "B-cell_type", "O", "B-other_artificial_source", "I-other_artificial_source", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]
Defective survival and activation of thymocytes in transgenic mice expressing a catalytically inactive form of Ca2+/calmodulin-dependent protein kinase IV.
[ "Defective", "survival", "and", "activation", "of", "thymocytes", "in", "transgenic", "mice", "expressing", "a", "catalytically", "inactive", "form", "of", "Ca2+/calmodulin", "-", "dependent", "protein", "kinase", "IV", "." ]
[ "protein_molecule", "protein_family_or_group", "other_name", "DNA_family_or_group", "cell_type", "DNA_domain_or_region", "other_artificial_source", "other_organic_compound", "body_part", "nucleotide" ]
thymocytes, transgenic mice, catalytically inactive form, Ca2+/calmodulin - dependent protein kinase IV
62360_task2
Sentence: Defective survival and activation of thymocytes in transgenic mice expressing a catalytically inactive form of Ca2+/calmodulin-dependent protein kinase IV. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-cell_type", "O", "B-other_artificial_source", "I-other_artificial_source", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]
Defective survival and activation of thymocytes in transgenic mice expressing a catalytically inactive form of Ca2+/calmodulin-dependent protein kinase IV.
[ "Defective", "survival", "and", "activation", "of", "thymocytes", "in", "transgenic", "mice", "expressing", "a", "catalytically", "inactive", "form", "of", "Ca2+/calmodulin", "-", "dependent", "protein", "kinase", "IV", "." ]
[ "protein_molecule", "protein_family_or_group", "other_name", "DNA_family_or_group", "cell_type", "DNA_domain_or_region", "other_artificial_source", "other_organic_compound", "body_part", "nucleotide" ]
sinapic Acid is a CHEMICAL
23470287_task0
Sentence: A newly synthesized sinapic Acid derivative inhibits endothelial activation in vitro and in vivo. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL
[ "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A newly synthesized sinapic Acid derivative inhibits endothelial activation in vitro and in vivo.
[ "A", "newly", "synthesized", "sinapic", "Acid", "derivative", "inhibits", "endothelial", "activation", "in", "vitro", "and", "in", "vivo", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
sinapic Acid is a CHEMICAL
23470287_task1
Sentence: A newly synthesized sinapic Acid derivative inhibits endothelial activation in vitro and in vivo. Instructions: please typing these entity words according to sentence: sinapic Acid Options: CHEMICAL
[ "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A newly synthesized sinapic Acid derivative inhibits endothelial activation in vitro and in vivo.
[ "A", "newly", "synthesized", "sinapic", "Acid", "derivative", "inhibits", "endothelial", "activation", "in", "vitro", "and", "in", "vivo", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
sinapic Acid
23470287_task2
Sentence: A newly synthesized sinapic Acid derivative inhibits endothelial activation in vitro and in vivo. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A newly synthesized sinapic Acid derivative inhibits endothelial activation in vitro and in vivo.
[ "A", "newly", "synthesized", "sinapic", "Acid", "derivative", "inhibits", "endothelial", "activation", "in", "vitro", "and", "in", "vivo", "." ]
[ "CHEMICAL", "GENE-Y", "GENE-N" ]
UCHL3 is a Protein, ubiquitin is a Protein, UCHL3 is a Protein, ubiquitin is a Protein, ubiquitin is a Protein, UCHL3 is a Protein, ubiquitin is a Protein
360_task0
Sentence: Substrate filtering by the active site crossover loop in UCHL3 revealed by sortagging and gain-of-function mutations. Determining how deubiquitinating enzymes discriminate between ubiquitin-conjugated substrates is critical to understand their function. Through application of a novel protein cleavage and tagging technique, sortagging, we show that human UCHL3 and the Plasmodium falciparum homologue, members of the ubiquitin C-terminal hydrolase family, use a unique active site crossover loop to restrict access of bulky ubiquitin adducts to the active site. Although it provides connectivity for critical active site residues in UCHL3, physical integrity of the crossover loop is dispensable for catalysis. By enlarging the active site crossover loop, we have constructed gain-of-function mutants that can accept substrates that the parent enzyme cannot, including ubiquitin chains of various linkages. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]
Substrate filtering by the active site crossover loop in UCHL3 revealed by sortagging and gain-of-function mutations. Determining how deubiquitinating enzymes discriminate between ubiquitin-conjugated substrates is critical to understand their function. Through application of a novel protein cleavage and tagging technique, sortagging, we show that human UCHL3 and the Plasmodium falciparum homologue, members of the ubiquitin C-terminal hydrolase family, use a unique active site crossover loop to restrict access of bulky ubiquitin adducts to the active site. Although it provides connectivity for critical active site residues in UCHL3, physical integrity of the crossover loop is dispensable for catalysis. By enlarging the active site crossover loop, we have constructed gain-of-function mutants that can accept substrates that the parent enzyme cannot, including ubiquitin chains of various linkages.
[ "Substrate", "filtering", "by", "the", "active", "site", "crossover", "loop", "in", "UCHL3", "revealed", "by", "sortagging", "and", "gain", "-", "of", "-", "function", "mutations", ".", "\n", "Determining", "how", "deubiquitinating", "enzymes", "discriminate", "between", "ubiquitin", "-", "conjugated", "substrates", "is", "critical", "to", "understand", "their", "function", ".", "Through", "application", "of", "a", "novel", "protein", "cleavage", "and", "tagging", "technique", ",", "sortagging", ",", "we", "show", "that", "human", "UCHL3", "and", "the", "Plasmodium", "falciparum", "homologue", ",", "members", "of", "the", "ubiquitin", "C", "-", "terminal", "hydrolase", "family", ",", "use", "a", "unique", "active", "site", "crossover", "loop", "to", "restrict", "access", "of", "bulky", "ubiquitin", "adducts", "to", "the", "active", "site", ".", "Although", "it", "provides", "connectivity", "for", "critical", "active", "site", "residues", "in", "UCHL3", ",", "physical", "integrity", "of", "the", "crossover", "loop", "is", "dispensable", "for", "catalysis", ".", "By", "enlarging", "the", "active", "site", "crossover", "loop", ",", "we", "have", "constructed", "gain", "-", "of", "-", "function", "mutants", "that", "can", "accept", "substrates", "that", "the", "parent", "enzyme", "cannot", ",", "including", "ubiquitin", "chains", "of", "various", "linkages", ".", "\n" ]
[ "Protein" ]
UCHL3 is a Protein, ubiquitin is a Protein, UCHL3 is a Protein, ubiquitin is a Protein, ubiquitin is a Protein, UCHL3 is a Protein, ubiquitin is a Protein
360_task1
Sentence: Substrate filtering by the active site crossover loop in UCHL3 revealed by sortagging and gain-of-function mutations. Determining how deubiquitinating enzymes discriminate between ubiquitin-conjugated substrates is critical to understand their function. Through application of a novel protein cleavage and tagging technique, sortagging, we show that human UCHL3 and the Plasmodium falciparum homologue, members of the ubiquitin C-terminal hydrolase family, use a unique active site crossover loop to restrict access of bulky ubiquitin adducts to the active site. Although it provides connectivity for critical active site residues in UCHL3, physical integrity of the crossover loop is dispensable for catalysis. By enlarging the active site crossover loop, we have constructed gain-of-function mutants that can accept substrates that the parent enzyme cannot, including ubiquitin chains of various linkages. Instructions: please typing these entity words according to sentence: UCHL3, ubiquitin, UCHL3, ubiquitin, ubiquitin, UCHL3, ubiquitin Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]
Substrate filtering by the active site crossover loop in UCHL3 revealed by sortagging and gain-of-function mutations. Determining how deubiquitinating enzymes discriminate between ubiquitin-conjugated substrates is critical to understand their function. Through application of a novel protein cleavage and tagging technique, sortagging, we show that human UCHL3 and the Plasmodium falciparum homologue, members of the ubiquitin C-terminal hydrolase family, use a unique active site crossover loop to restrict access of bulky ubiquitin adducts to the active site. Although it provides connectivity for critical active site residues in UCHL3, physical integrity of the crossover loop is dispensable for catalysis. By enlarging the active site crossover loop, we have constructed gain-of-function mutants that can accept substrates that the parent enzyme cannot, including ubiquitin chains of various linkages.
[ "Substrate", "filtering", "by", "the", "active", "site", "crossover", "loop", "in", "UCHL3", "revealed", "by", "sortagging", "and", "gain", "-", "of", "-", "function", "mutations", ".", "\n", "Determining", "how", "deubiquitinating", "enzymes", "discriminate", "between", "ubiquitin", "-", "conjugated", "substrates", "is", "critical", "to", "understand", "their", "function", ".", "Through", "application", "of", "a", "novel", "protein", "cleavage", "and", "tagging", "technique", ",", "sortagging", ",", "we", "show", "that", "human", "UCHL3", "and", "the", "Plasmodium", "falciparum", "homologue", ",", "members", "of", "the", "ubiquitin", "C", "-", "terminal", "hydrolase", "family", ",", "use", "a", "unique", "active", "site", "crossover", "loop", "to", "restrict", "access", "of", "bulky", "ubiquitin", "adducts", "to", "the", "active", "site", ".", "Although", "it", "provides", "connectivity", "for", "critical", "active", "site", "residues", "in", "UCHL3", ",", "physical", "integrity", "of", "the", "crossover", "loop", "is", "dispensable", "for", "catalysis", ".", "By", "enlarging", "the", "active", "site", "crossover", "loop", ",", "we", "have", "constructed", "gain", "-", "of", "-", "function", "mutants", "that", "can", "accept", "substrates", "that", "the", "parent", "enzyme", "cannot", ",", "including", "ubiquitin", "chains", "of", "various", "linkages", ".", "\n" ]
[ "Protein" ]
UCHL3, ubiquitin, UCHL3, ubiquitin, ubiquitin, UCHL3, ubiquitin
360_task2
Sentence: Substrate filtering by the active site crossover loop in UCHL3 revealed by sortagging and gain-of-function mutations. Determining how deubiquitinating enzymes discriminate between ubiquitin-conjugated substrates is critical to understand their function. Through application of a novel protein cleavage and tagging technique, sortagging, we show that human UCHL3 and the Plasmodium falciparum homologue, members of the ubiquitin C-terminal hydrolase family, use a unique active site crossover loop to restrict access of bulky ubiquitin adducts to the active site. Although it provides connectivity for critical active site residues in UCHL3, physical integrity of the crossover loop is dispensable for catalysis. By enlarging the active site crossover loop, we have constructed gain-of-function mutants that can accept substrates that the parent enzyme cannot, including ubiquitin chains of various linkages. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]
Substrate filtering by the active site crossover loop in UCHL3 revealed by sortagging and gain-of-function mutations. Determining how deubiquitinating enzymes discriminate between ubiquitin-conjugated substrates is critical to understand their function. Through application of a novel protein cleavage and tagging technique, sortagging, we show that human UCHL3 and the Plasmodium falciparum homologue, members of the ubiquitin C-terminal hydrolase family, use a unique active site crossover loop to restrict access of bulky ubiquitin adducts to the active site. Although it provides connectivity for critical active site residues in UCHL3, physical integrity of the crossover loop is dispensable for catalysis. By enlarging the active site crossover loop, we have constructed gain-of-function mutants that can accept substrates that the parent enzyme cannot, including ubiquitin chains of various linkages.
[ "Substrate", "filtering", "by", "the", "active", "site", "crossover", "loop", "in", "UCHL3", "revealed", "by", "sortagging", "and", "gain", "-", "of", "-", "function", "mutations", ".", "\n", "Determining", "how", "deubiquitinating", "enzymes", "discriminate", "between", "ubiquitin", "-", "conjugated", "substrates", "is", "critical", "to", "understand", "their", "function", ".", "Through", "application", "of", "a", "novel", "protein", "cleavage", "and", "tagging", "technique", ",", "sortagging", ",", "we", "show", "that", "human", "UCHL3", "and", "the", "Plasmodium", "falciparum", "homologue", ",", "members", "of", "the", "ubiquitin", "C", "-", "terminal", "hydrolase", "family", ",", "use", "a", "unique", "active", "site", "crossover", "loop", "to", "restrict", "access", "of", "bulky", "ubiquitin", "adducts", "to", "the", "active", "site", ".", "Although", "it", "provides", "connectivity", "for", "critical", "active", "site", "residues", "in", "UCHL3", ",", "physical", "integrity", "of", "the", "crossover", "loop", "is", "dispensable", "for", "catalysis", ".", "By", "enlarging", "the", "active", "site", "crossover", "loop", ",", "we", "have", "constructed", "gain", "-", "of", "-", "function", "mutants", "that", "can", "accept", "substrates", "that", "the", "parent", "enzyme", "cannot", ",", "including", "ubiquitin", "chains", "of", "various", "linkages", ".", "\n" ]
[ "Protein" ]
dynamin-2 is a Enzyme, GTPase is a Enzyme, dynamin GTPases is a Enzyme, receptor is a Protein, isoform dynamin-2 is a Enzyme, dyn2 is a Enzyme, dyn2 is a Enzyme, transcription factor p53 is a TranscriptionFactor, DNA is a DNA, caspase-3 is a Enzyme, dividing cells is a Cell, p53 is a TranscriptionFactor, protein is a Protein, p53 is a TranscriptionFactor, truncated dyn2 is a MutatedProtein, domain is a ProteinDomain, PRD is a ProteinDomain, SH3 domain is a ProteinDomain, partners is a Protein, wild - type is a Enzyme, GTPase domain is a ProteinDomain, phenotype is a Phenotype, dyn1 is a Enzyme, dyn2 is a Enzyme, GTPase is a Enzyme
59_task0
Sentence: Evidence that dynamin-2 functions as a signal-transducing GTPase. The role of dynamin GTPases in the regulation of receptor-mediated endocytosis is well established. Here, we present new evidence that the ubiquitously expressed isoform dynamin-2 (dyn2) can also function in a signal transduction pathway(s). A </=5-fold increase of dyn2 relative to endogenous levels activates the transcription factor p53 and induces apoptosis, as demonstrated by reduced cell proliferation, DNA fragmentation, and caspase-3 activation. Dyn2-triggered apoptosis occurs only in dividing cells and is p53 dependent. A mutant defective in GTP binding does not trigger apoptosis, indicating that increased levels of dyn2.GTP, rather than protein levels per se, are required to transduce signals that activate p53. A truncated dyn2 lacking the COOH-terminal proline/arginine-rich domain (PRD), which interacts with many SH3 domain-containing partners implicated in both endocytosis and signal transduction, triggers apoptosis even more potently than the wild-type. This observation provides additional support for the importance of the NH(2)-terminal GTPase domain for the apoptotic phenotype. All described effects are dyn2-specific because >200-fold overexpression of dyn1, the 70% identical neuronal isoform, has no effect. Our data suggest that dyn2 can act as a signal transducing GTPase affecting transcriptional regulation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA, Phenotype, TranscriptionFactor, Enzyme, MutatedProtein, ProteinDomain, Protein, Cell
[ "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "B-Enzyme", "I-Enzyme", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "I-Enzyme", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "B-MutatedProtein", "I-MutatedProtein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinDomain", "O", "B-ProteinDomain", "O", "O", "O", "O", "O", "O", "B-ProteinDomain", "I-ProteinDomain", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "I-Enzyme", "I-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinDomain", "I-ProteinDomain", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O" ]
Evidence that dynamin-2 functions as a signal-transducing GTPase. The role of dynamin GTPases in the regulation of receptor-mediated endocytosis is well established. Here, we present new evidence that the ubiquitously expressed isoform dynamin-2 (dyn2) can also function in a signal transduction pathway(s). A </=5-fold increase of dyn2 relative to endogenous levels activates the transcription factor p53 and induces apoptosis, as demonstrated by reduced cell proliferation, DNA fragmentation, and caspase-3 activation. Dyn2-triggered apoptosis occurs only in dividing cells and is p53 dependent. A mutant defective in GTP binding does not trigger apoptosis, indicating that increased levels of dyn2.GTP, rather than protein levels per se, are required to transduce signals that activate p53. A truncated dyn2 lacking the COOH-terminal proline/arginine-rich domain (PRD), which interacts with many SH3 domain-containing partners implicated in both endocytosis and signal transduction, triggers apoptosis even more potently than the wild-type. This observation provides additional support for the importance of the NH(2)-terminal GTPase domain for the apoptotic phenotype. All described effects are dyn2-specific because >200-fold overexpression of dyn1, the 70% identical neuronal isoform, has no effect. Our data suggest that dyn2 can act as a signal transducing GTPase affecting transcriptional regulation.
[ "Evidence", "that", "dynamin-2", "functions", "as", "a", "signal", "-", "transducing", "GTPase", ".", "The", "role", "of", "dynamin", "GTPases", "in", "the", "regulation", "of", "receptor", "-", "mediated", "endocytosis", "is", "well", "established", ".", "Here", ",", "we", "present", "new", "evidence", "that", "the", "ubiquitously", "expressed", "isoform", "dynamin-2", "(", "dyn2", ")", "can", "also", "function", "in", "a", "signal", "transduction", "pathway(s", ")", ".", "A", "<", "/=5-fold", "increase", "of", "dyn2", "relative", "to", "endogenous", "levels", "activates", "the", "transcription", "factor", "p53", "and", "induces", "apoptosis", ",", "as", "demonstrated", "by", "reduced", "cell", "proliferation", ",", "DNA", "fragmentation", ",", "and", "caspase-3", "activation", ".", "Dyn2-triggered", "apoptosis", "occurs", "only", "in", "dividing", "cells", "and", "is", "p53", "dependent", ".", "A", "mutant", "defective", "in", "GTP", "binding", "does", "not", "trigger", "apoptosis", ",", "indicating", "that", "increased", "levels", "of", "dyn2.GTP", ",", "rather", "than", "protein", "levels", "per", "se", ",", "are", "required", "to", "transduce", "signals", "that", "activate", "p53", ".", "A", "truncated", "dyn2", "lacking", "the", "COOH", "-", "terminal", "proline", "/", "arginine", "-", "rich", "domain", "(", "PRD", ")", ",", "which", "interacts", "with", "many", "SH3", "domain", "-", "containing", "partners", "implicated", "in", "both", "endocytosis", "and", "signal", "transduction", ",", "triggers", "apoptosis", "even", "more", "potently", "than", "the", "wild", "-", "type", ".", "This", "observation", "provides", "additional", "support", "for", "the", "importance", "of", "the", "NH(2)-terminal", "GTPase", "domain", "for", "the", "apoptotic", "phenotype", ".", "All", "described", "effects", "are", "dyn2-specific", "because", ">", "200-fold", "overexpression", "of", "dyn1", ",", "the", "70", "%", "identical", "neuronal", "isoform", ",", "has", "no", "effect", ".", "Our", "data", "suggest", "that", "dyn2", "can", "act", "as", "a", "signal", "transducing", "GTPase", "affecting", "transcriptional", "regulation", ".", "\n" ]
[ "TranscriptionFactor", "Enzyme", "Cell", "MutatedProtein", "ProteinDomain", "Phenotype", "Protein", "Nucleotide", "DNA" ]
dynamin-2 is a Enzyme, GTPase is a Enzyme, dynamin GTPases is a Enzyme, receptor is a Protein, isoform dynamin-2 is a Enzyme, dyn2 is a Enzyme, dyn2 is a Enzyme, transcription factor p53 is a TranscriptionFactor, DNA is a DNA, caspase-3 is a Enzyme, dividing cells is a Cell, p53 is a TranscriptionFactor, protein is a Protein, p53 is a TranscriptionFactor, truncated dyn2 is a MutatedProtein, domain is a ProteinDomain, PRD is a ProteinDomain, SH3 domain is a ProteinDomain, partners is a Protein, wild - type is a Enzyme, GTPase domain is a ProteinDomain, phenotype is a Phenotype, dyn1 is a Enzyme, dyn2 is a Enzyme, GTPase is a Enzyme
59_task1
Sentence: Evidence that dynamin-2 functions as a signal-transducing GTPase. The role of dynamin GTPases in the regulation of receptor-mediated endocytosis is well established. Here, we present new evidence that the ubiquitously expressed isoform dynamin-2 (dyn2) can also function in a signal transduction pathway(s). A </=5-fold increase of dyn2 relative to endogenous levels activates the transcription factor p53 and induces apoptosis, as demonstrated by reduced cell proliferation, DNA fragmentation, and caspase-3 activation. Dyn2-triggered apoptosis occurs only in dividing cells and is p53 dependent. A mutant defective in GTP binding does not trigger apoptosis, indicating that increased levels of dyn2.GTP, rather than protein levels per se, are required to transduce signals that activate p53. A truncated dyn2 lacking the COOH-terminal proline/arginine-rich domain (PRD), which interacts with many SH3 domain-containing partners implicated in both endocytosis and signal transduction, triggers apoptosis even more potently than the wild-type. This observation provides additional support for the importance of the NH(2)-terminal GTPase domain for the apoptotic phenotype. All described effects are dyn2-specific because >200-fold overexpression of dyn1, the 70% identical neuronal isoform, has no effect. Our data suggest that dyn2 can act as a signal transducing GTPase affecting transcriptional regulation. Instructions: please typing these entity words according to sentence: dynamin-2, GTPase, dynamin GTPases, receptor, isoform dynamin-2, dyn2, dyn2, transcription factor p53, DNA, caspase-3, dividing cells, p53, protein, p53, truncated dyn2, domain, PRD, SH3 domain, partners, wild - type, GTPase domain, phenotype, dyn1, dyn2, GTPase Options: DNA, Phenotype, TranscriptionFactor, Enzyme, MutatedProtein, ProteinDomain, Protein, Cell
[ "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "B-Enzyme", "I-Enzyme", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "I-Enzyme", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "B-MutatedProtein", "I-MutatedProtein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinDomain", "O", "B-ProteinDomain", "O", "O", "O", "O", "O", "O", "B-ProteinDomain", "I-ProteinDomain", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "I-Enzyme", "I-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinDomain", "I-ProteinDomain", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O" ]
Evidence that dynamin-2 functions as a signal-transducing GTPase. The role of dynamin GTPases in the regulation of receptor-mediated endocytosis is well established. Here, we present new evidence that the ubiquitously expressed isoform dynamin-2 (dyn2) can also function in a signal transduction pathway(s). A </=5-fold increase of dyn2 relative to endogenous levels activates the transcription factor p53 and induces apoptosis, as demonstrated by reduced cell proliferation, DNA fragmentation, and caspase-3 activation. Dyn2-triggered apoptosis occurs only in dividing cells and is p53 dependent. A mutant defective in GTP binding does not trigger apoptosis, indicating that increased levels of dyn2.GTP, rather than protein levels per se, are required to transduce signals that activate p53. A truncated dyn2 lacking the COOH-terminal proline/arginine-rich domain (PRD), which interacts with many SH3 domain-containing partners implicated in both endocytosis and signal transduction, triggers apoptosis even more potently than the wild-type. This observation provides additional support for the importance of the NH(2)-terminal GTPase domain for the apoptotic phenotype. All described effects are dyn2-specific because >200-fold overexpression of dyn1, the 70% identical neuronal isoform, has no effect. Our data suggest that dyn2 can act as a signal transducing GTPase affecting transcriptional regulation.
[ "Evidence", "that", "dynamin-2", "functions", "as", "a", "signal", "-", "transducing", "GTPase", ".", "The", "role", "of", "dynamin", "GTPases", "in", "the", "regulation", "of", "receptor", "-", "mediated", "endocytosis", "is", "well", "established", ".", "Here", ",", "we", "present", "new", "evidence", "that", "the", "ubiquitously", "expressed", "isoform", "dynamin-2", "(", "dyn2", ")", "can", "also", "function", "in", "a", "signal", "transduction", "pathway(s", ")", ".", "A", "<", "/=5-fold", "increase", "of", "dyn2", "relative", "to", "endogenous", "levels", "activates", "the", "transcription", "factor", "p53", "and", "induces", "apoptosis", ",", "as", "demonstrated", "by", "reduced", "cell", "proliferation", ",", "DNA", "fragmentation", ",", "and", "caspase-3", "activation", ".", "Dyn2-triggered", "apoptosis", "occurs", "only", "in", "dividing", "cells", "and", "is", "p53", "dependent", ".", "A", "mutant", "defective", "in", "GTP", "binding", "does", "not", "trigger", "apoptosis", ",", "indicating", "that", "increased", "levels", "of", "dyn2.GTP", ",", "rather", "than", "protein", "levels", "per", "se", ",", "are", "required", "to", "transduce", "signals", "that", "activate", "p53", ".", "A", "truncated", "dyn2", "lacking", "the", "COOH", "-", "terminal", "proline", "/", "arginine", "-", "rich", "domain", "(", "PRD", ")", ",", "which", "interacts", "with", "many", "SH3", "domain", "-", "containing", "partners", "implicated", "in", "both", "endocytosis", "and", "signal", "transduction", ",", "triggers", "apoptosis", "even", "more", "potently", "than", "the", "wild", "-", "type", ".", "This", "observation", "provides", "additional", "support", "for", "the", "importance", "of", "the", "NH(2)-terminal", "GTPase", "domain", "for", "the", "apoptotic", "phenotype", ".", "All", "described", "effects", "are", "dyn2-specific", "because", ">", "200-fold", "overexpression", "of", "dyn1", ",", "the", "70", "%", "identical", "neuronal", "isoform", ",", "has", "no", "effect", ".", "Our", "data", "suggest", "that", "dyn2", "can", "act", "as", "a", "signal", "transducing", "GTPase", "affecting", "transcriptional", "regulation", ".", "\n" ]
[ "TranscriptionFactor", "Enzyme", "Cell", "MutatedProtein", "ProteinDomain", "Phenotype", "Protein", "Nucleotide", "DNA" ]
dynamin-2, GTPase, dynamin GTPases, receptor, isoform dynamin-2, dyn2, dyn2, transcription factor p53, DNA, caspase-3, dividing cells, p53, protein, p53, truncated dyn2, domain, PRD, SH3 domain, partners, wild - type, GTPase domain, phenotype, dyn1, dyn2, GTPase
59_task2
Sentence: Evidence that dynamin-2 functions as a signal-transducing GTPase. The role of dynamin GTPases in the regulation of receptor-mediated endocytosis is well established. Here, we present new evidence that the ubiquitously expressed isoform dynamin-2 (dyn2) can also function in a signal transduction pathway(s). A </=5-fold increase of dyn2 relative to endogenous levels activates the transcription factor p53 and induces apoptosis, as demonstrated by reduced cell proliferation, DNA fragmentation, and caspase-3 activation. Dyn2-triggered apoptosis occurs only in dividing cells and is p53 dependent. A mutant defective in GTP binding does not trigger apoptosis, indicating that increased levels of dyn2.GTP, rather than protein levels per se, are required to transduce signals that activate p53. A truncated dyn2 lacking the COOH-terminal proline/arginine-rich domain (PRD), which interacts with many SH3 domain-containing partners implicated in both endocytosis and signal transduction, triggers apoptosis even more potently than the wild-type. This observation provides additional support for the importance of the NH(2)-terminal GTPase domain for the apoptotic phenotype. All described effects are dyn2-specific because >200-fold overexpression of dyn1, the 70% identical neuronal isoform, has no effect. Our data suggest that dyn2 can act as a signal transducing GTPase affecting transcriptional regulation. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "B-Enzyme", "I-Enzyme", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "I-Enzyme", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "I-TranscriptionFactor", "I-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-TranscriptionFactor", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TranscriptionFactor", "O", "O", "B-MutatedProtein", "I-MutatedProtein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinDomain", "O", "B-ProteinDomain", "O", "O", "O", "O", "O", "O", "B-ProteinDomain", "I-ProteinDomain", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "I-Enzyme", "I-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ProteinDomain", "I-ProteinDomain", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O", "O", "B-Enzyme", "O", "O", "O", "O", "O" ]
Evidence that dynamin-2 functions as a signal-transducing GTPase. The role of dynamin GTPases in the regulation of receptor-mediated endocytosis is well established. Here, we present new evidence that the ubiquitously expressed isoform dynamin-2 (dyn2) can also function in a signal transduction pathway(s). A </=5-fold increase of dyn2 relative to endogenous levels activates the transcription factor p53 and induces apoptosis, as demonstrated by reduced cell proliferation, DNA fragmentation, and caspase-3 activation. Dyn2-triggered apoptosis occurs only in dividing cells and is p53 dependent. A mutant defective in GTP binding does not trigger apoptosis, indicating that increased levels of dyn2.GTP, rather than protein levels per se, are required to transduce signals that activate p53. A truncated dyn2 lacking the COOH-terminal proline/arginine-rich domain (PRD), which interacts with many SH3 domain-containing partners implicated in both endocytosis and signal transduction, triggers apoptosis even more potently than the wild-type. This observation provides additional support for the importance of the NH(2)-terminal GTPase domain for the apoptotic phenotype. All described effects are dyn2-specific because >200-fold overexpression of dyn1, the 70% identical neuronal isoform, has no effect. Our data suggest that dyn2 can act as a signal transducing GTPase affecting transcriptional regulation.
[ "Evidence", "that", "dynamin-2", "functions", "as", "a", "signal", "-", "transducing", "GTPase", ".", "The", "role", "of", "dynamin", "GTPases", "in", "the", "regulation", "of", "receptor", "-", "mediated", "endocytosis", "is", "well", "established", ".", "Here", ",", "we", "present", "new", "evidence", "that", "the", "ubiquitously", "expressed", "isoform", "dynamin-2", "(", "dyn2", ")", "can", "also", "function", "in", "a", "signal", "transduction", "pathway(s", ")", ".", "A", "<", "/=5-fold", "increase", "of", "dyn2", "relative", "to", "endogenous", "levels", "activates", "the", "transcription", "factor", "p53", "and", "induces", "apoptosis", ",", "as", "demonstrated", "by", "reduced", "cell", "proliferation", ",", "DNA", "fragmentation", ",", "and", "caspase-3", "activation", ".", "Dyn2-triggered", "apoptosis", "occurs", "only", "in", "dividing", "cells", "and", "is", "p53", "dependent", ".", "A", "mutant", "defective", "in", "GTP", "binding", "does", "not", "trigger", "apoptosis", ",", "indicating", "that", "increased", "levels", "of", "dyn2.GTP", ",", "rather", "than", "protein", "levels", "per", "se", ",", "are", "required", "to", "transduce", "signals", "that", "activate", "p53", ".", "A", "truncated", "dyn2", "lacking", "the", "COOH", "-", "terminal", "proline", "/", "arginine", "-", "rich", "domain", "(", "PRD", ")", ",", "which", "interacts", "with", "many", "SH3", "domain", "-", "containing", "partners", "implicated", "in", "both", "endocytosis", "and", "signal", "transduction", ",", "triggers", "apoptosis", "even", "more", "potently", "than", "the", "wild", "-", "type", ".", "This", "observation", "provides", "additional", "support", "for", "the", "importance", "of", "the", "NH(2)-terminal", "GTPase", "domain", "for", "the", "apoptotic", "phenotype", ".", "All", "described", "effects", "are", "dyn2-specific", "because", ">", "200-fold", "overexpression", "of", "dyn1", ",", "the", "70", "%", "identical", "neuronal", "isoform", ",", "has", "no", "effect", ".", "Our", "data", "suggest", "that", "dyn2", "can", "act", "as", "a", "signal", "transducing", "GTPase", "affecting", "transcriptional", "regulation", ".", "\n" ]
[ "TranscriptionFactor", "Enzyme", "Cell", "MutatedProtein", "ProteinDomain", "Phenotype", "Protein", "Nucleotide", "DNA" ]
neoplasia is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA
531_task0
Sentence: Anamnesis Se trata de un varón de 60 años sin alergias conocidas, independiente para las actividades básicas de la vida diaria que, como antecedentes médicos de interés, tiene un consumo acumulado de tabaco de 40 años-paquete, así como un hábito enólico superior a 40 g/día que había abandonado hacía 2 años. No hay otros antecedentes de interés en el momento de inicio de la clínica. No hay antecedentes familiares de interés. Comienza en marzo de 2018 con un cuadro de disfonía de 1 mes de evolución que no mejora con tratamiento con corticoides a dosis bajas y reposo vocal, pautados en diversas consultas al servicio de Urgencias. Exploración física » Durante la exploración física encontramos un varón con buen estado general, ECOG 1, normocoloreado y normohidratado, eupneico en reposo. » La cavidad oral no presentaba lesión alguna. En la palpación no se encontraban adenopatías. » En la auscultación cardiorrespiratoria sólo apreciamos una hipoventilación global. » La exploración a nivel abdominal, miembros inferiores, y a nivel neurológico eran completamente normales. Pruebas complementarias » El paciente es valorado por Otorrinolaringología, quienes, en la fibrobroncoscopia, aprecian una parálisis de cuerda vocal izquierda. » En la radiografía de tórax que se realiza se observa una masa hiliar izquierda que provoca una atelectasia de lóbulo superior izquierdo. » En la TC torácica se aprecia una masa hiliar izquierda con extensión a mediastino, hacia ventana aortopulmonar, con unas dimensiones de 10 x 5,4 x 5,3cm, sin verse adenopatías. » Se realiza broncoscopia, que observa signos directos de neoplasia a la entrada del lóbulo superior izquierdo. Se toman muestras, y en la Anatomía Patológica se informa un adenocarcinoma de pulmón. EGFR, ALK y ROS-1 negativo. PD-L1 no evaluable. » En estudio de extensión con PET/TC, se aprecia, además de la masa pulmonar, afectación metastásica en diáfisis proximal de fémur izquierdo (1 lesión de 4,3 x 2,8 cm con SUV 7,3) y a nivel de pala iliaca derecha (1 lesión de 15 mm con SUV 7,1). Diagnóstico Por tanto, con todo el estudio de extensión realizado, llegamos al diagnóstico de adenocarcinoma de pulmón EGFR, ALK, ROS-1 y PD-L1 no medido, estadio IVB. Tratamiento Se realiza tratamiento con radioterapia externa (RT) sobre lesión de fémur izquierdo para control sintomático del dolor. En total se administraron 30 Grays (Gy) en 10 sesiones. Se decidió incluir al paciente en ensayo clínico, iniciándose tratamiento con 4 ciclos de cisplatino + pemetrexed + ipilimumab + nivolumab, y posterior mantenimiento con ipilimumab + nivolumab hasta tolerancia o progresión del paciente. Los cuatro ciclos de quimioinmunoterapia se administraron entre el 04/07/2018 y el 06/09/2018. Posteriormente, se continuó administrando ciclos de mantenimiento con ipilimumab + nivolumab que comenzó el 27/09/2018, llegando a administrarse un total de 3 ciclos, el último el 08/11/2018. Evolución Tras los primeros 4 ciclos se realiza TC de evaluación de respuesta, el 22/08/2018, apreciándose enfermedad estable según criterios RECIST. El 08/10/2018, se realiza nueva TC de evaluación tras 1 dosis de mantenimiento con inmunoterapia, observándose una respuesta parcial. En analítica de control del 18/10/2018 se aprecia un hipotiroidismo, con niveles elevados de TSH y descenso de T4 libre, por lo que se instaura tratamiento con levotiroxina 50 mcg 1 comprimido al día, llegándose al probable diagnóstico de hipotiroidismo autoinmune asociado a inmunoterapia. El paciente acude a consulta el 29/11/2018, tras el 4º ciclo de mantenimiento, con clínica de astenia, diarrea, y dolor en hipocondrio derecho. Analíticamente se objetiva elevación de transaminasas, llegando a alcanzar toxicidad hepática grado 3, por lo que en este contexto se procede a ingresar al paciente para monitorización y tratamiento con corticoides a dosis de metilprednisolona 2 mg/kg/día. Se realiza una serología para virus hepatotropos, resultando negativa para los mismos, y con la corticoterapia administrada se logra mejoría de los niveles de transaminasas, así como mejoría clínica por lo que se llega al diagnóstico de hepatitis autoinmune secundaria a inmunoterapia. Se realiza un descenso progresivo de la corticoterapia, y se da de alta al paciente continuando con la corticoterapia en pauta descendente progresiva. El 17/12/2018 el paciente acude a Urgencias por un cuadro de malestar general, vómitos, y aparición de pico febril. Analíticamente se objetiva empeoramiento importante del nivel de transaminasas, estando de nuevo en niveles de toxicidad grado 3, un rash cutáneo maculopapular que afecta a más de la mitad de la superficie corporal, y un deterioro de la función renal alcanzando también toxicidad grado 3. Por todo ello, se procede a ingresar de nuevo al paciente para volver a escalar la corticoterapia a dosis de 2 mg/kg/día. En esta ocasión, se consigue una mejoría transitoria, sin lograr corregir los parámetros analíticos, y en los días sucesivos empieza a aparecer elevación de marcadores de citólisis y colestasis. Se realiza una ecografía abdominal y colangio-RM que descartan una complicación aguda infecciosa/vascular/tumoral y, siguiendo las guías clínicas, se decide plantear seguimiento conjunto con hepatología y realización de biopsia hepática. Esta se realiza el 02/01/2019, objetivándose en la misma un patrón lesional mixto colestásico con inflamación portal y marcada dilatación sinusoidal, sin apreciarse fibrosis. Estos datos son compatibles con un síndrome venoclusivo incipiente. En cuanto al rash, se realiza una solicitud de valoración a Alergología y Dermatología, puesto que el paciente lo achaca a una primera toma de alopurinol por hiperuricemia, y se llega a la conclusión final de que podría tratarse de un síndrome de Dress potenciado por la inmunoterapia. Queda en duda el papel del alopurinol, debido a la secuencia temporal en la que se producen los hechos. Dados estos resultados, se achaca el deterioro clínico y analítico a una hepatotoxicidad autoinmune refractaria a corticoterapia, y se procede a iniciar micofenolato mofetilo a dosis de 1 g cada 12 horas. Tras la instauración del tratamiento, se objetiva una mejoría parcial de la función hepática y del estado general que permiten dar de alta al paciente el 11/01/2019 con seguimiento estricto por consultas externas, y con suspensión de los ciclos de mantenimiento. En la TC de reevaluación de la enfermedad el 04/02/2019, se detecta aún respuesta parcial de la enfermedad oncológica. Sin embargo, se revelan hallazgos característicos de enfermedad venoclusiva hepática establecida, con marcada alteración de la perfusión hepática, edema periportal y edema de pared vesicular, así como abundante cantidad de líquido ascítico. Finalmente, el paciente es traído a Urgencias por deterioro súbito del nivel de conciencia el 22/02/2019, objetivándose desconexión completa del medio, abdomen distendido, hipotensión y taquicardia. A pesar de tratamiento inicial con antibioterapia y fluidoterapia intensiva, persiste el deterioro a nivel clínico y hemodinámico, por lo que, tras hablar de la situación con la familia, se acuerda inicio de sedación paliativa del paciente. A las pocas horas del inicio de la misma, se produce el exitus el mismo día. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Se trata de un varón de 60 años sin alergias conocidas, independiente para las actividades básicas de la vida diaria que, como antecedentes médicos de interés, tiene un consumo acumulado de tabaco de 40 años-paquete, así como un hábito enólico superior a 40 g/día que había abandonado hacía 2 años. No hay otros antecedentes de interés en el momento de inicio de la clínica. No hay antecedentes familiares de interés. Comienza en marzo de 2018 con un cuadro de disfonía de 1 mes de evolución que no mejora con tratamiento con corticoides a dosis bajas y reposo vocal, pautados en diversas consultas al servicio de Urgencias. Exploración física » Durante la exploración física encontramos un varón con buen estado general, ECOG 1, normocoloreado y normohidratado, eupneico en reposo. » La cavidad oral no presentaba lesión alguna. En la palpación no se encontraban adenopatías. » En la auscultación cardiorrespiratoria sólo apreciamos una hipoventilación global. » La exploración a nivel abdominal, miembros inferiores, y a nivel neurológico eran completamente normales. Pruebas complementarias » El paciente es valorado por Otorrinolaringología, quienes, en la fibrobroncoscopia, aprecian una parálisis de cuerda vocal izquierda. » En la radiografía de tórax que se realiza se observa una masa hiliar izquierda que provoca una atelectasia de lóbulo superior izquierdo. » En la TC torácica se aprecia una masa hiliar izquierda con extensión a mediastino, hacia ventana aortopulmonar, con unas dimensiones de 10 x 5,4 x 5,3cm, sin verse adenopatías. » Se realiza broncoscopia, que observa signos directos de neoplasia a la entrada del lóbulo superior izquierdo. Se toman muestras, y en la Anatomía Patológica se informa un adenocarcinoma de pulmón. EGFR, ALK y ROS-1 negativo. PD-L1 no evaluable. » En estudio de extensión con PET/TC, se aprecia, además de la masa pulmonar, afectación metastásica en diáfisis proximal de fémur izquierdo (1 lesión de 4,3 x 2,8 cm con SUV 7,3) y a nivel de pala iliaca derecha (1 lesión de 15 mm con SUV 7,1). Diagnóstico Por tanto, con todo el estudio de extensión realizado, llegamos al diagnóstico de adenocarcinoma de pulmón EGFR, ALK, ROS-1 y PD-L1 no medido, estadio IVB. Tratamiento Se realiza tratamiento con radioterapia externa (RT) sobre lesión de fémur izquierdo para control sintomático del dolor. En total se administraron 30 Grays (Gy) en 10 sesiones. Se decidió incluir al paciente en ensayo clínico, iniciándose tratamiento con 4 ciclos de cisplatino + pemetrexed + ipilimumab + nivolumab, y posterior mantenimiento con ipilimumab + nivolumab hasta tolerancia o progresión del paciente. Los cuatro ciclos de quimioinmunoterapia se administraron entre el 04/07/2018 y el 06/09/2018. Posteriormente, se continuó administrando ciclos de mantenimiento con ipilimumab + nivolumab que comenzó el 27/09/2018, llegando a administrarse un total de 3 ciclos, el último el 08/11/2018. Evolución Tras los primeros 4 ciclos se realiza TC de evaluación de respuesta, el 22/08/2018, apreciándose enfermedad estable según criterios RECIST. El 08/10/2018, se realiza nueva TC de evaluación tras 1 dosis de mantenimiento con inmunoterapia, observándose una respuesta parcial. En analítica de control del 18/10/2018 se aprecia un hipotiroidismo, con niveles elevados de TSH y descenso de T4 libre, por lo que se instaura tratamiento con levotiroxina 50 mcg 1 comprimido al día, llegándose al probable diagnóstico de hipotiroidismo autoinmune asociado a inmunoterapia. El paciente acude a consulta el 29/11/2018, tras el 4º ciclo de mantenimiento, con clínica de astenia, diarrea, y dolor en hipocondrio derecho. Analíticamente se objetiva elevación de transaminasas, llegando a alcanzar toxicidad hepática grado 3, por lo que en este contexto se procede a ingresar al paciente para monitorización y tratamiento con corticoides a dosis de metilprednisolona 2 mg/kg/día. Se realiza una serología para virus hepatotropos, resultando negativa para los mismos, y con la corticoterapia administrada se logra mejoría de los niveles de transaminasas, así como mejoría clínica por lo que se llega al diagnóstico de hepatitis autoinmune secundaria a inmunoterapia. Se realiza un descenso progresivo de la corticoterapia, y se da de alta al paciente continuando con la corticoterapia en pauta descendente progresiva. El 17/12/2018 el paciente acude a Urgencias por un cuadro de malestar general, vómitos, y aparición de pico febril. Analíticamente se objetiva empeoramiento importante del nivel de transaminasas, estando de nuevo en niveles de toxicidad grado 3, un rash cutáneo maculopapular que afecta a más de la mitad de la superficie corporal, y un deterioro de la función renal alcanzando también toxicidad grado 3. Por todo ello, se procede a ingresar de nuevo al paciente para volver a escalar la corticoterapia a dosis de 2 mg/kg/día. En esta ocasión, se consigue una mejoría transitoria, sin lograr corregir los parámetros analíticos, y en los días sucesivos empieza a aparecer elevación de marcadores de citólisis y colestasis. Se realiza una ecografía abdominal y colangio-RM que descartan una complicación aguda infecciosa/vascular/tumoral y, siguiendo las guías clínicas, se decide plantear seguimiento conjunto con hepatología y realización de biopsia hepática. Esta se realiza el 02/01/2019, objetivándose en la misma un patrón lesional mixto colestásico con inflamación portal y marcada dilatación sinusoidal, sin apreciarse fibrosis. Estos datos son compatibles con un síndrome venoclusivo incipiente. En cuanto al rash, se realiza una solicitud de valoración a Alergología y Dermatología, puesto que el paciente lo achaca a una primera toma de alopurinol por hiperuricemia, y se llega a la conclusión final de que podría tratarse de un síndrome de Dress potenciado por la inmunoterapia. Queda en duda el papel del alopurinol, debido a la secuencia temporal en la que se producen los hechos. Dados estos resultados, se achaca el deterioro clínico y analítico a una hepatotoxicidad autoinmune refractaria a corticoterapia, y se procede a iniciar micofenolato mofetilo a dosis de 1 g cada 12 horas. Tras la instauración del tratamiento, se objetiva una mejoría parcial de la función hepática y del estado general que permiten dar de alta al paciente el 11/01/2019 con seguimiento estricto por consultas externas, y con suspensión de los ciclos de mantenimiento. En la TC de reevaluación de la enfermedad el 04/02/2019, se detecta aún respuesta parcial de la enfermedad oncológica. Sin embargo, se revelan hallazgos característicos de enfermedad venoclusiva hepática establecida, con marcada alteración de la perfusión hepática, edema periportal y edema de pared vesicular, así como abundante cantidad de líquido ascítico. Finalmente, el paciente es traído a Urgencias por deterioro súbito del nivel de conciencia el 22/02/2019, objetivándose desconexión completa del medio, abdomen distendido, hipotensión y taquicardia. A pesar de tratamiento inicial con antibioterapia y fluidoterapia intensiva, persiste el deterioro a nivel clínico y hemodinámico, por lo que, tras hablar de la situación con la familia, se acuerda inicio de sedación paliativa del paciente. A las pocas horas del inicio de la misma, se produce el exitus el mismo día.
[ "Anamnesis", "\n", "Se", "trata", "de", "un", "varón", "de", "60", "años", "sin", "alergias", "conocidas", ",", "independiente", "para", "las", "actividades", "básicas", "de", "la", "vida", "diaria", "que", ",", "como", "antecedentes", "médicos", "de", "interés", ",", "tiene", "un", "consumo", "acumulado", "de", "tabaco", "de", "40", "años", "-", "paquete", ",", "así", "como", "un", "hábito", "enólico", "superior", "a", "40", "g", "/", "día", "que", "había", "abandonado", "hacía", "2", "años", ".", "No", "hay", "otros", "antecedentes", "de", "interés", "en", "el", "momento", "de", "inicio", "de", "la", "clínica", ".", "No", "hay", "antecedentes", "familiares", "de", "interés", ".", "\n", "Comienza", "en", "marzo", "de", "2018", "con", "un", "cuadro", "de", "disfonía", "de", "1", "mes", "de", "evolución", "que", "no", "mejora", "con", "tratamiento", "con", "corticoides", "a", "dosis", "bajas", "y", "reposo", "vocal", ",", "pautados", "en", "diversas", "consultas", "al", "servicio", "de", "Urgencias", ".", "\n\n", "Exploración", "física", "\n", "»", "Durante", "la", "exploración", "física", "encontramos", "un", "varón", "con", "buen", "estado", "general", ",", "ECOG", "1", ",", "normocoloreado", "y", "normohidratado", ",", "eupneico", "en", "reposo", ".", "\n", "»", "La", "cavidad", "oral", "no", "presentaba", "lesión", "alguna", ".", "En", "la", "palpación", "no", "se", "encontraban", "adenopatías", ".", "\n", "»", "En", "la", "auscultación", "cardiorrespiratoria", "sólo", "apreciamos", "una", "hipoventilación", "global", ".", "\n", "»", "La", "exploración", "a", "nivel", "abdominal", ",", "miembros", "inferiores", ",", "y", "a", "nivel", "neurológico", "eran", "completamente", "normales", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "El", "paciente", "es", "valorado", "por", "Otorrinolaringología", ",", "quienes", ",", "en", "la", "fibrobroncoscopia", ",", "aprecian", "una", "parálisis", "de", "cuerda", "vocal", "izquierda", ".", "\n", "»", "En", "la", "radiografía", "de", "tórax", "que", "se", "realiza", "se", "observa", "una", "masa", "hiliar", "izquierda", "que", "provoca", "una", "atelectasia", "de", "lóbulo", "superior", "izquierdo", ".", "\n", "»", "En", "la", "TC", "torácica", "se", "aprecia", "una", "masa", "hiliar", "izquierda", "con", "extensión", "a", "mediastino", ",", "hacia", "ventana", "aortopulmonar", ",", "con", "unas", "dimensiones", "de", "10", "x", "5,4", "x", "5,3", "cm", ",", "sin", "verse", "adenopatías", ".", "\n", "»", "Se", "realiza", "broncoscopia", ",", "que", "observa", "signos", "directos", "de", "neoplasia", "a", "la", "entrada", "del", "lóbulo", "superior", "izquierdo", ".", "Se", "toman", "muestras", ",", "y", "en", "la", "Anatomía", "Patológica", "se", "informa", "un", "adenocarcinoma", "de", "pulmón", ".", "EGFR", ",", "ALK", "y", "ROS-1", "negativo", ".", "PD", "-", "L1", "no", "evaluable", ".", "\n", "»", "En", "estudio", "de", "extensión", "con", "PET", "/", "TC", ",", "se", "aprecia", ",", "además", "de", "la", "masa", "pulmonar", ",", "afectación", "metastásica", "en", "diáfisis", "proximal", "de", "fémur", "izquierdo", "(", "1", "lesión", "de", "4,3", "x", "2,8", "cm", "con", "SUV", "7,3", ")", "y", "a", "nivel", "de", "pala", "iliaca", "derecha", "(", "1", "lesión", "de", "15", "mm", "con", "SUV", "7,1", ")", ".", "\n\n", "Diagnóstico", "\n", "Por", "tanto", ",", "con", "todo", "el", "estudio", "de", "extensión", "realizado", ",", "llegamos", "al", "diagnóstico", "de", "adenocarcinoma", "de", "pulmón", "EGFR", ",", "ALK", ",", "ROS-1", "y", "PD", "-", "L1", "no", "medido", ",", "estadio", "IVB", ".", "\n\n", "Tratamiento", "\n", "Se", "realiza", "tratamiento", "con", "radioterapia", "externa", "(", "RT", ")", "sobre", "lesión", "de", "fémur", "izquierdo", "para", "control", "sintomático", "del", "dolor", ".", "En", "total", "se", "administraron", "30", "Grays", "(", "Gy", ")", "en", "10", "sesiones", ".", "\n", "Se", "decidió", "incluir", "al", "paciente", "en", "ensayo", "clínico", ",", "iniciándose", "tratamiento", "con", "4", "ciclos", "de", "cisplatino", "+", "pemetrexed", "+", "ipilimumab", "+", "nivolumab", ",", "y", "posterior", "mantenimiento", "con", "ipilimumab", "+", "nivolumab", "hasta", "tolerancia", "o", "progresión", "del", "paciente", ".", "\n", "Los", "cuatro", "ciclos", "de", "quimioinmunoterapia", "se", "administraron", "entre", "el", "04/07/2018", "y", "el", "06/09/2018", ".", "\n", "Posteriormente", ",", "se", "continuó", "administrando", "ciclos", "de", "mantenimiento", "con", "ipilimumab", "+", "nivolumab", "que", "comenzó", "el", "27/09/2018", ",", "llegando", "a", "administrarse", "un", "total", "de", "3", "ciclos", ",", "el", "último", "el", "08/11/2018", ".", "\n\n", "Evolución", "\n", "Tras", "los", "primeros", "4", "ciclos", "se", "realiza", "TC", "de", "evaluación", "de", "respuesta", ",", "el", "22/08/2018", ",", "apreciándose", "enfermedad", "estable", "según", "criterios", "RECIST", ".", "\n", "El", "08/10/2018", ",", "se", "realiza", "nueva", "TC", "de", "evaluación", "tras", "1", "dosis", "de", "mantenimiento", "con", "inmunoterapia", ",", "observándose", "una", "respuesta", "parcial", ".", "\n", "En", "analítica", "de", "control", "del", "18/10/2018", "se", "aprecia", "un", "hipotiroidismo", ",", "con", "niveles", "elevados", "de", "TSH", "y", "descenso", "de", "T4", "libre", ",", "por", "lo", "que", "se", "instaura", "tratamiento", "con", "levotiroxina", "50", "mcg", "1", "comprimido", "al", "día", ",", "llegándose", "al", "probable", "diagnóstico", "de", "hipotiroidismo", "autoinmune", "asociado", "a", "inmunoterapia", ".", "\n", "El", "paciente", "acude", "a", "consulta", "el", "29/11/2018", ",", "tras", "el", "4º", "ciclo", "de", "mantenimiento", ",", "con", "clínica", "de", "astenia", ",", "diarrea", ",", "y", "dolor", "en", "hipocondrio", "derecho", ".", "Analíticamente", "se", "objetiva", "elevación", "de", "transaminasas", ",", "llegando", "a", "alcanzar", "toxicidad", "hepática", "grado", "3", ",", "por", "lo", "que", "en", "este", "contexto", "se", "procede", "a", "ingresar", "al", "paciente", "para", "monitorización", "y", "tratamiento", "con", "corticoides", "a", "dosis", "de", "metilprednisolona", "2", "mg", "/", "kg", "/", "día", ".", "Se", "realiza", "una", "serología", "para", "virus", "hepatotropos", ",", "resultando", "negativa", "para", "los", "mismos", ",", "y", "con", "la", "corticoterapia", "administrada", "se", "logra", "mejoría", "de", "los", "niveles", "de", "transaminasas", ",", "así", "como", "mejoría", "clínica", "por", "lo", "que", "se", "llega", "al", "diagnóstico", "de", "hepatitis", "autoinmune", "secundaria", "a", "inmunoterapia", ".", "Se", "realiza", "un", "descenso", "progresivo", "de", "la", "corticoterapia", ",", "y", "se", "da", "de", "alta", "al", "paciente", "continuando", "con", "la", "corticoterapia", "en", "pauta", "descendente", "progresiva", ".", "\n", "El", "17/12/2018", "el", "paciente", "acude", "a", "Urgencias", "por", "un", "cuadro", "de", "malestar", "general", ",", "vómitos", ",", "y", "aparición", "de", "pico", "febril", ".", "Analíticamente", "se", "objetiva", "empeoramiento", "importante", "del", "nivel", "de", "transaminasas", ",", "estando", "de", "nuevo", "en", "niveles", "de", "toxicidad", "grado", "3", ",", "un", "rash", "cutáneo", "maculopapular", "que", "afecta", "a", "más", "de", "la", "mitad", "de", "la", "superficie", "corporal", ",", "y", "un", "deterioro", "de", "la", "función", "renal", "alcanzando", "también", "toxicidad", "grado", "\n", "3", ".", "Por", "todo", "ello", ",", "se", "procede", "a", "ingresar", "de", "nuevo", "al", "paciente", "para", "volver", "a", "escalar", "la", "corticoterapia", "a", "dosis", "de", "2", "mg", "/", "kg", "/", "día", ".", "En", "esta", "ocasión", ",", "se", "consigue", "una", "mejoría", "transitoria", ",", "sin", "lograr", "corregir", "los", "parámetros", "analíticos", ",", "y", "en", "los", "días", "sucesivos", "empieza", "a", "aparecer", "elevación", "de", "marcadores", "de", "citólisis", "y", "colestasis", ".", "Se", "realiza", "una", "ecografía", "abdominal", "y", "colangio", "-", "RM", "que", "descartan", "una", "complicación", "aguda", "infecciosa", "/", "vascular", "/", "tumoral", "y", ",", "siguiendo", "las", "guías", "clínicas", ",", "se", "decide", "plantear", "seguimiento", "conjunto", "con", "hepatología", "y", "realización", "de", "biopsia", "hepática", ".", "Esta", "se", "realiza", "el", "02/01/2019", ",", "objetivándose", "en", "la", "misma", "un", "patrón", "lesional", "mixto", "colestásico", "con", "inflamación", "portal", "y", "marcada", "dilatación", "sinusoidal", ",", "sin", "apreciarse", "fibrosis", ".", "Estos", "datos", "son", "compatibles", "con", "un", "síndrome", "venoclusivo", "incipiente", ".", "En", "cuanto", "al", "rash", ",", "se", "realiza", "una", "solicitud", "de", "valoración", "a", "Alergología", "y", "Dermatología", ",", "puesto", "que", "el", "paciente", "lo", "achaca", "a", "una", "primera", "toma", "de", "alopurinol", "por", "hiperuricemia", ",", "y", "se", "llega", "a", "la", "conclusión", "final", "de", "que", "podría", "tratarse", "de", "un", "síndrome", "de", "Dress", "potenciado", "por", "la", "inmunoterapia", ".", "Queda", "en", "duda", "el", "papel", "del", "alopurinol", ",", "debido", "a", "la", "secuencia", "temporal", "en", "la", "que", "se", "producen", "los", "hechos", ".", "Dados", "estos", "resultados", ",", "se", "achaca", "el", "deterioro", "clínico", "y", "analítico", "a", "una", "hepatotoxicidad", "autoinmune", "refractaria", "a", "corticoterapia", ",", "y", "se", "procede", "a", "iniciar", "micofenolato", "mofetilo", "a", "dosis", "de", "1", "g", "cada", "12", "horas", ".", "Tras", "la", "instauración", "del", "tratamiento", ",", "se", "objetiva", "una", "mejoría", "parcial", "de", "la", "función", "hepática", "y", "del", "estado", "general", "que", "permiten", "dar", "de", "alta", "al", "paciente", "el", "11/01/2019", "con", "seguimiento", "estricto", "por", "consultas", "externas", ",", "y", "con", "suspensión", "de", "los", "ciclos", "de", "mantenimiento", ".", "\n", "En", "la", "TC", "de", "reevaluación", "de", "la", "enfermedad", "el", "04/02/2019", ",", "se", "detecta", "aún", "respuesta", "parcial", "de", "la", "enfermedad", "oncológica", ".", "Sin", "embargo", ",", "se", "revelan", "hallazgos", "característicos", "de", "enfermedad", "venoclusiva", "hepática", "establecida", ",", "con", "marcada", "alteración", "de", "la", "perfusión", "hepática", ",", "edema", "periportal", "y", "edema", "de", "pared", "vesicular", ",", "así", "como", "abundante", "cantidad", "de", "líquido", "ascítico", ".", "\n", "Finalmente", ",", "el", "paciente", "es", "traído", "a", "Urgencias", "por", "deterioro", "súbito", "del", "nivel", "de", "conciencia", "el", "22/02/2019", ",", "objetivándose", "desconexión", "completa", "del", "medio", ",", "abdomen", "distendido", ",", "hipotensión", "y", "taquicardia", ".", "A", "pesar", "de", "tratamiento", "inicial", "con", "antibioterapia", "y", "fluidoterapia", "intensiva", ",", "persiste", "el", "deterioro", "a", "nivel", "clínico", "y", "hemodinámico", ",", "por", "lo", "que", ",", "tras", "hablar", "de", "la", "situación", "con", "la", "familia", ",", "se", "acuerda", "inicio", "de", "sedación", "paliativa", "del", "paciente", ".", "A", "las", "pocas", "horas", "del", "inicio", "de", "la", "misma", ",", "se", "produce", "el", "exitus", "el", "mismo", "día", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
neoplasia is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, tumoral is a MORFOLOGIA_NEOPLASIA
531_task1
Sentence: Anamnesis Se trata de un varón de 60 años sin alergias conocidas, independiente para las actividades básicas de la vida diaria que, como antecedentes médicos de interés, tiene un consumo acumulado de tabaco de 40 años-paquete, así como un hábito enólico superior a 40 g/día que había abandonado hacía 2 años. No hay otros antecedentes de interés en el momento de inicio de la clínica. No hay antecedentes familiares de interés. Comienza en marzo de 2018 con un cuadro de disfonía de 1 mes de evolución que no mejora con tratamiento con corticoides a dosis bajas y reposo vocal, pautados en diversas consultas al servicio de Urgencias. Exploración física » Durante la exploración física encontramos un varón con buen estado general, ECOG 1, normocoloreado y normohidratado, eupneico en reposo. » La cavidad oral no presentaba lesión alguna. En la palpación no se encontraban adenopatías. » En la auscultación cardiorrespiratoria sólo apreciamos una hipoventilación global. » La exploración a nivel abdominal, miembros inferiores, y a nivel neurológico eran completamente normales. Pruebas complementarias » El paciente es valorado por Otorrinolaringología, quienes, en la fibrobroncoscopia, aprecian una parálisis de cuerda vocal izquierda. » En la radiografía de tórax que se realiza se observa una masa hiliar izquierda que provoca una atelectasia de lóbulo superior izquierdo. » En la TC torácica se aprecia una masa hiliar izquierda con extensión a mediastino, hacia ventana aortopulmonar, con unas dimensiones de 10 x 5,4 x 5,3cm, sin verse adenopatías. » Se realiza broncoscopia, que observa signos directos de neoplasia a la entrada del lóbulo superior izquierdo. Se toman muestras, y en la Anatomía Patológica se informa un adenocarcinoma de pulmón. EGFR, ALK y ROS-1 negativo. PD-L1 no evaluable. » En estudio de extensión con PET/TC, se aprecia, además de la masa pulmonar, afectación metastásica en diáfisis proximal de fémur izquierdo (1 lesión de 4,3 x 2,8 cm con SUV 7,3) y a nivel de pala iliaca derecha (1 lesión de 15 mm con SUV 7,1). Diagnóstico Por tanto, con todo el estudio de extensión realizado, llegamos al diagnóstico de adenocarcinoma de pulmón EGFR, ALK, ROS-1 y PD-L1 no medido, estadio IVB. Tratamiento Se realiza tratamiento con radioterapia externa (RT) sobre lesión de fémur izquierdo para control sintomático del dolor. En total se administraron 30 Grays (Gy) en 10 sesiones. Se decidió incluir al paciente en ensayo clínico, iniciándose tratamiento con 4 ciclos de cisplatino + pemetrexed + ipilimumab + nivolumab, y posterior mantenimiento con ipilimumab + nivolumab hasta tolerancia o progresión del paciente. Los cuatro ciclos de quimioinmunoterapia se administraron entre el 04/07/2018 y el 06/09/2018. Posteriormente, se continuó administrando ciclos de mantenimiento con ipilimumab + nivolumab que comenzó el 27/09/2018, llegando a administrarse un total de 3 ciclos, el último el 08/11/2018. Evolución Tras los primeros 4 ciclos se realiza TC de evaluación de respuesta, el 22/08/2018, apreciándose enfermedad estable según criterios RECIST. El 08/10/2018, se realiza nueva TC de evaluación tras 1 dosis de mantenimiento con inmunoterapia, observándose una respuesta parcial. En analítica de control del 18/10/2018 se aprecia un hipotiroidismo, con niveles elevados de TSH y descenso de T4 libre, por lo que se instaura tratamiento con levotiroxina 50 mcg 1 comprimido al día, llegándose al probable diagnóstico de hipotiroidismo autoinmune asociado a inmunoterapia. El paciente acude a consulta el 29/11/2018, tras el 4º ciclo de mantenimiento, con clínica de astenia, diarrea, y dolor en hipocondrio derecho. Analíticamente se objetiva elevación de transaminasas, llegando a alcanzar toxicidad hepática grado 3, por lo que en este contexto se procede a ingresar al paciente para monitorización y tratamiento con corticoides a dosis de metilprednisolona 2 mg/kg/día. Se realiza una serología para virus hepatotropos, resultando negativa para los mismos, y con la corticoterapia administrada se logra mejoría de los niveles de transaminasas, así como mejoría clínica por lo que se llega al diagnóstico de hepatitis autoinmune secundaria a inmunoterapia. Se realiza un descenso progresivo de la corticoterapia, y se da de alta al paciente continuando con la corticoterapia en pauta descendente progresiva. El 17/12/2018 el paciente acude a Urgencias por un cuadro de malestar general, vómitos, y aparición de pico febril. Analíticamente se objetiva empeoramiento importante del nivel de transaminasas, estando de nuevo en niveles de toxicidad grado 3, un rash cutáneo maculopapular que afecta a más de la mitad de la superficie corporal, y un deterioro de la función renal alcanzando también toxicidad grado 3. Por todo ello, se procede a ingresar de nuevo al paciente para volver a escalar la corticoterapia a dosis de 2 mg/kg/día. En esta ocasión, se consigue una mejoría transitoria, sin lograr corregir los parámetros analíticos, y en los días sucesivos empieza a aparecer elevación de marcadores de citólisis y colestasis. Se realiza una ecografía abdominal y colangio-RM que descartan una complicación aguda infecciosa/vascular/tumoral y, siguiendo las guías clínicas, se decide plantear seguimiento conjunto con hepatología y realización de biopsia hepática. Esta se realiza el 02/01/2019, objetivándose en la misma un patrón lesional mixto colestásico con inflamación portal y marcada dilatación sinusoidal, sin apreciarse fibrosis. Estos datos son compatibles con un síndrome venoclusivo incipiente. En cuanto al rash, se realiza una solicitud de valoración a Alergología y Dermatología, puesto que el paciente lo achaca a una primera toma de alopurinol por hiperuricemia, y se llega a la conclusión final de que podría tratarse de un síndrome de Dress potenciado por la inmunoterapia. Queda en duda el papel del alopurinol, debido a la secuencia temporal en la que se producen los hechos. Dados estos resultados, se achaca el deterioro clínico y analítico a una hepatotoxicidad autoinmune refractaria a corticoterapia, y se procede a iniciar micofenolato mofetilo a dosis de 1 g cada 12 horas. Tras la instauración del tratamiento, se objetiva una mejoría parcial de la función hepática y del estado general que permiten dar de alta al paciente el 11/01/2019 con seguimiento estricto por consultas externas, y con suspensión de los ciclos de mantenimiento. En la TC de reevaluación de la enfermedad el 04/02/2019, se detecta aún respuesta parcial de la enfermedad oncológica. Sin embargo, se revelan hallazgos característicos de enfermedad venoclusiva hepática establecida, con marcada alteración de la perfusión hepática, edema periportal y edema de pared vesicular, así como abundante cantidad de líquido ascítico. Finalmente, el paciente es traído a Urgencias por deterioro súbito del nivel de conciencia el 22/02/2019, objetivándose desconexión completa del medio, abdomen distendido, hipotensión y taquicardia. A pesar de tratamiento inicial con antibioterapia y fluidoterapia intensiva, persiste el deterioro a nivel clínico y hemodinámico, por lo que, tras hablar de la situación con la familia, se acuerda inicio de sedación paliativa del paciente. A las pocas horas del inicio de la misma, se produce el exitus el mismo día. Instructions: please typing these entity words according to sentence: neoplasia, adenocarcinoma, metastásica, adenocarcinoma, tumoral Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Se trata de un varón de 60 años sin alergias conocidas, independiente para las actividades básicas de la vida diaria que, como antecedentes médicos de interés, tiene un consumo acumulado de tabaco de 40 años-paquete, así como un hábito enólico superior a 40 g/día que había abandonado hacía 2 años. No hay otros antecedentes de interés en el momento de inicio de la clínica. No hay antecedentes familiares de interés. Comienza en marzo de 2018 con un cuadro de disfonía de 1 mes de evolución que no mejora con tratamiento con corticoides a dosis bajas y reposo vocal, pautados en diversas consultas al servicio de Urgencias. Exploración física » Durante la exploración física encontramos un varón con buen estado general, ECOG 1, normocoloreado y normohidratado, eupneico en reposo. » La cavidad oral no presentaba lesión alguna. En la palpación no se encontraban adenopatías. » En la auscultación cardiorrespiratoria sólo apreciamos una hipoventilación global. » La exploración a nivel abdominal, miembros inferiores, y a nivel neurológico eran completamente normales. Pruebas complementarias » El paciente es valorado por Otorrinolaringología, quienes, en la fibrobroncoscopia, aprecian una parálisis de cuerda vocal izquierda. » En la radiografía de tórax que se realiza se observa una masa hiliar izquierda que provoca una atelectasia de lóbulo superior izquierdo. » En la TC torácica se aprecia una masa hiliar izquierda con extensión a mediastino, hacia ventana aortopulmonar, con unas dimensiones de 10 x 5,4 x 5,3cm, sin verse adenopatías. » Se realiza broncoscopia, que observa signos directos de neoplasia a la entrada del lóbulo superior izquierdo. Se toman muestras, y en la Anatomía Patológica se informa un adenocarcinoma de pulmón. EGFR, ALK y ROS-1 negativo. PD-L1 no evaluable. » En estudio de extensión con PET/TC, se aprecia, además de la masa pulmonar, afectación metastásica en diáfisis proximal de fémur izquierdo (1 lesión de 4,3 x 2,8 cm con SUV 7,3) y a nivel de pala iliaca derecha (1 lesión de 15 mm con SUV 7,1). Diagnóstico Por tanto, con todo el estudio de extensión realizado, llegamos al diagnóstico de adenocarcinoma de pulmón EGFR, ALK, ROS-1 y PD-L1 no medido, estadio IVB. Tratamiento Se realiza tratamiento con radioterapia externa (RT) sobre lesión de fémur izquierdo para control sintomático del dolor. En total se administraron 30 Grays (Gy) en 10 sesiones. Se decidió incluir al paciente en ensayo clínico, iniciándose tratamiento con 4 ciclos de cisplatino + pemetrexed + ipilimumab + nivolumab, y posterior mantenimiento con ipilimumab + nivolumab hasta tolerancia o progresión del paciente. Los cuatro ciclos de quimioinmunoterapia se administraron entre el 04/07/2018 y el 06/09/2018. Posteriormente, se continuó administrando ciclos de mantenimiento con ipilimumab + nivolumab que comenzó el 27/09/2018, llegando a administrarse un total de 3 ciclos, el último el 08/11/2018. Evolución Tras los primeros 4 ciclos se realiza TC de evaluación de respuesta, el 22/08/2018, apreciándose enfermedad estable según criterios RECIST. El 08/10/2018, se realiza nueva TC de evaluación tras 1 dosis de mantenimiento con inmunoterapia, observándose una respuesta parcial. En analítica de control del 18/10/2018 se aprecia un hipotiroidismo, con niveles elevados de TSH y descenso de T4 libre, por lo que se instaura tratamiento con levotiroxina 50 mcg 1 comprimido al día, llegándose al probable diagnóstico de hipotiroidismo autoinmune asociado a inmunoterapia. El paciente acude a consulta el 29/11/2018, tras el 4º ciclo de mantenimiento, con clínica de astenia, diarrea, y dolor en hipocondrio derecho. Analíticamente se objetiva elevación de transaminasas, llegando a alcanzar toxicidad hepática grado 3, por lo que en este contexto se procede a ingresar al paciente para monitorización y tratamiento con corticoides a dosis de metilprednisolona 2 mg/kg/día. Se realiza una serología para virus hepatotropos, resultando negativa para los mismos, y con la corticoterapia administrada se logra mejoría de los niveles de transaminasas, así como mejoría clínica por lo que se llega al diagnóstico de hepatitis autoinmune secundaria a inmunoterapia. Se realiza un descenso progresivo de la corticoterapia, y se da de alta al paciente continuando con la corticoterapia en pauta descendente progresiva. El 17/12/2018 el paciente acude a Urgencias por un cuadro de malestar general, vómitos, y aparición de pico febril. Analíticamente se objetiva empeoramiento importante del nivel de transaminasas, estando de nuevo en niveles de toxicidad grado 3, un rash cutáneo maculopapular que afecta a más de la mitad de la superficie corporal, y un deterioro de la función renal alcanzando también toxicidad grado 3. Por todo ello, se procede a ingresar de nuevo al paciente para volver a escalar la corticoterapia a dosis de 2 mg/kg/día. En esta ocasión, se consigue una mejoría transitoria, sin lograr corregir los parámetros analíticos, y en los días sucesivos empieza a aparecer elevación de marcadores de citólisis y colestasis. Se realiza una ecografía abdominal y colangio-RM que descartan una complicación aguda infecciosa/vascular/tumoral y, siguiendo las guías clínicas, se decide plantear seguimiento conjunto con hepatología y realización de biopsia hepática. Esta se realiza el 02/01/2019, objetivándose en la misma un patrón lesional mixto colestásico con inflamación portal y marcada dilatación sinusoidal, sin apreciarse fibrosis. Estos datos son compatibles con un síndrome venoclusivo incipiente. En cuanto al rash, se realiza una solicitud de valoración a Alergología y Dermatología, puesto que el paciente lo achaca a una primera toma de alopurinol por hiperuricemia, y se llega a la conclusión final de que podría tratarse de un síndrome de Dress potenciado por la inmunoterapia. Queda en duda el papel del alopurinol, debido a la secuencia temporal en la que se producen los hechos. Dados estos resultados, se achaca el deterioro clínico y analítico a una hepatotoxicidad autoinmune refractaria a corticoterapia, y se procede a iniciar micofenolato mofetilo a dosis de 1 g cada 12 horas. Tras la instauración del tratamiento, se objetiva una mejoría parcial de la función hepática y del estado general que permiten dar de alta al paciente el 11/01/2019 con seguimiento estricto por consultas externas, y con suspensión de los ciclos de mantenimiento. En la TC de reevaluación de la enfermedad el 04/02/2019, se detecta aún respuesta parcial de la enfermedad oncológica. Sin embargo, se revelan hallazgos característicos de enfermedad venoclusiva hepática establecida, con marcada alteración de la perfusión hepática, edema periportal y edema de pared vesicular, así como abundante cantidad de líquido ascítico. Finalmente, el paciente es traído a Urgencias por deterioro súbito del nivel de conciencia el 22/02/2019, objetivándose desconexión completa del medio, abdomen distendido, hipotensión y taquicardia. A pesar de tratamiento inicial con antibioterapia y fluidoterapia intensiva, persiste el deterioro a nivel clínico y hemodinámico, por lo que, tras hablar de la situación con la familia, se acuerda inicio de sedación paliativa del paciente. A las pocas horas del inicio de la misma, se produce el exitus el mismo día.
[ "Anamnesis", "\n", "Se", "trata", "de", "un", "varón", "de", "60", "años", "sin", "alergias", "conocidas", ",", "independiente", "para", "las", "actividades", "básicas", "de", "la", "vida", "diaria", "que", ",", "como", "antecedentes", "médicos", "de", "interés", ",", "tiene", "un", "consumo", "acumulado", "de", "tabaco", "de", "40", "años", "-", "paquete", ",", "así", "como", "un", "hábito", "enólico", "superior", "a", "40", "g", "/", "día", "que", "había", "abandonado", "hacía", "2", "años", ".", "No", "hay", "otros", "antecedentes", "de", "interés", "en", "el", "momento", "de", "inicio", "de", "la", "clínica", ".", "No", "hay", "antecedentes", "familiares", "de", "interés", ".", "\n", "Comienza", "en", "marzo", "de", "2018", "con", "un", "cuadro", "de", "disfonía", "de", "1", "mes", "de", "evolución", "que", "no", "mejora", "con", "tratamiento", "con", "corticoides", "a", "dosis", "bajas", "y", "reposo", "vocal", ",", "pautados", "en", "diversas", "consultas", "al", "servicio", "de", "Urgencias", ".", "\n\n", "Exploración", "física", "\n", "»", "Durante", "la", "exploración", "física", "encontramos", "un", "varón", "con", "buen", "estado", "general", ",", "ECOG", "1", ",", "normocoloreado", "y", "normohidratado", ",", "eupneico", "en", "reposo", ".", "\n", "»", "La", "cavidad", "oral", "no", "presentaba", "lesión", "alguna", ".", "En", "la", "palpación", "no", "se", "encontraban", "adenopatías", ".", "\n", "»", "En", "la", "auscultación", "cardiorrespiratoria", "sólo", "apreciamos", "una", "hipoventilación", "global", ".", "\n", "»", "La", "exploración", "a", "nivel", "abdominal", ",", "miembros", "inferiores", ",", "y", "a", "nivel", "neurológico", "eran", "completamente", "normales", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "El", "paciente", "es", "valorado", "por", "Otorrinolaringología", ",", "quienes", ",", "en", "la", "fibrobroncoscopia", ",", "aprecian", "una", "parálisis", "de", "cuerda", "vocal", "izquierda", ".", "\n", "»", "En", "la", "radiografía", "de", "tórax", "que", "se", "realiza", "se", "observa", "una", "masa", "hiliar", "izquierda", "que", "provoca", "una", "atelectasia", "de", "lóbulo", "superior", "izquierdo", ".", "\n", "»", "En", "la", "TC", "torácica", "se", "aprecia", "una", "masa", "hiliar", "izquierda", "con", "extensión", "a", "mediastino", ",", "hacia", "ventana", "aortopulmonar", ",", "con", "unas", "dimensiones", "de", "10", "x", "5,4", "x", "5,3", "cm", ",", "sin", "verse", "adenopatías", ".", "\n", "»", "Se", "realiza", "broncoscopia", ",", "que", "observa", "signos", "directos", "de", "neoplasia", "a", "la", "entrada", "del", "lóbulo", "superior", "izquierdo", ".", "Se", "toman", "muestras", ",", "y", "en", "la", "Anatomía", "Patológica", "se", "informa", "un", "adenocarcinoma", "de", "pulmón", ".", "EGFR", ",", "ALK", "y", "ROS-1", "negativo", ".", "PD", "-", "L1", "no", "evaluable", ".", "\n", "»", "En", "estudio", "de", "extensión", "con", "PET", "/", "TC", ",", "se", "aprecia", ",", "además", "de", "la", "masa", "pulmonar", ",", "afectación", "metastásica", "en", "diáfisis", "proximal", "de", "fémur", "izquierdo", "(", "1", "lesión", "de", "4,3", "x", "2,8", "cm", "con", "SUV", "7,3", ")", "y", "a", "nivel", "de", "pala", "iliaca", "derecha", "(", "1", "lesión", "de", "15", "mm", "con", "SUV", "7,1", ")", ".", "\n\n", "Diagnóstico", "\n", "Por", "tanto", ",", "con", "todo", "el", "estudio", "de", "extensión", "realizado", ",", "llegamos", "al", "diagnóstico", "de", "adenocarcinoma", "de", "pulmón", "EGFR", ",", "ALK", ",", "ROS-1", "y", "PD", "-", "L1", "no", "medido", ",", "estadio", "IVB", ".", "\n\n", "Tratamiento", "\n", "Se", "realiza", "tratamiento", "con", "radioterapia", "externa", "(", "RT", ")", "sobre", "lesión", "de", "fémur", "izquierdo", "para", "control", "sintomático", "del", "dolor", ".", "En", "total", "se", "administraron", "30", "Grays", "(", "Gy", ")", "en", "10", "sesiones", ".", "\n", "Se", "decidió", "incluir", "al", "paciente", "en", "ensayo", "clínico", ",", "iniciándose", "tratamiento", "con", "4", "ciclos", "de", "cisplatino", "+", "pemetrexed", "+", "ipilimumab", "+", "nivolumab", ",", "y", "posterior", "mantenimiento", "con", "ipilimumab", "+", "nivolumab", "hasta", "tolerancia", "o", "progresión", "del", "paciente", ".", "\n", "Los", "cuatro", "ciclos", "de", "quimioinmunoterapia", "se", "administraron", "entre", "el", "04/07/2018", "y", "el", "06/09/2018", ".", "\n", "Posteriormente", ",", "se", "continuó", "administrando", "ciclos", "de", "mantenimiento", "con", "ipilimumab", "+", "nivolumab", "que", "comenzó", "el", "27/09/2018", ",", "llegando", "a", "administrarse", "un", "total", "de", "3", "ciclos", ",", "el", "último", "el", "08/11/2018", ".", "\n\n", "Evolución", "\n", "Tras", "los", "primeros", "4", "ciclos", "se", "realiza", "TC", "de", "evaluación", "de", "respuesta", ",", "el", "22/08/2018", ",", "apreciándose", "enfermedad", "estable", "según", "criterios", "RECIST", ".", "\n", "El", "08/10/2018", ",", "se", "realiza", "nueva", "TC", "de", "evaluación", "tras", "1", "dosis", "de", "mantenimiento", "con", "inmunoterapia", ",", "observándose", "una", "respuesta", "parcial", ".", "\n", "En", "analítica", "de", "control", "del", "18/10/2018", "se", "aprecia", "un", "hipotiroidismo", ",", "con", "niveles", "elevados", "de", "TSH", "y", "descenso", "de", "T4", "libre", ",", "por", "lo", "que", "se", "instaura", "tratamiento", "con", "levotiroxina", "50", "mcg", "1", "comprimido", "al", "día", ",", "llegándose", "al", "probable", "diagnóstico", "de", "hipotiroidismo", "autoinmune", "asociado", "a", "inmunoterapia", ".", "\n", "El", "paciente", "acude", "a", "consulta", "el", "29/11/2018", ",", "tras", "el", "4º", "ciclo", "de", "mantenimiento", ",", "con", "clínica", "de", "astenia", ",", "diarrea", ",", "y", "dolor", "en", "hipocondrio", "derecho", ".", "Analíticamente", "se", "objetiva", "elevación", "de", "transaminasas", ",", "llegando", "a", "alcanzar", "toxicidad", "hepática", "grado", "3", ",", "por", "lo", "que", "en", "este", "contexto", "se", "procede", "a", "ingresar", "al", "paciente", "para", "monitorización", "y", "tratamiento", "con", "corticoides", "a", "dosis", "de", "metilprednisolona", "2", "mg", "/", "kg", "/", "día", ".", "Se", "realiza", "una", "serología", "para", "virus", "hepatotropos", ",", "resultando", "negativa", "para", "los", "mismos", ",", "y", "con", "la", "corticoterapia", "administrada", "se", "logra", "mejoría", "de", "los", "niveles", "de", "transaminasas", ",", "así", "como", "mejoría", "clínica", "por", "lo", "que", "se", "llega", "al", "diagnóstico", "de", "hepatitis", "autoinmune", "secundaria", "a", "inmunoterapia", ".", "Se", "realiza", "un", "descenso", "progresivo", "de", "la", "corticoterapia", ",", "y", "se", "da", "de", "alta", "al", "paciente", "continuando", "con", "la", "corticoterapia", "en", "pauta", "descendente", "progresiva", ".", "\n", "El", "17/12/2018", "el", "paciente", "acude", "a", "Urgencias", "por", "un", "cuadro", "de", "malestar", "general", ",", "vómitos", ",", "y", "aparición", "de", "pico", "febril", ".", "Analíticamente", "se", "objetiva", "empeoramiento", "importante", "del", "nivel", "de", "transaminasas", ",", "estando", "de", "nuevo", "en", "niveles", "de", "toxicidad", "grado", "3", ",", "un", "rash", "cutáneo", "maculopapular", "que", "afecta", "a", "más", "de", "la", "mitad", "de", "la", "superficie", "corporal", ",", "y", "un", "deterioro", "de", "la", "función", "renal", "alcanzando", "también", "toxicidad", "grado", "\n", "3", ".", "Por", "todo", "ello", ",", "se", "procede", "a", "ingresar", "de", "nuevo", "al", "paciente", "para", "volver", "a", "escalar", "la", "corticoterapia", "a", "dosis", "de", "2", "mg", "/", "kg", "/", "día", ".", "En", "esta", "ocasión", ",", "se", "consigue", "una", "mejoría", "transitoria", ",", "sin", "lograr", "corregir", "los", "parámetros", "analíticos", ",", "y", "en", "los", "días", "sucesivos", "empieza", "a", "aparecer", "elevación", "de", "marcadores", "de", "citólisis", "y", "colestasis", ".", "Se", "realiza", "una", "ecografía", "abdominal", "y", "colangio", "-", "RM", "que", "descartan", "una", "complicación", "aguda", "infecciosa", "/", "vascular", "/", "tumoral", "y", ",", "siguiendo", "las", "guías", "clínicas", ",", "se", "decide", "plantear", "seguimiento", "conjunto", "con", "hepatología", "y", "realización", "de", "biopsia", "hepática", ".", "Esta", "se", "realiza", "el", "02/01/2019", ",", "objetivándose", "en", "la", "misma", "un", "patrón", "lesional", "mixto", "colestásico", "con", "inflamación", "portal", "y", "marcada", "dilatación", "sinusoidal", ",", "sin", "apreciarse", "fibrosis", ".", "Estos", "datos", "son", "compatibles", "con", "un", "síndrome", "venoclusivo", "incipiente", ".", "En", "cuanto", "al", "rash", ",", "se", "realiza", "una", "solicitud", "de", "valoración", "a", "Alergología", "y", "Dermatología", ",", "puesto", "que", "el", "paciente", "lo", "achaca", "a", "una", "primera", "toma", "de", "alopurinol", "por", "hiperuricemia", ",", "y", "se", "llega", "a", "la", "conclusión", "final", "de", "que", "podría", "tratarse", "de", "un", "síndrome", "de", "Dress", "potenciado", "por", "la", "inmunoterapia", ".", "Queda", "en", "duda", "el", "papel", "del", "alopurinol", ",", "debido", "a", "la", "secuencia", "temporal", "en", "la", "que", "se", "producen", "los", "hechos", ".", "Dados", "estos", "resultados", ",", "se", "achaca", "el", "deterioro", "clínico", "y", "analítico", "a", "una", "hepatotoxicidad", "autoinmune", "refractaria", "a", "corticoterapia", ",", "y", "se", "procede", "a", "iniciar", "micofenolato", "mofetilo", "a", "dosis", "de", "1", "g", "cada", "12", "horas", ".", "Tras", "la", "instauración", "del", "tratamiento", ",", "se", "objetiva", "una", "mejoría", "parcial", "de", "la", "función", "hepática", "y", "del", "estado", "general", "que", "permiten", "dar", "de", "alta", "al", "paciente", "el", "11/01/2019", "con", "seguimiento", "estricto", "por", "consultas", "externas", ",", "y", "con", "suspensión", "de", "los", "ciclos", "de", "mantenimiento", ".", "\n", "En", "la", "TC", "de", "reevaluación", "de", "la", "enfermedad", "el", "04/02/2019", ",", "se", "detecta", "aún", "respuesta", "parcial", "de", "la", "enfermedad", "oncológica", ".", "Sin", "embargo", ",", "se", "revelan", "hallazgos", "característicos", "de", "enfermedad", "venoclusiva", "hepática", "establecida", ",", "con", "marcada", "alteración", "de", "la", "perfusión", "hepática", ",", "edema", "periportal", "y", "edema", "de", "pared", "vesicular", ",", "así", "como", "abundante", "cantidad", "de", "líquido", "ascítico", ".", "\n", "Finalmente", ",", "el", "paciente", "es", "traído", "a", "Urgencias", "por", "deterioro", "súbito", "del", "nivel", "de", "conciencia", "el", "22/02/2019", ",", "objetivándose", "desconexión", "completa", "del", "medio", ",", "abdomen", "distendido", ",", "hipotensión", "y", "taquicardia", ".", "A", "pesar", "de", "tratamiento", "inicial", "con", "antibioterapia", "y", "fluidoterapia", "intensiva", ",", "persiste", "el", "deterioro", "a", "nivel", "clínico", "y", "hemodinámico", ",", "por", "lo", "que", ",", "tras", "hablar", "de", "la", "situación", "con", "la", "familia", ",", "se", "acuerda", "inicio", "de", "sedación", "paliativa", "del", "paciente", ".", "A", "las", "pocas", "horas", "del", "inicio", "de", "la", "misma", ",", "se", "produce", "el", "exitus", "el", "mismo", "día", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
neoplasia, adenocarcinoma, metastásica, adenocarcinoma, tumoral
531_task2
Sentence: Anamnesis Se trata de un varón de 60 años sin alergias conocidas, independiente para las actividades básicas de la vida diaria que, como antecedentes médicos de interés, tiene un consumo acumulado de tabaco de 40 años-paquete, así como un hábito enólico superior a 40 g/día que había abandonado hacía 2 años. No hay otros antecedentes de interés en el momento de inicio de la clínica. No hay antecedentes familiares de interés. Comienza en marzo de 2018 con un cuadro de disfonía de 1 mes de evolución que no mejora con tratamiento con corticoides a dosis bajas y reposo vocal, pautados en diversas consultas al servicio de Urgencias. Exploración física » Durante la exploración física encontramos un varón con buen estado general, ECOG 1, normocoloreado y normohidratado, eupneico en reposo. » La cavidad oral no presentaba lesión alguna. En la palpación no se encontraban adenopatías. » En la auscultación cardiorrespiratoria sólo apreciamos una hipoventilación global. » La exploración a nivel abdominal, miembros inferiores, y a nivel neurológico eran completamente normales. Pruebas complementarias » El paciente es valorado por Otorrinolaringología, quienes, en la fibrobroncoscopia, aprecian una parálisis de cuerda vocal izquierda. » En la radiografía de tórax que se realiza se observa una masa hiliar izquierda que provoca una atelectasia de lóbulo superior izquierdo. » En la TC torácica se aprecia una masa hiliar izquierda con extensión a mediastino, hacia ventana aortopulmonar, con unas dimensiones de 10 x 5,4 x 5,3cm, sin verse adenopatías. » Se realiza broncoscopia, que observa signos directos de neoplasia a la entrada del lóbulo superior izquierdo. Se toman muestras, y en la Anatomía Patológica se informa un adenocarcinoma de pulmón. EGFR, ALK y ROS-1 negativo. PD-L1 no evaluable. » En estudio de extensión con PET/TC, se aprecia, además de la masa pulmonar, afectación metastásica en diáfisis proximal de fémur izquierdo (1 lesión de 4,3 x 2,8 cm con SUV 7,3) y a nivel de pala iliaca derecha (1 lesión de 15 mm con SUV 7,1). Diagnóstico Por tanto, con todo el estudio de extensión realizado, llegamos al diagnóstico de adenocarcinoma de pulmón EGFR, ALK, ROS-1 y PD-L1 no medido, estadio IVB. Tratamiento Se realiza tratamiento con radioterapia externa (RT) sobre lesión de fémur izquierdo para control sintomático del dolor. En total se administraron 30 Grays (Gy) en 10 sesiones. Se decidió incluir al paciente en ensayo clínico, iniciándose tratamiento con 4 ciclos de cisplatino + pemetrexed + ipilimumab + nivolumab, y posterior mantenimiento con ipilimumab + nivolumab hasta tolerancia o progresión del paciente. Los cuatro ciclos de quimioinmunoterapia se administraron entre el 04/07/2018 y el 06/09/2018. Posteriormente, se continuó administrando ciclos de mantenimiento con ipilimumab + nivolumab que comenzó el 27/09/2018, llegando a administrarse un total de 3 ciclos, el último el 08/11/2018. Evolución Tras los primeros 4 ciclos se realiza TC de evaluación de respuesta, el 22/08/2018, apreciándose enfermedad estable según criterios RECIST. El 08/10/2018, se realiza nueva TC de evaluación tras 1 dosis de mantenimiento con inmunoterapia, observándose una respuesta parcial. En analítica de control del 18/10/2018 se aprecia un hipotiroidismo, con niveles elevados de TSH y descenso de T4 libre, por lo que se instaura tratamiento con levotiroxina 50 mcg 1 comprimido al día, llegándose al probable diagnóstico de hipotiroidismo autoinmune asociado a inmunoterapia. El paciente acude a consulta el 29/11/2018, tras el 4º ciclo de mantenimiento, con clínica de astenia, diarrea, y dolor en hipocondrio derecho. Analíticamente se objetiva elevación de transaminasas, llegando a alcanzar toxicidad hepática grado 3, por lo que en este contexto se procede a ingresar al paciente para monitorización y tratamiento con corticoides a dosis de metilprednisolona 2 mg/kg/día. Se realiza una serología para virus hepatotropos, resultando negativa para los mismos, y con la corticoterapia administrada se logra mejoría de los niveles de transaminasas, así como mejoría clínica por lo que se llega al diagnóstico de hepatitis autoinmune secundaria a inmunoterapia. Se realiza un descenso progresivo de la corticoterapia, y se da de alta al paciente continuando con la corticoterapia en pauta descendente progresiva. El 17/12/2018 el paciente acude a Urgencias por un cuadro de malestar general, vómitos, y aparición de pico febril. Analíticamente se objetiva empeoramiento importante del nivel de transaminasas, estando de nuevo en niveles de toxicidad grado 3, un rash cutáneo maculopapular que afecta a más de la mitad de la superficie corporal, y un deterioro de la función renal alcanzando también toxicidad grado 3. Por todo ello, se procede a ingresar de nuevo al paciente para volver a escalar la corticoterapia a dosis de 2 mg/kg/día. En esta ocasión, se consigue una mejoría transitoria, sin lograr corregir los parámetros analíticos, y en los días sucesivos empieza a aparecer elevación de marcadores de citólisis y colestasis. Se realiza una ecografía abdominal y colangio-RM que descartan una complicación aguda infecciosa/vascular/tumoral y, siguiendo las guías clínicas, se decide plantear seguimiento conjunto con hepatología y realización de biopsia hepática. Esta se realiza el 02/01/2019, objetivándose en la misma un patrón lesional mixto colestásico con inflamación portal y marcada dilatación sinusoidal, sin apreciarse fibrosis. Estos datos son compatibles con un síndrome venoclusivo incipiente. En cuanto al rash, se realiza una solicitud de valoración a Alergología y Dermatología, puesto que el paciente lo achaca a una primera toma de alopurinol por hiperuricemia, y se llega a la conclusión final de que podría tratarse de un síndrome de Dress potenciado por la inmunoterapia. Queda en duda el papel del alopurinol, debido a la secuencia temporal en la que se producen los hechos. Dados estos resultados, se achaca el deterioro clínico y analítico a una hepatotoxicidad autoinmune refractaria a corticoterapia, y se procede a iniciar micofenolato mofetilo a dosis de 1 g cada 12 horas. Tras la instauración del tratamiento, se objetiva una mejoría parcial de la función hepática y del estado general que permiten dar de alta al paciente el 11/01/2019 con seguimiento estricto por consultas externas, y con suspensión de los ciclos de mantenimiento. En la TC de reevaluación de la enfermedad el 04/02/2019, se detecta aún respuesta parcial de la enfermedad oncológica. Sin embargo, se revelan hallazgos característicos de enfermedad venoclusiva hepática establecida, con marcada alteración de la perfusión hepática, edema periportal y edema de pared vesicular, así como abundante cantidad de líquido ascítico. Finalmente, el paciente es traído a Urgencias por deterioro súbito del nivel de conciencia el 22/02/2019, objetivándose desconexión completa del medio, abdomen distendido, hipotensión y taquicardia. A pesar de tratamiento inicial con antibioterapia y fluidoterapia intensiva, persiste el deterioro a nivel clínico y hemodinámico, por lo que, tras hablar de la situación con la familia, se acuerda inicio de sedación paliativa del paciente. A las pocas horas del inicio de la misma, se produce el exitus el mismo día. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Se trata de un varón de 60 años sin alergias conocidas, independiente para las actividades básicas de la vida diaria que, como antecedentes médicos de interés, tiene un consumo acumulado de tabaco de 40 años-paquete, así como un hábito enólico superior a 40 g/día que había abandonado hacía 2 años. No hay otros antecedentes de interés en el momento de inicio de la clínica. No hay antecedentes familiares de interés. Comienza en marzo de 2018 con un cuadro de disfonía de 1 mes de evolución que no mejora con tratamiento con corticoides a dosis bajas y reposo vocal, pautados en diversas consultas al servicio de Urgencias. Exploración física » Durante la exploración física encontramos un varón con buen estado general, ECOG 1, normocoloreado y normohidratado, eupneico en reposo. » La cavidad oral no presentaba lesión alguna. En la palpación no se encontraban adenopatías. » En la auscultación cardiorrespiratoria sólo apreciamos una hipoventilación global. » La exploración a nivel abdominal, miembros inferiores, y a nivel neurológico eran completamente normales. Pruebas complementarias » El paciente es valorado por Otorrinolaringología, quienes, en la fibrobroncoscopia, aprecian una parálisis de cuerda vocal izquierda. » En la radiografía de tórax que se realiza se observa una masa hiliar izquierda que provoca una atelectasia de lóbulo superior izquierdo. » En la TC torácica se aprecia una masa hiliar izquierda con extensión a mediastino, hacia ventana aortopulmonar, con unas dimensiones de 10 x 5,4 x 5,3cm, sin verse adenopatías. » Se realiza broncoscopia, que observa signos directos de neoplasia a la entrada del lóbulo superior izquierdo. Se toman muestras, y en la Anatomía Patológica se informa un adenocarcinoma de pulmón. EGFR, ALK y ROS-1 negativo. PD-L1 no evaluable. » En estudio de extensión con PET/TC, se aprecia, además de la masa pulmonar, afectación metastásica en diáfisis proximal de fémur izquierdo (1 lesión de 4,3 x 2,8 cm con SUV 7,3) y a nivel de pala iliaca derecha (1 lesión de 15 mm con SUV 7,1). Diagnóstico Por tanto, con todo el estudio de extensión realizado, llegamos al diagnóstico de adenocarcinoma de pulmón EGFR, ALK, ROS-1 y PD-L1 no medido, estadio IVB. Tratamiento Se realiza tratamiento con radioterapia externa (RT) sobre lesión de fémur izquierdo para control sintomático del dolor. En total se administraron 30 Grays (Gy) en 10 sesiones. Se decidió incluir al paciente en ensayo clínico, iniciándose tratamiento con 4 ciclos de cisplatino + pemetrexed + ipilimumab + nivolumab, y posterior mantenimiento con ipilimumab + nivolumab hasta tolerancia o progresión del paciente. Los cuatro ciclos de quimioinmunoterapia se administraron entre el 04/07/2018 y el 06/09/2018. Posteriormente, se continuó administrando ciclos de mantenimiento con ipilimumab + nivolumab que comenzó el 27/09/2018, llegando a administrarse un total de 3 ciclos, el último el 08/11/2018. Evolución Tras los primeros 4 ciclos se realiza TC de evaluación de respuesta, el 22/08/2018, apreciándose enfermedad estable según criterios RECIST. El 08/10/2018, se realiza nueva TC de evaluación tras 1 dosis de mantenimiento con inmunoterapia, observándose una respuesta parcial. En analítica de control del 18/10/2018 se aprecia un hipotiroidismo, con niveles elevados de TSH y descenso de T4 libre, por lo que se instaura tratamiento con levotiroxina 50 mcg 1 comprimido al día, llegándose al probable diagnóstico de hipotiroidismo autoinmune asociado a inmunoterapia. El paciente acude a consulta el 29/11/2018, tras el 4º ciclo de mantenimiento, con clínica de astenia, diarrea, y dolor en hipocondrio derecho. Analíticamente se objetiva elevación de transaminasas, llegando a alcanzar toxicidad hepática grado 3, por lo que en este contexto se procede a ingresar al paciente para monitorización y tratamiento con corticoides a dosis de metilprednisolona 2 mg/kg/día. Se realiza una serología para virus hepatotropos, resultando negativa para los mismos, y con la corticoterapia administrada se logra mejoría de los niveles de transaminasas, así como mejoría clínica por lo que se llega al diagnóstico de hepatitis autoinmune secundaria a inmunoterapia. Se realiza un descenso progresivo de la corticoterapia, y se da de alta al paciente continuando con la corticoterapia en pauta descendente progresiva. El 17/12/2018 el paciente acude a Urgencias por un cuadro de malestar general, vómitos, y aparición de pico febril. Analíticamente se objetiva empeoramiento importante del nivel de transaminasas, estando de nuevo en niveles de toxicidad grado 3, un rash cutáneo maculopapular que afecta a más de la mitad de la superficie corporal, y un deterioro de la función renal alcanzando también toxicidad grado 3. Por todo ello, se procede a ingresar de nuevo al paciente para volver a escalar la corticoterapia a dosis de 2 mg/kg/día. En esta ocasión, se consigue una mejoría transitoria, sin lograr corregir los parámetros analíticos, y en los días sucesivos empieza a aparecer elevación de marcadores de citólisis y colestasis. Se realiza una ecografía abdominal y colangio-RM que descartan una complicación aguda infecciosa/vascular/tumoral y, siguiendo las guías clínicas, se decide plantear seguimiento conjunto con hepatología y realización de biopsia hepática. Esta se realiza el 02/01/2019, objetivándose en la misma un patrón lesional mixto colestásico con inflamación portal y marcada dilatación sinusoidal, sin apreciarse fibrosis. Estos datos son compatibles con un síndrome venoclusivo incipiente. En cuanto al rash, se realiza una solicitud de valoración a Alergología y Dermatología, puesto que el paciente lo achaca a una primera toma de alopurinol por hiperuricemia, y se llega a la conclusión final de que podría tratarse de un síndrome de Dress potenciado por la inmunoterapia. Queda en duda el papel del alopurinol, debido a la secuencia temporal en la que se producen los hechos. Dados estos resultados, se achaca el deterioro clínico y analítico a una hepatotoxicidad autoinmune refractaria a corticoterapia, y se procede a iniciar micofenolato mofetilo a dosis de 1 g cada 12 horas. Tras la instauración del tratamiento, se objetiva una mejoría parcial de la función hepática y del estado general que permiten dar de alta al paciente el 11/01/2019 con seguimiento estricto por consultas externas, y con suspensión de los ciclos de mantenimiento. En la TC de reevaluación de la enfermedad el 04/02/2019, se detecta aún respuesta parcial de la enfermedad oncológica. Sin embargo, se revelan hallazgos característicos de enfermedad venoclusiva hepática establecida, con marcada alteración de la perfusión hepática, edema periportal y edema de pared vesicular, así como abundante cantidad de líquido ascítico. Finalmente, el paciente es traído a Urgencias por deterioro súbito del nivel de conciencia el 22/02/2019, objetivándose desconexión completa del medio, abdomen distendido, hipotensión y taquicardia. A pesar de tratamiento inicial con antibioterapia y fluidoterapia intensiva, persiste el deterioro a nivel clínico y hemodinámico, por lo que, tras hablar de la situación con la familia, se acuerda inicio de sedación paliativa del paciente. A las pocas horas del inicio de la misma, se produce el exitus el mismo día.
[ "Anamnesis", "\n", "Se", "trata", "de", "un", "varón", "de", "60", "años", "sin", "alergias", "conocidas", ",", "independiente", "para", "las", "actividades", "básicas", "de", "la", "vida", "diaria", "que", ",", "como", "antecedentes", "médicos", "de", "interés", ",", "tiene", "un", "consumo", "acumulado", "de", "tabaco", "de", "40", "años", "-", "paquete", ",", "así", "como", "un", "hábito", "enólico", "superior", "a", "40", "g", "/", "día", "que", "había", "abandonado", "hacía", "2", "años", ".", "No", "hay", "otros", "antecedentes", "de", "interés", "en", "el", "momento", "de", "inicio", "de", "la", "clínica", ".", "No", "hay", "antecedentes", "familiares", "de", "interés", ".", "\n", "Comienza", "en", "marzo", "de", "2018", "con", "un", "cuadro", "de", "disfonía", "de", "1", "mes", "de", "evolución", "que", "no", "mejora", "con", "tratamiento", "con", "corticoides", "a", "dosis", "bajas", "y", "reposo", "vocal", ",", "pautados", "en", "diversas", "consultas", "al", "servicio", "de", "Urgencias", ".", "\n\n", "Exploración", "física", "\n", "»", "Durante", "la", "exploración", "física", "encontramos", "un", "varón", "con", "buen", "estado", "general", ",", "ECOG", "1", ",", "normocoloreado", "y", "normohidratado", ",", "eupneico", "en", "reposo", ".", "\n", "»", "La", "cavidad", "oral", "no", "presentaba", "lesión", "alguna", ".", "En", "la", "palpación", "no", "se", "encontraban", "adenopatías", ".", "\n", "»", "En", "la", "auscultación", "cardiorrespiratoria", "sólo", "apreciamos", "una", "hipoventilación", "global", ".", "\n", "»", "La", "exploración", "a", "nivel", "abdominal", ",", "miembros", "inferiores", ",", "y", "a", "nivel", "neurológico", "eran", "completamente", "normales", ".", "\n\n", "Pruebas", "complementarias", "\n", "»", "El", "paciente", "es", "valorado", "por", "Otorrinolaringología", ",", "quienes", ",", "en", "la", "fibrobroncoscopia", ",", "aprecian", "una", "parálisis", "de", "cuerda", "vocal", "izquierda", ".", "\n", "»", "En", "la", "radiografía", "de", "tórax", "que", "se", "realiza", "se", "observa", "una", "masa", "hiliar", "izquierda", "que", "provoca", "una", "atelectasia", "de", "lóbulo", "superior", "izquierdo", ".", "\n", "»", "En", "la", "TC", "torácica", "se", "aprecia", "una", "masa", "hiliar", "izquierda", "con", "extensión", "a", "mediastino", ",", "hacia", "ventana", "aortopulmonar", ",", "con", "unas", "dimensiones", "de", "10", "x", "5,4", "x", "5,3", "cm", ",", "sin", "verse", "adenopatías", ".", "\n", "»", "Se", "realiza", "broncoscopia", ",", "que", "observa", "signos", "directos", "de", "neoplasia", "a", "la", "entrada", "del", "lóbulo", "superior", "izquierdo", ".", "Se", "toman", "muestras", ",", "y", "en", "la", "Anatomía", "Patológica", "se", "informa", "un", "adenocarcinoma", "de", "pulmón", ".", "EGFR", ",", "ALK", "y", "ROS-1", "negativo", ".", "PD", "-", "L1", "no", "evaluable", ".", "\n", "»", "En", "estudio", "de", "extensión", "con", "PET", "/", "TC", ",", "se", "aprecia", ",", "además", "de", "la", "masa", "pulmonar", ",", "afectación", "metastásica", "en", "diáfisis", "proximal", "de", "fémur", "izquierdo", "(", "1", "lesión", "de", "4,3", "x", "2,8", "cm", "con", "SUV", "7,3", ")", "y", "a", "nivel", "de", "pala", "iliaca", "derecha", "(", "1", "lesión", "de", "15", "mm", "con", "SUV", "7,1", ")", ".", "\n\n", "Diagnóstico", "\n", "Por", "tanto", ",", "con", "todo", "el", "estudio", "de", "extensión", "realizado", ",", "llegamos", "al", "diagnóstico", "de", "adenocarcinoma", "de", "pulmón", "EGFR", ",", "ALK", ",", "ROS-1", "y", "PD", "-", "L1", "no", "medido", ",", "estadio", "IVB", ".", "\n\n", "Tratamiento", "\n", "Se", "realiza", "tratamiento", "con", "radioterapia", "externa", "(", "RT", ")", "sobre", "lesión", "de", "fémur", "izquierdo", "para", "control", "sintomático", "del", "dolor", ".", "En", "total", "se", "administraron", "30", "Grays", "(", "Gy", ")", "en", "10", "sesiones", ".", "\n", "Se", "decidió", "incluir", "al", "paciente", "en", "ensayo", "clínico", ",", "iniciándose", "tratamiento", "con", "4", "ciclos", "de", "cisplatino", "+", "pemetrexed", "+", "ipilimumab", "+", "nivolumab", ",", "y", "posterior", "mantenimiento", "con", "ipilimumab", "+", "nivolumab", "hasta", "tolerancia", "o", "progresión", "del", "paciente", ".", "\n", "Los", "cuatro", "ciclos", "de", "quimioinmunoterapia", "se", "administraron", "entre", "el", "04/07/2018", "y", "el", "06/09/2018", ".", "\n", "Posteriormente", ",", "se", "continuó", "administrando", "ciclos", "de", "mantenimiento", "con", "ipilimumab", "+", "nivolumab", "que", "comenzó", "el", "27/09/2018", ",", "llegando", "a", "administrarse", "un", "total", "de", "3", "ciclos", ",", "el", "último", "el", "08/11/2018", ".", "\n\n", "Evolución", "\n", "Tras", "los", "primeros", "4", "ciclos", "se", "realiza", "TC", "de", "evaluación", "de", "respuesta", ",", "el", "22/08/2018", ",", "apreciándose", "enfermedad", "estable", "según", "criterios", "RECIST", ".", "\n", "El", "08/10/2018", ",", "se", "realiza", "nueva", "TC", "de", "evaluación", "tras", "1", "dosis", "de", "mantenimiento", "con", "inmunoterapia", ",", "observándose", "una", "respuesta", "parcial", ".", "\n", "En", "analítica", "de", "control", "del", "18/10/2018", "se", "aprecia", "un", "hipotiroidismo", ",", "con", "niveles", "elevados", "de", "TSH", "y", "descenso", "de", "T4", "libre", ",", "por", "lo", "que", "se", "instaura", "tratamiento", "con", "levotiroxina", "50", "mcg", "1", "comprimido", "al", "día", ",", "llegándose", "al", "probable", "diagnóstico", "de", "hipotiroidismo", "autoinmune", "asociado", "a", "inmunoterapia", ".", "\n", "El", "paciente", "acude", "a", "consulta", "el", "29/11/2018", ",", "tras", "el", "4º", "ciclo", "de", "mantenimiento", ",", "con", "clínica", "de", "astenia", ",", "diarrea", ",", "y", "dolor", "en", "hipocondrio", "derecho", ".", "Analíticamente", "se", "objetiva", "elevación", "de", "transaminasas", ",", "llegando", "a", "alcanzar", "toxicidad", "hepática", "grado", "3", ",", "por", "lo", "que", "en", "este", "contexto", "se", "procede", "a", "ingresar", "al", "paciente", "para", "monitorización", "y", "tratamiento", "con", "corticoides", "a", "dosis", "de", "metilprednisolona", "2", "mg", "/", "kg", "/", "día", ".", "Se", "realiza", "una", "serología", "para", "virus", "hepatotropos", ",", "resultando", "negativa", "para", "los", "mismos", ",", "y", "con", "la", "corticoterapia", "administrada", "se", "logra", "mejoría", "de", "los", "niveles", "de", "transaminasas", ",", "así", "como", "mejoría", "clínica", "por", "lo", "que", "se", "llega", "al", "diagnóstico", "de", "hepatitis", "autoinmune", "secundaria", "a", "inmunoterapia", ".", "Se", "realiza", "un", "descenso", "progresivo", "de", "la", "corticoterapia", ",", "y", "se", "da", "de", "alta", "al", "paciente", "continuando", "con", "la", "corticoterapia", "en", "pauta", "descendente", "progresiva", ".", "\n", "El", "17/12/2018", "el", "paciente", "acude", "a", "Urgencias", "por", "un", "cuadro", "de", "malestar", "general", ",", "vómitos", ",", "y", "aparición", "de", "pico", "febril", ".", "Analíticamente", "se", "objetiva", "empeoramiento", "importante", "del", "nivel", "de", "transaminasas", ",", "estando", "de", "nuevo", "en", "niveles", "de", "toxicidad", "grado", "3", ",", "un", "rash", "cutáneo", "maculopapular", "que", "afecta", "a", "más", "de", "la", "mitad", "de", "la", "superficie", "corporal", ",", "y", "un", "deterioro", "de", "la", "función", "renal", "alcanzando", "también", "toxicidad", "grado", "\n", "3", ".", "Por", "todo", "ello", ",", "se", "procede", "a", "ingresar", "de", "nuevo", "al", "paciente", "para", "volver", "a", "escalar", "la", "corticoterapia", "a", "dosis", "de", "2", "mg", "/", "kg", "/", "día", ".", "En", "esta", "ocasión", ",", "se", "consigue", "una", "mejoría", "transitoria", ",", "sin", "lograr", "corregir", "los", "parámetros", "analíticos", ",", "y", "en", "los", "días", "sucesivos", "empieza", "a", "aparecer", "elevación", "de", "marcadores", "de", "citólisis", "y", "colestasis", ".", "Se", "realiza", "una", "ecografía", "abdominal", "y", "colangio", "-", "RM", "que", "descartan", "una", "complicación", "aguda", "infecciosa", "/", "vascular", "/", "tumoral", "y", ",", "siguiendo", "las", "guías", "clínicas", ",", "se", "decide", "plantear", "seguimiento", "conjunto", "con", "hepatología", "y", "realización", "de", "biopsia", "hepática", ".", "Esta", "se", "realiza", "el", "02/01/2019", ",", "objetivándose", "en", "la", "misma", "un", "patrón", "lesional", "mixto", "colestásico", "con", "inflamación", "portal", "y", "marcada", "dilatación", "sinusoidal", ",", "sin", "apreciarse", "fibrosis", ".", "Estos", "datos", "son", "compatibles", "con", "un", "síndrome", "venoclusivo", "incipiente", ".", "En", "cuanto", "al", "rash", ",", "se", "realiza", "una", "solicitud", "de", "valoración", "a", "Alergología", "y", "Dermatología", ",", "puesto", "que", "el", "paciente", "lo", "achaca", "a", "una", "primera", "toma", "de", "alopurinol", "por", "hiperuricemia", ",", "y", "se", "llega", "a", "la", "conclusión", "final", "de", "que", "podría", "tratarse", "de", "un", "síndrome", "de", "Dress", "potenciado", "por", "la", "inmunoterapia", ".", "Queda", "en", "duda", "el", "papel", "del", "alopurinol", ",", "debido", "a", "la", "secuencia", "temporal", "en", "la", "que", "se", "producen", "los", "hechos", ".", "Dados", "estos", "resultados", ",", "se", "achaca", "el", "deterioro", "clínico", "y", "analítico", "a", "una", "hepatotoxicidad", "autoinmune", "refractaria", "a", "corticoterapia", ",", "y", "se", "procede", "a", "iniciar", "micofenolato", "mofetilo", "a", "dosis", "de", "1", "g", "cada", "12", "horas", ".", "Tras", "la", "instauración", "del", "tratamiento", ",", "se", "objetiva", "una", "mejoría", "parcial", "de", "la", "función", "hepática", "y", "del", "estado", "general", "que", "permiten", "dar", "de", "alta", "al", "paciente", "el", "11/01/2019", "con", "seguimiento", "estricto", "por", "consultas", "externas", ",", "y", "con", "suspensión", "de", "los", "ciclos", "de", "mantenimiento", ".", "\n", "En", "la", "TC", "de", "reevaluación", "de", "la", "enfermedad", "el", "04/02/2019", ",", "se", "detecta", "aún", "respuesta", "parcial", "de", "la", "enfermedad", "oncológica", ".", "Sin", "embargo", ",", "se", "revelan", "hallazgos", "característicos", "de", "enfermedad", "venoclusiva", "hepática", "establecida", ",", "con", "marcada", "alteración", "de", "la", "perfusión", "hepática", ",", "edema", "periportal", "y", "edema", "de", "pared", "vesicular", ",", "así", "como", "abundante", "cantidad", "de", "líquido", "ascítico", ".", "\n", "Finalmente", ",", "el", "paciente", "es", "traído", "a", "Urgencias", "por", "deterioro", "súbito", "del", "nivel", "de", "conciencia", "el", "22/02/2019", ",", "objetivándose", "desconexión", "completa", "del", "medio", ",", "abdomen", "distendido", ",", "hipotensión", "y", "taquicardia", ".", "A", "pesar", "de", "tratamiento", "inicial", "con", "antibioterapia", "y", "fluidoterapia", "intensiva", ",", "persiste", "el", "deterioro", "a", "nivel", "clínico", "y", "hemodinámico", ",", "por", "lo", "que", ",", "tras", "hablar", "de", "la", "situación", "con", "la", "familia", ",", "se", "acuerda", "inicio", "de", "sedación", "paliativa", "del", "paciente", ".", "A", "las", "pocas", "horas", "del", "inicio", "de", "la", "misma", ",", "se", "produce", "el", "exitus", "el", "mismo", "día", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
nuclear factor - kappa B is a protein_complex, beta - amyloid peptides is a peptide, interferon - gamma is a protein_molecule, murine microglia is an other_name
62245_task0
Sentence: Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name, peptide, protein_molecule, protein_complex
[ "O", "O", "B-protein_complex", "I-protein_complex", "I-protein_complex", "I-protein_complex", "I-protein_complex", "O", "B-peptide", "I-peptide", "I-peptide", "I-peptide", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "O" ]
Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia.
[ "Activation", "of", "nuclear", "factor", "-", "kappa", "B", "by", "beta", "-", "amyloid", "peptides", "and", "interferon", "-", "gamma", "in", "murine", "microglia", "." ]
[ "other_name", "peptide", "cell_line", "protein_complex", "DNA_family_or_group", "protein_molecule", "cell_component", "cell_type", "protein_family_or_group", "protein_subunit", "lipid" ]
nuclear factor - kappa B is a protein_complex, beta - amyloid peptides is a peptide, interferon - gamma is a protein_molecule, murine microglia is an other_name
62245_task1
Sentence: Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia. Instructions: please typing these entity words according to sentence: nuclear factor - kappa B, beta - amyloid peptides, interferon - gamma, murine microglia Options: other_name, peptide, protein_molecule, protein_complex
[ "O", "O", "B-protein_complex", "I-protein_complex", "I-protein_complex", "I-protein_complex", "I-protein_complex", "O", "B-peptide", "I-peptide", "I-peptide", "I-peptide", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "O" ]
Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia.
[ "Activation", "of", "nuclear", "factor", "-", "kappa", "B", "by", "beta", "-", "amyloid", "peptides", "and", "interferon", "-", "gamma", "in", "murine", "microglia", "." ]
[ "other_name", "peptide", "cell_line", "protein_complex", "DNA_family_or_group", "protein_molecule", "cell_component", "cell_type", "protein_family_or_group", "protein_subunit", "lipid" ]
nuclear factor - kappa B, beta - amyloid peptides, interferon - gamma, murine microglia
62245_task2
Sentence: Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-protein_complex", "I-protein_complex", "I-protein_complex", "I-protein_complex", "I-protein_complex", "O", "B-peptide", "I-peptide", "I-peptide", "I-peptide", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "O" ]
Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia.
[ "Activation", "of", "nuclear", "factor", "-", "kappa", "B", "by", "beta", "-", "amyloid", "peptides", "and", "interferon", "-", "gamma", "in", "murine", "microglia", "." ]
[ "other_name", "peptide", "cell_line", "protein_complex", "DNA_family_or_group", "protein_molecule", "cell_component", "cell_type", "protein_family_or_group", "protein_subunit", "lipid" ]
Patienten is an umlsterm, Psoriasis is an umlsterm, Patienten is an umlsterm, Neurodermitis is an umlsterm, hautgesunde is an umlsterm, Personen is an umlsterm, Sexualverhaltens is an umlsterm, Sexualverhalten is an umlsterm, Fragebogen is an umlsterm, Sexualitaet is an umlsterm, Hautkranken is an umlsterm, Hautgesunden is an umlsterm, Sexuallebens is an umlsterm, Geschlechtern is an umlsterm, Orgasmusfaehigkeit is an umlsterm, weiblichen is an umlsterm, Patienten is an umlsterm, Koitushaeufigkeit is an umlsterm, Patienten is an umlsterm, Neurodermitis is an umlsterm, Psoriasispatienten is an umlsterm, Patienten is an umlsterm, Neurodermitis is an umlsterm, Arzt is an umlsterm, Sexualleben is an umlsterm, Arzt is an umlsterm, Haut- is an umlsterm, Geschlechtskrankheiten is an umlsterm, Hautkrankheit is an umlsterm, Sexualleben is an umlsterm, Hautkrankheit is an umlsterm
DerHautarzt.70480629.ger.abstr_task0
Sentence: Es werden 53 Patienten mit Psoriasis , 24 Patienten mit Neurodermitis und eine hautgesunde Stichprobe von 52 Personen bezueglich ihres Sexualverhaltens miteinander verglichen . Als Testverfahren wurden Frageboegen zum Sexualverhalten nach Arentewicz und ein eigener Fragebogen zur Sexualitaet und Partnerschaft eingesetzt . Die untersuchten Hautkranken unterscheiden sich signifikant von Hautgesunden im Sinne eines beeintraechtigten Sexuallebens . Der Austausch von Zaertlichkeiten ist bei beiden Geschlechtern , die Orgasmusfaehigkeit ist bei den weiblichen Patienten hochsignifikant reduziert . Demgegenueber zeigt sich bezueglich der Koitushaeufigkeit kein signifikanter Unterschied . Psoriatiker fuehlen sich im Vergleich zu Patienten mit Neurodermitis staerker beeintraechtigt . 93% der Psoriasispatienten und 96% der Patienten mit Neurodermitis sind von ihrem behandelnden Arzt bisher nie auf ihr Sexualleben angesprochen worden . Bei aller Problematik , diesen intimen Bereich anzusprechen , sollte der Arzt fuer Haut- und Geschlechtskrankheiten jedoch ein kompetenter Gespraechspartner fuer Fragestellungen , die die Hautkrankheit und ihre Folgen fuer das Sexualleben betreffen , sein . Es wird diskutiert , inwieweit die Hautkrankheit moeglicherweise zur Regelung von Naehe und Distanz eingesetzt wird . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Es werden 53 Patienten mit Psoriasis , 24 Patienten mit Neurodermitis und eine hautgesunde Stichprobe von 52 Personen bezueglich ihres Sexualverhaltens miteinander verglichen . Als Testverfahren wurden Frageboegen zum Sexualverhalten nach Arentewicz und ein eigener Fragebogen zur Sexualitaet und Partnerschaft eingesetzt . Die untersuchten Hautkranken unterscheiden sich signifikant von Hautgesunden im Sinne eines beeintraechtigten Sexuallebens . Der Austausch von Zaertlichkeiten ist bei beiden Geschlechtern , die Orgasmusfaehigkeit ist bei den weiblichen Patienten hochsignifikant reduziert . Demgegenueber zeigt sich bezueglich der Koitushaeufigkeit kein signifikanter Unterschied . Psoriatiker fuehlen sich im Vergleich zu Patienten mit Neurodermitis staerker beeintraechtigt . 93% der Psoriasispatienten und 96% der Patienten mit Neurodermitis sind von ihrem behandelnden Arzt bisher nie auf ihr Sexualleben angesprochen worden . Bei aller Problematik , diesen intimen Bereich anzusprechen , sollte der Arzt fuer Haut- und Geschlechtskrankheiten jedoch ein kompetenter Gespraechspartner fuer Fragestellungen , die die Hautkrankheit und ihre Folgen fuer das Sexualleben betreffen , sein . Es wird diskutiert , inwieweit die Hautkrankheit moeglicherweise zur Regelung von Naehe und Distanz eingesetzt wird .
[ "Es", "werden", "53", "Patienten", "mit", "Psoriasis", ",", "24", "Patienten", "mit", "Neurodermitis", "und", "eine", "hautgesunde", "Stichprobe", "von", "52", "Personen", "bezueglich", "ihres", "Sexualverhaltens", "miteinander", "verglichen", ".", "Als", "Testverfahren", "wurden", "Frageboegen", "zum", "Sexualverhalten", "nach", "Arentewicz", "und", "ein", "eigener", "Fragebogen", "zur", "Sexualitaet", "und", "Partnerschaft", "eingesetzt", ".", "Die", "untersuchten", "Hautkranken", "unterscheiden", "sich", "signifikant", "von", "Hautgesunden", "im", "Sinne", "eines", "beeintraechtigten", "Sexuallebens", ".", "Der", "Austausch", "von", "Zaertlichkeiten", "ist", "bei", "beiden", "Geschlechtern", ",", "die", "Orgasmusfaehigkeit", "ist", "bei", "den", "weiblichen", "Patienten", "hochsignifikant", "reduziert", ".", "Demgegenueber", "zeigt", "sich", "bezueglich", "der", "Koitushaeufigkeit", "kein", "signifikanter", "Unterschied", ".", "Psoriatiker", "fuehlen", "sich", "im", "Vergleich", "zu", "Patienten", "mit", "Neurodermitis", "staerker", "beeintraechtigt", ".", "93", "%", "der", "Psoriasispatienten", "und", "96", "%", "der", "Patienten", "mit", "Neurodermitis", "sind", "von", "ihrem", "behandelnden", "Arzt", "bisher", "nie", "auf", "ihr", "Sexualleben", "angesprochen", "worden", ".", "Bei", "aller", "Problematik", ",", "diesen", "intimen", "Bereich", "anzusprechen", ",", "sollte", "der", "Arzt", "fuer", "Haut-", "und", "Geschlechtskrankheiten", "jedoch", "ein", "kompetenter", "Gespraechspartner", "fuer", "Fragestellungen", ",", "die", "die", "Hautkrankheit", "und", "ihre", "Folgen", "fuer", "das", "Sexualleben", "betreffen", ",", "sein", ".", "Es", "wird", "diskutiert", ",", "inwieweit", "die", "Hautkrankheit", "moeglicherweise", "zur", "Regelung", "von", "Naehe", "und", "Distanz", "eingesetzt", "wird", "." ]
[ "umlsterm" ]
Patienten is an umlsterm, Psoriasis is an umlsterm, Patienten is an umlsterm, Neurodermitis is an umlsterm, hautgesunde is an umlsterm, Personen is an umlsterm, Sexualverhaltens is an umlsterm, Sexualverhalten is an umlsterm, Fragebogen is an umlsterm, Sexualitaet is an umlsterm, Hautkranken is an umlsterm, Hautgesunden is an umlsterm, Sexuallebens is an umlsterm, Geschlechtern is an umlsterm, Orgasmusfaehigkeit is an umlsterm, weiblichen is an umlsterm, Patienten is an umlsterm, Koitushaeufigkeit is an umlsterm, Patienten is an umlsterm, Neurodermitis is an umlsterm, Psoriasispatienten is an umlsterm, Patienten is an umlsterm, Neurodermitis is an umlsterm, Arzt is an umlsterm, Sexualleben is an umlsterm, Arzt is an umlsterm, Haut- is an umlsterm, Geschlechtskrankheiten is an umlsterm, Hautkrankheit is an umlsterm, Sexualleben is an umlsterm, Hautkrankheit is an umlsterm
DerHautarzt.70480629.ger.abstr_task1
Sentence: Es werden 53 Patienten mit Psoriasis , 24 Patienten mit Neurodermitis und eine hautgesunde Stichprobe von 52 Personen bezueglich ihres Sexualverhaltens miteinander verglichen . Als Testverfahren wurden Frageboegen zum Sexualverhalten nach Arentewicz und ein eigener Fragebogen zur Sexualitaet und Partnerschaft eingesetzt . Die untersuchten Hautkranken unterscheiden sich signifikant von Hautgesunden im Sinne eines beeintraechtigten Sexuallebens . Der Austausch von Zaertlichkeiten ist bei beiden Geschlechtern , die Orgasmusfaehigkeit ist bei den weiblichen Patienten hochsignifikant reduziert . Demgegenueber zeigt sich bezueglich der Koitushaeufigkeit kein signifikanter Unterschied . Psoriatiker fuehlen sich im Vergleich zu Patienten mit Neurodermitis staerker beeintraechtigt . 93% der Psoriasispatienten und 96% der Patienten mit Neurodermitis sind von ihrem behandelnden Arzt bisher nie auf ihr Sexualleben angesprochen worden . Bei aller Problematik , diesen intimen Bereich anzusprechen , sollte der Arzt fuer Haut- und Geschlechtskrankheiten jedoch ein kompetenter Gespraechspartner fuer Fragestellungen , die die Hautkrankheit und ihre Folgen fuer das Sexualleben betreffen , sein . Es wird diskutiert , inwieweit die Hautkrankheit moeglicherweise zur Regelung von Naehe und Distanz eingesetzt wird . Instructions: please typing these entity words according to sentence: Patienten, Psoriasis, Patienten, Neurodermitis, hautgesunde, Personen, Sexualverhaltens, Sexualverhalten, Fragebogen, Sexualitaet, Hautkranken, Hautgesunden, Sexuallebens, Geschlechtern, Orgasmusfaehigkeit, weiblichen, Patienten, Koitushaeufigkeit, Patienten, Neurodermitis, Psoriasispatienten, Patienten, Neurodermitis, Arzt, Sexualleben, Arzt, Haut-, Geschlechtskrankheiten, Hautkrankheit, Sexualleben, Hautkrankheit Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Es werden 53 Patienten mit Psoriasis , 24 Patienten mit Neurodermitis und eine hautgesunde Stichprobe von 52 Personen bezueglich ihres Sexualverhaltens miteinander verglichen . Als Testverfahren wurden Frageboegen zum Sexualverhalten nach Arentewicz und ein eigener Fragebogen zur Sexualitaet und Partnerschaft eingesetzt . Die untersuchten Hautkranken unterscheiden sich signifikant von Hautgesunden im Sinne eines beeintraechtigten Sexuallebens . Der Austausch von Zaertlichkeiten ist bei beiden Geschlechtern , die Orgasmusfaehigkeit ist bei den weiblichen Patienten hochsignifikant reduziert . Demgegenueber zeigt sich bezueglich der Koitushaeufigkeit kein signifikanter Unterschied . Psoriatiker fuehlen sich im Vergleich zu Patienten mit Neurodermitis staerker beeintraechtigt . 93% der Psoriasispatienten und 96% der Patienten mit Neurodermitis sind von ihrem behandelnden Arzt bisher nie auf ihr Sexualleben angesprochen worden . Bei aller Problematik , diesen intimen Bereich anzusprechen , sollte der Arzt fuer Haut- und Geschlechtskrankheiten jedoch ein kompetenter Gespraechspartner fuer Fragestellungen , die die Hautkrankheit und ihre Folgen fuer das Sexualleben betreffen , sein . Es wird diskutiert , inwieweit die Hautkrankheit moeglicherweise zur Regelung von Naehe und Distanz eingesetzt wird .
[ "Es", "werden", "53", "Patienten", "mit", "Psoriasis", ",", "24", "Patienten", "mit", "Neurodermitis", "und", "eine", "hautgesunde", "Stichprobe", "von", "52", "Personen", "bezueglich", "ihres", "Sexualverhaltens", "miteinander", "verglichen", ".", "Als", "Testverfahren", "wurden", "Frageboegen", "zum", "Sexualverhalten", "nach", "Arentewicz", "und", "ein", "eigener", "Fragebogen", "zur", "Sexualitaet", "und", "Partnerschaft", "eingesetzt", ".", "Die", "untersuchten", "Hautkranken", "unterscheiden", "sich", "signifikant", "von", "Hautgesunden", "im", "Sinne", "eines", "beeintraechtigten", "Sexuallebens", ".", "Der", "Austausch", "von", "Zaertlichkeiten", "ist", "bei", "beiden", "Geschlechtern", ",", "die", "Orgasmusfaehigkeit", "ist", "bei", "den", "weiblichen", "Patienten", "hochsignifikant", "reduziert", ".", "Demgegenueber", "zeigt", "sich", "bezueglich", "der", "Koitushaeufigkeit", "kein", "signifikanter", "Unterschied", ".", "Psoriatiker", "fuehlen", "sich", "im", "Vergleich", "zu", "Patienten", "mit", "Neurodermitis", "staerker", "beeintraechtigt", ".", "93", "%", "der", "Psoriasispatienten", "und", "96", "%", "der", "Patienten", "mit", "Neurodermitis", "sind", "von", "ihrem", "behandelnden", "Arzt", "bisher", "nie", "auf", "ihr", "Sexualleben", "angesprochen", "worden", ".", "Bei", "aller", "Problematik", ",", "diesen", "intimen", "Bereich", "anzusprechen", ",", "sollte", "der", "Arzt", "fuer", "Haut-", "und", "Geschlechtskrankheiten", "jedoch", "ein", "kompetenter", "Gespraechspartner", "fuer", "Fragestellungen", ",", "die", "die", "Hautkrankheit", "und", "ihre", "Folgen", "fuer", "das", "Sexualleben", "betreffen", ",", "sein", ".", "Es", "wird", "diskutiert", ",", "inwieweit", "die", "Hautkrankheit", "moeglicherweise", "zur", "Regelung", "von", "Naehe", "und", "Distanz", "eingesetzt", "wird", "." ]
[ "umlsterm" ]
Patienten, Psoriasis, Patienten, Neurodermitis, hautgesunde, Personen, Sexualverhaltens, Sexualverhalten, Fragebogen, Sexualitaet, Hautkranken, Hautgesunden, Sexuallebens, Geschlechtern, Orgasmusfaehigkeit, weiblichen, Patienten, Koitushaeufigkeit, Patienten, Neurodermitis, Psoriasispatienten, Patienten, Neurodermitis, Arzt, Sexualleben, Arzt, Haut-, Geschlechtskrankheiten, Hautkrankheit, Sexualleben, Hautkrankheit
DerHautarzt.70480629.ger.abstr_task2
Sentence: Es werden 53 Patienten mit Psoriasis , 24 Patienten mit Neurodermitis und eine hautgesunde Stichprobe von 52 Personen bezueglich ihres Sexualverhaltens miteinander verglichen . Als Testverfahren wurden Frageboegen zum Sexualverhalten nach Arentewicz und ein eigener Fragebogen zur Sexualitaet und Partnerschaft eingesetzt . Die untersuchten Hautkranken unterscheiden sich signifikant von Hautgesunden im Sinne eines beeintraechtigten Sexuallebens . Der Austausch von Zaertlichkeiten ist bei beiden Geschlechtern , die Orgasmusfaehigkeit ist bei den weiblichen Patienten hochsignifikant reduziert . Demgegenueber zeigt sich bezueglich der Koitushaeufigkeit kein signifikanter Unterschied . Psoriatiker fuehlen sich im Vergleich zu Patienten mit Neurodermitis staerker beeintraechtigt . 93% der Psoriasispatienten und 96% der Patienten mit Neurodermitis sind von ihrem behandelnden Arzt bisher nie auf ihr Sexualleben angesprochen worden . Bei aller Problematik , diesen intimen Bereich anzusprechen , sollte der Arzt fuer Haut- und Geschlechtskrankheiten jedoch ein kompetenter Gespraechspartner fuer Fragestellungen , die die Hautkrankheit und ihre Folgen fuer das Sexualleben betreffen , sein . Es wird diskutiert , inwieweit die Hautkrankheit moeglicherweise zur Regelung von Naehe und Distanz eingesetzt wird . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Es werden 53 Patienten mit Psoriasis , 24 Patienten mit Neurodermitis und eine hautgesunde Stichprobe von 52 Personen bezueglich ihres Sexualverhaltens miteinander verglichen . Als Testverfahren wurden Frageboegen zum Sexualverhalten nach Arentewicz und ein eigener Fragebogen zur Sexualitaet und Partnerschaft eingesetzt . Die untersuchten Hautkranken unterscheiden sich signifikant von Hautgesunden im Sinne eines beeintraechtigten Sexuallebens . Der Austausch von Zaertlichkeiten ist bei beiden Geschlechtern , die Orgasmusfaehigkeit ist bei den weiblichen Patienten hochsignifikant reduziert . Demgegenueber zeigt sich bezueglich der Koitushaeufigkeit kein signifikanter Unterschied . Psoriatiker fuehlen sich im Vergleich zu Patienten mit Neurodermitis staerker beeintraechtigt . 93% der Psoriasispatienten und 96% der Patienten mit Neurodermitis sind von ihrem behandelnden Arzt bisher nie auf ihr Sexualleben angesprochen worden . Bei aller Problematik , diesen intimen Bereich anzusprechen , sollte der Arzt fuer Haut- und Geschlechtskrankheiten jedoch ein kompetenter Gespraechspartner fuer Fragestellungen , die die Hautkrankheit und ihre Folgen fuer das Sexualleben betreffen , sein . Es wird diskutiert , inwieweit die Hautkrankheit moeglicherweise zur Regelung von Naehe und Distanz eingesetzt wird .
[ "Es", "werden", "53", "Patienten", "mit", "Psoriasis", ",", "24", "Patienten", "mit", "Neurodermitis", "und", "eine", "hautgesunde", "Stichprobe", "von", "52", "Personen", "bezueglich", "ihres", "Sexualverhaltens", "miteinander", "verglichen", ".", "Als", "Testverfahren", "wurden", "Frageboegen", "zum", "Sexualverhalten", "nach", "Arentewicz", "und", "ein", "eigener", "Fragebogen", "zur", "Sexualitaet", "und", "Partnerschaft", "eingesetzt", ".", "Die", "untersuchten", "Hautkranken", "unterscheiden", "sich", "signifikant", "von", "Hautgesunden", "im", "Sinne", "eines", "beeintraechtigten", "Sexuallebens", ".", "Der", "Austausch", "von", "Zaertlichkeiten", "ist", "bei", "beiden", "Geschlechtern", ",", "die", "Orgasmusfaehigkeit", "ist", "bei", "den", "weiblichen", "Patienten", "hochsignifikant", "reduziert", ".", "Demgegenueber", "zeigt", "sich", "bezueglich", "der", "Koitushaeufigkeit", "kein", "signifikanter", "Unterschied", ".", "Psoriatiker", "fuehlen", "sich", "im", "Vergleich", "zu", "Patienten", "mit", "Neurodermitis", "staerker", "beeintraechtigt", ".", "93", "%", "der", "Psoriasispatienten", "und", "96", "%", "der", "Patienten", "mit", "Neurodermitis", "sind", "von", "ihrem", "behandelnden", "Arzt", "bisher", "nie", "auf", "ihr", "Sexualleben", "angesprochen", "worden", ".", "Bei", "aller", "Problematik", ",", "diesen", "intimen", "Bereich", "anzusprechen", ",", "sollte", "der", "Arzt", "fuer", "Haut-", "und", "Geschlechtskrankheiten", "jedoch", "ein", "kompetenter", "Gespraechspartner", "fuer", "Fragestellungen", ",", "die", "die", "Hautkrankheit", "und", "ihre", "Folgen", "fuer", "das", "Sexualleben", "betreffen", ",", "sein", ".", "Es", "wird", "diskutiert", ",", "inwieweit", "die", "Hautkrankheit", "moeglicherweise", "zur", "Regelung", "von", "Naehe", "und", "Distanz", "eingesetzt", "wird", "." ]
[ "umlsterm" ]
Co(2 is a compound, cytochrome c is a protein, AIF is a protein
DS.d807_task0
Sentence: Co(2+) also induces the release of the pro-apoptotic factors, cytochrome c and AIF. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O" ]
Co(2+) also induces the release of the pro-apoptotic factors, cytochrome c and AIF.
[ "Co(2", "+", ")", "also", "induces", "the", "release", "of", "the", "pro", "-", "apoptotic", "factors", ",", "cytochrome", "c", "and", "AIF", "." ]
[ "protein", "compound" ]
Co(2 is a compound, cytochrome c is a protein, AIF is a protein
DS.d807_task1
Sentence: Co(2+) also induces the release of the pro-apoptotic factors, cytochrome c and AIF. Instructions: please typing these entity words according to sentence: Co(2, cytochrome c, AIF Options: compound, protein
[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O" ]
Co(2+) also induces the release of the pro-apoptotic factors, cytochrome c and AIF.
[ "Co(2", "+", ")", "also", "induces", "the", "release", "of", "the", "pro", "-", "apoptotic", "factors", ",", "cytochrome", "c", "and", "AIF", "." ]
[ "protein", "compound" ]
Co(2, cytochrome c, AIF
DS.d807_task2
Sentence: Co(2+) also induces the release of the pro-apoptotic factors, cytochrome c and AIF. Instructions: please extract entity words from the input sentence
[ "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O" ]
Co(2+) also induces the release of the pro-apoptotic factors, cytochrome c and AIF.
[ "Co(2", "+", ")", "also", "induces", "the", "release", "of", "the", "pro", "-", "apoptotic", "factors", ",", "cytochrome", "c", "and", "AIF", "." ]
[ "protein", "compound" ]
and is a Intervention_Pharmacological, tumor oxygenation is a Outcome_Physical, head - and - neck cancer is a Participant_Condition, Eppendorf PO2 histograph is a Intervention_Other, alkaline comet assay is a Intervention_Other, tumor hypoxia is a Outcome_Physical, head - and - neck squamous cell carcinomas is a Participant_Condition, 65 patients is a Participant_Sample-size, tumor oxygenation measurements with Eppendorf PO2 histographs and comet assays is a Outcome_Other, , performed on fine - needle aspirates at 1 and 2 min after 5 Gy is a Intervention_Pharmacological, Fifty - four patients is a Participant_Sample-size, 5 Gy in vitro is a Intervention_Pharmacological, DNA damage in tumor cells is a Outcome_Physical, Eppendorf PO2 measurements and comet MTM is a Outcome_Other
12915_task0
Sentence: Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients . PURPOSE To compare the Eppendorf PO2 histograph and the alkaline comet assay as methods of measuring tumor hypoxia in patients with head-and-neck squamous cell carcinomas . MATERIALS AND METHODS As part of a larger clinical trial , 65 patients with head-and-neck squamous cell carcinoma nodal metastasis underwent tumor oxygenation measurements with Eppendorf PO2 histographs and comet assays , performed on fine-needle aspirates at 1 and 2 min after 5 Gy . Fifty-four patients had sufficient tumor cells for comet analysis at 1 min and 26 at both 1 and 2 min . Individual cells were examined for DNA single-strand breaks by alkaline gel electrophoresis , and the distribution of values was quantified using median tail moment ( MTM ) . Nonirradiated tumor cells from pretreatment fine-needle aspirates received 5 Gy in vitro to establish the oxygenated response . RESULTS There was a significant correlation between the 1- and 2-min MTM ( slope = 0.77 +/- 0.03 ) . There was no relationship between DNA damage in tumor cells irradiated in vitro and in vivo . No correlation was found between Eppendorf PO2 measurements and comet MTM . There was a statistically significant correlation between the treatment response in the node studied and comet MTMs , whereas no correlation was observed between treatment response and Eppendorf measurements . CONCLUSIONS Comet assays are reproducible , as shown by biopsies at 1 and 2 min . Intertumor variation in the MTM is not a result of intrinsic radiosensitivity but of tumor hypoxia . There was no correlation between Eppendorf PO2 measurements and comet MTM . Comet assays were better than Eppendorf in predicting treatment response as an end point for short-term outcome . Longer follow-up is needed to determine the role of the comet assay as a predictor for locoregional tumor control and survivals . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Intervention_Other, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients . PURPOSE To compare the Eppendorf PO2 histograph and the alkaline comet assay as methods of measuring tumor hypoxia in patients with head-and-neck squamous cell carcinomas . MATERIALS AND METHODS As part of a larger clinical trial , 65 patients with head-and-neck squamous cell carcinoma nodal metastasis underwent tumor oxygenation measurements with Eppendorf PO2 histographs and comet assays , performed on fine-needle aspirates at 1 and 2 min after 5 Gy . Fifty-four patients had sufficient tumor cells for comet analysis at 1 min and 26 at both 1 and 2 min . Individual cells were examined for DNA single-strand breaks by alkaline gel electrophoresis , and the distribution of values was quantified using median tail moment ( MTM ) . Nonirradiated tumor cells from pretreatment fine-needle aspirates received 5 Gy in vitro to establish the oxygenated response . RESULTS There was a significant correlation between the 1- and 2-min MTM ( slope = 0.77 +/- 0.03 ) . There was no relationship between DNA damage in tumor cells irradiated in vitro and in vivo . No correlation was found between Eppendorf PO2 measurements and comet MTM . There was a statistically significant correlation between the treatment response in the node studied and comet MTMs , whereas no correlation was observed between treatment response and Eppendorf measurements . CONCLUSIONS Comet assays are reproducible , as shown by biopsies at 1 and 2 min . Intertumor variation in the MTM is not a result of intrinsic radiosensitivity but of tumor hypoxia . There was no correlation between Eppendorf PO2 measurements and comet MTM . Comet assays were better than Eppendorf in predicting treatment response as an end point for short-term outcome . Longer follow-up is needed to determine the role of the comet assay as a predictor for locoregional tumor control and survivals .
[ "Comparison", "of", "the", "comet", "assay", "and", "the", "oxygen", "microelectrode", "for", "measuring", "tumor", "oxygenation", "in", "head", "-", "and", "-", "neck", "cancer", "patients", ".", "PURPOSE", "To", "compare", "the", "Eppendorf", "PO2", "histograph", "and", "the", "alkaline", "comet", "assay", "as", "methods", "of", "measuring", "tumor", "hypoxia", "in", "patients", "with", "head", "-", "and", "-", "neck", "squamous", "cell", "carcinomas", ".", "MATERIALS", "AND", "METHODS", "As", "part", "of", "a", "larger", "clinical", "trial", ",", "65", "patients", "with", "head", "-", "and", "-", "neck", "squamous", "cell", "carcinoma", "nodal", "metastasis", "underwent", "tumor", "oxygenation", "measurements", "with", "Eppendorf", "PO2", "histographs", "and", "comet", "assays", ",", "performed", "on", "fine", "-", "needle", "aspirates", "at", "1", "and", "2", "min", "after", "5", "Gy", ".", "Fifty", "-", "four", "patients", "had", "sufficient", "tumor", "cells", "for", "comet", "analysis", "at", "1", "min", "and", "26", "at", "both", "1", "and", "2", "min", ".", "Individual", "cells", "were", "examined", "for", "DNA", "single", "-", "strand", "breaks", "by", "alkaline", "gel", "electrophoresis", ",", "and", "the", "distribution", "of", "values", "was", "quantified", "using", "median", "tail", "moment", "(", "MTM", ")", ".", "Nonirradiated", "tumor", "cells", "from", "pretreatment", "fine", "-", "needle", "aspirates", "received", "5", "Gy", "in", "vitro", "to", "establish", "the", "oxygenated", "response", ".", "RESULTS", "There", "was", "a", "significant", "correlation", "between", "the", "1-", "and", "2-min", "MTM", "(", "slope", "=", "0.77", "+", "/-", "0.03", ")", ".", "There", "was", "no", "relationship", "between", "DNA", "damage", "in", "tumor", "cells", "irradiated", "in", "vitro", "and", "in", "vivo", ".", "No", "correlation", "was", "found", "between", "Eppendorf", "PO2", "measurements", "and", "comet", "MTM", ".", "There", "was", "a", "statistically", "significant", "correlation", "between", "the", "treatment", "response", "in", "the", "node", "studied", "and", "comet", "MTMs", ",", "whereas", "no", "correlation", "was", "observed", "between", "treatment", "response", "and", "Eppendorf", "measurements", ".", "CONCLUSIONS", "Comet", "assays", "are", "reproducible", ",", "as", "shown", "by", "biopsies", "at", "1", "and", "2", "min", ".", "Intertumor", "variation", "in", "the", "MTM", "is", "not", "a", "result", "of", "intrinsic", "radiosensitivity", "but", "of", "tumor", "hypoxia", ".", "There", "was", "no", "correlation", "between", "Eppendorf", "PO2", "measurements", "and", "comet", "MTM", ".", "Comet", "assays", "were", "better", "than", "Eppendorf", "in", "predicting", "treatment", "response", "as", "an", "end", "point", "for", "short", "-", "term", "outcome", ".", "Longer", "follow", "-", "up", "is", "needed", "to", "determine", "the", "role", "of", "the", "comet", "assay", "as", "a", "predictor", "for", "locoregional", "tumor", "control", "and", "survivals", "." ]
[ "Outcome_Other", "Intervention_Pharmacological", "Participant_Condition", "Intervention_Other", "Outcome_Physical", "Participant_Sample-size" ]
and is a Intervention_Pharmacological, tumor oxygenation is a Outcome_Physical, head - and - neck cancer is a Participant_Condition, Eppendorf PO2 histograph is a Intervention_Other, alkaline comet assay is a Intervention_Other, tumor hypoxia is a Outcome_Physical, head - and - neck squamous cell carcinomas is a Participant_Condition, 65 patients is a Participant_Sample-size, tumor oxygenation measurements with Eppendorf PO2 histographs and comet assays is a Outcome_Other, , performed on fine - needle aspirates at 1 and 2 min after 5 Gy is a Intervention_Pharmacological, Fifty - four patients is a Participant_Sample-size, 5 Gy in vitro is a Intervention_Pharmacological, DNA damage in tumor cells is a Outcome_Physical, Eppendorf PO2 measurements and comet MTM is a Outcome_Other
12915_task1
Sentence: Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients . PURPOSE To compare the Eppendorf PO2 histograph and the alkaline comet assay as methods of measuring tumor hypoxia in patients with head-and-neck squamous cell carcinomas . MATERIALS AND METHODS As part of a larger clinical trial , 65 patients with head-and-neck squamous cell carcinoma nodal metastasis underwent tumor oxygenation measurements with Eppendorf PO2 histographs and comet assays , performed on fine-needle aspirates at 1 and 2 min after 5 Gy . Fifty-four patients had sufficient tumor cells for comet analysis at 1 min and 26 at both 1 and 2 min . Individual cells were examined for DNA single-strand breaks by alkaline gel electrophoresis , and the distribution of values was quantified using median tail moment ( MTM ) . Nonirradiated tumor cells from pretreatment fine-needle aspirates received 5 Gy in vitro to establish the oxygenated response . RESULTS There was a significant correlation between the 1- and 2-min MTM ( slope = 0.77 +/- 0.03 ) . There was no relationship between DNA damage in tumor cells irradiated in vitro and in vivo . No correlation was found between Eppendorf PO2 measurements and comet MTM . There was a statistically significant correlation between the treatment response in the node studied and comet MTMs , whereas no correlation was observed between treatment response and Eppendorf measurements . CONCLUSIONS Comet assays are reproducible , as shown by biopsies at 1 and 2 min . Intertumor variation in the MTM is not a result of intrinsic radiosensitivity but of tumor hypoxia . There was no correlation between Eppendorf PO2 measurements and comet MTM . Comet assays were better than Eppendorf in predicting treatment response as an end point for short-term outcome . Longer follow-up is needed to determine the role of the comet assay as a predictor for locoregional tumor control and survivals . Instructions: please typing these entity words according to sentence: and, tumor oxygenation, head - and - neck cancer, Eppendorf PO2 histograph, alkaline comet assay, tumor hypoxia, head - and - neck squamous cell carcinomas, 65 patients, tumor oxygenation measurements with Eppendorf PO2 histographs and comet assays, , performed on fine - needle aspirates at 1 and 2 min after 5 Gy, Fifty - four patients, 5 Gy in vitro, DNA damage in tumor cells, Eppendorf PO2 measurements and comet MTM Options: Intervention_Pharmacological, Participant_Condition, Intervention_Other, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients . PURPOSE To compare the Eppendorf PO2 histograph and the alkaline comet assay as methods of measuring tumor hypoxia in patients with head-and-neck squamous cell carcinomas . MATERIALS AND METHODS As part of a larger clinical trial , 65 patients with head-and-neck squamous cell carcinoma nodal metastasis underwent tumor oxygenation measurements with Eppendorf PO2 histographs and comet assays , performed on fine-needle aspirates at 1 and 2 min after 5 Gy . Fifty-four patients had sufficient tumor cells for comet analysis at 1 min and 26 at both 1 and 2 min . Individual cells were examined for DNA single-strand breaks by alkaline gel electrophoresis , and the distribution of values was quantified using median tail moment ( MTM ) . Nonirradiated tumor cells from pretreatment fine-needle aspirates received 5 Gy in vitro to establish the oxygenated response . RESULTS There was a significant correlation between the 1- and 2-min MTM ( slope = 0.77 +/- 0.03 ) . There was no relationship between DNA damage in tumor cells irradiated in vitro and in vivo . No correlation was found between Eppendorf PO2 measurements and comet MTM . There was a statistically significant correlation between the treatment response in the node studied and comet MTMs , whereas no correlation was observed between treatment response and Eppendorf measurements . CONCLUSIONS Comet assays are reproducible , as shown by biopsies at 1 and 2 min . Intertumor variation in the MTM is not a result of intrinsic radiosensitivity but of tumor hypoxia . There was no correlation between Eppendorf PO2 measurements and comet MTM . Comet assays were better than Eppendorf in predicting treatment response as an end point for short-term outcome . Longer follow-up is needed to determine the role of the comet assay as a predictor for locoregional tumor control and survivals .
[ "Comparison", "of", "the", "comet", "assay", "and", "the", "oxygen", "microelectrode", "for", "measuring", "tumor", "oxygenation", "in", "head", "-", "and", "-", "neck", "cancer", "patients", ".", "PURPOSE", "To", "compare", "the", "Eppendorf", "PO2", "histograph", "and", "the", "alkaline", "comet", "assay", "as", "methods", "of", "measuring", "tumor", "hypoxia", "in", "patients", "with", "head", "-", "and", "-", "neck", "squamous", "cell", "carcinomas", ".", "MATERIALS", "AND", "METHODS", "As", "part", "of", "a", "larger", "clinical", "trial", ",", "65", "patients", "with", "head", "-", "and", "-", "neck", "squamous", "cell", "carcinoma", "nodal", "metastasis", "underwent", "tumor", "oxygenation", "measurements", "with", "Eppendorf", "PO2", "histographs", "and", "comet", "assays", ",", "performed", "on", "fine", "-", "needle", "aspirates", "at", "1", "and", "2", "min", "after", "5", "Gy", ".", "Fifty", "-", "four", "patients", "had", "sufficient", "tumor", "cells", "for", "comet", "analysis", "at", "1", "min", "and", "26", "at", "both", "1", "and", "2", "min", ".", "Individual", "cells", "were", "examined", "for", "DNA", "single", "-", "strand", "breaks", "by", "alkaline", "gel", "electrophoresis", ",", "and", "the", "distribution", "of", "values", "was", "quantified", "using", "median", "tail", "moment", "(", "MTM", ")", ".", "Nonirradiated", "tumor", "cells", "from", "pretreatment", "fine", "-", "needle", "aspirates", "received", "5", "Gy", "in", "vitro", "to", "establish", "the", "oxygenated", "response", ".", "RESULTS", "There", "was", "a", "significant", "correlation", "between", "the", "1-", "and", "2-min", "MTM", "(", "slope", "=", "0.77", "+", "/-", "0.03", ")", ".", "There", "was", "no", "relationship", "between", "DNA", "damage", "in", "tumor", "cells", "irradiated", "in", "vitro", "and", "in", "vivo", ".", "No", "correlation", "was", "found", "between", "Eppendorf", "PO2", "measurements", "and", "comet", "MTM", ".", "There", "was", "a", "statistically", "significant", "correlation", "between", "the", "treatment", "response", "in", "the", "node", "studied", "and", "comet", "MTMs", ",", "whereas", "no", "correlation", "was", "observed", "between", "treatment", "response", "and", "Eppendorf", "measurements", ".", "CONCLUSIONS", "Comet", "assays", "are", "reproducible", ",", "as", "shown", "by", "biopsies", "at", "1", "and", "2", "min", ".", "Intertumor", "variation", "in", "the", "MTM", "is", "not", "a", "result", "of", "intrinsic", "radiosensitivity", "but", "of", "tumor", "hypoxia", ".", "There", "was", "no", "correlation", "between", "Eppendorf", "PO2", "measurements", "and", "comet", "MTM", ".", "Comet", "assays", "were", "better", "than", "Eppendorf", "in", "predicting", "treatment", "response", "as", "an", "end", "point", "for", "short", "-", "term", "outcome", ".", "Longer", "follow", "-", "up", "is", "needed", "to", "determine", "the", "role", "of", "the", "comet", "assay", "as", "a", "predictor", "for", "locoregional", "tumor", "control", "and", "survivals", "." ]
[ "Outcome_Other", "Intervention_Pharmacological", "Participant_Condition", "Intervention_Other", "Outcome_Physical", "Participant_Sample-size" ]
and, tumor oxygenation, head - and - neck cancer, Eppendorf PO2 histograph, alkaline comet assay, tumor hypoxia, head - and - neck squamous cell carcinomas, 65 patients, tumor oxygenation measurements with Eppendorf PO2 histographs and comet assays, , performed on fine - needle aspirates at 1 and 2 min after 5 Gy, Fifty - four patients, 5 Gy in vitro, DNA damage in tumor cells, Eppendorf PO2 measurements and comet MTM
12915_task2
Sentence: Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients . PURPOSE To compare the Eppendorf PO2 histograph and the alkaline comet assay as methods of measuring tumor hypoxia in patients with head-and-neck squamous cell carcinomas . MATERIALS AND METHODS As part of a larger clinical trial , 65 patients with head-and-neck squamous cell carcinoma nodal metastasis underwent tumor oxygenation measurements with Eppendorf PO2 histographs and comet assays , performed on fine-needle aspirates at 1 and 2 min after 5 Gy . Fifty-four patients had sufficient tumor cells for comet analysis at 1 min and 26 at both 1 and 2 min . Individual cells were examined for DNA single-strand breaks by alkaline gel electrophoresis , and the distribution of values was quantified using median tail moment ( MTM ) . Nonirradiated tumor cells from pretreatment fine-needle aspirates received 5 Gy in vitro to establish the oxygenated response . RESULTS There was a significant correlation between the 1- and 2-min MTM ( slope = 0.77 +/- 0.03 ) . There was no relationship between DNA damage in tumor cells irradiated in vitro and in vivo . No correlation was found between Eppendorf PO2 measurements and comet MTM . There was a statistically significant correlation between the treatment response in the node studied and comet MTMs , whereas no correlation was observed between treatment response and Eppendorf measurements . CONCLUSIONS Comet assays are reproducible , as shown by biopsies at 1 and 2 min . Intertumor variation in the MTM is not a result of intrinsic radiosensitivity but of tumor hypoxia . There was no correlation between Eppendorf PO2 measurements and comet MTM . Comet assays were better than Eppendorf in predicting treatment response as an end point for short-term outcome . Longer follow-up is needed to determine the role of the comet assay as a predictor for locoregional tumor control and survivals . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients . PURPOSE To compare the Eppendorf PO2 histograph and the alkaline comet assay as methods of measuring tumor hypoxia in patients with head-and-neck squamous cell carcinomas . MATERIALS AND METHODS As part of a larger clinical trial , 65 patients with head-and-neck squamous cell carcinoma nodal metastasis underwent tumor oxygenation measurements with Eppendorf PO2 histographs and comet assays , performed on fine-needle aspirates at 1 and 2 min after 5 Gy . Fifty-four patients had sufficient tumor cells for comet analysis at 1 min and 26 at both 1 and 2 min . Individual cells were examined for DNA single-strand breaks by alkaline gel electrophoresis , and the distribution of values was quantified using median tail moment ( MTM ) . Nonirradiated tumor cells from pretreatment fine-needle aspirates received 5 Gy in vitro to establish the oxygenated response . RESULTS There was a significant correlation between the 1- and 2-min MTM ( slope = 0.77 +/- 0.03 ) . There was no relationship between DNA damage in tumor cells irradiated in vitro and in vivo . No correlation was found between Eppendorf PO2 measurements and comet MTM . There was a statistically significant correlation between the treatment response in the node studied and comet MTMs , whereas no correlation was observed between treatment response and Eppendorf measurements . CONCLUSIONS Comet assays are reproducible , as shown by biopsies at 1 and 2 min . Intertumor variation in the MTM is not a result of intrinsic radiosensitivity but of tumor hypoxia . There was no correlation between Eppendorf PO2 measurements and comet MTM . Comet assays were better than Eppendorf in predicting treatment response as an end point for short-term outcome . Longer follow-up is needed to determine the role of the comet assay as a predictor for locoregional tumor control and survivals .
[ "Comparison", "of", "the", "comet", "assay", "and", "the", "oxygen", "microelectrode", "for", "measuring", "tumor", "oxygenation", "in", "head", "-", "and", "-", "neck", "cancer", "patients", ".", "PURPOSE", "To", "compare", "the", "Eppendorf", "PO2", "histograph", "and", "the", "alkaline", "comet", "assay", "as", "methods", "of", "measuring", "tumor", "hypoxia", "in", "patients", "with", "head", "-", "and", "-", "neck", "squamous", "cell", "carcinomas", ".", "MATERIALS", "AND", "METHODS", "As", "part", "of", "a", "larger", "clinical", "trial", ",", "65", "patients", "with", "head", "-", "and", "-", "neck", "squamous", "cell", "carcinoma", "nodal", "metastasis", "underwent", "tumor", "oxygenation", "measurements", "with", "Eppendorf", "PO2", "histographs", "and", "comet", "assays", ",", "performed", "on", "fine", "-", "needle", "aspirates", "at", "1", "and", "2", "min", "after", "5", "Gy", ".", "Fifty", "-", "four", "patients", "had", "sufficient", "tumor", "cells", "for", "comet", "analysis", "at", "1", "min", "and", "26", "at", "both", "1", "and", "2", "min", ".", "Individual", "cells", "were", "examined", "for", "DNA", "single", "-", "strand", "breaks", "by", "alkaline", "gel", "electrophoresis", ",", "and", "the", "distribution", "of", "values", "was", "quantified", "using", "median", "tail", "moment", "(", "MTM", ")", ".", "Nonirradiated", "tumor", "cells", "from", "pretreatment", "fine", "-", "needle", "aspirates", "received", "5", "Gy", "in", "vitro", "to", "establish", "the", "oxygenated", "response", ".", "RESULTS", "There", "was", "a", "significant", "correlation", "between", "the", "1-", "and", "2-min", "MTM", "(", "slope", "=", "0.77", "+", "/-", "0.03", ")", ".", "There", "was", "no", "relationship", "between", "DNA", "damage", "in", "tumor", "cells", "irradiated", "in", "vitro", "and", "in", "vivo", ".", "No", "correlation", "was", "found", "between", "Eppendorf", "PO2", "measurements", "and", "comet", "MTM", ".", "There", "was", "a", "statistically", "significant", "correlation", "between", "the", "treatment", "response", "in", "the", "node", "studied", "and", "comet", "MTMs", ",", "whereas", "no", "correlation", "was", "observed", "between", "treatment", "response", "and", "Eppendorf", "measurements", ".", "CONCLUSIONS", "Comet", "assays", "are", "reproducible", ",", "as", "shown", "by", "biopsies", "at", "1", "and", "2", "min", ".", "Intertumor", "variation", "in", "the", "MTM", "is", "not", "a", "result", "of", "intrinsic", "radiosensitivity", "but", "of", "tumor", "hypoxia", ".", "There", "was", "no", "correlation", "between", "Eppendorf", "PO2", "measurements", "and", "comet", "MTM", ".", "Comet", "assays", "were", "better", "than", "Eppendorf", "in", "predicting", "treatment", "response", "as", "an", "end", "point", "for", "short", "-", "term", "outcome", ".", "Longer", "follow", "-", "up", "is", "needed", "to", "determine", "the", "role", "of", "the", "comet", "assay", "as", "a", "predictor", "for", "locoregional", "tumor", "control", "and", "survivals", "." ]
[ "Outcome_Other", "Intervention_Pharmacological", "Participant_Condition", "Intervention_Other", "Outcome_Physical", "Participant_Sample-size" ]
PU.1 is a Protein, GATA-1 is a Protein, PU.1 is a Protein, PU.1 is a Protein, PU.1 is a Protein, PU.1 is a Protein, PU.1 is a Protein, PU.1 is a Protein, GATA-1 is a Protein, PU.1 is a Protein, GATA-1 is a Protein, DNA - binding domains is a Entity, PU.1 is a Protein, domains is a Entity, PU.1 is a Protein, PU.1 is a Protein, GATA-1 is a Protein, PU.1 is a Protein
520_task0
Sentence: Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Malignant transformation usually inhibits terminal cell differentiation but the precise mechanisms involved are not understood. PU.1 is a hematopoietic-specific Ets family transcription factor that is required for development of some lymphoid and myeloid lineages. PU.1 can also act as an oncoprotein as activation of its expression in erythroid precursors by proviral insertion or transgenesis causes erythroleukemias in mice. Restoration of terminal differentiation in the mouse erythroleukemia (MEL) cells requires a decline in the level of PU.1, indicating that PU.1 can block erythroid differentiation. Here we investigate the mechanism by which PU.1 interferes with erythroid differentiation. We find that PU.1 interacts directly with GATA-1, a zinc finger transcription factor required for erythroid differentiation. Interaction between PU.1 and GATA-1 requires intact DNA-binding domains in both proteins. PU.1 represses GATA-1-mediated transcriptional activation. Both the DNA binding and transactivation domains of PU.1 are required for repression and both domains are also needed to block terminal differentiation in MEL cells. We also show that ectopic expression of PU.1 in Xenopus embryos is sufficient to block erythropoiesis during normal development. Furthermore, introduction of exogenous GATA-1 in both MEL cells and Xenopus embryos and explants relieves the block to erythroid differentiation imposed by PU.1. Our results indicate that the stoichiometry of directly interacting but opposing transcription factors may be a crucial determinant governing processes of normal differentiation and malignant transformation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Malignant transformation usually inhibits terminal cell differentiation but the precise mechanisms involved are not understood. PU.1 is a hematopoietic-specific Ets family transcription factor that is required for development of some lymphoid and myeloid lineages. PU.1 can also act as an oncoprotein as activation of its expression in erythroid precursors by proviral insertion or transgenesis causes erythroleukemias in mice. Restoration of terminal differentiation in the mouse erythroleukemia (MEL) cells requires a decline in the level of PU.1, indicating that PU.1 can block erythroid differentiation. Here we investigate the mechanism by which PU.1 interferes with erythroid differentiation. We find that PU.1 interacts directly with GATA-1, a zinc finger transcription factor required for erythroid differentiation. Interaction between PU.1 and GATA-1 requires intact DNA-binding domains in both proteins. PU.1 represses GATA-1-mediated transcriptional activation. Both the DNA binding and transactivation domains of PU.1 are required for repression and both domains are also needed to block terminal differentiation in MEL cells. We also show that ectopic expression of PU.1 in Xenopus embryos is sufficient to block erythropoiesis during normal development. Furthermore, introduction of exogenous GATA-1 in both MEL cells and Xenopus embryos and explants relieves the block to erythroid differentiation imposed by PU.1. Our results indicate that the stoichiometry of directly interacting but opposing transcription factors may be a crucial determinant governing processes of normal differentiation and malignant transformation.
[ "Direct", "interaction", "of", "hematopoietic", "transcription", "factors", "PU.1", "and", "GATA-1", ":", "functional", "antagonism", "in", "erythroid", "cells", ".", "\n", "Malignant", "transformation", "usually", "inhibits", "terminal", "cell", "differentiation", "but", "the", "precise", "mechanisms", "involved", "are", "not", "understood", ".", "PU.1", "is", "a", "hematopoietic", "-", "specific", "Ets", "family", "transcription", "factor", "that", "is", "required", "for", "development", "of", "some", "lymphoid", "and", "myeloid", "lineages", ".", "PU.1", "can", "also", "act", "as", "an", "oncoprotein", "as", "activation", "of", "its", "expression", "in", "erythroid", "precursors", "by", "proviral", "insertion", "or", "transgenesis", "causes", "erythroleukemias", "in", "mice", ".", "Restoration", "of", "terminal", "differentiation", "in", "the", "mouse", "erythroleukemia", "(", "MEL", ")", "cells", "requires", "a", "decline", "in", "the", "level", "of", "PU.1", ",", "indicating", "that", "PU.1", "can", "block", "erythroid", "differentiation", ".", "Here", "we", "investigate", "the", "mechanism", "by", "which", "PU.1", "interferes", "with", "erythroid", "differentiation", ".", "We", "find", "that", "PU.1", "interacts", "directly", "with", "GATA-1", ",", "a", "zinc", "finger", "transcription", "factor", "required", "for", "erythroid", "differentiation", ".", "Interaction", "between", "PU.1", "and", "GATA-1", "requires", "intact", "DNA", "-", "binding", "domains", "in", "both", "proteins", ".", "PU.1", "represses", "GATA-1-mediated", "transcriptional", "activation", ".", "Both", "the", "DNA", "binding", "and", "transactivation", "domains", "of", "PU.1", "are", "required", "for", "repression", "and", "both", "domains", "are", "also", "needed", "to", "block", "terminal", "differentiation", "in", "MEL", "cells", ".", "We", "also", "show", "that", "ectopic", "expression", "of", "PU.1", "in", "Xenopus", "embryos", "is", "sufficient", "to", "block", "erythropoiesis", "during", "normal", "development", ".", "Furthermore", ",", "introduction", "of", "exogenous", "GATA-1", "in", "both", "MEL", "cells", "and", "Xenopus", "embryos", "and", "explants", "relieves", "the", "block", "to", "erythroid", "differentiation", "imposed", "by", "PU.1", ".", "Our", "results", "indicate", "that", "the", "stoichiometry", "of", "directly", "interacting", "but", "opposing", "transcription", "factors", "may", "be", "a", "crucial", "determinant", "governing", "processes", "of", "normal", "differentiation", "and", "malignant", "transformation", ".", "\n" ]
[ "Entity", "Protein" ]
PU.1 is a Protein, GATA-1 is a Protein, PU.1 is a Protein, PU.1 is a Protein, PU.1 is a Protein, PU.1 is a Protein, PU.1 is a Protein, PU.1 is a Protein, GATA-1 is a Protein, PU.1 is a Protein, GATA-1 is a Protein, DNA - binding domains is a Entity, PU.1 is a Protein, domains is a Entity, PU.1 is a Protein, PU.1 is a Protein, GATA-1 is a Protein, PU.1 is a Protein
520_task1
Sentence: Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Malignant transformation usually inhibits terminal cell differentiation but the precise mechanisms involved are not understood. PU.1 is a hematopoietic-specific Ets family transcription factor that is required for development of some lymphoid and myeloid lineages. PU.1 can also act as an oncoprotein as activation of its expression in erythroid precursors by proviral insertion or transgenesis causes erythroleukemias in mice. Restoration of terminal differentiation in the mouse erythroleukemia (MEL) cells requires a decline in the level of PU.1, indicating that PU.1 can block erythroid differentiation. Here we investigate the mechanism by which PU.1 interferes with erythroid differentiation. We find that PU.1 interacts directly with GATA-1, a zinc finger transcription factor required for erythroid differentiation. Interaction between PU.1 and GATA-1 requires intact DNA-binding domains in both proteins. PU.1 represses GATA-1-mediated transcriptional activation. Both the DNA binding and transactivation domains of PU.1 are required for repression and both domains are also needed to block terminal differentiation in MEL cells. We also show that ectopic expression of PU.1 in Xenopus embryos is sufficient to block erythropoiesis during normal development. Furthermore, introduction of exogenous GATA-1 in both MEL cells and Xenopus embryos and explants relieves the block to erythroid differentiation imposed by PU.1. Our results indicate that the stoichiometry of directly interacting but opposing transcription factors may be a crucial determinant governing processes of normal differentiation and malignant transformation. Instructions: please typing these entity words according to sentence: PU.1, GATA-1, PU.1, PU.1, PU.1, PU.1, PU.1, PU.1, GATA-1, PU.1, GATA-1, DNA - binding domains, PU.1, domains, PU.1, PU.1, GATA-1, PU.1 Options: Entity, Protein
[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Malignant transformation usually inhibits terminal cell differentiation but the precise mechanisms involved are not understood. PU.1 is a hematopoietic-specific Ets family transcription factor that is required for development of some lymphoid and myeloid lineages. PU.1 can also act as an oncoprotein as activation of its expression in erythroid precursors by proviral insertion or transgenesis causes erythroleukemias in mice. Restoration of terminal differentiation in the mouse erythroleukemia (MEL) cells requires a decline in the level of PU.1, indicating that PU.1 can block erythroid differentiation. Here we investigate the mechanism by which PU.1 interferes with erythroid differentiation. We find that PU.1 interacts directly with GATA-1, a zinc finger transcription factor required for erythroid differentiation. Interaction between PU.1 and GATA-1 requires intact DNA-binding domains in both proteins. PU.1 represses GATA-1-mediated transcriptional activation. Both the DNA binding and transactivation domains of PU.1 are required for repression and both domains are also needed to block terminal differentiation in MEL cells. We also show that ectopic expression of PU.1 in Xenopus embryos is sufficient to block erythropoiesis during normal development. Furthermore, introduction of exogenous GATA-1 in both MEL cells and Xenopus embryos and explants relieves the block to erythroid differentiation imposed by PU.1. Our results indicate that the stoichiometry of directly interacting but opposing transcription factors may be a crucial determinant governing processes of normal differentiation and malignant transformation.
[ "Direct", "interaction", "of", "hematopoietic", "transcription", "factors", "PU.1", "and", "GATA-1", ":", "functional", "antagonism", "in", "erythroid", "cells", ".", "\n", "Malignant", "transformation", "usually", "inhibits", "terminal", "cell", "differentiation", "but", "the", "precise", "mechanisms", "involved", "are", "not", "understood", ".", "PU.1", "is", "a", "hematopoietic", "-", "specific", "Ets", "family", "transcription", "factor", "that", "is", "required", "for", "development", "of", "some", "lymphoid", "and", "myeloid", "lineages", ".", "PU.1", "can", "also", "act", "as", "an", "oncoprotein", "as", "activation", "of", "its", "expression", "in", "erythroid", "precursors", "by", "proviral", "insertion", "or", "transgenesis", "causes", "erythroleukemias", "in", "mice", ".", "Restoration", "of", "terminal", "differentiation", "in", "the", "mouse", "erythroleukemia", "(", "MEL", ")", "cells", "requires", "a", "decline", "in", "the", "level", "of", "PU.1", ",", "indicating", "that", "PU.1", "can", "block", "erythroid", "differentiation", ".", "Here", "we", "investigate", "the", "mechanism", "by", "which", "PU.1", "interferes", "with", "erythroid", "differentiation", ".", "We", "find", "that", "PU.1", "interacts", "directly", "with", "GATA-1", ",", "a", "zinc", "finger", "transcription", "factor", "required", "for", "erythroid", "differentiation", ".", "Interaction", "between", "PU.1", "and", "GATA-1", "requires", "intact", "DNA", "-", "binding", "domains", "in", "both", "proteins", ".", "PU.1", "represses", "GATA-1-mediated", "transcriptional", "activation", ".", "Both", "the", "DNA", "binding", "and", "transactivation", "domains", "of", "PU.1", "are", "required", "for", "repression", "and", "both", "domains", "are", "also", "needed", "to", "block", "terminal", "differentiation", "in", "MEL", "cells", ".", "We", "also", "show", "that", "ectopic", "expression", "of", "PU.1", "in", "Xenopus", "embryos", "is", "sufficient", "to", "block", "erythropoiesis", "during", "normal", "development", ".", "Furthermore", ",", "introduction", "of", "exogenous", "GATA-1", "in", "both", "MEL", "cells", "and", "Xenopus", "embryos", "and", "explants", "relieves", "the", "block", "to", "erythroid", "differentiation", "imposed", "by", "PU.1", ".", "Our", "results", "indicate", "that", "the", "stoichiometry", "of", "directly", "interacting", "but", "opposing", "transcription", "factors", "may", "be", "a", "crucial", "determinant", "governing", "processes", "of", "normal", "differentiation", "and", "malignant", "transformation", ".", "\n" ]
[ "Entity", "Protein" ]
PU.1, GATA-1, PU.1, PU.1, PU.1, PU.1, PU.1, PU.1, GATA-1, PU.1, GATA-1, DNA - binding domains, PU.1, domains, PU.1, PU.1, GATA-1, PU.1
520_task2
Sentence: Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Malignant transformation usually inhibits terminal cell differentiation but the precise mechanisms involved are not understood. PU.1 is a hematopoietic-specific Ets family transcription factor that is required for development of some lymphoid and myeloid lineages. PU.1 can also act as an oncoprotein as activation of its expression in erythroid precursors by proviral insertion or transgenesis causes erythroleukemias in mice. Restoration of terminal differentiation in the mouse erythroleukemia (MEL) cells requires a decline in the level of PU.1, indicating that PU.1 can block erythroid differentiation. Here we investigate the mechanism by which PU.1 interferes with erythroid differentiation. We find that PU.1 interacts directly with GATA-1, a zinc finger transcription factor required for erythroid differentiation. Interaction between PU.1 and GATA-1 requires intact DNA-binding domains in both proteins. PU.1 represses GATA-1-mediated transcriptional activation. Both the DNA binding and transactivation domains of PU.1 are required for repression and both domains are also needed to block terminal differentiation in MEL cells. We also show that ectopic expression of PU.1 in Xenopus embryos is sufficient to block erythropoiesis during normal development. Furthermore, introduction of exogenous GATA-1 in both MEL cells and Xenopus embryos and explants relieves the block to erythroid differentiation imposed by PU.1. Our results indicate that the stoichiometry of directly interacting but opposing transcription factors may be a crucial determinant governing processes of normal differentiation and malignant transformation. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Malignant transformation usually inhibits terminal cell differentiation but the precise mechanisms involved are not understood. PU.1 is a hematopoietic-specific Ets family transcription factor that is required for development of some lymphoid and myeloid lineages. PU.1 can also act as an oncoprotein as activation of its expression in erythroid precursors by proviral insertion or transgenesis causes erythroleukemias in mice. Restoration of terminal differentiation in the mouse erythroleukemia (MEL) cells requires a decline in the level of PU.1, indicating that PU.1 can block erythroid differentiation. Here we investigate the mechanism by which PU.1 interferes with erythroid differentiation. We find that PU.1 interacts directly with GATA-1, a zinc finger transcription factor required for erythroid differentiation. Interaction between PU.1 and GATA-1 requires intact DNA-binding domains in both proteins. PU.1 represses GATA-1-mediated transcriptional activation. Both the DNA binding and transactivation domains of PU.1 are required for repression and both domains are also needed to block terminal differentiation in MEL cells. We also show that ectopic expression of PU.1 in Xenopus embryos is sufficient to block erythropoiesis during normal development. Furthermore, introduction of exogenous GATA-1 in both MEL cells and Xenopus embryos and explants relieves the block to erythroid differentiation imposed by PU.1. Our results indicate that the stoichiometry of directly interacting but opposing transcription factors may be a crucial determinant governing processes of normal differentiation and malignant transformation.
[ "Direct", "interaction", "of", "hematopoietic", "transcription", "factors", "PU.1", "and", "GATA-1", ":", "functional", "antagonism", "in", "erythroid", "cells", ".", "\n", "Malignant", "transformation", "usually", "inhibits", "terminal", "cell", "differentiation", "but", "the", "precise", "mechanisms", "involved", "are", "not", "understood", ".", "PU.1", "is", "a", "hematopoietic", "-", "specific", "Ets", "family", "transcription", "factor", "that", "is", "required", "for", "development", "of", "some", "lymphoid", "and", "myeloid", "lineages", ".", "PU.1", "can", "also", "act", "as", "an", "oncoprotein", "as", "activation", "of", "its", "expression", "in", "erythroid", "precursors", "by", "proviral", "insertion", "or", "transgenesis", "causes", "erythroleukemias", "in", "mice", ".", "Restoration", "of", "terminal", "differentiation", "in", "the", "mouse", "erythroleukemia", "(", "MEL", ")", "cells", "requires", "a", "decline", "in", "the", "level", "of", "PU.1", ",", "indicating", "that", "PU.1", "can", "block", "erythroid", "differentiation", ".", "Here", "we", "investigate", "the", "mechanism", "by", "which", "PU.1", "interferes", "with", "erythroid", "differentiation", ".", "We", "find", "that", "PU.1", "interacts", "directly", "with", "GATA-1", ",", "a", "zinc", "finger", "transcription", "factor", "required", "for", "erythroid", "differentiation", ".", "Interaction", "between", "PU.1", "and", "GATA-1", "requires", "intact", "DNA", "-", "binding", "domains", "in", "both", "proteins", ".", "PU.1", "represses", "GATA-1-mediated", "transcriptional", "activation", ".", "Both", "the", "DNA", "binding", "and", "transactivation", "domains", "of", "PU.1", "are", "required", "for", "repression", "and", "both", "domains", "are", "also", "needed", "to", "block", "terminal", "differentiation", "in", "MEL", "cells", ".", "We", "also", "show", "that", "ectopic", "expression", "of", "PU.1", "in", "Xenopus", "embryos", "is", "sufficient", "to", "block", "erythropoiesis", "during", "normal", "development", ".", "Furthermore", ",", "introduction", "of", "exogenous", "GATA-1", "in", "both", "MEL", "cells", "and", "Xenopus", "embryos", "and", "explants", "relieves", "the", "block", "to", "erythroid", "differentiation", "imposed", "by", "PU.1", ".", "Our", "results", "indicate", "that", "the", "stoichiometry", "of", "directly", "interacting", "but", "opposing", "transcription", "factors", "may", "be", "a", "crucial", "determinant", "governing", "processes", "of", "normal", "differentiation", "and", "malignant", "transformation", ".", "\n" ]
[ "Entity", "Protein" ]
Wundheilung is an umlsterm, Wachstumsfaktoren is an umlsterm, Rolle is an umlsterm, Wundheilung is an umlsterm, Patienten is an umlsterm, Antibiose is an umlsterm, Wundheilung is an umlsterm, Schleimhautdesinfektionsmittel is an umlsterm, in vitro is an umlsterm, Behandlung is an umlsterm, Strahlenschaeden is an umlsterm, Desinfektionsmittel is an umlsterm
DerHautarzt.50460319.ger.abstr_task0
Sentence: Die Wundheilung stellt ein komplexes dynamisches Geschehen dar , welchem vor allem nach der Charakterisierung der Wachstumsfaktoren zunehmendes wissenschaftliches Interesse entgegengebracht wird . Auf der anderen Seite spielen aber auch erhebliche wirtschaftliche Gruende eine Rolle bei der Erforschung von Substanzen , die bei der Wundheilung eingesetzt werden koennen . Immerhin leiden 25% aller Patienten ( ca. 1 Million ) mit schwerer venoeser Insuffizienz an einem Ulcus cruris . Der bakteriellen Besiedlung von Ulcera crura wird eine unterschiedliche pathogenetische Bedeutung zugesprochen , wobei sicher die Keimzahl von Bedeutung ist . Die lokale Antibiose ist aber deshalb problematisch , weil die ueberwiegende Zahl von Substanzen , die hier eingesetzt werden , nachweislich die Wundheilung hemmen . Durch In-vivo und In-vitro-Untersuchungen konnte gezeigt werden , dass das chiniofonhaltige Schleimhautdesinfektionsmittel bei der Reinigung von Ulzera eine bakteriostatische Wirkung aufweist . Duch In-vitro-Untersuchungen an Fibroblastenkulturen , liess sich ausserdem zeigen , dass diese Substanz das Fibroblastenwachstum nicht beeinflusst . Im Gegensatz dazu weist PVP-Jod-Loesung , ein haeufig verwendetes Antiseptikum , eine starke Beeintraechtigung des Fibroblastenwachstums in vitro auf . Ausserdem geben die guten klinischen Ergebnisse bei der Behandlung von akuten und chronischen Strahlenschaeden mit dem chiniofonhaltigen Desinfektionsmittel Hinweise auf eine antiinflammatorische Wirkung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Die Wundheilung stellt ein komplexes dynamisches Geschehen dar , welchem vor allem nach der Charakterisierung der Wachstumsfaktoren zunehmendes wissenschaftliches Interesse entgegengebracht wird . Auf der anderen Seite spielen aber auch erhebliche wirtschaftliche Gruende eine Rolle bei der Erforschung von Substanzen , die bei der Wundheilung eingesetzt werden koennen . Immerhin leiden 25% aller Patienten ( ca. 1 Million ) mit schwerer venoeser Insuffizienz an einem Ulcus cruris . Der bakteriellen Besiedlung von Ulcera crura wird eine unterschiedliche pathogenetische Bedeutung zugesprochen , wobei sicher die Keimzahl von Bedeutung ist . Die lokale Antibiose ist aber deshalb problematisch , weil die ueberwiegende Zahl von Substanzen , die hier eingesetzt werden , nachweislich die Wundheilung hemmen . Durch In-vivo und In-vitro-Untersuchungen konnte gezeigt werden , dass das chiniofonhaltige Schleimhautdesinfektionsmittel bei der Reinigung von Ulzera eine bakteriostatische Wirkung aufweist . Duch In-vitro-Untersuchungen an Fibroblastenkulturen , liess sich ausserdem zeigen , dass diese Substanz das Fibroblastenwachstum nicht beeinflusst . Im Gegensatz dazu weist PVP-Jod-Loesung , ein haeufig verwendetes Antiseptikum , eine starke Beeintraechtigung des Fibroblastenwachstums in vitro auf . Ausserdem geben die guten klinischen Ergebnisse bei der Behandlung von akuten und chronischen Strahlenschaeden mit dem chiniofonhaltigen Desinfektionsmittel Hinweise auf eine antiinflammatorische Wirkung .
[ "Die", "Wundheilung", "stellt", "ein", "komplexes", "dynamisches", "Geschehen", "dar", ",", "welchem", "vor", "allem", "nach", "der", "Charakterisierung", "der", "Wachstumsfaktoren", "zunehmendes", "wissenschaftliches", "Interesse", "entgegengebracht", "wird", ".", "Auf", "der", "anderen", "Seite", "spielen", "aber", "auch", "erhebliche", "wirtschaftliche", "Gruende", "eine", "Rolle", "bei", "der", "Erforschung", "von", "Substanzen", ",", "die", "bei", "der", "Wundheilung", "eingesetzt", "werden", "koennen", ".", "Immerhin", "leiden", "25", "%", "aller", "Patienten", "(", "ca", ".", "1", "Million", ")", "mit", "schwerer", "venoeser", "Insuffizienz", "an", "einem", "Ulcus", "cruris", ".", "Der", "bakteriellen", "Besiedlung", "von", "Ulcera", "crura", "wird", "eine", "unterschiedliche", "pathogenetische", "Bedeutung", "zugesprochen", ",", "wobei", "sicher", "die", "Keimzahl", "von", "Bedeutung", "ist", ".", "Die", "lokale", "Antibiose", "ist", "aber", "deshalb", "problematisch", ",", "weil", "die", "ueberwiegende", "Zahl", "von", "Substanzen", ",", "die", "hier", "eingesetzt", "werden", ",", "nachweislich", "die", "Wundheilung", "hemmen", ".", "Durch", "In", "-", "vivo", "und", "In", "-", "vitro", "-", "Untersuchungen", "konnte", "gezeigt", "werden", ",", "dass", "das", "chiniofonhaltige", "Schleimhautdesinfektionsmittel", "bei", "der", "Reinigung", "von", "Ulzera", "eine", "bakteriostatische", "Wirkung", "aufweist", ".", "Duch", "In", "-", "vitro", "-", "Untersuchungen", "an", "Fibroblastenkulturen", ",", "liess", "sich", "ausserdem", "zeigen", ",", "dass", "diese", "Substanz", "das", "Fibroblastenwachstum", "nicht", "beeinflusst", ".", "Im", "Gegensatz", "dazu", "weist", "PVP", "-", "Jod", "-", "Loesung", ",", "ein", "haeufig", "verwendetes", "Antiseptikum", ",", "eine", "starke", "Beeintraechtigung", "des", "Fibroblastenwachstums", "in", "vitro", "auf", ".", "Ausserdem", "geben", "die", "guten", "klinischen", "Ergebnisse", "bei", "der", "Behandlung", "von", "akuten", "und", "chronischen", "Strahlenschaeden", "mit", "dem", "chiniofonhaltigen", "Desinfektionsmittel", "Hinweise", "auf", "eine", "antiinflammatorische", "Wirkung", "." ]
[ "umlsterm" ]
Wundheilung is an umlsterm, Wachstumsfaktoren is an umlsterm, Rolle is an umlsterm, Wundheilung is an umlsterm, Patienten is an umlsterm, Antibiose is an umlsterm, Wundheilung is an umlsterm, Schleimhautdesinfektionsmittel is an umlsterm, in vitro is an umlsterm, Behandlung is an umlsterm, Strahlenschaeden is an umlsterm, Desinfektionsmittel is an umlsterm
DerHautarzt.50460319.ger.abstr_task1
Sentence: Die Wundheilung stellt ein komplexes dynamisches Geschehen dar , welchem vor allem nach der Charakterisierung der Wachstumsfaktoren zunehmendes wissenschaftliches Interesse entgegengebracht wird . Auf der anderen Seite spielen aber auch erhebliche wirtschaftliche Gruende eine Rolle bei der Erforschung von Substanzen , die bei der Wundheilung eingesetzt werden koennen . Immerhin leiden 25% aller Patienten ( ca. 1 Million ) mit schwerer venoeser Insuffizienz an einem Ulcus cruris . Der bakteriellen Besiedlung von Ulcera crura wird eine unterschiedliche pathogenetische Bedeutung zugesprochen , wobei sicher die Keimzahl von Bedeutung ist . Die lokale Antibiose ist aber deshalb problematisch , weil die ueberwiegende Zahl von Substanzen , die hier eingesetzt werden , nachweislich die Wundheilung hemmen . Durch In-vivo und In-vitro-Untersuchungen konnte gezeigt werden , dass das chiniofonhaltige Schleimhautdesinfektionsmittel bei der Reinigung von Ulzera eine bakteriostatische Wirkung aufweist . Duch In-vitro-Untersuchungen an Fibroblastenkulturen , liess sich ausserdem zeigen , dass diese Substanz das Fibroblastenwachstum nicht beeinflusst . Im Gegensatz dazu weist PVP-Jod-Loesung , ein haeufig verwendetes Antiseptikum , eine starke Beeintraechtigung des Fibroblastenwachstums in vitro auf . Ausserdem geben die guten klinischen Ergebnisse bei der Behandlung von akuten und chronischen Strahlenschaeden mit dem chiniofonhaltigen Desinfektionsmittel Hinweise auf eine antiinflammatorische Wirkung . Instructions: please typing these entity words according to sentence: Wundheilung, Wachstumsfaktoren, Rolle, Wundheilung, Patienten, Antibiose, Wundheilung, Schleimhautdesinfektionsmittel, in vitro, Behandlung, Strahlenschaeden, Desinfektionsmittel Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Die Wundheilung stellt ein komplexes dynamisches Geschehen dar , welchem vor allem nach der Charakterisierung der Wachstumsfaktoren zunehmendes wissenschaftliches Interesse entgegengebracht wird . Auf der anderen Seite spielen aber auch erhebliche wirtschaftliche Gruende eine Rolle bei der Erforschung von Substanzen , die bei der Wundheilung eingesetzt werden koennen . Immerhin leiden 25% aller Patienten ( ca. 1 Million ) mit schwerer venoeser Insuffizienz an einem Ulcus cruris . Der bakteriellen Besiedlung von Ulcera crura wird eine unterschiedliche pathogenetische Bedeutung zugesprochen , wobei sicher die Keimzahl von Bedeutung ist . Die lokale Antibiose ist aber deshalb problematisch , weil die ueberwiegende Zahl von Substanzen , die hier eingesetzt werden , nachweislich die Wundheilung hemmen . Durch In-vivo und In-vitro-Untersuchungen konnte gezeigt werden , dass das chiniofonhaltige Schleimhautdesinfektionsmittel bei der Reinigung von Ulzera eine bakteriostatische Wirkung aufweist . Duch In-vitro-Untersuchungen an Fibroblastenkulturen , liess sich ausserdem zeigen , dass diese Substanz das Fibroblastenwachstum nicht beeinflusst . Im Gegensatz dazu weist PVP-Jod-Loesung , ein haeufig verwendetes Antiseptikum , eine starke Beeintraechtigung des Fibroblastenwachstums in vitro auf . Ausserdem geben die guten klinischen Ergebnisse bei der Behandlung von akuten und chronischen Strahlenschaeden mit dem chiniofonhaltigen Desinfektionsmittel Hinweise auf eine antiinflammatorische Wirkung .
[ "Die", "Wundheilung", "stellt", "ein", "komplexes", "dynamisches", "Geschehen", "dar", ",", "welchem", "vor", "allem", "nach", "der", "Charakterisierung", "der", "Wachstumsfaktoren", "zunehmendes", "wissenschaftliches", "Interesse", "entgegengebracht", "wird", ".", "Auf", "der", "anderen", "Seite", "spielen", "aber", "auch", "erhebliche", "wirtschaftliche", "Gruende", "eine", "Rolle", "bei", "der", "Erforschung", "von", "Substanzen", ",", "die", "bei", "der", "Wundheilung", "eingesetzt", "werden", "koennen", ".", "Immerhin", "leiden", "25", "%", "aller", "Patienten", "(", "ca", ".", "1", "Million", ")", "mit", "schwerer", "venoeser", "Insuffizienz", "an", "einem", "Ulcus", "cruris", ".", "Der", "bakteriellen", "Besiedlung", "von", "Ulcera", "crura", "wird", "eine", "unterschiedliche", "pathogenetische", "Bedeutung", "zugesprochen", ",", "wobei", "sicher", "die", "Keimzahl", "von", "Bedeutung", "ist", ".", "Die", "lokale", "Antibiose", "ist", "aber", "deshalb", "problematisch", ",", "weil", "die", "ueberwiegende", "Zahl", "von", "Substanzen", ",", "die", "hier", "eingesetzt", "werden", ",", "nachweislich", "die", "Wundheilung", "hemmen", ".", "Durch", "In", "-", "vivo", "und", "In", "-", "vitro", "-", "Untersuchungen", "konnte", "gezeigt", "werden", ",", "dass", "das", "chiniofonhaltige", "Schleimhautdesinfektionsmittel", "bei", "der", "Reinigung", "von", "Ulzera", "eine", "bakteriostatische", "Wirkung", "aufweist", ".", "Duch", "In", "-", "vitro", "-", "Untersuchungen", "an", "Fibroblastenkulturen", ",", "liess", "sich", "ausserdem", "zeigen", ",", "dass", "diese", "Substanz", "das", "Fibroblastenwachstum", "nicht", "beeinflusst", ".", "Im", "Gegensatz", "dazu", "weist", "PVP", "-", "Jod", "-", "Loesung", ",", "ein", "haeufig", "verwendetes", "Antiseptikum", ",", "eine", "starke", "Beeintraechtigung", "des", "Fibroblastenwachstums", "in", "vitro", "auf", ".", "Ausserdem", "geben", "die", "guten", "klinischen", "Ergebnisse", "bei", "der", "Behandlung", "von", "akuten", "und", "chronischen", "Strahlenschaeden", "mit", "dem", "chiniofonhaltigen", "Desinfektionsmittel", "Hinweise", "auf", "eine", "antiinflammatorische", "Wirkung", "." ]
[ "umlsterm" ]
Wundheilung, Wachstumsfaktoren, Rolle, Wundheilung, Patienten, Antibiose, Wundheilung, Schleimhautdesinfektionsmittel, in vitro, Behandlung, Strahlenschaeden, Desinfektionsmittel
DerHautarzt.50460319.ger.abstr_task2
Sentence: Die Wundheilung stellt ein komplexes dynamisches Geschehen dar , welchem vor allem nach der Charakterisierung der Wachstumsfaktoren zunehmendes wissenschaftliches Interesse entgegengebracht wird . Auf der anderen Seite spielen aber auch erhebliche wirtschaftliche Gruende eine Rolle bei der Erforschung von Substanzen , die bei der Wundheilung eingesetzt werden koennen . Immerhin leiden 25% aller Patienten ( ca. 1 Million ) mit schwerer venoeser Insuffizienz an einem Ulcus cruris . Der bakteriellen Besiedlung von Ulcera crura wird eine unterschiedliche pathogenetische Bedeutung zugesprochen , wobei sicher die Keimzahl von Bedeutung ist . Die lokale Antibiose ist aber deshalb problematisch , weil die ueberwiegende Zahl von Substanzen , die hier eingesetzt werden , nachweislich die Wundheilung hemmen . Durch In-vivo und In-vitro-Untersuchungen konnte gezeigt werden , dass das chiniofonhaltige Schleimhautdesinfektionsmittel bei der Reinigung von Ulzera eine bakteriostatische Wirkung aufweist . Duch In-vitro-Untersuchungen an Fibroblastenkulturen , liess sich ausserdem zeigen , dass diese Substanz das Fibroblastenwachstum nicht beeinflusst . Im Gegensatz dazu weist PVP-Jod-Loesung , ein haeufig verwendetes Antiseptikum , eine starke Beeintraechtigung des Fibroblastenwachstums in vitro auf . Ausserdem geben die guten klinischen Ergebnisse bei der Behandlung von akuten und chronischen Strahlenschaeden mit dem chiniofonhaltigen Desinfektionsmittel Hinweise auf eine antiinflammatorische Wirkung . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]
Die Wundheilung stellt ein komplexes dynamisches Geschehen dar , welchem vor allem nach der Charakterisierung der Wachstumsfaktoren zunehmendes wissenschaftliches Interesse entgegengebracht wird . Auf der anderen Seite spielen aber auch erhebliche wirtschaftliche Gruende eine Rolle bei der Erforschung von Substanzen , die bei der Wundheilung eingesetzt werden koennen . Immerhin leiden 25% aller Patienten ( ca. 1 Million ) mit schwerer venoeser Insuffizienz an einem Ulcus cruris . Der bakteriellen Besiedlung von Ulcera crura wird eine unterschiedliche pathogenetische Bedeutung zugesprochen , wobei sicher die Keimzahl von Bedeutung ist . Die lokale Antibiose ist aber deshalb problematisch , weil die ueberwiegende Zahl von Substanzen , die hier eingesetzt werden , nachweislich die Wundheilung hemmen . Durch In-vivo und In-vitro-Untersuchungen konnte gezeigt werden , dass das chiniofonhaltige Schleimhautdesinfektionsmittel bei der Reinigung von Ulzera eine bakteriostatische Wirkung aufweist . Duch In-vitro-Untersuchungen an Fibroblastenkulturen , liess sich ausserdem zeigen , dass diese Substanz das Fibroblastenwachstum nicht beeinflusst . Im Gegensatz dazu weist PVP-Jod-Loesung , ein haeufig verwendetes Antiseptikum , eine starke Beeintraechtigung des Fibroblastenwachstums in vitro auf . Ausserdem geben die guten klinischen Ergebnisse bei der Behandlung von akuten und chronischen Strahlenschaeden mit dem chiniofonhaltigen Desinfektionsmittel Hinweise auf eine antiinflammatorische Wirkung .
[ "Die", "Wundheilung", "stellt", "ein", "komplexes", "dynamisches", "Geschehen", "dar", ",", "welchem", "vor", "allem", "nach", "der", "Charakterisierung", "der", "Wachstumsfaktoren", "zunehmendes", "wissenschaftliches", "Interesse", "entgegengebracht", "wird", ".", "Auf", "der", "anderen", "Seite", "spielen", "aber", "auch", "erhebliche", "wirtschaftliche", "Gruende", "eine", "Rolle", "bei", "der", "Erforschung", "von", "Substanzen", ",", "die", "bei", "der", "Wundheilung", "eingesetzt", "werden", "koennen", ".", "Immerhin", "leiden", "25", "%", "aller", "Patienten", "(", "ca", ".", "1", "Million", ")", "mit", "schwerer", "venoeser", "Insuffizienz", "an", "einem", "Ulcus", "cruris", ".", "Der", "bakteriellen", "Besiedlung", "von", "Ulcera", "crura", "wird", "eine", "unterschiedliche", "pathogenetische", "Bedeutung", "zugesprochen", ",", "wobei", "sicher", "die", "Keimzahl", "von", "Bedeutung", "ist", ".", "Die", "lokale", "Antibiose", "ist", "aber", "deshalb", "problematisch", ",", "weil", "die", "ueberwiegende", "Zahl", "von", "Substanzen", ",", "die", "hier", "eingesetzt", "werden", ",", "nachweislich", "die", "Wundheilung", "hemmen", ".", "Durch", "In", "-", "vivo", "und", "In", "-", "vitro", "-", "Untersuchungen", "konnte", "gezeigt", "werden", ",", "dass", "das", "chiniofonhaltige", "Schleimhautdesinfektionsmittel", "bei", "der", "Reinigung", "von", "Ulzera", "eine", "bakteriostatische", "Wirkung", "aufweist", ".", "Duch", "In", "-", "vitro", "-", "Untersuchungen", "an", "Fibroblastenkulturen", ",", "liess", "sich", "ausserdem", "zeigen", ",", "dass", "diese", "Substanz", "das", "Fibroblastenwachstum", "nicht", "beeinflusst", ".", "Im", "Gegensatz", "dazu", "weist", "PVP", "-", "Jod", "-", "Loesung", ",", "ein", "haeufig", "verwendetes", "Antiseptikum", ",", "eine", "starke", "Beeintraechtigung", "des", "Fibroblastenwachstums", "in", "vitro", "auf", ".", "Ausserdem", "geben", "die", "guten", "klinischen", "Ergebnisse", "bei", "der", "Behandlung", "von", "akuten", "und", "chronischen", "Strahlenschaeden", "mit", "dem", "chiniofonhaltigen", "Desinfektionsmittel", "Hinweise", "auf", "eine", "antiinflammatorische", "Wirkung", "." ]
[ "umlsterm" ]
and is a Intervention_Surgical, aerobic exercise training is a Intervention_Physical, older is a Participant_Age, men and women is a Participant_Sex, 101 is a Participant_Sample-size, Aerobic Exercise is a Intervention_Physical, group is a Intervention_Surgical, Yoga is a Intervention_Physical, Flexibility control is a Intervention_Physical, Waiting List control group is a Intervention_Other, Physiological measures included measurement of blood pressure , lipids , bone density , and cardiorespiratory fitness including direct measurements of peak oxygen consumption ( VO2 ) and anaerobic threshold . is a Outcome_Physical, Psychological measures included measures of mood , psychiatric symptoms , and neuropsychological functioning . is a Outcome_Mental
73732_task0
Sentence: Cardiovascular and behavioral effects of aerobic exercise training in healthy older men and women . The cardiovascular and behavioral adaptations associated with a 4-month program of aerobic exercise training were examined in 101 older men and women ( mean age = 67 years ) . Subjects were randomly assigned to an Aerobic Exercise group , a Yoga and Flexibility control group , or a Waiting List control group . Prior to and following the 4-month program , subjects underwent comprehensive physiological and psychological evaluations . Physiological measures included measurement of blood pressure , lipids , bone density , and cardiorespiratory fitness including direct measurements of peak oxygen consumption ( VO2 ) and anaerobic threshold . Psychological measures included measures of mood , psychiatric symptoms , and neuropsychological functioning . This study demonstrated that 4 months of aerobic exercise training produced an overall 11.6 % improvement in peak VO2 and a 13 % increase in anaerobic threshold . In contrast , the Yoga and Waiting List control groups experienced no change in cardiorespiratory fitness . Other favorable physiological changes observed among aerobic exercise participants included lower cholesterol levels , diastolic blood pressure levels , and for subjects at risk for bone fracture , a trend toward an increase in bone mineral content . Although few significant psychological changes could be attributed to aerobic exercise training , participants in the two active treatment groups perceived themselves as improving on a number of psychological and behavioral dimensions . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Sex, Intervention_Other, Participant_Age, Outcome_Physical, Participant_Sample-size, Intervention_Surgical, Outcome_Mental
[ "O", "B-Intervention_Surgical", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Participant_Age", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "B-Intervention_Surgical", "O", "O", "B-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cardiovascular and behavioral effects of aerobic exercise training in healthy older men and women . The cardiovascular and behavioral adaptations associated with a 4-month program of aerobic exercise training were examined in 101 older men and women ( mean age = 67 years ) . Subjects were randomly assigned to an Aerobic Exercise group , a Yoga and Flexibility control group , or a Waiting List control group . Prior to and following the 4-month program , subjects underwent comprehensive physiological and psychological evaluations . Physiological measures included measurement of blood pressure , lipids , bone density , and cardiorespiratory fitness including direct measurements of peak oxygen consumption ( VO2 ) and anaerobic threshold . Psychological measures included measures of mood , psychiatric symptoms , and neuropsychological functioning . This study demonstrated that 4 months of aerobic exercise training produced an overall 11.6 % improvement in peak VO2 and a 13 % increase in anaerobic threshold . In contrast , the Yoga and Waiting List control groups experienced no change in cardiorespiratory fitness . Other favorable physiological changes observed among aerobic exercise participants included lower cholesterol levels , diastolic blood pressure levels , and for subjects at risk for bone fracture , a trend toward an increase in bone mineral content . Although few significant psychological changes could be attributed to aerobic exercise training , participants in the two active treatment groups perceived themselves as improving on a number of psychological and behavioral dimensions .
[ "Cardiovascular", "and", "behavioral", "effects", "of", "aerobic", "exercise", "training", "in", "healthy", "older", "men", "and", "women", ".", "The", "cardiovascular", "and", "behavioral", "adaptations", "associated", "with", "a", "4-month", "program", "of", "aerobic", "exercise", "training", "were", "examined", "in", "101", "older", "men", "and", "women", "(", "mean", "age", "=", "67", "years", ")", ".", "Subjects", "were", "randomly", "assigned", "to", "an", "Aerobic", "Exercise", "group", ",", "a", "Yoga", "and", "Flexibility", "control", "group", ",", "or", "a", "Waiting", "List", "control", "group", ".", "Prior", "to", "and", "following", "the", "4-month", "program", ",", "subjects", "underwent", "comprehensive", "physiological", "and", "psychological", "evaluations", ".", "Physiological", "measures", "included", "measurement", "of", "blood", "pressure", ",", "lipids", ",", "bone", "density", ",", "and", "cardiorespiratory", "fitness", "including", "direct", "measurements", "of", "peak", "oxygen", "consumption", "(", "VO2", ")", "and", "anaerobic", "threshold", ".", "Psychological", "measures", "included", "measures", "of", "mood", ",", "psychiatric", "symptoms", ",", "and", "neuropsychological", "functioning", ".", "This", "study", "demonstrated", "that", "4", "months", "of", "aerobic", "exercise", "training", "produced", "an", "overall", "11.6", "%", "improvement", "in", "peak", "VO2", "and", "a", "13", "%", "increase", "in", "anaerobic", "threshold", ".", "In", "contrast", ",", "the", "Yoga", "and", "Waiting", "List", "control", "groups", "experienced", "no", "change", "in", "cardiorespiratory", "fitness", ".", "Other", "favorable", "physiological", "changes", "observed", "among", "aerobic", "exercise", "participants", "included", "lower", "cholesterol", "levels", ",", "diastolic", "blood", "pressure", "levels", ",", "and", "for", "subjects", "at", "risk", "for", "bone", "fracture", ",", "a", "trend", "toward", "an", "increase", "in", "bone", "mineral", "content", ".", "Although", "few", "significant", "psychological", "changes", "could", "be", "attributed", "to", "aerobic", "exercise", "training", ",", "participants", "in", "the", "two", "active", "treatment", "groups", "perceived", "themselves", "as", "improving", "on", "a", "number", "of", "psychological", "and", "behavioral", "dimensions", "." ]
[ "Outcome_Physical", "Outcome_Mental", "Intervention_Other", "Intervention_Physical", "Participant_Sex", "Intervention_Surgical", "Participant_Age", "Participant_Sample-size" ]
and is a Intervention_Surgical, aerobic exercise training is a Intervention_Physical, older is a Participant_Age, men and women is a Participant_Sex, 101 is a Participant_Sample-size, Aerobic Exercise is a Intervention_Physical, group is a Intervention_Surgical, Yoga is a Intervention_Physical, Flexibility control is a Intervention_Physical, Waiting List control group is a Intervention_Other, Physiological measures included measurement of blood pressure , lipids , bone density , and cardiorespiratory fitness including direct measurements of peak oxygen consumption ( VO2 ) and anaerobic threshold . is a Outcome_Physical, Psychological measures included measures of mood , psychiatric symptoms , and neuropsychological functioning . is a Outcome_Mental
73732_task1
Sentence: Cardiovascular and behavioral effects of aerobic exercise training in healthy older men and women . The cardiovascular and behavioral adaptations associated with a 4-month program of aerobic exercise training were examined in 101 older men and women ( mean age = 67 years ) . Subjects were randomly assigned to an Aerobic Exercise group , a Yoga and Flexibility control group , or a Waiting List control group . Prior to and following the 4-month program , subjects underwent comprehensive physiological and psychological evaluations . Physiological measures included measurement of blood pressure , lipids , bone density , and cardiorespiratory fitness including direct measurements of peak oxygen consumption ( VO2 ) and anaerobic threshold . Psychological measures included measures of mood , psychiatric symptoms , and neuropsychological functioning . This study demonstrated that 4 months of aerobic exercise training produced an overall 11.6 % improvement in peak VO2 and a 13 % increase in anaerobic threshold . In contrast , the Yoga and Waiting List control groups experienced no change in cardiorespiratory fitness . Other favorable physiological changes observed among aerobic exercise participants included lower cholesterol levels , diastolic blood pressure levels , and for subjects at risk for bone fracture , a trend toward an increase in bone mineral content . Although few significant psychological changes could be attributed to aerobic exercise training , participants in the two active treatment groups perceived themselves as improving on a number of psychological and behavioral dimensions . Instructions: please typing these entity words according to sentence: and, aerobic exercise training, older, men and women, 101, Aerobic Exercise, group, Yoga, Flexibility control, Waiting List control group, Physiological measures included measurement of blood pressure , lipids , bone density , and cardiorespiratory fitness including direct measurements of peak oxygen consumption ( VO2 ) and anaerobic threshold ., Psychological measures included measures of mood , psychiatric symptoms , and neuropsychological functioning . Options: Intervention_Physical, Participant_Sex, Intervention_Other, Participant_Age, Outcome_Physical, Participant_Sample-size, Intervention_Surgical, Outcome_Mental
[ "O", "B-Intervention_Surgical", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Participant_Age", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "B-Intervention_Surgical", "O", "O", "B-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cardiovascular and behavioral effects of aerobic exercise training in healthy older men and women . The cardiovascular and behavioral adaptations associated with a 4-month program of aerobic exercise training were examined in 101 older men and women ( mean age = 67 years ) . Subjects were randomly assigned to an Aerobic Exercise group , a Yoga and Flexibility control group , or a Waiting List control group . Prior to and following the 4-month program , subjects underwent comprehensive physiological and psychological evaluations . Physiological measures included measurement of blood pressure , lipids , bone density , and cardiorespiratory fitness including direct measurements of peak oxygen consumption ( VO2 ) and anaerobic threshold . Psychological measures included measures of mood , psychiatric symptoms , and neuropsychological functioning . This study demonstrated that 4 months of aerobic exercise training produced an overall 11.6 % improvement in peak VO2 and a 13 % increase in anaerobic threshold . In contrast , the Yoga and Waiting List control groups experienced no change in cardiorespiratory fitness . Other favorable physiological changes observed among aerobic exercise participants included lower cholesterol levels , diastolic blood pressure levels , and for subjects at risk for bone fracture , a trend toward an increase in bone mineral content . Although few significant psychological changes could be attributed to aerobic exercise training , participants in the two active treatment groups perceived themselves as improving on a number of psychological and behavioral dimensions .
[ "Cardiovascular", "and", "behavioral", "effects", "of", "aerobic", "exercise", "training", "in", "healthy", "older", "men", "and", "women", ".", "The", "cardiovascular", "and", "behavioral", "adaptations", "associated", "with", "a", "4-month", "program", "of", "aerobic", "exercise", "training", "were", "examined", "in", "101", "older", "men", "and", "women", "(", "mean", "age", "=", "67", "years", ")", ".", "Subjects", "were", "randomly", "assigned", "to", "an", "Aerobic", "Exercise", "group", ",", "a", "Yoga", "and", "Flexibility", "control", "group", ",", "or", "a", "Waiting", "List", "control", "group", ".", "Prior", "to", "and", "following", "the", "4-month", "program", ",", "subjects", "underwent", "comprehensive", "physiological", "and", "psychological", "evaluations", ".", "Physiological", "measures", "included", "measurement", "of", "blood", "pressure", ",", "lipids", ",", "bone", "density", ",", "and", "cardiorespiratory", "fitness", "including", "direct", "measurements", "of", "peak", "oxygen", "consumption", "(", "VO2", ")", "and", "anaerobic", "threshold", ".", "Psychological", "measures", "included", "measures", "of", "mood", ",", "psychiatric", "symptoms", ",", "and", "neuropsychological", "functioning", ".", "This", "study", "demonstrated", "that", "4", "months", "of", "aerobic", "exercise", "training", "produced", "an", "overall", "11.6", "%", "improvement", "in", "peak", "VO2", "and", "a", "13", "%", "increase", "in", "anaerobic", "threshold", ".", "In", "contrast", ",", "the", "Yoga", "and", "Waiting", "List", "control", "groups", "experienced", "no", "change", "in", "cardiorespiratory", "fitness", ".", "Other", "favorable", "physiological", "changes", "observed", "among", "aerobic", "exercise", "participants", "included", "lower", "cholesterol", "levels", ",", "diastolic", "blood", "pressure", "levels", ",", "and", "for", "subjects", "at", "risk", "for", "bone", "fracture", ",", "a", "trend", "toward", "an", "increase", "in", "bone", "mineral", "content", ".", "Although", "few", "significant", "psychological", "changes", "could", "be", "attributed", "to", "aerobic", "exercise", "training", ",", "participants", "in", "the", "two", "active", "treatment", "groups", "perceived", "themselves", "as", "improving", "on", "a", "number", "of", "psychological", "and", "behavioral", "dimensions", "." ]
[ "Outcome_Physical", "Outcome_Mental", "Intervention_Other", "Intervention_Physical", "Participant_Sex", "Intervention_Surgical", "Participant_Age", "Participant_Sample-size" ]
and, aerobic exercise training, older, men and women, 101, Aerobic Exercise, group, Yoga, Flexibility control, Waiting List control group, Physiological measures included measurement of blood pressure , lipids , bone density , and cardiorespiratory fitness including direct measurements of peak oxygen consumption ( VO2 ) and anaerobic threshold ., Psychological measures included measures of mood , psychiatric symptoms , and neuropsychological functioning .
73732_task2
Sentence: Cardiovascular and behavioral effects of aerobic exercise training in healthy older men and women . The cardiovascular and behavioral adaptations associated with a 4-month program of aerobic exercise training were examined in 101 older men and women ( mean age = 67 years ) . Subjects were randomly assigned to an Aerobic Exercise group , a Yoga and Flexibility control group , or a Waiting List control group . Prior to and following the 4-month program , subjects underwent comprehensive physiological and psychological evaluations . Physiological measures included measurement of blood pressure , lipids , bone density , and cardiorespiratory fitness including direct measurements of peak oxygen consumption ( VO2 ) and anaerobic threshold . Psychological measures included measures of mood , psychiatric symptoms , and neuropsychological functioning . This study demonstrated that 4 months of aerobic exercise training produced an overall 11.6 % improvement in peak VO2 and a 13 % increase in anaerobic threshold . In contrast , the Yoga and Waiting List control groups experienced no change in cardiorespiratory fitness . Other favorable physiological changes observed among aerobic exercise participants included lower cholesterol levels , diastolic blood pressure levels , and for subjects at risk for bone fracture , a trend toward an increase in bone mineral content . Although few significant psychological changes could be attributed to aerobic exercise training , participants in the two active treatment groups perceived themselves as improving on a number of psychological and behavioral dimensions . Instructions: please extract entity words from the input sentence
[ "O", "B-Intervention_Surgical", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Participant_Age", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "B-Intervention_Surgical", "O", "O", "B-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cardiovascular and behavioral effects of aerobic exercise training in healthy older men and women . The cardiovascular and behavioral adaptations associated with a 4-month program of aerobic exercise training were examined in 101 older men and women ( mean age = 67 years ) . Subjects were randomly assigned to an Aerobic Exercise group , a Yoga and Flexibility control group , or a Waiting List control group . Prior to and following the 4-month program , subjects underwent comprehensive physiological and psychological evaluations . Physiological measures included measurement of blood pressure , lipids , bone density , and cardiorespiratory fitness including direct measurements of peak oxygen consumption ( VO2 ) and anaerobic threshold . Psychological measures included measures of mood , psychiatric symptoms , and neuropsychological functioning . This study demonstrated that 4 months of aerobic exercise training produced an overall 11.6 % improvement in peak VO2 and a 13 % increase in anaerobic threshold . In contrast , the Yoga and Waiting List control groups experienced no change in cardiorespiratory fitness . Other favorable physiological changes observed among aerobic exercise participants included lower cholesterol levels , diastolic blood pressure levels , and for subjects at risk for bone fracture , a trend toward an increase in bone mineral content . Although few significant psychological changes could be attributed to aerobic exercise training , participants in the two active treatment groups perceived themselves as improving on a number of psychological and behavioral dimensions .
[ "Cardiovascular", "and", "behavioral", "effects", "of", "aerobic", "exercise", "training", "in", "healthy", "older", "men", "and", "women", ".", "The", "cardiovascular", "and", "behavioral", "adaptations", "associated", "with", "a", "4-month", "program", "of", "aerobic", "exercise", "training", "were", "examined", "in", "101", "older", "men", "and", "women", "(", "mean", "age", "=", "67", "years", ")", ".", "Subjects", "were", "randomly", "assigned", "to", "an", "Aerobic", "Exercise", "group", ",", "a", "Yoga", "and", "Flexibility", "control", "group", ",", "or", "a", "Waiting", "List", "control", "group", ".", "Prior", "to", "and", "following", "the", "4-month", "program", ",", "subjects", "underwent", "comprehensive", "physiological", "and", "psychological", "evaluations", ".", "Physiological", "measures", "included", "measurement", "of", "blood", "pressure", ",", "lipids", ",", "bone", "density", ",", "and", "cardiorespiratory", "fitness", "including", "direct", "measurements", "of", "peak", "oxygen", "consumption", "(", "VO2", ")", "and", "anaerobic", "threshold", ".", "Psychological", "measures", "included", "measures", "of", "mood", ",", "psychiatric", "symptoms", ",", "and", "neuropsychological", "functioning", ".", "This", "study", "demonstrated", "that", "4", "months", "of", "aerobic", "exercise", "training", "produced", "an", "overall", "11.6", "%", "improvement", "in", "peak", "VO2", "and", "a", "13", "%", "increase", "in", "anaerobic", "threshold", ".", "In", "contrast", ",", "the", "Yoga", "and", "Waiting", "List", "control", "groups", "experienced", "no", "change", "in", "cardiorespiratory", "fitness", ".", "Other", "favorable", "physiological", "changes", "observed", "among", "aerobic", "exercise", "participants", "included", "lower", "cholesterol", "levels", ",", "diastolic", "blood", "pressure", "levels", ",", "and", "for", "subjects", "at", "risk", "for", "bone", "fracture", ",", "a", "trend", "toward", "an", "increase", "in", "bone", "mineral", "content", ".", "Although", "few", "significant", "psychological", "changes", "could", "be", "attributed", "to", "aerobic", "exercise", "training", ",", "participants", "in", "the", "two", "active", "treatment", "groups", "perceived", "themselves", "as", "improving", "on", "a", "number", "of", "psychological", "and", "behavioral", "dimensions", "." ]
[ "Outcome_Physical", "Outcome_Mental", "Intervention_Other", "Intervention_Physical", "Participant_Sex", "Intervention_Surgical", "Participant_Age", "Participant_Sample-size" ]
Monocytic cell type - specific transcriptional induction is an other_name, collagenase is a protein_molecule
31143_task0
Sentence: Monocytic cell type-specific transcriptional induction of collagenase. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_molecule, other_name
[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "O" ]
Monocytic cell type-specific transcriptional induction of collagenase.
[ "Monocytic", "cell", "type", "-", "specific", "transcriptional", "induction", "of", "collagenase", "." ]
[ "other_name", "(AND cell_line cell_line)", "(OR other_name other_name)", "DNA_domain_or_region", "", "(AND cell_type cell_type)", "DNA_family_or_group", "other_organic_compound", "(AND DNA_family_or_group DNA_family_or_group)", "protein_complex", "cell_type", "protein_family_or_group", "lipid", "protein_molecule", "mono_cell", "body_part", "polynucleotide" ]
Monocytic cell type - specific transcriptional induction is an other_name, collagenase is a protein_molecule
31143_task1
Sentence: Monocytic cell type-specific transcriptional induction of collagenase. Instructions: please typing these entity words according to sentence: Monocytic cell type - specific transcriptional induction, collagenase Options: protein_molecule, other_name
[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "O" ]
Monocytic cell type-specific transcriptional induction of collagenase.
[ "Monocytic", "cell", "type", "-", "specific", "transcriptional", "induction", "of", "collagenase", "." ]
[ "other_name", "(AND cell_line cell_line)", "(OR other_name other_name)", "DNA_domain_or_region", "", "(AND cell_type cell_type)", "DNA_family_or_group", "other_organic_compound", "(AND DNA_family_or_group DNA_family_or_group)", "protein_complex", "cell_type", "protein_family_or_group", "lipid", "protein_molecule", "mono_cell", "body_part", "polynucleotide" ]
Monocytic cell type - specific transcriptional induction, collagenase
31143_task2
Sentence: Monocytic cell type-specific transcriptional induction of collagenase. Instructions: please extract entity words from the input sentence
[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "B-protein_molecule", "O" ]
Monocytic cell type-specific transcriptional induction of collagenase.
[ "Monocytic", "cell", "type", "-", "specific", "transcriptional", "induction", "of", "collagenase", "." ]
[ "other_name", "(AND cell_line cell_line)", "(OR other_name other_name)", "DNA_domain_or_region", "", "(AND cell_type cell_type)", "DNA_family_or_group", "other_organic_compound", "(AND DNA_family_or_group DNA_family_or_group)", "protein_complex", "cell_type", "protein_family_or_group", "lipid", "protein_molecule", "mono_cell", "body_part", "polynucleotide" ]
Intensive insulin therapy is a Intervention_Physical, endothelial function is a Outcome_Physical, young people is a Participant_Age, type 1 diabetes is a Participant_Condition, intensive diabetes management [ intensive is a Intervention_Physical, ' Sweet Talk ' text - messaging support ] is a Intervention_Educational, One hundred and twenty - six patients is a Participant_Sample-size, conventional insulin therapy ( CIT ) is a Intervention_Pharmacological, aged between 8 and 18 years is a Participant_Age, only ( n=28 ) ; group 2 , is a Intervention_Educational, CIT and Sweet is a Intervention_Physical, Talk ( n=33 ) ; or group 3 , IIT and Sweet Talk ( n=31 ) is a Intervention_Educational, Vascular assessments ( including measures of endothelial damage , activation , dysfunction and oxidative stress ) is a Outcome_Physical, HbA1c is a Outcome_Physical, Glycaemic control is a Outcome_Physical, E - selectin is a Outcome_Physical, Vascular responses is a Outcome_Physical, vascular markers is a Outcome_Physical, glycaemic control is a Outcome_Physical
33774_task0
Sentence: Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes . AIMS/HYPOTHESIS Macrovascular disease is an important cause of the increased morbidity and mortality rates associated with type 1 diabetes , and this vascular impairment begins in childhood . The aim of this study was to determine whether introducing intensive diabetes management [ intensive insulin therapy ( IIT ) and 'Sweet Talk ' text-messaging support ] produces measurable improvements in endothelial function . METHODS One hundred and twenty-six patients fulfilled the eligibility criteria ( type 1 diabetes for > 1 year ; on conventional insulin therapy ( CIT ) ; aged between 8 and 18 years ) , of whom 92 enrolled . Patients were randomised to group 1 , CIT only ( n=28 ) ; group 2 , CIT and Sweet Talk ( n=33 ) ; or group 3 , IIT and Sweet Talk ( n=31 ) . Vascular assessments ( including measures of endothelial damage , activation , dysfunction and oxidative stress ) and HbA1c were performed at baseline and repeated after 12 months of the study . RESULTS Glycaemic control deteriorated in patients on CIT , but improved significantly in patients allocated to IIT ( p=0.007 ) . IIT was associated with significantly greater improvements in E-selectin ( p < 0.0001 ) than CIT ( group 1 , p=0.026 and group 2 , p=0.053 ) . Vascular responses to acetylcholine improved in patients on IIT ( p=0.017 ) , but not in patients receiving CIT . These changes were all independent of HbA1c level . CONCLUSIONS/INTERPRETATION IIT appears to be associated with improvements in vascular markers , independently of changes in HbA1c , suggesting that IIT may confer vascular protection in addition to improving glycaemic control . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Intervention_Educational, Participant_Age, Outcome_Physical, Participant_Sample-size
[ "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O" ]
Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes . AIMS/HYPOTHESIS Macrovascular disease is an important cause of the increased morbidity and mortality rates associated with type 1 diabetes , and this vascular impairment begins in childhood . The aim of this study was to determine whether introducing intensive diabetes management [ intensive insulin therapy ( IIT ) and 'Sweet Talk ' text-messaging support ] produces measurable improvements in endothelial function . METHODS One hundred and twenty-six patients fulfilled the eligibility criteria ( type 1 diabetes for > 1 year ; on conventional insulin therapy ( CIT ) ; aged between 8 and 18 years ) , of whom 92 enrolled . Patients were randomised to group 1 , CIT only ( n=28 ) ; group 2 , CIT and Sweet Talk ( n=33 ) ; or group 3 , IIT and Sweet Talk ( n=31 ) . Vascular assessments ( including measures of endothelial damage , activation , dysfunction and oxidative stress ) and HbA1c were performed at baseline and repeated after 12 months of the study . RESULTS Glycaemic control deteriorated in patients on CIT , but improved significantly in patients allocated to IIT ( p=0.007 ) . IIT was associated with significantly greater improvements in E-selectin ( p < 0.0001 ) than CIT ( group 1 , p=0.026 and group 2 , p=0.053 ) . Vascular responses to acetylcholine improved in patients on IIT ( p=0.017 ) , but not in patients receiving CIT . These changes were all independent of HbA1c level . CONCLUSIONS/INTERPRETATION IIT appears to be associated with improvements in vascular markers , independently of changes in HbA1c , suggesting that IIT may confer vascular protection in addition to improving glycaemic control .
[ "Intensive", "insulin", "therapy", "improves", "endothelial", "function", "and", "microvascular", "reactivity", "in", "young", "people", "with", "type", "1", "diabetes", ".", "AIMS", "/", "HYPOTHESIS", "Macrovascular", "disease", "is", "an", "important", "cause", "of", "the", "increased", "morbidity", "and", "mortality", "rates", "associated", "with", "type", "1", "diabetes", ",", "and", "this", "vascular", "impairment", "begins", "in", "childhood", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "whether", "introducing", "intensive", "diabetes", "management", "[", "intensive", "insulin", "therapy", "(", "IIT", ")", "and", "'", "Sweet", "Talk", "'", "text", "-", "messaging", "support", "]", "produces", "measurable", "improvements", "in", "endothelial", "function", ".", "METHODS", "One", "hundred", "and", "twenty", "-", "six", "patients", "fulfilled", "the", "eligibility", "criteria", "(", "type", "1", "diabetes", "for", ">", "1", "year", ";", "on", "conventional", "insulin", "therapy", "(", "CIT", ")", ";", "aged", "between", "8", "and", "18", "years", ")", ",", "of", "whom", "92", "enrolled", ".", "Patients", "were", "randomised", "to", "group", "1", ",", "CIT", "only", "(", "n=28", ")", ";", "group", "2", ",", "CIT", "and", "Sweet", "Talk", "(", "n=33", ")", ";", "or", "group", "3", ",", "IIT", "and", "Sweet", "Talk", "(", "n=31", ")", ".", "Vascular", "assessments", "(", "including", "measures", "of", "endothelial", "damage", ",", "activation", ",", "dysfunction", "and", "oxidative", "stress", ")", "and", "HbA1c", "were", "performed", "at", "baseline", "and", "repeated", "after", "12", "months", "of", "the", "study", ".", "RESULTS", "Glycaemic", "control", "deteriorated", "in", "patients", "on", "CIT", ",", "but", "improved", "significantly", "in", "patients", "allocated", "to", "IIT", "(", "p=0.007", ")", ".", "IIT", "was", "associated", "with", "significantly", "greater", "improvements", "in", "E", "-", "selectin", "(", "p", "<", "0.0001", ")", "than", "CIT", "(", "group", "1", ",", "p=0.026", "and", "group", "2", ",", "p=0.053", ")", ".", "Vascular", "responses", "to", "acetylcholine", "improved", "in", "patients", "on", "IIT", "(", "p=0.017", ")", ",", "but", "not", "in", "patients", "receiving", "CIT", ".", "These", "changes", "were", "all", "independent", "of", "HbA1c", "level", ".", "CONCLUSIONS", "/", "INTERPRETATION", "IIT", "appears", "to", "be", "associated", "with", "improvements", "in", "vascular", "markers", ",", "independently", "of", "changes", "in", "HbA1c", ",", "suggesting", "that", "IIT", "may", "confer", "vascular", "protection", "in", "addition", "to", "improving", "glycaemic", "control", "." ]
[ "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Age", "Participant_Condition" ]
Intensive insulin therapy is a Intervention_Physical, endothelial function is a Outcome_Physical, young people is a Participant_Age, type 1 diabetes is a Participant_Condition, intensive diabetes management [ intensive is a Intervention_Physical, ' Sweet Talk ' text - messaging support ] is a Intervention_Educational, One hundred and twenty - six patients is a Participant_Sample-size, conventional insulin therapy ( CIT ) is a Intervention_Pharmacological, aged between 8 and 18 years is a Participant_Age, only ( n=28 ) ; group 2 , is a Intervention_Educational, CIT and Sweet is a Intervention_Physical, Talk ( n=33 ) ; or group 3 , IIT and Sweet Talk ( n=31 ) is a Intervention_Educational, Vascular assessments ( including measures of endothelial damage , activation , dysfunction and oxidative stress ) is a Outcome_Physical, HbA1c is a Outcome_Physical, Glycaemic control is a Outcome_Physical, E - selectin is a Outcome_Physical, Vascular responses is a Outcome_Physical, vascular markers is a Outcome_Physical, glycaemic control is a Outcome_Physical
33774_task1
Sentence: Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes . AIMS/HYPOTHESIS Macrovascular disease is an important cause of the increased morbidity and mortality rates associated with type 1 diabetes , and this vascular impairment begins in childhood . The aim of this study was to determine whether introducing intensive diabetes management [ intensive insulin therapy ( IIT ) and 'Sweet Talk ' text-messaging support ] produces measurable improvements in endothelial function . METHODS One hundred and twenty-six patients fulfilled the eligibility criteria ( type 1 diabetes for > 1 year ; on conventional insulin therapy ( CIT ) ; aged between 8 and 18 years ) , of whom 92 enrolled . Patients were randomised to group 1 , CIT only ( n=28 ) ; group 2 , CIT and Sweet Talk ( n=33 ) ; or group 3 , IIT and Sweet Talk ( n=31 ) . Vascular assessments ( including measures of endothelial damage , activation , dysfunction and oxidative stress ) and HbA1c were performed at baseline and repeated after 12 months of the study . RESULTS Glycaemic control deteriorated in patients on CIT , but improved significantly in patients allocated to IIT ( p=0.007 ) . IIT was associated with significantly greater improvements in E-selectin ( p < 0.0001 ) than CIT ( group 1 , p=0.026 and group 2 , p=0.053 ) . Vascular responses to acetylcholine improved in patients on IIT ( p=0.017 ) , but not in patients receiving CIT . These changes were all independent of HbA1c level . CONCLUSIONS/INTERPRETATION IIT appears to be associated with improvements in vascular markers , independently of changes in HbA1c , suggesting that IIT may confer vascular protection in addition to improving glycaemic control . Instructions: please typing these entity words according to sentence: Intensive insulin therapy, endothelial function, young people, type 1 diabetes, intensive diabetes management [ intensive, ' Sweet Talk ' text - messaging support ], One hundred and twenty - six patients, conventional insulin therapy ( CIT ), aged between 8 and 18 years, only ( n=28 ) ; group 2 ,, CIT and Sweet, Talk ( n=33 ) ; or group 3 , IIT and Sweet Talk ( n=31 ), Vascular assessments ( including measures of endothelial damage , activation , dysfunction and oxidative stress ), HbA1c, Glycaemic control, E - selectin, Vascular responses, vascular markers, glycaemic control Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Intervention_Educational, Participant_Age, Outcome_Physical, Participant_Sample-size
[ "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O" ]
Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes . AIMS/HYPOTHESIS Macrovascular disease is an important cause of the increased morbidity and mortality rates associated with type 1 diabetes , and this vascular impairment begins in childhood . The aim of this study was to determine whether introducing intensive diabetes management [ intensive insulin therapy ( IIT ) and 'Sweet Talk ' text-messaging support ] produces measurable improvements in endothelial function . METHODS One hundred and twenty-six patients fulfilled the eligibility criteria ( type 1 diabetes for > 1 year ; on conventional insulin therapy ( CIT ) ; aged between 8 and 18 years ) , of whom 92 enrolled . Patients were randomised to group 1 , CIT only ( n=28 ) ; group 2 , CIT and Sweet Talk ( n=33 ) ; or group 3 , IIT and Sweet Talk ( n=31 ) . Vascular assessments ( including measures of endothelial damage , activation , dysfunction and oxidative stress ) and HbA1c were performed at baseline and repeated after 12 months of the study . RESULTS Glycaemic control deteriorated in patients on CIT , but improved significantly in patients allocated to IIT ( p=0.007 ) . IIT was associated with significantly greater improvements in E-selectin ( p < 0.0001 ) than CIT ( group 1 , p=0.026 and group 2 , p=0.053 ) . Vascular responses to acetylcholine improved in patients on IIT ( p=0.017 ) , but not in patients receiving CIT . These changes were all independent of HbA1c level . CONCLUSIONS/INTERPRETATION IIT appears to be associated with improvements in vascular markers , independently of changes in HbA1c , suggesting that IIT may confer vascular protection in addition to improving glycaemic control .
[ "Intensive", "insulin", "therapy", "improves", "endothelial", "function", "and", "microvascular", "reactivity", "in", "young", "people", "with", "type", "1", "diabetes", ".", "AIMS", "/", "HYPOTHESIS", "Macrovascular", "disease", "is", "an", "important", "cause", "of", "the", "increased", "morbidity", "and", "mortality", "rates", "associated", "with", "type", "1", "diabetes", ",", "and", "this", "vascular", "impairment", "begins", "in", "childhood", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "whether", "introducing", "intensive", "diabetes", "management", "[", "intensive", "insulin", "therapy", "(", "IIT", ")", "and", "'", "Sweet", "Talk", "'", "text", "-", "messaging", "support", "]", "produces", "measurable", "improvements", "in", "endothelial", "function", ".", "METHODS", "One", "hundred", "and", "twenty", "-", "six", "patients", "fulfilled", "the", "eligibility", "criteria", "(", "type", "1", "diabetes", "for", ">", "1", "year", ";", "on", "conventional", "insulin", "therapy", "(", "CIT", ")", ";", "aged", "between", "8", "and", "18", "years", ")", ",", "of", "whom", "92", "enrolled", ".", "Patients", "were", "randomised", "to", "group", "1", ",", "CIT", "only", "(", "n=28", ")", ";", "group", "2", ",", "CIT", "and", "Sweet", "Talk", "(", "n=33", ")", ";", "or", "group", "3", ",", "IIT", "and", "Sweet", "Talk", "(", "n=31", ")", ".", "Vascular", "assessments", "(", "including", "measures", "of", "endothelial", "damage", ",", "activation", ",", "dysfunction", "and", "oxidative", "stress", ")", "and", "HbA1c", "were", "performed", "at", "baseline", "and", "repeated", "after", "12", "months", "of", "the", "study", ".", "RESULTS", "Glycaemic", "control", "deteriorated", "in", "patients", "on", "CIT", ",", "but", "improved", "significantly", "in", "patients", "allocated", "to", "IIT", "(", "p=0.007", ")", ".", "IIT", "was", "associated", "with", "significantly", "greater", "improvements", "in", "E", "-", "selectin", "(", "p", "<", "0.0001", ")", "than", "CIT", "(", "group", "1", ",", "p=0.026", "and", "group", "2", ",", "p=0.053", ")", ".", "Vascular", "responses", "to", "acetylcholine", "improved", "in", "patients", "on", "IIT", "(", "p=0.017", ")", ",", "but", "not", "in", "patients", "receiving", "CIT", ".", "These", "changes", "were", "all", "independent", "of", "HbA1c", "level", ".", "CONCLUSIONS", "/", "INTERPRETATION", "IIT", "appears", "to", "be", "associated", "with", "improvements", "in", "vascular", "markers", ",", "independently", "of", "changes", "in", "HbA1c", ",", "suggesting", "that", "IIT", "may", "confer", "vascular", "protection", "in", "addition", "to", "improving", "glycaemic", "control", "." ]
[ "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Age", "Participant_Condition" ]
Intensive insulin therapy, endothelial function, young people, type 1 diabetes, intensive diabetes management [ intensive, ' Sweet Talk ' text - messaging support ], One hundred and twenty - six patients, conventional insulin therapy ( CIT ), aged between 8 and 18 years, only ( n=28 ) ; group 2 ,, CIT and Sweet, Talk ( n=33 ) ; or group 3 , IIT and Sweet Talk ( n=31 ), Vascular assessments ( including measures of endothelial damage , activation , dysfunction and oxidative stress ), HbA1c, Glycaemic control, E - selectin, Vascular responses, vascular markers, glycaemic control
33774_task2
Sentence: Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes . AIMS/HYPOTHESIS Macrovascular disease is an important cause of the increased morbidity and mortality rates associated with type 1 diabetes , and this vascular impairment begins in childhood . The aim of this study was to determine whether introducing intensive diabetes management [ intensive insulin therapy ( IIT ) and 'Sweet Talk ' text-messaging support ] produces measurable improvements in endothelial function . METHODS One hundred and twenty-six patients fulfilled the eligibility criteria ( type 1 diabetes for > 1 year ; on conventional insulin therapy ( CIT ) ; aged between 8 and 18 years ) , of whom 92 enrolled . Patients were randomised to group 1 , CIT only ( n=28 ) ; group 2 , CIT and Sweet Talk ( n=33 ) ; or group 3 , IIT and Sweet Talk ( n=31 ) . Vascular assessments ( including measures of endothelial damage , activation , dysfunction and oxidative stress ) and HbA1c were performed at baseline and repeated after 12 months of the study . RESULTS Glycaemic control deteriorated in patients on CIT , but improved significantly in patients allocated to IIT ( p=0.007 ) . IIT was associated with significantly greater improvements in E-selectin ( p < 0.0001 ) than CIT ( group 1 , p=0.026 and group 2 , p=0.053 ) . Vascular responses to acetylcholine improved in patients on IIT ( p=0.017 ) , but not in patients receiving CIT . These changes were all independent of HbA1c level . CONCLUSIONS/INTERPRETATION IIT appears to be associated with improvements in vascular markers , independently of changes in HbA1c , suggesting that IIT may confer vascular protection in addition to improving glycaemic control . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O" ]
Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes . AIMS/HYPOTHESIS Macrovascular disease is an important cause of the increased morbidity and mortality rates associated with type 1 diabetes , and this vascular impairment begins in childhood . The aim of this study was to determine whether introducing intensive diabetes management [ intensive insulin therapy ( IIT ) and 'Sweet Talk ' text-messaging support ] produces measurable improvements in endothelial function . METHODS One hundred and twenty-six patients fulfilled the eligibility criteria ( type 1 diabetes for > 1 year ; on conventional insulin therapy ( CIT ) ; aged between 8 and 18 years ) , of whom 92 enrolled . Patients were randomised to group 1 , CIT only ( n=28 ) ; group 2 , CIT and Sweet Talk ( n=33 ) ; or group 3 , IIT and Sweet Talk ( n=31 ) . Vascular assessments ( including measures of endothelial damage , activation , dysfunction and oxidative stress ) and HbA1c were performed at baseline and repeated after 12 months of the study . RESULTS Glycaemic control deteriorated in patients on CIT , but improved significantly in patients allocated to IIT ( p=0.007 ) . IIT was associated with significantly greater improvements in E-selectin ( p < 0.0001 ) than CIT ( group 1 , p=0.026 and group 2 , p=0.053 ) . Vascular responses to acetylcholine improved in patients on IIT ( p=0.017 ) , but not in patients receiving CIT . These changes were all independent of HbA1c level . CONCLUSIONS/INTERPRETATION IIT appears to be associated with improvements in vascular markers , independently of changes in HbA1c , suggesting that IIT may confer vascular protection in addition to improving glycaemic control .
[ "Intensive", "insulin", "therapy", "improves", "endothelial", "function", "and", "microvascular", "reactivity", "in", "young", "people", "with", "type", "1", "diabetes", ".", "AIMS", "/", "HYPOTHESIS", "Macrovascular", "disease", "is", "an", "important", "cause", "of", "the", "increased", "morbidity", "and", "mortality", "rates", "associated", "with", "type", "1", "diabetes", ",", "and", "this", "vascular", "impairment", "begins", "in", "childhood", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "whether", "introducing", "intensive", "diabetes", "management", "[", "intensive", "insulin", "therapy", "(", "IIT", ")", "and", "'", "Sweet", "Talk", "'", "text", "-", "messaging", "support", "]", "produces", "measurable", "improvements", "in", "endothelial", "function", ".", "METHODS", "One", "hundred", "and", "twenty", "-", "six", "patients", "fulfilled", "the", "eligibility", "criteria", "(", "type", "1", "diabetes", "for", ">", "1", "year", ";", "on", "conventional", "insulin", "therapy", "(", "CIT", ")", ";", "aged", "between", "8", "and", "18", "years", ")", ",", "of", "whom", "92", "enrolled", ".", "Patients", "were", "randomised", "to", "group", "1", ",", "CIT", "only", "(", "n=28", ")", ";", "group", "2", ",", "CIT", "and", "Sweet", "Talk", "(", "n=33", ")", ";", "or", "group", "3", ",", "IIT", "and", "Sweet", "Talk", "(", "n=31", ")", ".", "Vascular", "assessments", "(", "including", "measures", "of", "endothelial", "damage", ",", "activation", ",", "dysfunction", "and", "oxidative", "stress", ")", "and", "HbA1c", "were", "performed", "at", "baseline", "and", "repeated", "after", "12", "months", "of", "the", "study", ".", "RESULTS", "Glycaemic", "control", "deteriorated", "in", "patients", "on", "CIT", ",", "but", "improved", "significantly", "in", "patients", "allocated", "to", "IIT", "(", "p=0.007", ")", ".", "IIT", "was", "associated", "with", "significantly", "greater", "improvements", "in", "E", "-", "selectin", "(", "p", "<", "0.0001", ")", "than", "CIT", "(", "group", "1", ",", "p=0.026", "and", "group", "2", ",", "p=0.053", ")", ".", "Vascular", "responses", "to", "acetylcholine", "improved", "in", "patients", "on", "IIT", "(", "p=0.017", ")", ",", "but", "not", "in", "patients", "receiving", "CIT", ".", "These", "changes", "were", "all", "independent", "of", "HbA1c", "level", ".", "CONCLUSIONS", "/", "INTERPRETATION", "IIT", "appears", "to", "be", "associated", "with", "improvements", "in", "vascular", "markers", ",", "independently", "of", "changes", "in", "HbA1c", ",", "suggesting", "that", "IIT", "may", "confer", "vascular", "protection", "in", "addition", "to", "improving", "glycaemic", "control", "." ]
[ "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Intervention_Pharmacological", "Participant_Sample-size", "Participant_Age", "Participant_Condition" ]
phosphate ions is a compound, osteocalcin is a protein
DS.d1476_task0
Sentence: The culture medium was analyzed for pH value, concentration of free calcium and phosphate ions and osteocalcin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "B-protein", "O" ]
The culture medium was analyzed for pH value, concentration of free calcium and phosphate ions and osteocalcin.
[ "The", "culture", "medium", "was", "analyzed", "for", "pH", "value", ",", "concentration", "of", "free", "calcium", "and", "phosphate", "ions", "and", "osteocalcin", "." ]
[ "compound", "protein" ]
phosphate ions is a compound, osteocalcin is a protein
DS.d1476_task1
Sentence: The culture medium was analyzed for pH value, concentration of free calcium and phosphate ions and osteocalcin. Instructions: please typing these entity words according to sentence: phosphate ions, osteocalcin Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "B-protein", "O" ]
The culture medium was analyzed for pH value, concentration of free calcium and phosphate ions and osteocalcin.
[ "The", "culture", "medium", "was", "analyzed", "for", "pH", "value", ",", "concentration", "of", "free", "calcium", "and", "phosphate", "ions", "and", "osteocalcin", "." ]
[ "compound", "protein" ]
phosphate ions, osteocalcin
DS.d1476_task2
Sentence: The culture medium was analyzed for pH value, concentration of free calcium and phosphate ions and osteocalcin. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "O", "B-protein", "O" ]
The culture medium was analyzed for pH value, concentration of free calcium and phosphate ions and osteocalcin.
[ "The", "culture", "medium", "was", "analyzed", "for", "pH", "value", ",", "concentration", "of", "free", "calcium", "and", "phosphate", "ions", "and", "osteocalcin", "." ]
[ "compound", "protein" ]
Xanthomonas campestris pv . vesicatoria is a Microorganism, Pathogenicity is a Phenotype, gram - negative is a Phenotype, plant pathogen is a Phenotype, Xanthomonas campestris pv . vesicatoria is a Microorganism, type III secretion is a Phenotype, plant cell is a Habitat, virulence is a Phenotype, Xanthomonas is a Microorganism, plant cell is a Habitat, plant is a Habitat, animal pathogenic is a Phenotype, pathogenicity is a Phenotype, Xanthomonas is a Microorganism, Pseudomonas syringae pv . maculicola is a Microorganism, X. campestris pv . vesicatoria is a Microorganism, function as transglycosylase is a Phenotype
10_task0
Sentence: XopC and XopJ, two novel type III effector proteins from Xanthomonas campestris pv. vesicatoria. Pathogenicity of the gram-negative plant pathogen Xanthomonas campestris pv. vesicatoria depends on a type III secretion (TTS) system which translocates bacterial effector proteins into the plant cell. Previous transcriptome analysis identified a genome-wide regulon of putative virulence genes that are coexpressed with the TTS system. In this study, we characterized two of these genes, xopC and xopJ. Both genes encode Xanthomonas outer proteins (Xops) that were shown to be secreted by the TTS system. In addition, type III-dependent translocation of both proteins into the plant cell was demonstrated using the AvrBs3 effector domain as a reporter. XopJ belongs to the AvrRxv/YopJ family of effector proteins from plant and animal pathogenic bacteria. By contrast, XopC does not share significant homology to proteins in the database. Sequence analysis revealed that the xopC locus contains several features that are reminiscent of pathogenicity islands. Interestingly, the xopC region is flanked by 62-bp inverted repeats that are also associated with members of the Xanthomonas avrBs3 effector family. Besides xopC, a second gene of the locus, designated hpaJ, was shown to be coexpressed with the TTS system. hpaJ encodes a protein with similarity to transglycosylases and to the Pseudomonas syringae pv. maculicola protein HopPmaG. HpaJ secretion and translocation by the X. campestris pv. vesicatoria TTS system was not detectable, which is consistent with its predicted Sec signal and a putative function as transglycosylase in the bacterial periplasm. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Phenotype, Habitat
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "B-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "B-Phenotype", "I-Phenotype", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O" ]
XopC and XopJ, two novel type III effector proteins from Xanthomonas campestris pv. vesicatoria. Pathogenicity of the gram-negative plant pathogen Xanthomonas campestris pv. vesicatoria depends on a type III secretion (TTS) system which translocates bacterial effector proteins into the plant cell. Previous transcriptome analysis identified a genome-wide regulon of putative virulence genes that are coexpressed with the TTS system. In this study, we characterized two of these genes, xopC and xopJ. Both genes encode Xanthomonas outer proteins (Xops) that were shown to be secreted by the TTS system. In addition, type III-dependent translocation of both proteins into the plant cell was demonstrated using the AvrBs3 effector domain as a reporter. XopJ belongs to the AvrRxv/YopJ family of effector proteins from plant and animal pathogenic bacteria. By contrast, XopC does not share significant homology to proteins in the database. Sequence analysis revealed that the xopC locus contains several features that are reminiscent of pathogenicity islands. Interestingly, the xopC region is flanked by 62-bp inverted repeats that are also associated with members of the Xanthomonas avrBs3 effector family. Besides xopC, a second gene of the locus, designated hpaJ, was shown to be coexpressed with the TTS system. hpaJ encodes a protein with similarity to transglycosylases and to the Pseudomonas syringae pv. maculicola protein HopPmaG. HpaJ secretion and translocation by the X. campestris pv. vesicatoria TTS system was not detectable, which is consistent with its predicted Sec signal and a putative function as transglycosylase in the bacterial periplasm.
[ "XopC", "and", "XopJ", ",", "two", "novel", "type", "III", "effector", "proteins", "from", "Xanthomonas", "campestris", "pv", ".", "vesicatoria", ".", "Pathogenicity", "of", "the", "gram", "-", "negative", "plant", "pathogen", "Xanthomonas", "campestris", "pv", ".", "vesicatoria", "depends", "on", "a", "type", "III", "secretion", "(", "TTS", ")", "system", "which", "translocates", "bacterial", "effector", "proteins", "into", "the", "plant", "cell", ".", "Previous", "transcriptome", "analysis", "identified", "a", "genome", "-", "wide", "regulon", "of", "putative", "virulence", "genes", "that", "are", "coexpressed", "with", "the", "TTS", "system", ".", "In", "this", "study", ",", "we", "characterized", "two", "of", "these", "genes", ",", "xopC", "and", "xopJ.", "Both", "genes", "encode", "Xanthomonas", "outer", "proteins", "(", "Xops", ")", "that", "were", "shown", "to", "be", "secreted", "by", "the", "TTS", "system", ".", "In", "addition", ",", "type", "III", "-", "dependent", "translocation", "of", "both", "proteins", "into", "the", "plant", "cell", "was", "demonstrated", "using", "the", "AvrBs3", "effector", "domain", "as", "a", "reporter", ".", "XopJ", "belongs", "to", "the", "AvrRxv", "/", "YopJ", "family", "of", "effector", "proteins", "from", "plant", "and", "animal", "pathogenic", "bacteria", ".", "By", "contrast", ",", "XopC", "does", "not", "share", "significant", "homology", "to", "proteins", "in", "the", "database", ".", "Sequence", "analysis", "revealed", "that", "the", "xopC", "locus", "contains", "several", "features", "that", "are", "reminiscent", "of", "pathogenicity", "islands", ".", "Interestingly", ",", "the", "xopC", "region", "is", "flanked", "by", "62-bp", "inverted", "repeats", "that", "are", "also", "associated", "with", "members", "of", "the", "Xanthomonas", "avrBs3", "effector", "family", ".", "Besides", "xopC", ",", "a", "second", "gene", "of", "the", "locus", ",", "designated", "hpaJ", ",", "was", "shown", "to", "be", "coexpressed", "with", "the", "TTS", "system", ".", "hpaJ", "encodes", "a", "protein", "with", "similarity", "to", "transglycosylases", "and", "to", "the", "Pseudomonas", "syringae", "pv", ".", "maculicola", "protein", "HopPmaG.", "HpaJ", "secretion", "and", "translocation", "by", "the", "X.", "campestris", "pv", ".", "vesicatoria", "TTS", "system", "was", "not", "detectable", ",", "which", "is", "consistent", "with", "its", "predicted", "Sec", "signal", "and", "a", "putative", "function", "as", "transglycosylase", "in", "the", "bacterial", "periplasm", ".", " " ]
[ "Microorganism", "Phenotype", "Habitat" ]
Xanthomonas campestris pv . vesicatoria is a Microorganism, Pathogenicity is a Phenotype, gram - negative is a Phenotype, plant pathogen is a Phenotype, Xanthomonas campestris pv . vesicatoria is a Microorganism, type III secretion is a Phenotype, plant cell is a Habitat, virulence is a Phenotype, Xanthomonas is a Microorganism, plant cell is a Habitat, plant is a Habitat, animal pathogenic is a Phenotype, pathogenicity is a Phenotype, Xanthomonas is a Microorganism, Pseudomonas syringae pv . maculicola is a Microorganism, X. campestris pv . vesicatoria is a Microorganism, function as transglycosylase is a Phenotype
10_task1
Sentence: XopC and XopJ, two novel type III effector proteins from Xanthomonas campestris pv. vesicatoria. Pathogenicity of the gram-negative plant pathogen Xanthomonas campestris pv. vesicatoria depends on a type III secretion (TTS) system which translocates bacterial effector proteins into the plant cell. Previous transcriptome analysis identified a genome-wide regulon of putative virulence genes that are coexpressed with the TTS system. In this study, we characterized two of these genes, xopC and xopJ. Both genes encode Xanthomonas outer proteins (Xops) that were shown to be secreted by the TTS system. In addition, type III-dependent translocation of both proteins into the plant cell was demonstrated using the AvrBs3 effector domain as a reporter. XopJ belongs to the AvrRxv/YopJ family of effector proteins from plant and animal pathogenic bacteria. By contrast, XopC does not share significant homology to proteins in the database. Sequence analysis revealed that the xopC locus contains several features that are reminiscent of pathogenicity islands. Interestingly, the xopC region is flanked by 62-bp inverted repeats that are also associated with members of the Xanthomonas avrBs3 effector family. Besides xopC, a second gene of the locus, designated hpaJ, was shown to be coexpressed with the TTS system. hpaJ encodes a protein with similarity to transglycosylases and to the Pseudomonas syringae pv. maculicola protein HopPmaG. HpaJ secretion and translocation by the X. campestris pv. vesicatoria TTS system was not detectable, which is consistent with its predicted Sec signal and a putative function as transglycosylase in the bacterial periplasm. Instructions: please typing these entity words according to sentence: Xanthomonas campestris pv . vesicatoria, Pathogenicity, gram - negative, plant pathogen, Xanthomonas campestris pv . vesicatoria, type III secretion, plant cell, virulence, Xanthomonas, plant cell, plant, animal pathogenic, pathogenicity, Xanthomonas, Pseudomonas syringae pv . maculicola, X. campestris pv . vesicatoria, function as transglycosylase Options: Microorganism, Phenotype, Habitat
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "B-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "B-Phenotype", "I-Phenotype", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O" ]
XopC and XopJ, two novel type III effector proteins from Xanthomonas campestris pv. vesicatoria. Pathogenicity of the gram-negative plant pathogen Xanthomonas campestris pv. vesicatoria depends on a type III secretion (TTS) system which translocates bacterial effector proteins into the plant cell. Previous transcriptome analysis identified a genome-wide regulon of putative virulence genes that are coexpressed with the TTS system. In this study, we characterized two of these genes, xopC and xopJ. Both genes encode Xanthomonas outer proteins (Xops) that were shown to be secreted by the TTS system. In addition, type III-dependent translocation of both proteins into the plant cell was demonstrated using the AvrBs3 effector domain as a reporter. XopJ belongs to the AvrRxv/YopJ family of effector proteins from plant and animal pathogenic bacteria. By contrast, XopC does not share significant homology to proteins in the database. Sequence analysis revealed that the xopC locus contains several features that are reminiscent of pathogenicity islands. Interestingly, the xopC region is flanked by 62-bp inverted repeats that are also associated with members of the Xanthomonas avrBs3 effector family. Besides xopC, a second gene of the locus, designated hpaJ, was shown to be coexpressed with the TTS system. hpaJ encodes a protein with similarity to transglycosylases and to the Pseudomonas syringae pv. maculicola protein HopPmaG. HpaJ secretion and translocation by the X. campestris pv. vesicatoria TTS system was not detectable, which is consistent with its predicted Sec signal and a putative function as transglycosylase in the bacterial periplasm.
[ "XopC", "and", "XopJ", ",", "two", "novel", "type", "III", "effector", "proteins", "from", "Xanthomonas", "campestris", "pv", ".", "vesicatoria", ".", "Pathogenicity", "of", "the", "gram", "-", "negative", "plant", "pathogen", "Xanthomonas", "campestris", "pv", ".", "vesicatoria", "depends", "on", "a", "type", "III", "secretion", "(", "TTS", ")", "system", "which", "translocates", "bacterial", "effector", "proteins", "into", "the", "plant", "cell", ".", "Previous", "transcriptome", "analysis", "identified", "a", "genome", "-", "wide", "regulon", "of", "putative", "virulence", "genes", "that", "are", "coexpressed", "with", "the", "TTS", "system", ".", "In", "this", "study", ",", "we", "characterized", "two", "of", "these", "genes", ",", "xopC", "and", "xopJ.", "Both", "genes", "encode", "Xanthomonas", "outer", "proteins", "(", "Xops", ")", "that", "were", "shown", "to", "be", "secreted", "by", "the", "TTS", "system", ".", "In", "addition", ",", "type", "III", "-", "dependent", "translocation", "of", "both", "proteins", "into", "the", "plant", "cell", "was", "demonstrated", "using", "the", "AvrBs3", "effector", "domain", "as", "a", "reporter", ".", "XopJ", "belongs", "to", "the", "AvrRxv", "/", "YopJ", "family", "of", "effector", "proteins", "from", "plant", "and", "animal", "pathogenic", "bacteria", ".", "By", "contrast", ",", "XopC", "does", "not", "share", "significant", "homology", "to", "proteins", "in", "the", "database", ".", "Sequence", "analysis", "revealed", "that", "the", "xopC", "locus", "contains", "several", "features", "that", "are", "reminiscent", "of", "pathogenicity", "islands", ".", "Interestingly", ",", "the", "xopC", "region", "is", "flanked", "by", "62-bp", "inverted", "repeats", "that", "are", "also", "associated", "with", "members", "of", "the", "Xanthomonas", "avrBs3", "effector", "family", ".", "Besides", "xopC", ",", "a", "second", "gene", "of", "the", "locus", ",", "designated", "hpaJ", ",", "was", "shown", "to", "be", "coexpressed", "with", "the", "TTS", "system", ".", "hpaJ", "encodes", "a", "protein", "with", "similarity", "to", "transglycosylases", "and", "to", "the", "Pseudomonas", "syringae", "pv", ".", "maculicola", "protein", "HopPmaG.", "HpaJ", "secretion", "and", "translocation", "by", "the", "X.", "campestris", "pv", ".", "vesicatoria", "TTS", "system", "was", "not", "detectable", ",", "which", "is", "consistent", "with", "its", "predicted", "Sec", "signal", "and", "a", "putative", "function", "as", "transglycosylase", "in", "the", "bacterial", "periplasm", ".", " " ]
[ "Microorganism", "Phenotype", "Habitat" ]
Xanthomonas campestris pv . vesicatoria, Pathogenicity, gram - negative, plant pathogen, Xanthomonas campestris pv . vesicatoria, type III secretion, plant cell, virulence, Xanthomonas, plant cell, plant, animal pathogenic, pathogenicity, Xanthomonas, Pseudomonas syringae pv . maculicola, X. campestris pv . vesicatoria, function as transglycosylase
10_task2
Sentence: XopC and XopJ, two novel type III effector proteins from Xanthomonas campestris pv. vesicatoria. Pathogenicity of the gram-negative plant pathogen Xanthomonas campestris pv. vesicatoria depends on a type III secretion (TTS) system which translocates bacterial effector proteins into the plant cell. Previous transcriptome analysis identified a genome-wide regulon of putative virulence genes that are coexpressed with the TTS system. In this study, we characterized two of these genes, xopC and xopJ. Both genes encode Xanthomonas outer proteins (Xops) that were shown to be secreted by the TTS system. In addition, type III-dependent translocation of both proteins into the plant cell was demonstrated using the AvrBs3 effector domain as a reporter. XopJ belongs to the AvrRxv/YopJ family of effector proteins from plant and animal pathogenic bacteria. By contrast, XopC does not share significant homology to proteins in the database. Sequence analysis revealed that the xopC locus contains several features that are reminiscent of pathogenicity islands. Interestingly, the xopC region is flanked by 62-bp inverted repeats that are also associated with members of the Xanthomonas avrBs3 effector family. Besides xopC, a second gene of the locus, designated hpaJ, was shown to be coexpressed with the TTS system. hpaJ encodes a protein with similarity to transglycosylases and to the Pseudomonas syringae pv. maculicola protein HopPmaG. HpaJ secretion and translocation by the X. campestris pv. vesicatoria TTS system was not detectable, which is consistent with its predicted Sec signal and a putative function as transglycosylase in the bacterial periplasm. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "B-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "B-Phenotype", "I-Phenotype", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O" ]
XopC and XopJ, two novel type III effector proteins from Xanthomonas campestris pv. vesicatoria. Pathogenicity of the gram-negative plant pathogen Xanthomonas campestris pv. vesicatoria depends on a type III secretion (TTS) system which translocates bacterial effector proteins into the plant cell. Previous transcriptome analysis identified a genome-wide regulon of putative virulence genes that are coexpressed with the TTS system. In this study, we characterized two of these genes, xopC and xopJ. Both genes encode Xanthomonas outer proteins (Xops) that were shown to be secreted by the TTS system. In addition, type III-dependent translocation of both proteins into the plant cell was demonstrated using the AvrBs3 effector domain as a reporter. XopJ belongs to the AvrRxv/YopJ family of effector proteins from plant and animal pathogenic bacteria. By contrast, XopC does not share significant homology to proteins in the database. Sequence analysis revealed that the xopC locus contains several features that are reminiscent of pathogenicity islands. Interestingly, the xopC region is flanked by 62-bp inverted repeats that are also associated with members of the Xanthomonas avrBs3 effector family. Besides xopC, a second gene of the locus, designated hpaJ, was shown to be coexpressed with the TTS system. hpaJ encodes a protein with similarity to transglycosylases and to the Pseudomonas syringae pv. maculicola protein HopPmaG. HpaJ secretion and translocation by the X. campestris pv. vesicatoria TTS system was not detectable, which is consistent with its predicted Sec signal and a putative function as transglycosylase in the bacterial periplasm.
[ "XopC", "and", "XopJ", ",", "two", "novel", "type", "III", "effector", "proteins", "from", "Xanthomonas", "campestris", "pv", ".", "vesicatoria", ".", "Pathogenicity", "of", "the", "gram", "-", "negative", "plant", "pathogen", "Xanthomonas", "campestris", "pv", ".", "vesicatoria", "depends", "on", "a", "type", "III", "secretion", "(", "TTS", ")", "system", "which", "translocates", "bacterial", "effector", "proteins", "into", "the", "plant", "cell", ".", "Previous", "transcriptome", "analysis", "identified", "a", "genome", "-", "wide", "regulon", "of", "putative", "virulence", "genes", "that", "are", "coexpressed", "with", "the", "TTS", "system", ".", "In", "this", "study", ",", "we", "characterized", "two", "of", "these", "genes", ",", "xopC", "and", "xopJ.", "Both", "genes", "encode", "Xanthomonas", "outer", "proteins", "(", "Xops", ")", "that", "were", "shown", "to", "be", "secreted", "by", "the", "TTS", "system", ".", "In", "addition", ",", "type", "III", "-", "dependent", "translocation", "of", "both", "proteins", "into", "the", "plant", "cell", "was", "demonstrated", "using", "the", "AvrBs3", "effector", "domain", "as", "a", "reporter", ".", "XopJ", "belongs", "to", "the", "AvrRxv", "/", "YopJ", "family", "of", "effector", "proteins", "from", "plant", "and", "animal", "pathogenic", "bacteria", ".", "By", "contrast", ",", "XopC", "does", "not", "share", "significant", "homology", "to", "proteins", "in", "the", "database", ".", "Sequence", "analysis", "revealed", "that", "the", "xopC", "locus", "contains", "several", "features", "that", "are", "reminiscent", "of", "pathogenicity", "islands", ".", "Interestingly", ",", "the", "xopC", "region", "is", "flanked", "by", "62-bp", "inverted", "repeats", "that", "are", "also", "associated", "with", "members", "of", "the", "Xanthomonas", "avrBs3", "effector", "family", ".", "Besides", "xopC", ",", "a", "second", "gene", "of", "the", "locus", ",", "designated", "hpaJ", ",", "was", "shown", "to", "be", "coexpressed", "with", "the", "TTS", "system", ".", "hpaJ", "encodes", "a", "protein", "with", "similarity", "to", "transglycosylases", "and", "to", "the", "Pseudomonas", "syringae", "pv", ".", "maculicola", "protein", "HopPmaG.", "HpaJ", "secretion", "and", "translocation", "by", "the", "X.", "campestris", "pv", ".", "vesicatoria", "TTS", "system", "was", "not", "detectable", ",", "which", "is", "consistent", "with", "its", "predicted", "Sec", "signal", "and", "a", "putative", "function", "as", "transglycosylase", "in", "the", "bacterial", "periplasm", ".", " " ]
[ "Microorganism", "Phenotype", "Habitat" ]
Secondary is an umlsterm, fistulas is an umlsterm, complication is an umlsterm, open is an umlsterm, repair is an umlsterm, abdominal aortic aneurysm is an umlsterm, fistula is an umlsterm, treatment is an umlsterm, abdominal aortic aneurysm is an umlsterm, diagnosis is an umlsterm, infection is an umlsterm, defect is an umlsterm, duodenum is an umlsterm, omentumplasty is an umlsterm
Gefaesschirurgie.90040101.eng.abstr_task0
Sentence: Secondary aortoenteric fistulas are a well-known complication after open repair of an abdominal aortic aneurysm . This is the first case description of an aortoenteric fistula after endoluminal treatment of an abdominal aortic aneurysm . Preoperative diagnosis by antigranulocyte immunscintigraphy established infection of the protheses . The problem was solved by closing the defect of duodenum , removing the endoprotheses and in situ reconstruction with omentumplasty . The reasons and consequences are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Secondary aortoenteric fistulas are a well-known complication after open repair of an abdominal aortic aneurysm . This is the first case description of an aortoenteric fistula after endoluminal treatment of an abdominal aortic aneurysm . Preoperative diagnosis by antigranulocyte immunscintigraphy established infection of the protheses . The problem was solved by closing the defect of duodenum , removing the endoprotheses and in situ reconstruction with omentumplasty . The reasons and consequences are discussed .
[ "Secondary", "aortoenteric", "fistulas", "are", "a", "well", "-", "known", "complication", "after", "open", "repair", "of", "an", "abdominal", "aortic", "aneurysm", ".", "This", "is", "the", "first", "case", "description", "of", "an", "aortoenteric", "fistula", "after", "endoluminal", "treatment", "of", "an", "abdominal", "aortic", "aneurysm", ".", "Preoperative", "diagnosis", "by", "antigranulocyte", "immunscintigraphy", "established", "infection", "of", "the", "protheses", ".", "The", "problem", "was", "solved", "by", "closing", "the", "defect", "of", "duodenum", ",", "removing", "the", "endoprotheses", "and", "in", "situ", "reconstruction", "with", "omentumplasty", ".", "The", "reasons", "and", "consequences", "are", "discussed", "." ]
[ "umlsterm" ]
Secondary is an umlsterm, fistulas is an umlsterm, complication is an umlsterm, open is an umlsterm, repair is an umlsterm, abdominal aortic aneurysm is an umlsterm, fistula is an umlsterm, treatment is an umlsterm, abdominal aortic aneurysm is an umlsterm, diagnosis is an umlsterm, infection is an umlsterm, defect is an umlsterm, duodenum is an umlsterm, omentumplasty is an umlsterm
Gefaesschirurgie.90040101.eng.abstr_task1
Sentence: Secondary aortoenteric fistulas are a well-known complication after open repair of an abdominal aortic aneurysm . This is the first case description of an aortoenteric fistula after endoluminal treatment of an abdominal aortic aneurysm . Preoperative diagnosis by antigranulocyte immunscintigraphy established infection of the protheses . The problem was solved by closing the defect of duodenum , removing the endoprotheses and in situ reconstruction with omentumplasty . The reasons and consequences are discussed . Instructions: please typing these entity words according to sentence: Secondary, fistulas, complication, open, repair, abdominal aortic aneurysm, fistula, treatment, abdominal aortic aneurysm, diagnosis, infection, defect, duodenum, omentumplasty Options: umlsterm
[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Secondary aortoenteric fistulas are a well-known complication after open repair of an abdominal aortic aneurysm . This is the first case description of an aortoenteric fistula after endoluminal treatment of an abdominal aortic aneurysm . Preoperative diagnosis by antigranulocyte immunscintigraphy established infection of the protheses . The problem was solved by closing the defect of duodenum , removing the endoprotheses and in situ reconstruction with omentumplasty . The reasons and consequences are discussed .
[ "Secondary", "aortoenteric", "fistulas", "are", "a", "well", "-", "known", "complication", "after", "open", "repair", "of", "an", "abdominal", "aortic", "aneurysm", ".", "This", "is", "the", "first", "case", "description", "of", "an", "aortoenteric", "fistula", "after", "endoluminal", "treatment", "of", "an", "abdominal", "aortic", "aneurysm", ".", "Preoperative", "diagnosis", "by", "antigranulocyte", "immunscintigraphy", "established", "infection", "of", "the", "protheses", ".", "The", "problem", "was", "solved", "by", "closing", "the", "defect", "of", "duodenum", ",", "removing", "the", "endoprotheses", "and", "in", "situ", "reconstruction", "with", "omentumplasty", ".", "The", "reasons", "and", "consequences", "are", "discussed", "." ]
[ "umlsterm" ]
Secondary, fistulas, complication, open, repair, abdominal aortic aneurysm, fistula, treatment, abdominal aortic aneurysm, diagnosis, infection, defect, duodenum, omentumplasty
Gefaesschirurgie.90040101.eng.abstr_task2
Sentence: Secondary aortoenteric fistulas are a well-known complication after open repair of an abdominal aortic aneurysm . This is the first case description of an aortoenteric fistula after endoluminal treatment of an abdominal aortic aneurysm . Preoperative diagnosis by antigranulocyte immunscintigraphy established infection of the protheses . The problem was solved by closing the defect of duodenum , removing the endoprotheses and in situ reconstruction with omentumplasty . The reasons and consequences are discussed . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]
Secondary aortoenteric fistulas are a well-known complication after open repair of an abdominal aortic aneurysm . This is the first case description of an aortoenteric fistula after endoluminal treatment of an abdominal aortic aneurysm . Preoperative diagnosis by antigranulocyte immunscintigraphy established infection of the protheses . The problem was solved by closing the defect of duodenum , removing the endoprotheses and in situ reconstruction with omentumplasty . The reasons and consequences are discussed .
[ "Secondary", "aortoenteric", "fistulas", "are", "a", "well", "-", "known", "complication", "after", "open", "repair", "of", "an", "abdominal", "aortic", "aneurysm", ".", "This", "is", "the", "first", "case", "description", "of", "an", "aortoenteric", "fistula", "after", "endoluminal", "treatment", "of", "an", "abdominal", "aortic", "aneurysm", ".", "Preoperative", "diagnosis", "by", "antigranulocyte", "immunscintigraphy", "established", "infection", "of", "the", "protheses", ".", "The", "problem", "was", "solved", "by", "closing", "the", "defect", "of", "duodenum", ",", "removing", "the", "endoprotheses", "and", "in", "situ", "reconstruction", "with", "omentumplasty", ".", "The", "reasons", "and", "consequences", "are", "discussed", "." ]
[ "umlsterm" ]
analgesia is a Outcome_Physical, . is a Outcome_Physical, bupivacaine is a Intervention_Pharmacological, diamorphine is a Intervention_Pharmacological, Seventy - three is a Participant_Sample-size, elective perianal surgery is a Participant_Condition, caudal injection is a Intervention_Pharmacological, Side effects is a Outcome_Adverse-effects, some degree of urinary retention is a Outcome_Adverse-effects, temporary catheterisation is a Outcome_Adverse-effects
74597_task0
Sentence: Caudal analgesia for perianal surgery . A comparison between bupivacaine and diamorphine . Seventy-three patients undergoing elective perianal surgery were randomly divided into a control group , a group who received a caudal injection of 20 ml bupivacaine 0.5 % plain and a group who received diamorphine 2.5 mg in 10 ml normal saline by caudal injection ; a comparison was then made of postoperative analgesia requirements . The bupivacaine group had better analgesia than the control group for the first 8 hours , after which there was no difference . The diamorphine group had better analgesia than the control group for the first 24 hours postoperatively . Side effects were less in the diamorphine group than the control , or the bupivacaine group . In particular , 41 % of the bupivacaine group complained of some degree of urinary retention and one patient required temporary catheterisation . It is concluded that caudal diamorphine gives good postoperative analgesia for perianal operations , particularly when motor blockade is not wanted by the surgeon . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Participant_Sample-size
[ "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Caudal analgesia for perianal surgery . A comparison between bupivacaine and diamorphine . Seventy-three patients undergoing elective perianal surgery were randomly divided into a control group , a group who received a caudal injection of 20 ml bupivacaine 0.5 % plain and a group who received diamorphine 2.5 mg in 10 ml normal saline by caudal injection ; a comparison was then made of postoperative analgesia requirements . The bupivacaine group had better analgesia than the control group for the first 8 hours , after which there was no difference . The diamorphine group had better analgesia than the control group for the first 24 hours postoperatively . Side effects were less in the diamorphine group than the control , or the bupivacaine group . In particular , 41 % of the bupivacaine group complained of some degree of urinary retention and one patient required temporary catheterisation . It is concluded that caudal diamorphine gives good postoperative analgesia for perianal operations , particularly when motor blockade is not wanted by the surgeon .
[ "Caudal", "analgesia", "for", "perianal", "surgery", ".", "A", "comparison", "between", "bupivacaine", "and", "diamorphine", ".", "Seventy", "-", "three", "patients", "undergoing", "elective", "perianal", "surgery", "were", "randomly", "divided", "into", "a", "control", "group", ",", "a", "group", "who", "received", "a", "caudal", "injection", "of", "20", "ml", "bupivacaine", "0.5", "%", "plain", "and", "a", "group", "who", "received", "diamorphine", "2.5", "mg", "in", "10", "ml", "normal", "saline", "by", "caudal", "injection", ";", "a", "comparison", "was", "then", "made", "of", "postoperative", "analgesia", "requirements", ".", "The", "bupivacaine", "group", "had", "better", "analgesia", "than", "the", "control", "group", "for", "the", "first", "8", "hours", ",", "after", "which", "there", "was", "no", "difference", ".", "The", "diamorphine", "group", "had", "better", "analgesia", "than", "the", "control", "group", "for", "the", "first", "24", "hours", "postoperatively", ".", "Side", "effects", "were", "less", "in", "the", "diamorphine", "group", "than", "the", "control", ",", "or", "the", "bupivacaine", "group", ".", "In", "particular", ",", "41", "%", "of", "the", "bupivacaine", "group", "complained", "of", "some", "degree", "of", "urinary", "retention", "and", "one", "patient", "required", "temporary", "catheterisation", ".", "It", "is", "concluded", "that", "caudal", "diamorphine", "gives", "good", "postoperative", "analgesia", "for", "perianal", "operations", ",", "particularly", "when", "motor", "blockade", "is", "not", "wanted", "by", "the", "surgeon", "." ]
[ "Outcome_Adverse-effects", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sample-size", "Outcome_Physical" ]
analgesia is a Outcome_Physical, . is a Outcome_Physical, bupivacaine is a Intervention_Pharmacological, diamorphine is a Intervention_Pharmacological, Seventy - three is a Participant_Sample-size, elective perianal surgery is a Participant_Condition, caudal injection is a Intervention_Pharmacological, Side effects is a Outcome_Adverse-effects, some degree of urinary retention is a Outcome_Adverse-effects, temporary catheterisation is a Outcome_Adverse-effects
74597_task1
Sentence: Caudal analgesia for perianal surgery . A comparison between bupivacaine and diamorphine . Seventy-three patients undergoing elective perianal surgery were randomly divided into a control group , a group who received a caudal injection of 20 ml bupivacaine 0.5 % plain and a group who received diamorphine 2.5 mg in 10 ml normal saline by caudal injection ; a comparison was then made of postoperative analgesia requirements . The bupivacaine group had better analgesia than the control group for the first 8 hours , after which there was no difference . The diamorphine group had better analgesia than the control group for the first 24 hours postoperatively . Side effects were less in the diamorphine group than the control , or the bupivacaine group . In particular , 41 % of the bupivacaine group complained of some degree of urinary retention and one patient required temporary catheterisation . It is concluded that caudal diamorphine gives good postoperative analgesia for perianal operations , particularly when motor blockade is not wanted by the surgeon . Instructions: please typing these entity words according to sentence: analgesia, ., bupivacaine, diamorphine, Seventy - three, elective perianal surgery, caudal injection, Side effects, some degree of urinary retention, temporary catheterisation Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Participant_Sample-size
[ "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Caudal analgesia for perianal surgery . A comparison between bupivacaine and diamorphine . Seventy-three patients undergoing elective perianal surgery were randomly divided into a control group , a group who received a caudal injection of 20 ml bupivacaine 0.5 % plain and a group who received diamorphine 2.5 mg in 10 ml normal saline by caudal injection ; a comparison was then made of postoperative analgesia requirements . The bupivacaine group had better analgesia than the control group for the first 8 hours , after which there was no difference . The diamorphine group had better analgesia than the control group for the first 24 hours postoperatively . Side effects were less in the diamorphine group than the control , or the bupivacaine group . In particular , 41 % of the bupivacaine group complained of some degree of urinary retention and one patient required temporary catheterisation . It is concluded that caudal diamorphine gives good postoperative analgesia for perianal operations , particularly when motor blockade is not wanted by the surgeon .
[ "Caudal", "analgesia", "for", "perianal", "surgery", ".", "A", "comparison", "between", "bupivacaine", "and", "diamorphine", ".", "Seventy", "-", "three", "patients", "undergoing", "elective", "perianal", "surgery", "were", "randomly", "divided", "into", "a", "control", "group", ",", "a", "group", "who", "received", "a", "caudal", "injection", "of", "20", "ml", "bupivacaine", "0.5", "%", "plain", "and", "a", "group", "who", "received", "diamorphine", "2.5", "mg", "in", "10", "ml", "normal", "saline", "by", "caudal", "injection", ";", "a", "comparison", "was", "then", "made", "of", "postoperative", "analgesia", "requirements", ".", "The", "bupivacaine", "group", "had", "better", "analgesia", "than", "the", "control", "group", "for", "the", "first", "8", "hours", ",", "after", "which", "there", "was", "no", "difference", ".", "The", "diamorphine", "group", "had", "better", "analgesia", "than", "the", "control", "group", "for", "the", "first", "24", "hours", "postoperatively", ".", "Side", "effects", "were", "less", "in", "the", "diamorphine", "group", "than", "the", "control", ",", "or", "the", "bupivacaine", "group", ".", "In", "particular", ",", "41", "%", "of", "the", "bupivacaine", "group", "complained", "of", "some", "degree", "of", "urinary", "retention", "and", "one", "patient", "required", "temporary", "catheterisation", ".", "It", "is", "concluded", "that", "caudal", "diamorphine", "gives", "good", "postoperative", "analgesia", "for", "perianal", "operations", ",", "particularly", "when", "motor", "blockade", "is", "not", "wanted", "by", "the", "surgeon", "." ]
[ "Outcome_Adverse-effects", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sample-size", "Outcome_Physical" ]
analgesia, ., bupivacaine, diamorphine, Seventy - three, elective perianal surgery, caudal injection, Side effects, some degree of urinary retention, temporary catheterisation
74597_task2
Sentence: Caudal analgesia for perianal surgery . A comparison between bupivacaine and diamorphine . Seventy-three patients undergoing elective perianal surgery were randomly divided into a control group , a group who received a caudal injection of 20 ml bupivacaine 0.5 % plain and a group who received diamorphine 2.5 mg in 10 ml normal saline by caudal injection ; a comparison was then made of postoperative analgesia requirements . The bupivacaine group had better analgesia than the control group for the first 8 hours , after which there was no difference . The diamorphine group had better analgesia than the control group for the first 24 hours postoperatively . Side effects were less in the diamorphine group than the control , or the bupivacaine group . In particular , 41 % of the bupivacaine group complained of some degree of urinary retention and one patient required temporary catheterisation . It is concluded that caudal diamorphine gives good postoperative analgesia for perianal operations , particularly when motor blockade is not wanted by the surgeon . Instructions: please extract entity words from the input sentence
[ "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Caudal analgesia for perianal surgery . A comparison between bupivacaine and diamorphine . Seventy-three patients undergoing elective perianal surgery were randomly divided into a control group , a group who received a caudal injection of 20 ml bupivacaine 0.5 % plain and a group who received diamorphine 2.5 mg in 10 ml normal saline by caudal injection ; a comparison was then made of postoperative analgesia requirements . The bupivacaine group had better analgesia than the control group for the first 8 hours , after which there was no difference . The diamorphine group had better analgesia than the control group for the first 24 hours postoperatively . Side effects were less in the diamorphine group than the control , or the bupivacaine group . In particular , 41 % of the bupivacaine group complained of some degree of urinary retention and one patient required temporary catheterisation . It is concluded that caudal diamorphine gives good postoperative analgesia for perianal operations , particularly when motor blockade is not wanted by the surgeon .
[ "Caudal", "analgesia", "for", "perianal", "surgery", ".", "A", "comparison", "between", "bupivacaine", "and", "diamorphine", ".", "Seventy", "-", "three", "patients", "undergoing", "elective", "perianal", "surgery", "were", "randomly", "divided", "into", "a", "control", "group", ",", "a", "group", "who", "received", "a", "caudal", "injection", "of", "20", "ml", "bupivacaine", "0.5", "%", "plain", "and", "a", "group", "who", "received", "diamorphine", "2.5", "mg", "in", "10", "ml", "normal", "saline", "by", "caudal", "injection", ";", "a", "comparison", "was", "then", "made", "of", "postoperative", "analgesia", "requirements", ".", "The", "bupivacaine", "group", "had", "better", "analgesia", "than", "the", "control", "group", "for", "the", "first", "8", "hours", ",", "after", "which", "there", "was", "no", "difference", ".", "The", "diamorphine", "group", "had", "better", "analgesia", "than", "the", "control", "group", "for", "the", "first", "24", "hours", "postoperatively", ".", "Side", "effects", "were", "less", "in", "the", "diamorphine", "group", "than", "the", "control", ",", "or", "the", "bupivacaine", "group", ".", "In", "particular", ",", "41", "%", "of", "the", "bupivacaine", "group", "complained", "of", "some", "degree", "of", "urinary", "retention", "and", "one", "patient", "required", "temporary", "catheterisation", ".", "It", "is", "concluded", "that", "caudal", "diamorphine", "gives", "good", "postoperative", "analgesia", "for", "perianal", "operations", ",", "particularly", "when", "motor", "blockade", "is", "not", "wanted", "by", "the", "surgeon", "." ]
[ "Outcome_Adverse-effects", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sample-size", "Outcome_Physical" ]
EP1 is a GENE-Y, EP2 receptors is a GENE-Y, Na , K - ATPase is a GENE-N, prostaglandins is a CHEMICAL, Prostaglandins is a CHEMICAL, Na , K - ATPase beta1 is a GENE-N, EP receptors is a GENE-N, EP1 is a GENE-Y, EP2 receptors is a GENE-Y, EP1 is a GENE-Y, 17-phenyl trinor PGE2 is a CHEMICAL, EP2 is a GENE-Y, butaprost is a CHEMICAL, SC-51089 is a CHEMICAL, AH 6809 is a CHEMICAL, EP1 is a GENE-Y, EP2 is a GENE-Y, Gs is a GENE-N, EP2 receptors is a GENE-Y, PGE1 is a CHEMICAL, PKAI is a GENE-N, protein kinase A ( PKA ) inhibitory protein is a GENE-N, myristolated PKA inhibitory peptide is a GENE-N, EP2 receptors is a GENE-Y, EP1 receptors is a GENE-Y, PGE1 is a CHEMICAL, Na , K - ATPase beta is a GENE-N, 17-phenyl trinor PGE2 is a CHEMICAL, SC-51089 is a CHEMICAL, Gq is a GENE-N, EP1 receptors is a GENE-Y, PGE1 is a CHEMICAL, PKCI is a GENE-N, PKC inhibitory domain is a GENE-N, PKC is a GENE-N, Go 6976 is a CHEMICAL, thapsigargin is a CHEMICAL, calmodulin is a GENE-N, W7 is a CHEMICAL, W13 is a CHEMICAL
15047_task0
Sentence: Involvement of EP1 and EP2 receptors in the regulation of the Na,K-ATPase by prostaglandins in MDCK cells. Prostaglandins are key regulators of ion transport in the kidney. In MDCK cells, which model distal tubule cells, the transcription of the Na,K-ATPase beta1 subunit is regulated by PGE1 and PGE2. To identify the EP receptors that mediate transcriptional regulation, transient transfection studies are conducted using the human beta1promoter/luciferase construct, pHbeta1-1141 Luc. The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific). Consistent with the involvement of Gs coupled EP2 receptors, is that the PGE1 stimulation is inhibited by the PKAI expression vector (encoding the protein kinase A (PKA) inhibitory protein), as well as by the myristolated PKA inhibitory peptide PKI. In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089. Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL, GENE-Y, GENE-N
[ "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O" ]
Involvement of EP1 and EP2 receptors in the regulation of the Na,K-ATPase by prostaglandins in MDCK cells. Prostaglandins are key regulators of ion transport in the kidney. In MDCK cells, which model distal tubule cells, the transcription of the Na,K-ATPase beta1 subunit is regulated by PGE1 and PGE2. To identify the EP receptors that mediate transcriptional regulation, transient transfection studies are conducted using the human beta1promoter/luciferase construct, pHbeta1-1141 Luc. The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific). Consistent with the involvement of Gs coupled EP2 receptors, is that the PGE1 stimulation is inhibited by the PKAI expression vector (encoding the protein kinase A (PKA) inhibitory protein), as well as by the myristolated PKA inhibitory peptide PKI. In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089. Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13.
[ "Involvement", "of", "EP1", "and", "EP2", "receptors", "in", "the", "regulation", "of", "the", "Na", ",", "K", "-", "ATPase", "by", "prostaglandins", "in", "MDCK", "cells", ".", "\n", "Prostaglandins", "are", "key", "regulators", "of", "ion", "transport", "in", "the", "kidney", ".", "In", "MDCK", "cells", ",", "which", "model", "distal", "tubule", "cells", ",", "the", "transcription", "of", "the", "Na", ",", "K", "-", "ATPase", "beta1", "subunit", "is", "regulated", "by", "PGE1", "and", "PGE2", ".", "To", "identify", "the", "EP", "receptors", "that", "mediate", "transcriptional", "regulation", ",", "transient", "transfection", "studies", "are", "conducted", "using", "the", "human", "beta1promoter", "/", "luciferase", "construct", ",", "pHbeta1", "-", "1141", "Luc", ".", "The", "involvement", "of", "EP1", "and", "EP2", "receptors", "is", "indicated", "by", "studies", "with", "the", "EP1", "selective", "agonist", "17-phenyl", "trinor", "PGE2", ",", "and", "the", "EP2", "selective", "agonist", "butaprost", "(", "which", "stimulate", ")", ",", "as", "well", "as", "by", "studies", "with", "the", "antagonists", "SC-51089", "(", "EP1", "specific", ")", "and", "AH", "6809", "(", "EP1", "and", "EP2", "specific", ")", ".", "Consistent", "with", "the", "involvement", "of", "Gs", "coupled", "EP2", "receptors", ",", "is", "that", "the", "PGE1", "stimulation", "is", "inhibited", "by", "the", "PKAI", "expression", "vector", "(", "encoding", "the", "protein", "kinase", "A", "(", "PKA", ")", "inhibitory", "protein", ")", ",", "as", "well", "as", "by", "the", "myristolated", "PKA", "inhibitory", "peptide", "PKI", ".", "In", "addition", "to", "this", "evidence", "(", "for", "the", "involvement", "of", "EP2", "receptors", ")", ",", "evidence", "for", "the", "involvement", "of", "EP1", "receptors", "in", "the", "PGE1", "mediated", "stimulation", "of", "Na", ",", "K", "-", "ATPase", "beta", "subunit", "gene", "transcription", "includes", "the", "stimulatory", "effect", "of", "17-phenyl", "trinor", "PGE2", ",", "as", "well", "as", "the", "inhibitory", "effects", "of", "SC-51089", ".", "Also", "consistent", "with", "the", "involvement", "of", "Gq", "coupled", "EP1", "receptors", ",", "the", "PGE1", "stimulation", "is", "inhibited", "by", "the", "PKCI", "vector", "(", "encoding", "the", "PKC", "inhibitory", "domain", ")", ",", "the", "PKC", "inhibitor", "Go", "6976", ",", "thapsigargin", ",", "as", "well", "as", "the", "calmodulin", "antagonists", "W7", "and", "W13", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
EP1 is a GENE-Y, EP2 receptors is a GENE-Y, Na , K - ATPase is a GENE-N, prostaglandins is a CHEMICAL, Prostaglandins is a CHEMICAL, Na , K - ATPase beta1 is a GENE-N, EP receptors is a GENE-N, EP1 is a GENE-Y, EP2 receptors is a GENE-Y, EP1 is a GENE-Y, 17-phenyl trinor PGE2 is a CHEMICAL, EP2 is a GENE-Y, butaprost is a CHEMICAL, SC-51089 is a CHEMICAL, AH 6809 is a CHEMICAL, EP1 is a GENE-Y, EP2 is a GENE-Y, Gs is a GENE-N, EP2 receptors is a GENE-Y, PGE1 is a CHEMICAL, PKAI is a GENE-N, protein kinase A ( PKA ) inhibitory protein is a GENE-N, myristolated PKA inhibitory peptide is a GENE-N, EP2 receptors is a GENE-Y, EP1 receptors is a GENE-Y, PGE1 is a CHEMICAL, Na , K - ATPase beta is a GENE-N, 17-phenyl trinor PGE2 is a CHEMICAL, SC-51089 is a CHEMICAL, Gq is a GENE-N, EP1 receptors is a GENE-Y, PGE1 is a CHEMICAL, PKCI is a GENE-N, PKC inhibitory domain is a GENE-N, PKC is a GENE-N, Go 6976 is a CHEMICAL, thapsigargin is a CHEMICAL, calmodulin is a GENE-N, W7 is a CHEMICAL, W13 is a CHEMICAL
15047_task1
Sentence: Involvement of EP1 and EP2 receptors in the regulation of the Na,K-ATPase by prostaglandins in MDCK cells. Prostaglandins are key regulators of ion transport in the kidney. In MDCK cells, which model distal tubule cells, the transcription of the Na,K-ATPase beta1 subunit is regulated by PGE1 and PGE2. To identify the EP receptors that mediate transcriptional regulation, transient transfection studies are conducted using the human beta1promoter/luciferase construct, pHbeta1-1141 Luc. The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific). Consistent with the involvement of Gs coupled EP2 receptors, is that the PGE1 stimulation is inhibited by the PKAI expression vector (encoding the protein kinase A (PKA) inhibitory protein), as well as by the myristolated PKA inhibitory peptide PKI. In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089. Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13. Instructions: please typing these entity words according to sentence: EP1, EP2 receptors, Na , K - ATPase, prostaglandins, Prostaglandins, Na , K - ATPase beta1, EP receptors, EP1, EP2 receptors, EP1, 17-phenyl trinor PGE2, EP2, butaprost, SC-51089, AH 6809, EP1, EP2, Gs, EP2 receptors, PGE1, PKAI, protein kinase A ( PKA ) inhibitory protein, myristolated PKA inhibitory peptide, EP2 receptors, EP1 receptors, PGE1, Na , K - ATPase beta, 17-phenyl trinor PGE2, SC-51089, Gq, EP1 receptors, PGE1, PKCI, PKC inhibitory domain, PKC, Go 6976, thapsigargin, calmodulin, W7, W13 Options: CHEMICAL, GENE-Y, GENE-N
[ "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O" ]
Involvement of EP1 and EP2 receptors in the regulation of the Na,K-ATPase by prostaglandins in MDCK cells. Prostaglandins are key regulators of ion transport in the kidney. In MDCK cells, which model distal tubule cells, the transcription of the Na,K-ATPase beta1 subunit is regulated by PGE1 and PGE2. To identify the EP receptors that mediate transcriptional regulation, transient transfection studies are conducted using the human beta1promoter/luciferase construct, pHbeta1-1141 Luc. The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific). Consistent with the involvement of Gs coupled EP2 receptors, is that the PGE1 stimulation is inhibited by the PKAI expression vector (encoding the protein kinase A (PKA) inhibitory protein), as well as by the myristolated PKA inhibitory peptide PKI. In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089. Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13.
[ "Involvement", "of", "EP1", "and", "EP2", "receptors", "in", "the", "regulation", "of", "the", "Na", ",", "K", "-", "ATPase", "by", "prostaglandins", "in", "MDCK", "cells", ".", "\n", "Prostaglandins", "are", "key", "regulators", "of", "ion", "transport", "in", "the", "kidney", ".", "In", "MDCK", "cells", ",", "which", "model", "distal", "tubule", "cells", ",", "the", "transcription", "of", "the", "Na", ",", "K", "-", "ATPase", "beta1", "subunit", "is", "regulated", "by", "PGE1", "and", "PGE2", ".", "To", "identify", "the", "EP", "receptors", "that", "mediate", "transcriptional", "regulation", ",", "transient", "transfection", "studies", "are", "conducted", "using", "the", "human", "beta1promoter", "/", "luciferase", "construct", ",", "pHbeta1", "-", "1141", "Luc", ".", "The", "involvement", "of", "EP1", "and", "EP2", "receptors", "is", "indicated", "by", "studies", "with", "the", "EP1", "selective", "agonist", "17-phenyl", "trinor", "PGE2", ",", "and", "the", "EP2", "selective", "agonist", "butaprost", "(", "which", "stimulate", ")", ",", "as", "well", "as", "by", "studies", "with", "the", "antagonists", "SC-51089", "(", "EP1", "specific", ")", "and", "AH", "6809", "(", "EP1", "and", "EP2", "specific", ")", ".", "Consistent", "with", "the", "involvement", "of", "Gs", "coupled", "EP2", "receptors", ",", "is", "that", "the", "PGE1", "stimulation", "is", "inhibited", "by", "the", "PKAI", "expression", "vector", "(", "encoding", "the", "protein", "kinase", "A", "(", "PKA", ")", "inhibitory", "protein", ")", ",", "as", "well", "as", "by", "the", "myristolated", "PKA", "inhibitory", "peptide", "PKI", ".", "In", "addition", "to", "this", "evidence", "(", "for", "the", "involvement", "of", "EP2", "receptors", ")", ",", "evidence", "for", "the", "involvement", "of", "EP1", "receptors", "in", "the", "PGE1", "mediated", "stimulation", "of", "Na", ",", "K", "-", "ATPase", "beta", "subunit", "gene", "transcription", "includes", "the", "stimulatory", "effect", "of", "17-phenyl", "trinor", "PGE2", ",", "as", "well", "as", "the", "inhibitory", "effects", "of", "SC-51089", ".", "Also", "consistent", "with", "the", "involvement", "of", "Gq", "coupled", "EP1", "receptors", ",", "the", "PGE1", "stimulation", "is", "inhibited", "by", "the", "PKCI", "vector", "(", "encoding", "the", "PKC", "inhibitory", "domain", ")", ",", "the", "PKC", "inhibitor", "Go", "6976", ",", "thapsigargin", ",", "as", "well", "as", "the", "calmodulin", "antagonists", "W7", "and", "W13", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
EP1, EP2 receptors, Na , K - ATPase, prostaglandins, Prostaglandins, Na , K - ATPase beta1, EP receptors, EP1, EP2 receptors, EP1, 17-phenyl trinor PGE2, EP2, butaprost, SC-51089, AH 6809, EP1, EP2, Gs, EP2 receptors, PGE1, PKAI, protein kinase A ( PKA ) inhibitory protein, myristolated PKA inhibitory peptide, EP2 receptors, EP1 receptors, PGE1, Na , K - ATPase beta, 17-phenyl trinor PGE2, SC-51089, Gq, EP1 receptors, PGE1, PKCI, PKC inhibitory domain, PKC, Go 6976, thapsigargin, calmodulin, W7, W13
15047_task2
Sentence: Involvement of EP1 and EP2 receptors in the regulation of the Na,K-ATPase by prostaglandins in MDCK cells. Prostaglandins are key regulators of ion transport in the kidney. In MDCK cells, which model distal tubule cells, the transcription of the Na,K-ATPase beta1 subunit is regulated by PGE1 and PGE2. To identify the EP receptors that mediate transcriptional regulation, transient transfection studies are conducted using the human beta1promoter/luciferase construct, pHbeta1-1141 Luc. The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific). Consistent with the involvement of Gs coupled EP2 receptors, is that the PGE1 stimulation is inhibited by the PKAI expression vector (encoding the protein kinase A (PKA) inhibitory protein), as well as by the myristolated PKA inhibitory peptide PKI. In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089. Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O" ]
Involvement of EP1 and EP2 receptors in the regulation of the Na,K-ATPase by prostaglandins in MDCK cells. Prostaglandins are key regulators of ion transport in the kidney. In MDCK cells, which model distal tubule cells, the transcription of the Na,K-ATPase beta1 subunit is regulated by PGE1 and PGE2. To identify the EP receptors that mediate transcriptional regulation, transient transfection studies are conducted using the human beta1promoter/luciferase construct, pHbeta1-1141 Luc. The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific). Consistent with the involvement of Gs coupled EP2 receptors, is that the PGE1 stimulation is inhibited by the PKAI expression vector (encoding the protein kinase A (PKA) inhibitory protein), as well as by the myristolated PKA inhibitory peptide PKI. In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of Na,K-ATPase beta subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089. Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13.
[ "Involvement", "of", "EP1", "and", "EP2", "receptors", "in", "the", "regulation", "of", "the", "Na", ",", "K", "-", "ATPase", "by", "prostaglandins", "in", "MDCK", "cells", ".", "\n", "Prostaglandins", "are", "key", "regulators", "of", "ion", "transport", "in", "the", "kidney", ".", "In", "MDCK", "cells", ",", "which", "model", "distal", "tubule", "cells", ",", "the", "transcription", "of", "the", "Na", ",", "K", "-", "ATPase", "beta1", "subunit", "is", "regulated", "by", "PGE1", "and", "PGE2", ".", "To", "identify", "the", "EP", "receptors", "that", "mediate", "transcriptional", "regulation", ",", "transient", "transfection", "studies", "are", "conducted", "using", "the", "human", "beta1promoter", "/", "luciferase", "construct", ",", "pHbeta1", "-", "1141", "Luc", ".", "The", "involvement", "of", "EP1", "and", "EP2", "receptors", "is", "indicated", "by", "studies", "with", "the", "EP1", "selective", "agonist", "17-phenyl", "trinor", "PGE2", ",", "and", "the", "EP2", "selective", "agonist", "butaprost", "(", "which", "stimulate", ")", ",", "as", "well", "as", "by", "studies", "with", "the", "antagonists", "SC-51089", "(", "EP1", "specific", ")", "and", "AH", "6809", "(", "EP1", "and", "EP2", "specific", ")", ".", "Consistent", "with", "the", "involvement", "of", "Gs", "coupled", "EP2", "receptors", ",", "is", "that", "the", "PGE1", "stimulation", "is", "inhibited", "by", "the", "PKAI", "expression", "vector", "(", "encoding", "the", "protein", "kinase", "A", "(", "PKA", ")", "inhibitory", "protein", ")", ",", "as", "well", "as", "by", "the", "myristolated", "PKA", "inhibitory", "peptide", "PKI", ".", "In", "addition", "to", "this", "evidence", "(", "for", "the", "involvement", "of", "EP2", "receptors", ")", ",", "evidence", "for", "the", "involvement", "of", "EP1", "receptors", "in", "the", "PGE1", "mediated", "stimulation", "of", "Na", ",", "K", "-", "ATPase", "beta", "subunit", "gene", "transcription", "includes", "the", "stimulatory", "effect", "of", "17-phenyl", "trinor", "PGE2", ",", "as", "well", "as", "the", "inhibitory", "effects", "of", "SC-51089", ".", "Also", "consistent", "with", "the", "involvement", "of", "Gq", "coupled", "EP1", "receptors", ",", "the", "PGE1", "stimulation", "is", "inhibited", "by", "the", "PKCI", "vector", "(", "encoding", "the", "PKC", "inhibitory", "domain", ")", ",", "the", "PKC", "inhibitor", "Go", "6976", ",", "thapsigargin", ",", "as", "well", "as", "the", "calmodulin", "antagonists", "W7", "and", "W13", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
lymph node is a Multi-tissue_structure, esophageal squamous cell carcinoma is a Cancer, tumors is a Cancer, primary esophageal squamous cell carcinoma ( ESCC ) tumor tissues is a Tissue, lymph node is a Multi-tissue_structure, ESCC cell line is a Cell, EC9706 is a Cell, cell is a Cell, lymph node is a Multi-tissue_structure, cell is a Cell, PTTG - HA / EC9706 is a Cell, KYSE150 cells is a Cell, tissue is a Tissue, PTTG - HA / EC9706 cell is a Cell, EC9706 cells is a Cell, Chromatin is a Cellular_component, tumor is a Cancer, cell is a Cell
PMID-19351864_task0
Sentence: PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Human pituitary tumor transforming gene (PTTG) overexpression correlates with metastasis in multiple tumors, and yet its molecular mechanisms of action remain elusive. We detected PTTG overexpression in 66% (111 of 169) of primary esophageal squamous cell carcinoma (ESCC) tumor tissues by in situ hybridization. PTTG overexpression correlated with lymph node metastasis (P < 0.05). Ectopic PTTG overexpression in a representative ESCC cell line, EC9706, increased in vitro cell migration and invasion and promoted in vivo lymph node metastasis. Suppressing PTTG expression by siRNA decreased cell motility in both PTTG-HA/EC9706 and KYSE150 cells. By using mass spectrometric analysis, we identified that PTTG up-regulated S100A4 and galectin-1 secretion and down-regulated tissue inhibitor of metalloproteinase-2 secretion to the culture media. PTTG induced S100A4 and galectin-1 mRNA and protein expression as assessed by Western blot and reverse transcription-PCR. Attenuating galectin-1 expression by siRNA constrained PTTG-HA/EC9706 cell motility (P < 0.05). PTTG activated E-box transcription and induced c-Myc protein expression in EC9706 cells, which in turn may act on an E-box motif within the galectin-1 promoter. Chromatin immunoprecipitation assays further confirmed specific c-Myc binding to galectin-1 promoter. PTTG-induced galectin-1 transactivation and expression were mediated by c-Myc, and both inductions were suppressed by c-Myc RNAi cotranfection. These findings elucidate the molecular mechanisms of PTTG overexpression in promoting tumor metastasis, whereby up-regulated PTTG modulates expression and secretion of metastasis-related factors to facilitate cell motility. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Multi-tissue_structure, Tissue, Cancer, Cellular_component, Cell
[ "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "B-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O" ]
PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Human pituitary tumor transforming gene (PTTG) overexpression correlates with metastasis in multiple tumors, and yet its molecular mechanisms of action remain elusive. We detected PTTG overexpression in 66% (111 of 169) of primary esophageal squamous cell carcinoma (ESCC) tumor tissues by in situ hybridization. PTTG overexpression correlated with lymph node metastasis (P < 0.05). Ectopic PTTG overexpression in a representative ESCC cell line, EC9706, increased in vitro cell migration and invasion and promoted in vivo lymph node metastasis. Suppressing PTTG expression by siRNA decreased cell motility in both PTTG-HA/EC9706 and KYSE150 cells. By using mass spectrometric analysis, we identified that PTTG up-regulated S100A4 and galectin-1 secretion and down-regulated tissue inhibitor of metalloproteinase-2 secretion to the culture media. PTTG induced S100A4 and galectin-1 mRNA and protein expression as assessed by Western blot and reverse transcription-PCR. Attenuating galectin-1 expression by siRNA constrained PTTG-HA/EC9706 cell motility (P < 0.05). PTTG activated E-box transcription and induced c-Myc protein expression in EC9706 cells, which in turn may act on an E-box motif within the galectin-1 promoter. Chromatin immunoprecipitation assays further confirmed specific c-Myc binding to galectin-1 promoter. PTTG-induced galectin-1 transactivation and expression were mediated by c-Myc, and both inductions were suppressed by c-Myc RNAi cotranfection. These findings elucidate the molecular mechanisms of PTTG overexpression in promoting tumor metastasis, whereby up-regulated PTTG modulates expression and secretion of metastasis-related factors to facilitate cell motility.
[ "PTTG", "overexpression", "promotes", "lymph", "node", "metastasis", "in", "human", "esophageal", "squamous", "cell", "carcinoma", ".", "\n", "Human", "pituitary", "tumor", "transforming", "gene", "(", "PTTG", ")", "overexpression", "correlates", "with", "metastasis", "in", "multiple", "tumors", ",", "and", "yet", "its", "molecular", "mechanisms", "of", "action", "remain", "elusive", ".", "We", "detected", "PTTG", "overexpression", "in", "66", "%", "(", "111", "of", "169", ")", "of", "primary", "esophageal", "squamous", "cell", "carcinoma", "(", "ESCC", ")", "tumor", "tissues", "by", "in", "situ", "hybridization", ".", "PTTG", "overexpression", "correlated", "with", "lymph", "node", "metastasis", "(", "P", "<", "0.05", ")", ".", "Ectopic", "PTTG", "overexpression", "in", "a", "representative", "ESCC", "cell", "line", ",", "EC9706", ",", "increased", "in", "vitro", "cell", "migration", "and", "invasion", "and", "promoted", "in", "vivo", "lymph", "node", "metastasis", ".", "Suppressing", "PTTG", "expression", "by", "siRNA", "decreased", "cell", "motility", "in", "both", "PTTG", "-", "HA", "/", "EC9706", "and", "KYSE150", "cells", ".", "By", "using", "mass", "spectrometric", "analysis", ",", "we", "identified", "that", "PTTG", "up", "-", "regulated", "S100A4", "and", "galectin-1", "secretion", "and", "down", "-", "regulated", "tissue", "inhibitor", "of", "metalloproteinase-2", "secretion", "to", "the", "culture", "media", ".", "PTTG", "induced", "S100A4", "and", "galectin-1", "mRNA", "and", "protein", "expression", "as", "assessed", "by", "Western", "blot", "and", "reverse", "transcription", "-", "PCR", ".", "Attenuating", "galectin-1", "expression", "by", "siRNA", "constrained", "PTTG", "-", "HA", "/", "EC9706", "cell", "motility", "(", "P", "<", "0.05", ")", ".", "PTTG", "activated", "E", "-", "box", "transcription", "and", "induced", "c", "-", "Myc", "protein", "expression", "in", "EC9706", "cells", ",", "which", "in", "turn", "may", "act", "on", "an", "E", "-", "box", "motif", "within", "the", "galectin-1", "promoter", ".", "Chromatin", "immunoprecipitation", "assays", "further", "confirmed", "specific", "c", "-", "Myc", "binding", "to", "galectin-1", "promoter", ".", "PTTG", "-", "induced", "galectin-1", "transactivation", "and", "expression", "were", "mediated", "by", "c", "-", "Myc", ",", "and", "both", "inductions", "were", "suppressed", "by", "c", "-", "Myc", "RNAi", "cotranfection", ".", "These", "findings", "elucidate", "the", "molecular", "mechanisms", "of", "PTTG", "overexpression", "in", "promoting", "tumor", "metastasis", ",", "whereby", "up", "-", "regulated", "PTTG", "modulates", "expression", "and", "secretion", "of", "metastasis", "-", "related", "factors", "to", "facilitate", "cell", "motility", ".", "\n" ]
[ "Tissue", "Cancer", "Cell", "Multi-tissue_structure", "Cellular_component" ]
lymph node is a Multi-tissue_structure, esophageal squamous cell carcinoma is a Cancer, tumors is a Cancer, primary esophageal squamous cell carcinoma ( ESCC ) tumor tissues is a Tissue, lymph node is a Multi-tissue_structure, ESCC cell line is a Cell, EC9706 is a Cell, cell is a Cell, lymph node is a Multi-tissue_structure, cell is a Cell, PTTG - HA / EC9706 is a Cell, KYSE150 cells is a Cell, tissue is a Tissue, PTTG - HA / EC9706 cell is a Cell, EC9706 cells is a Cell, Chromatin is a Cellular_component, tumor is a Cancer, cell is a Cell
PMID-19351864_task1
Sentence: PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Human pituitary tumor transforming gene (PTTG) overexpression correlates with metastasis in multiple tumors, and yet its molecular mechanisms of action remain elusive. We detected PTTG overexpression in 66% (111 of 169) of primary esophageal squamous cell carcinoma (ESCC) tumor tissues by in situ hybridization. PTTG overexpression correlated with lymph node metastasis (P < 0.05). Ectopic PTTG overexpression in a representative ESCC cell line, EC9706, increased in vitro cell migration and invasion and promoted in vivo lymph node metastasis. Suppressing PTTG expression by siRNA decreased cell motility in both PTTG-HA/EC9706 and KYSE150 cells. By using mass spectrometric analysis, we identified that PTTG up-regulated S100A4 and galectin-1 secretion and down-regulated tissue inhibitor of metalloproteinase-2 secretion to the culture media. PTTG induced S100A4 and galectin-1 mRNA and protein expression as assessed by Western blot and reverse transcription-PCR. Attenuating galectin-1 expression by siRNA constrained PTTG-HA/EC9706 cell motility (P < 0.05). PTTG activated E-box transcription and induced c-Myc protein expression in EC9706 cells, which in turn may act on an E-box motif within the galectin-1 promoter. Chromatin immunoprecipitation assays further confirmed specific c-Myc binding to galectin-1 promoter. PTTG-induced galectin-1 transactivation and expression were mediated by c-Myc, and both inductions were suppressed by c-Myc RNAi cotranfection. These findings elucidate the molecular mechanisms of PTTG overexpression in promoting tumor metastasis, whereby up-regulated PTTG modulates expression and secretion of metastasis-related factors to facilitate cell motility. Instructions: please typing these entity words according to sentence: lymph node, esophageal squamous cell carcinoma, tumors, primary esophageal squamous cell carcinoma ( ESCC ) tumor tissues, lymph node, ESCC cell line, EC9706, cell, lymph node, cell, PTTG - HA / EC9706, KYSE150 cells, tissue, PTTG - HA / EC9706 cell, EC9706 cells, Chromatin, tumor, cell Options: Multi-tissue_structure, Tissue, Cancer, Cellular_component, Cell
[ "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "B-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O" ]
PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Human pituitary tumor transforming gene (PTTG) overexpression correlates with metastasis in multiple tumors, and yet its molecular mechanisms of action remain elusive. We detected PTTG overexpression in 66% (111 of 169) of primary esophageal squamous cell carcinoma (ESCC) tumor tissues by in situ hybridization. PTTG overexpression correlated with lymph node metastasis (P < 0.05). Ectopic PTTG overexpression in a representative ESCC cell line, EC9706, increased in vitro cell migration and invasion and promoted in vivo lymph node metastasis. Suppressing PTTG expression by siRNA decreased cell motility in both PTTG-HA/EC9706 and KYSE150 cells. By using mass spectrometric analysis, we identified that PTTG up-regulated S100A4 and galectin-1 secretion and down-regulated tissue inhibitor of metalloproteinase-2 secretion to the culture media. PTTG induced S100A4 and galectin-1 mRNA and protein expression as assessed by Western blot and reverse transcription-PCR. Attenuating galectin-1 expression by siRNA constrained PTTG-HA/EC9706 cell motility (P < 0.05). PTTG activated E-box transcription and induced c-Myc protein expression in EC9706 cells, which in turn may act on an E-box motif within the galectin-1 promoter. Chromatin immunoprecipitation assays further confirmed specific c-Myc binding to galectin-1 promoter. PTTG-induced galectin-1 transactivation and expression were mediated by c-Myc, and both inductions were suppressed by c-Myc RNAi cotranfection. These findings elucidate the molecular mechanisms of PTTG overexpression in promoting tumor metastasis, whereby up-regulated PTTG modulates expression and secretion of metastasis-related factors to facilitate cell motility.
[ "PTTG", "overexpression", "promotes", "lymph", "node", "metastasis", "in", "human", "esophageal", "squamous", "cell", "carcinoma", ".", "\n", "Human", "pituitary", "tumor", "transforming", "gene", "(", "PTTG", ")", "overexpression", "correlates", "with", "metastasis", "in", "multiple", "tumors", ",", "and", "yet", "its", "molecular", "mechanisms", "of", "action", "remain", "elusive", ".", "We", "detected", "PTTG", "overexpression", "in", "66", "%", "(", "111", "of", "169", ")", "of", "primary", "esophageal", "squamous", "cell", "carcinoma", "(", "ESCC", ")", "tumor", "tissues", "by", "in", "situ", "hybridization", ".", "PTTG", "overexpression", "correlated", "with", "lymph", "node", "metastasis", "(", "P", "<", "0.05", ")", ".", "Ectopic", "PTTG", "overexpression", "in", "a", "representative", "ESCC", "cell", "line", ",", "EC9706", ",", "increased", "in", "vitro", "cell", "migration", "and", "invasion", "and", "promoted", "in", "vivo", "lymph", "node", "metastasis", ".", "Suppressing", "PTTG", "expression", "by", "siRNA", "decreased", "cell", "motility", "in", "both", "PTTG", "-", "HA", "/", "EC9706", "and", "KYSE150", "cells", ".", "By", "using", "mass", "spectrometric", "analysis", ",", "we", "identified", "that", "PTTG", "up", "-", "regulated", "S100A4", "and", "galectin-1", "secretion", "and", "down", "-", "regulated", "tissue", "inhibitor", "of", "metalloproteinase-2", "secretion", "to", "the", "culture", "media", ".", "PTTG", "induced", "S100A4", "and", "galectin-1", "mRNA", "and", "protein", "expression", "as", "assessed", "by", "Western", "blot", "and", "reverse", "transcription", "-", "PCR", ".", "Attenuating", "galectin-1", "expression", "by", "siRNA", "constrained", "PTTG", "-", "HA", "/", "EC9706", "cell", "motility", "(", "P", "<", "0.05", ")", ".", "PTTG", "activated", "E", "-", "box", "transcription", "and", "induced", "c", "-", "Myc", "protein", "expression", "in", "EC9706", "cells", ",", "which", "in", "turn", "may", "act", "on", "an", "E", "-", "box", "motif", "within", "the", "galectin-1", "promoter", ".", "Chromatin", "immunoprecipitation", "assays", "further", "confirmed", "specific", "c", "-", "Myc", "binding", "to", "galectin-1", "promoter", ".", "PTTG", "-", "induced", "galectin-1", "transactivation", "and", "expression", "were", "mediated", "by", "c", "-", "Myc", ",", "and", "both", "inductions", "were", "suppressed", "by", "c", "-", "Myc", "RNAi", "cotranfection", ".", "These", "findings", "elucidate", "the", "molecular", "mechanisms", "of", "PTTG", "overexpression", "in", "promoting", "tumor", "metastasis", ",", "whereby", "up", "-", "regulated", "PTTG", "modulates", "expression", "and", "secretion", "of", "metastasis", "-", "related", "factors", "to", "facilitate", "cell", "motility", ".", "\n" ]
[ "Tissue", "Cancer", "Cell", "Multi-tissue_structure", "Cellular_component" ]
lymph node, esophageal squamous cell carcinoma, tumors, primary esophageal squamous cell carcinoma ( ESCC ) tumor tissues, lymph node, ESCC cell line, EC9706, cell, lymph node, cell, PTTG - HA / EC9706, KYSE150 cells, tissue, PTTG - HA / EC9706 cell, EC9706 cells, Chromatin, tumor, cell
PMID-19351864_task2
Sentence: PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Human pituitary tumor transforming gene (PTTG) overexpression correlates with metastasis in multiple tumors, and yet its molecular mechanisms of action remain elusive. We detected PTTG overexpression in 66% (111 of 169) of primary esophageal squamous cell carcinoma (ESCC) tumor tissues by in situ hybridization. PTTG overexpression correlated with lymph node metastasis (P < 0.05). Ectopic PTTG overexpression in a representative ESCC cell line, EC9706, increased in vitro cell migration and invasion and promoted in vivo lymph node metastasis. Suppressing PTTG expression by siRNA decreased cell motility in both PTTG-HA/EC9706 and KYSE150 cells. By using mass spectrometric analysis, we identified that PTTG up-regulated S100A4 and galectin-1 secretion and down-regulated tissue inhibitor of metalloproteinase-2 secretion to the culture media. PTTG induced S100A4 and galectin-1 mRNA and protein expression as assessed by Western blot and reverse transcription-PCR. Attenuating galectin-1 expression by siRNA constrained PTTG-HA/EC9706 cell motility (P < 0.05). PTTG activated E-box transcription and induced c-Myc protein expression in EC9706 cells, which in turn may act on an E-box motif within the galectin-1 promoter. Chromatin immunoprecipitation assays further confirmed specific c-Myc binding to galectin-1 promoter. PTTG-induced galectin-1 transactivation and expression were mediated by c-Myc, and both inductions were suppressed by c-Myc RNAi cotranfection. These findings elucidate the molecular mechanisms of PTTG overexpression in promoting tumor metastasis, whereby up-regulated PTTG modulates expression and secretion of metastasis-related factors to facilitate cell motility. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "I-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "B-Cell", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O" ]
PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Human pituitary tumor transforming gene (PTTG) overexpression correlates with metastasis in multiple tumors, and yet its molecular mechanisms of action remain elusive. We detected PTTG overexpression in 66% (111 of 169) of primary esophageal squamous cell carcinoma (ESCC) tumor tissues by in situ hybridization. PTTG overexpression correlated with lymph node metastasis (P < 0.05). Ectopic PTTG overexpression in a representative ESCC cell line, EC9706, increased in vitro cell migration and invasion and promoted in vivo lymph node metastasis. Suppressing PTTG expression by siRNA decreased cell motility in both PTTG-HA/EC9706 and KYSE150 cells. By using mass spectrometric analysis, we identified that PTTG up-regulated S100A4 and galectin-1 secretion and down-regulated tissue inhibitor of metalloproteinase-2 secretion to the culture media. PTTG induced S100A4 and galectin-1 mRNA and protein expression as assessed by Western blot and reverse transcription-PCR. Attenuating galectin-1 expression by siRNA constrained PTTG-HA/EC9706 cell motility (P < 0.05). PTTG activated E-box transcription and induced c-Myc protein expression in EC9706 cells, which in turn may act on an E-box motif within the galectin-1 promoter. Chromatin immunoprecipitation assays further confirmed specific c-Myc binding to galectin-1 promoter. PTTG-induced galectin-1 transactivation and expression were mediated by c-Myc, and both inductions were suppressed by c-Myc RNAi cotranfection. These findings elucidate the molecular mechanisms of PTTG overexpression in promoting tumor metastasis, whereby up-regulated PTTG modulates expression and secretion of metastasis-related factors to facilitate cell motility.
[ "PTTG", "overexpression", "promotes", "lymph", "node", "metastasis", "in", "human", "esophageal", "squamous", "cell", "carcinoma", ".", "\n", "Human", "pituitary", "tumor", "transforming", "gene", "(", "PTTG", ")", "overexpression", "correlates", "with", "metastasis", "in", "multiple", "tumors", ",", "and", "yet", "its", "molecular", "mechanisms", "of", "action", "remain", "elusive", ".", "We", "detected", "PTTG", "overexpression", "in", "66", "%", "(", "111", "of", "169", ")", "of", "primary", "esophageal", "squamous", "cell", "carcinoma", "(", "ESCC", ")", "tumor", "tissues", "by", "in", "situ", "hybridization", ".", "PTTG", "overexpression", "correlated", "with", "lymph", "node", "metastasis", "(", "P", "<", "0.05", ")", ".", "Ectopic", "PTTG", "overexpression", "in", "a", "representative", "ESCC", "cell", "line", ",", "EC9706", ",", "increased", "in", "vitro", "cell", "migration", "and", "invasion", "and", "promoted", "in", "vivo", "lymph", "node", "metastasis", ".", "Suppressing", "PTTG", "expression", "by", "siRNA", "decreased", "cell", "motility", "in", "both", "PTTG", "-", "HA", "/", "EC9706", "and", "KYSE150", "cells", ".", "By", "using", "mass", "spectrometric", "analysis", ",", "we", "identified", "that", "PTTG", "up", "-", "regulated", "S100A4", "and", "galectin-1", "secretion", "and", "down", "-", "regulated", "tissue", "inhibitor", "of", "metalloproteinase-2", "secretion", "to", "the", "culture", "media", ".", "PTTG", "induced", "S100A4", "and", "galectin-1", "mRNA", "and", "protein", "expression", "as", "assessed", "by", "Western", "blot", "and", "reverse", "transcription", "-", "PCR", ".", "Attenuating", "galectin-1", "expression", "by", "siRNA", "constrained", "PTTG", "-", "HA", "/", "EC9706", "cell", "motility", "(", "P", "<", "0.05", ")", ".", "PTTG", "activated", "E", "-", "box", "transcription", "and", "induced", "c", "-", "Myc", "protein", "expression", "in", "EC9706", "cells", ",", "which", "in", "turn", "may", "act", "on", "an", "E", "-", "box", "motif", "within", "the", "galectin-1", "promoter", ".", "Chromatin", "immunoprecipitation", "assays", "further", "confirmed", "specific", "c", "-", "Myc", "binding", "to", "galectin-1", "promoter", ".", "PTTG", "-", "induced", "galectin-1", "transactivation", "and", "expression", "were", "mediated", "by", "c", "-", "Myc", ",", "and", "both", "inductions", "were", "suppressed", "by", "c", "-", "Myc", "RNAi", "cotranfection", ".", "These", "findings", "elucidate", "the", "molecular", "mechanisms", "of", "PTTG", "overexpression", "in", "promoting", "tumor", "metastasis", ",", "whereby", "up", "-", "regulated", "PTTG", "modulates", "expression", "and", "secretion", "of", "metastasis", "-", "related", "factors", "to", "facilitate", "cell", "motility", ".", "\n" ]
[ "Tissue", "Cancer", "Cell", "Multi-tissue_structure", "Cellular_component" ]
radiologischen is an umlsterm, Zeit is an umlsterm, Diagnostik is an umlsterm, Lungenerkrankungen is an umlsterm, pathologischer Prozesse is an umlsterm, Diagnostik is an umlsterm, Lungenembolie is an umlsterm, Pulmonalarterien is an umlsterm, Rolle is an umlsterm, Pulmonalarterien is an umlsterm, Diagnostik is an umlsterm, Flussmessungen is an umlsterm, Beurteilung is an umlsterm, Ventilation is an umlsterm, Zeit is an umlsterm, Nuklearmedizin is an umlsterm, Lungenbelueftung is an umlsterm, Edelgase is an umlsterm, Ventilation is an umlsterm, Diagnostik is an umlsterm, Tumoren is an umlsterm, Entzuendungen is an umlsterm
DerRadiologe.00400870.ger.abstr_task0
Sentence: Die radiologischen Schnittbildverfahren , insbesondere die CT , haben sich innerhalb kurzer Zeit einen herausragenden Stellenwert in der Diagnostik von Lungenerkrankungen erworben . Dies umfasst in erster Linie die morphologische Darstellung pathologischer Prozesse mit hoher raeumlicher Aufloesung . Moderne technische Entwicklungen und kombinierte Untersuchungsstrategien eroeffnen neue Einsatzgebiete und auch funktionelle Aussagen , die nach einer aktuellen Standortbestimmung gemeinsam mit den nuklearmedizinischen Verfahren verlangen . Dazu gehoert die Diagnostik der Lungenembolie mittels Spiral-CT-Angiographie und MR-Angiographie der Pulmonalarterien . Hier hat sich mittlerweile die CT als alternatives Verfahren der Wahl etabliert und die Rolle der Pulmonalisangiographie als Goldstandard infrage gestellt . Die reine direkte Darstellung der durchstroemten Pulmonalarterien und des thromboembolischen Materials wird durch Diagnostik intrapulmonaler und kardialer Veraenderungen , Perfusionsuntersuchungen sowie MR-basierte Flussmessungen zur haemodynamischen Beurteilung erweitert . Nachdem Untersuchungen der Ventilation lange Zeit eine Domaene der Nuklearmedizin waren , eroeffnen aktuelle Entwicklungen in der MRT neue Verfahren zur direkten Visualisierung der Lungenbelueftung , z . B. mittels polarisierter Edelgase . Aus diesen Verfahren lassen sich auch neue funktionelle Parameter der Ventilation ableiten . In der Diagnostik von Tumoren und Entzuendungen ueberzeugt die CT insbesondere durch ihre hohe Sensitivitaet , z . B. beim Screening auf intrapulmonale Rundherde mittels Niedrigdosis-CT oder bei der Frueherkennung pneumonischer Infiltrate bei Risikopatienten . Insbesondere bei der Charakterisierung intrapulmonaler Rundherde ist eine Kombination mit nuklearmedizinischen Verfahren ( PET ) grundsaetzlich anzustreben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die radiologischen Schnittbildverfahren , insbesondere die CT , haben sich innerhalb kurzer Zeit einen herausragenden Stellenwert in der Diagnostik von Lungenerkrankungen erworben . Dies umfasst in erster Linie die morphologische Darstellung pathologischer Prozesse mit hoher raeumlicher Aufloesung . Moderne technische Entwicklungen und kombinierte Untersuchungsstrategien eroeffnen neue Einsatzgebiete und auch funktionelle Aussagen , die nach einer aktuellen Standortbestimmung gemeinsam mit den nuklearmedizinischen Verfahren verlangen . Dazu gehoert die Diagnostik der Lungenembolie mittels Spiral-CT-Angiographie und MR-Angiographie der Pulmonalarterien . Hier hat sich mittlerweile die CT als alternatives Verfahren der Wahl etabliert und die Rolle der Pulmonalisangiographie als Goldstandard infrage gestellt . Die reine direkte Darstellung der durchstroemten Pulmonalarterien und des thromboembolischen Materials wird durch Diagnostik intrapulmonaler und kardialer Veraenderungen , Perfusionsuntersuchungen sowie MR-basierte Flussmessungen zur haemodynamischen Beurteilung erweitert . Nachdem Untersuchungen der Ventilation lange Zeit eine Domaene der Nuklearmedizin waren , eroeffnen aktuelle Entwicklungen in der MRT neue Verfahren zur direkten Visualisierung der Lungenbelueftung , z . B. mittels polarisierter Edelgase . Aus diesen Verfahren lassen sich auch neue funktionelle Parameter der Ventilation ableiten . In der Diagnostik von Tumoren und Entzuendungen ueberzeugt die CT insbesondere durch ihre hohe Sensitivitaet , z . B. beim Screening auf intrapulmonale Rundherde mittels Niedrigdosis-CT oder bei der Frueherkennung pneumonischer Infiltrate bei Risikopatienten . Insbesondere bei der Charakterisierung intrapulmonaler Rundherde ist eine Kombination mit nuklearmedizinischen Verfahren ( PET ) grundsaetzlich anzustreben .
[ "Die", "radiologischen", "Schnittbildverfahren", ",", "insbesondere", "die", "CT", ",", "haben", "sich", "innerhalb", "kurzer", "Zeit", "einen", "herausragenden", "Stellenwert", "in", "der", "Diagnostik", "von", "Lungenerkrankungen", "erworben", ".", "Dies", "umfasst", "in", "erster", "Linie", "die", "morphologische", "Darstellung", "pathologischer", "Prozesse", "mit", "hoher", "raeumlicher", "Aufloesung", ".", "Moderne", "technische", "Entwicklungen", "und", "kombinierte", "Untersuchungsstrategien", "eroeffnen", "neue", "Einsatzgebiete", "und", "auch", "funktionelle", "Aussagen", ",", "die", "nach", "einer", "aktuellen", "Standortbestimmung", "gemeinsam", "mit", "den", "nuklearmedizinischen", "Verfahren", "verlangen", ".", "Dazu", "gehoert", "die", "Diagnostik", "der", "Lungenembolie", "mittels", "Spiral", "-", "CT", "-", "Angiographie", "und", "MR", "-", "Angiographie", "der", "Pulmonalarterien", ".", "Hier", "hat", "sich", "mittlerweile", "die", "CT", "als", "alternatives", "Verfahren", "der", "Wahl", "etabliert", "und", "die", "Rolle", "der", "Pulmonalisangiographie", "als", "Goldstandard", "infrage", "gestellt", ".", "Die", "reine", "direkte", "Darstellung", "der", "durchstroemten", "Pulmonalarterien", "und", "des", "thromboembolischen", "Materials", "wird", "durch", "Diagnostik", "intrapulmonaler", "und", "kardialer", "Veraenderungen", ",", "Perfusionsuntersuchungen", "sowie", "MR", "-", "basierte", "Flussmessungen", "zur", "haemodynamischen", "Beurteilung", "erweitert", ".", "Nachdem", "Untersuchungen", "der", "Ventilation", "lange", "Zeit", "eine", "Domaene", "der", "Nuklearmedizin", "waren", ",", "eroeffnen", "aktuelle", "Entwicklungen", "in", "der", "MRT", "neue", "Verfahren", "zur", "direkten", "Visualisierung", "der", "Lungenbelueftung", ",", "z", ".", "B.", "mittels", "polarisierter", "Edelgase", ".", "Aus", "diesen", "Verfahren", "lassen", "sich", "auch", "neue", "funktionelle", "Parameter", "der", "Ventilation", "ableiten", ".", "In", "der", "Diagnostik", "von", "Tumoren", "und", "Entzuendungen", "ueberzeugt", "die", "CT", "insbesondere", "durch", "ihre", "hohe", "Sensitivitaet", ",", "z", ".", "B.", "beim", "Screening", "auf", "intrapulmonale", "Rundherde", "mittels", "Niedrigdosis", "-", "CT", "oder", "bei", "der", "Frueherkennung", "pneumonischer", "Infiltrate", "bei", "Risikopatienten", ".", "Insbesondere", "bei", "der", "Charakterisierung", "intrapulmonaler", "Rundherde", "ist", "eine", "Kombination", "mit", "nuklearmedizinischen", "Verfahren", "(", "PET", ")", "grundsaetzlich", "anzustreben", "." ]
[ "umlsterm" ]
radiologischen is an umlsterm, Zeit is an umlsterm, Diagnostik is an umlsterm, Lungenerkrankungen is an umlsterm, pathologischer Prozesse is an umlsterm, Diagnostik is an umlsterm, Lungenembolie is an umlsterm, Pulmonalarterien is an umlsterm, Rolle is an umlsterm, Pulmonalarterien is an umlsterm, Diagnostik is an umlsterm, Flussmessungen is an umlsterm, Beurteilung is an umlsterm, Ventilation is an umlsterm, Zeit is an umlsterm, Nuklearmedizin is an umlsterm, Lungenbelueftung is an umlsterm, Edelgase is an umlsterm, Ventilation is an umlsterm, Diagnostik is an umlsterm, Tumoren is an umlsterm, Entzuendungen is an umlsterm
DerRadiologe.00400870.ger.abstr_task1
Sentence: Die radiologischen Schnittbildverfahren , insbesondere die CT , haben sich innerhalb kurzer Zeit einen herausragenden Stellenwert in der Diagnostik von Lungenerkrankungen erworben . Dies umfasst in erster Linie die morphologische Darstellung pathologischer Prozesse mit hoher raeumlicher Aufloesung . Moderne technische Entwicklungen und kombinierte Untersuchungsstrategien eroeffnen neue Einsatzgebiete und auch funktionelle Aussagen , die nach einer aktuellen Standortbestimmung gemeinsam mit den nuklearmedizinischen Verfahren verlangen . Dazu gehoert die Diagnostik der Lungenembolie mittels Spiral-CT-Angiographie und MR-Angiographie der Pulmonalarterien . Hier hat sich mittlerweile die CT als alternatives Verfahren der Wahl etabliert und die Rolle der Pulmonalisangiographie als Goldstandard infrage gestellt . Die reine direkte Darstellung der durchstroemten Pulmonalarterien und des thromboembolischen Materials wird durch Diagnostik intrapulmonaler und kardialer Veraenderungen , Perfusionsuntersuchungen sowie MR-basierte Flussmessungen zur haemodynamischen Beurteilung erweitert . Nachdem Untersuchungen der Ventilation lange Zeit eine Domaene der Nuklearmedizin waren , eroeffnen aktuelle Entwicklungen in der MRT neue Verfahren zur direkten Visualisierung der Lungenbelueftung , z . B. mittels polarisierter Edelgase . Aus diesen Verfahren lassen sich auch neue funktionelle Parameter der Ventilation ableiten . In der Diagnostik von Tumoren und Entzuendungen ueberzeugt die CT insbesondere durch ihre hohe Sensitivitaet , z . B. beim Screening auf intrapulmonale Rundherde mittels Niedrigdosis-CT oder bei der Frueherkennung pneumonischer Infiltrate bei Risikopatienten . Insbesondere bei der Charakterisierung intrapulmonaler Rundherde ist eine Kombination mit nuklearmedizinischen Verfahren ( PET ) grundsaetzlich anzustreben . Instructions: please typing these entity words according to sentence: radiologischen, Zeit, Diagnostik, Lungenerkrankungen, pathologischer Prozesse, Diagnostik, Lungenembolie, Pulmonalarterien, Rolle, Pulmonalarterien, Diagnostik, Flussmessungen, Beurteilung, Ventilation, Zeit, Nuklearmedizin, Lungenbelueftung, Edelgase, Ventilation, Diagnostik, Tumoren, Entzuendungen Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die radiologischen Schnittbildverfahren , insbesondere die CT , haben sich innerhalb kurzer Zeit einen herausragenden Stellenwert in der Diagnostik von Lungenerkrankungen erworben . Dies umfasst in erster Linie die morphologische Darstellung pathologischer Prozesse mit hoher raeumlicher Aufloesung . Moderne technische Entwicklungen und kombinierte Untersuchungsstrategien eroeffnen neue Einsatzgebiete und auch funktionelle Aussagen , die nach einer aktuellen Standortbestimmung gemeinsam mit den nuklearmedizinischen Verfahren verlangen . Dazu gehoert die Diagnostik der Lungenembolie mittels Spiral-CT-Angiographie und MR-Angiographie der Pulmonalarterien . Hier hat sich mittlerweile die CT als alternatives Verfahren der Wahl etabliert und die Rolle der Pulmonalisangiographie als Goldstandard infrage gestellt . Die reine direkte Darstellung der durchstroemten Pulmonalarterien und des thromboembolischen Materials wird durch Diagnostik intrapulmonaler und kardialer Veraenderungen , Perfusionsuntersuchungen sowie MR-basierte Flussmessungen zur haemodynamischen Beurteilung erweitert . Nachdem Untersuchungen der Ventilation lange Zeit eine Domaene der Nuklearmedizin waren , eroeffnen aktuelle Entwicklungen in der MRT neue Verfahren zur direkten Visualisierung der Lungenbelueftung , z . B. mittels polarisierter Edelgase . Aus diesen Verfahren lassen sich auch neue funktionelle Parameter der Ventilation ableiten . In der Diagnostik von Tumoren und Entzuendungen ueberzeugt die CT insbesondere durch ihre hohe Sensitivitaet , z . B. beim Screening auf intrapulmonale Rundherde mittels Niedrigdosis-CT oder bei der Frueherkennung pneumonischer Infiltrate bei Risikopatienten . Insbesondere bei der Charakterisierung intrapulmonaler Rundherde ist eine Kombination mit nuklearmedizinischen Verfahren ( PET ) grundsaetzlich anzustreben .
[ "Die", "radiologischen", "Schnittbildverfahren", ",", "insbesondere", "die", "CT", ",", "haben", "sich", "innerhalb", "kurzer", "Zeit", "einen", "herausragenden", "Stellenwert", "in", "der", "Diagnostik", "von", "Lungenerkrankungen", "erworben", ".", "Dies", "umfasst", "in", "erster", "Linie", "die", "morphologische", "Darstellung", "pathologischer", "Prozesse", "mit", "hoher", "raeumlicher", "Aufloesung", ".", "Moderne", "technische", "Entwicklungen", "und", "kombinierte", "Untersuchungsstrategien", "eroeffnen", "neue", "Einsatzgebiete", "und", "auch", "funktionelle", "Aussagen", ",", "die", "nach", "einer", "aktuellen", "Standortbestimmung", "gemeinsam", "mit", "den", "nuklearmedizinischen", "Verfahren", "verlangen", ".", "Dazu", "gehoert", "die", "Diagnostik", "der", "Lungenembolie", "mittels", "Spiral", "-", "CT", "-", "Angiographie", "und", "MR", "-", "Angiographie", "der", "Pulmonalarterien", ".", "Hier", "hat", "sich", "mittlerweile", "die", "CT", "als", "alternatives", "Verfahren", "der", "Wahl", "etabliert", "und", "die", "Rolle", "der", "Pulmonalisangiographie", "als", "Goldstandard", "infrage", "gestellt", ".", "Die", "reine", "direkte", "Darstellung", "der", "durchstroemten", "Pulmonalarterien", "und", "des", "thromboembolischen", "Materials", "wird", "durch", "Diagnostik", "intrapulmonaler", "und", "kardialer", "Veraenderungen", ",", "Perfusionsuntersuchungen", "sowie", "MR", "-", "basierte", "Flussmessungen", "zur", "haemodynamischen", "Beurteilung", "erweitert", ".", "Nachdem", "Untersuchungen", "der", "Ventilation", "lange", "Zeit", "eine", "Domaene", "der", "Nuklearmedizin", "waren", ",", "eroeffnen", "aktuelle", "Entwicklungen", "in", "der", "MRT", "neue", "Verfahren", "zur", "direkten", "Visualisierung", "der", "Lungenbelueftung", ",", "z", ".", "B.", "mittels", "polarisierter", "Edelgase", ".", "Aus", "diesen", "Verfahren", "lassen", "sich", "auch", "neue", "funktionelle", "Parameter", "der", "Ventilation", "ableiten", ".", "In", "der", "Diagnostik", "von", "Tumoren", "und", "Entzuendungen", "ueberzeugt", "die", "CT", "insbesondere", "durch", "ihre", "hohe", "Sensitivitaet", ",", "z", ".", "B.", "beim", "Screening", "auf", "intrapulmonale", "Rundherde", "mittels", "Niedrigdosis", "-", "CT", "oder", "bei", "der", "Frueherkennung", "pneumonischer", "Infiltrate", "bei", "Risikopatienten", ".", "Insbesondere", "bei", "der", "Charakterisierung", "intrapulmonaler", "Rundherde", "ist", "eine", "Kombination", "mit", "nuklearmedizinischen", "Verfahren", "(", "PET", ")", "grundsaetzlich", "anzustreben", "." ]
[ "umlsterm" ]
radiologischen, Zeit, Diagnostik, Lungenerkrankungen, pathologischer Prozesse, Diagnostik, Lungenembolie, Pulmonalarterien, Rolle, Pulmonalarterien, Diagnostik, Flussmessungen, Beurteilung, Ventilation, Zeit, Nuklearmedizin, Lungenbelueftung, Edelgase, Ventilation, Diagnostik, Tumoren, Entzuendungen
DerRadiologe.00400870.ger.abstr_task2
Sentence: Die radiologischen Schnittbildverfahren , insbesondere die CT , haben sich innerhalb kurzer Zeit einen herausragenden Stellenwert in der Diagnostik von Lungenerkrankungen erworben . Dies umfasst in erster Linie die morphologische Darstellung pathologischer Prozesse mit hoher raeumlicher Aufloesung . Moderne technische Entwicklungen und kombinierte Untersuchungsstrategien eroeffnen neue Einsatzgebiete und auch funktionelle Aussagen , die nach einer aktuellen Standortbestimmung gemeinsam mit den nuklearmedizinischen Verfahren verlangen . Dazu gehoert die Diagnostik der Lungenembolie mittels Spiral-CT-Angiographie und MR-Angiographie der Pulmonalarterien . Hier hat sich mittlerweile die CT als alternatives Verfahren der Wahl etabliert und die Rolle der Pulmonalisangiographie als Goldstandard infrage gestellt . Die reine direkte Darstellung der durchstroemten Pulmonalarterien und des thromboembolischen Materials wird durch Diagnostik intrapulmonaler und kardialer Veraenderungen , Perfusionsuntersuchungen sowie MR-basierte Flussmessungen zur haemodynamischen Beurteilung erweitert . Nachdem Untersuchungen der Ventilation lange Zeit eine Domaene der Nuklearmedizin waren , eroeffnen aktuelle Entwicklungen in der MRT neue Verfahren zur direkten Visualisierung der Lungenbelueftung , z . B. mittels polarisierter Edelgase . Aus diesen Verfahren lassen sich auch neue funktionelle Parameter der Ventilation ableiten . In der Diagnostik von Tumoren und Entzuendungen ueberzeugt die CT insbesondere durch ihre hohe Sensitivitaet , z . B. beim Screening auf intrapulmonale Rundherde mittels Niedrigdosis-CT oder bei der Frueherkennung pneumonischer Infiltrate bei Risikopatienten . Insbesondere bei der Charakterisierung intrapulmonaler Rundherde ist eine Kombination mit nuklearmedizinischen Verfahren ( PET ) grundsaetzlich anzustreben . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die radiologischen Schnittbildverfahren , insbesondere die CT , haben sich innerhalb kurzer Zeit einen herausragenden Stellenwert in der Diagnostik von Lungenerkrankungen erworben . Dies umfasst in erster Linie die morphologische Darstellung pathologischer Prozesse mit hoher raeumlicher Aufloesung . Moderne technische Entwicklungen und kombinierte Untersuchungsstrategien eroeffnen neue Einsatzgebiete und auch funktionelle Aussagen , die nach einer aktuellen Standortbestimmung gemeinsam mit den nuklearmedizinischen Verfahren verlangen . Dazu gehoert die Diagnostik der Lungenembolie mittels Spiral-CT-Angiographie und MR-Angiographie der Pulmonalarterien . Hier hat sich mittlerweile die CT als alternatives Verfahren der Wahl etabliert und die Rolle der Pulmonalisangiographie als Goldstandard infrage gestellt . Die reine direkte Darstellung der durchstroemten Pulmonalarterien und des thromboembolischen Materials wird durch Diagnostik intrapulmonaler und kardialer Veraenderungen , Perfusionsuntersuchungen sowie MR-basierte Flussmessungen zur haemodynamischen Beurteilung erweitert . Nachdem Untersuchungen der Ventilation lange Zeit eine Domaene der Nuklearmedizin waren , eroeffnen aktuelle Entwicklungen in der MRT neue Verfahren zur direkten Visualisierung der Lungenbelueftung , z . B. mittels polarisierter Edelgase . Aus diesen Verfahren lassen sich auch neue funktionelle Parameter der Ventilation ableiten . In der Diagnostik von Tumoren und Entzuendungen ueberzeugt die CT insbesondere durch ihre hohe Sensitivitaet , z . B. beim Screening auf intrapulmonale Rundherde mittels Niedrigdosis-CT oder bei der Frueherkennung pneumonischer Infiltrate bei Risikopatienten . Insbesondere bei der Charakterisierung intrapulmonaler Rundherde ist eine Kombination mit nuklearmedizinischen Verfahren ( PET ) grundsaetzlich anzustreben .
[ "Die", "radiologischen", "Schnittbildverfahren", ",", "insbesondere", "die", "CT", ",", "haben", "sich", "innerhalb", "kurzer", "Zeit", "einen", "herausragenden", "Stellenwert", "in", "der", "Diagnostik", "von", "Lungenerkrankungen", "erworben", ".", "Dies", "umfasst", "in", "erster", "Linie", "die", "morphologische", "Darstellung", "pathologischer", "Prozesse", "mit", "hoher", "raeumlicher", "Aufloesung", ".", "Moderne", "technische", "Entwicklungen", "und", "kombinierte", "Untersuchungsstrategien", "eroeffnen", "neue", "Einsatzgebiete", "und", "auch", "funktionelle", "Aussagen", ",", "die", "nach", "einer", "aktuellen", "Standortbestimmung", "gemeinsam", "mit", "den", "nuklearmedizinischen", "Verfahren", "verlangen", ".", "Dazu", "gehoert", "die", "Diagnostik", "der", "Lungenembolie", "mittels", "Spiral", "-", "CT", "-", "Angiographie", "und", "MR", "-", "Angiographie", "der", "Pulmonalarterien", ".", "Hier", "hat", "sich", "mittlerweile", "die", "CT", "als", "alternatives", "Verfahren", "der", "Wahl", "etabliert", "und", "die", "Rolle", "der", "Pulmonalisangiographie", "als", "Goldstandard", "infrage", "gestellt", ".", "Die", "reine", "direkte", "Darstellung", "der", "durchstroemten", "Pulmonalarterien", "und", "des", "thromboembolischen", "Materials", "wird", "durch", "Diagnostik", "intrapulmonaler", "und", "kardialer", "Veraenderungen", ",", "Perfusionsuntersuchungen", "sowie", "MR", "-", "basierte", "Flussmessungen", "zur", "haemodynamischen", "Beurteilung", "erweitert", ".", "Nachdem", "Untersuchungen", "der", "Ventilation", "lange", "Zeit", "eine", "Domaene", "der", "Nuklearmedizin", "waren", ",", "eroeffnen", "aktuelle", "Entwicklungen", "in", "der", "MRT", "neue", "Verfahren", "zur", "direkten", "Visualisierung", "der", "Lungenbelueftung", ",", "z", ".", "B.", "mittels", "polarisierter", "Edelgase", ".", "Aus", "diesen", "Verfahren", "lassen", "sich", "auch", "neue", "funktionelle", "Parameter", "der", "Ventilation", "ableiten", ".", "In", "der", "Diagnostik", "von", "Tumoren", "und", "Entzuendungen", "ueberzeugt", "die", "CT", "insbesondere", "durch", "ihre", "hohe", "Sensitivitaet", ",", "z", ".", "B.", "beim", "Screening", "auf", "intrapulmonale", "Rundherde", "mittels", "Niedrigdosis", "-", "CT", "oder", "bei", "der", "Frueherkennung", "pneumonischer", "Infiltrate", "bei", "Risikopatienten", ".", "Insbesondere", "bei", "der", "Charakterisierung", "intrapulmonaler", "Rundherde", "ist", "eine", "Kombination", "mit", "nuklearmedizinischen", "Verfahren", "(", "PET", ")", "grundsaetzlich", "anzustreben", "." ]
[ "umlsterm" ]
Kardiomyopathie is an umlsterm, ARVCM is an umlsterm, Patienten is an umlsterm, Tachykardien is an umlsterm, Therapie is an umlsterm, Behandlung is an umlsterm, Kammertachykardien is an umlsterm, ploetzlichen Herztodes is an umlsterm, Patienten is an umlsterm, ARVCM is an umlsterm, Therapierichtlinien is an umlsterm
Herzschrittmachertherapie.80090169.ger.abstr_task0
Sentence: Die arrhythmogene rechtsventrikulaere Kardiomyopathie ( ARVCM ) ist insbesondere bei jungen Patienten eine nicht zu unterschaetzende Ursache ventrikulaerer Tachykardien ( VT ) . Im Vordergrund der Therapie steht die Behandlung der Kammertachykardien und die Prophylaxe des ploetzlichen Herztodes . Bei einzelnen Patienten mit ausgepraegter und progressiver ARVCM besteht eine manifeste Herzinsuffizienz , die nach ueblichen Therapierichtlinien medikamentoes behandelt wird . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Die arrhythmogene rechtsventrikulaere Kardiomyopathie ( ARVCM ) ist insbesondere bei jungen Patienten eine nicht zu unterschaetzende Ursache ventrikulaerer Tachykardien ( VT ) . Im Vordergrund der Therapie steht die Behandlung der Kammertachykardien und die Prophylaxe des ploetzlichen Herztodes . Bei einzelnen Patienten mit ausgepraegter und progressiver ARVCM besteht eine manifeste Herzinsuffizienz , die nach ueblichen Therapierichtlinien medikamentoes behandelt wird .
[ "Die", "arrhythmogene", "rechtsventrikulaere", "Kardiomyopathie", "(", "ARVCM", ")", "ist", "insbesondere", "bei", "jungen", "Patienten", "eine", "nicht", "zu", "unterschaetzende", "Ursache", "ventrikulaerer", "Tachykardien", "(", "VT", ")", ".", "Im", "Vordergrund", "der", "Therapie", "steht", "die", "Behandlung", "der", "Kammertachykardien", "und", "die", "Prophylaxe", "des", "ploetzlichen", "Herztodes", ".", "Bei", "einzelnen", "Patienten", "mit", "ausgepraegter", "und", "progressiver", "ARVCM", "besteht", "eine", "manifeste", "Herzinsuffizienz", ",", "die", "nach", "ueblichen", "Therapierichtlinien", "medikamentoes", "behandelt", "wird", "." ]
[ "umlsterm" ]
Kardiomyopathie is an umlsterm, ARVCM is an umlsterm, Patienten is an umlsterm, Tachykardien is an umlsterm, Therapie is an umlsterm, Behandlung is an umlsterm, Kammertachykardien is an umlsterm, ploetzlichen Herztodes is an umlsterm, Patienten is an umlsterm, ARVCM is an umlsterm, Therapierichtlinien is an umlsterm
Herzschrittmachertherapie.80090169.ger.abstr_task1
Sentence: Die arrhythmogene rechtsventrikulaere Kardiomyopathie ( ARVCM ) ist insbesondere bei jungen Patienten eine nicht zu unterschaetzende Ursache ventrikulaerer Tachykardien ( VT ) . Im Vordergrund der Therapie steht die Behandlung der Kammertachykardien und die Prophylaxe des ploetzlichen Herztodes . Bei einzelnen Patienten mit ausgepraegter und progressiver ARVCM besteht eine manifeste Herzinsuffizienz , die nach ueblichen Therapierichtlinien medikamentoes behandelt wird . Instructions: please typing these entity words according to sentence: Kardiomyopathie, ARVCM, Patienten, Tachykardien, Therapie, Behandlung, Kammertachykardien, ploetzlichen Herztodes, Patienten, ARVCM, Therapierichtlinien Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Die arrhythmogene rechtsventrikulaere Kardiomyopathie ( ARVCM ) ist insbesondere bei jungen Patienten eine nicht zu unterschaetzende Ursache ventrikulaerer Tachykardien ( VT ) . Im Vordergrund der Therapie steht die Behandlung der Kammertachykardien und die Prophylaxe des ploetzlichen Herztodes . Bei einzelnen Patienten mit ausgepraegter und progressiver ARVCM besteht eine manifeste Herzinsuffizienz , die nach ueblichen Therapierichtlinien medikamentoes behandelt wird .
[ "Die", "arrhythmogene", "rechtsventrikulaere", "Kardiomyopathie", "(", "ARVCM", ")", "ist", "insbesondere", "bei", "jungen", "Patienten", "eine", "nicht", "zu", "unterschaetzende", "Ursache", "ventrikulaerer", "Tachykardien", "(", "VT", ")", ".", "Im", "Vordergrund", "der", "Therapie", "steht", "die", "Behandlung", "der", "Kammertachykardien", "und", "die", "Prophylaxe", "des", "ploetzlichen", "Herztodes", ".", "Bei", "einzelnen", "Patienten", "mit", "ausgepraegter", "und", "progressiver", "ARVCM", "besteht", "eine", "manifeste", "Herzinsuffizienz", ",", "die", "nach", "ueblichen", "Therapierichtlinien", "medikamentoes", "behandelt", "wird", "." ]
[ "umlsterm" ]
Kardiomyopathie, ARVCM, Patienten, Tachykardien, Therapie, Behandlung, Kammertachykardien, ploetzlichen Herztodes, Patienten, ARVCM, Therapierichtlinien
Herzschrittmachertherapie.80090169.ger.abstr_task2
Sentence: Die arrhythmogene rechtsventrikulaere Kardiomyopathie ( ARVCM ) ist insbesondere bei jungen Patienten eine nicht zu unterschaetzende Ursache ventrikulaerer Tachykardien ( VT ) . Im Vordergrund der Therapie steht die Behandlung der Kammertachykardien und die Prophylaxe des ploetzlichen Herztodes . Bei einzelnen Patienten mit ausgepraegter und progressiver ARVCM besteht eine manifeste Herzinsuffizienz , die nach ueblichen Therapierichtlinien medikamentoes behandelt wird . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Die arrhythmogene rechtsventrikulaere Kardiomyopathie ( ARVCM ) ist insbesondere bei jungen Patienten eine nicht zu unterschaetzende Ursache ventrikulaerer Tachykardien ( VT ) . Im Vordergrund der Therapie steht die Behandlung der Kammertachykardien und die Prophylaxe des ploetzlichen Herztodes . Bei einzelnen Patienten mit ausgepraegter und progressiver ARVCM besteht eine manifeste Herzinsuffizienz , die nach ueblichen Therapierichtlinien medikamentoes behandelt wird .
[ "Die", "arrhythmogene", "rechtsventrikulaere", "Kardiomyopathie", "(", "ARVCM", ")", "ist", "insbesondere", "bei", "jungen", "Patienten", "eine", "nicht", "zu", "unterschaetzende", "Ursache", "ventrikulaerer", "Tachykardien", "(", "VT", ")", ".", "Im", "Vordergrund", "der", "Therapie", "steht", "die", "Behandlung", "der", "Kammertachykardien", "und", "die", "Prophylaxe", "des", "ploetzlichen", "Herztodes", ".", "Bei", "einzelnen", "Patienten", "mit", "ausgepraegter", "und", "progressiver", "ARVCM", "besteht", "eine", "manifeste", "Herzinsuffizienz", ",", "die", "nach", "ueblichen", "Therapierichtlinien", "medikamentoes", "behandelt", "wird", "." ]
[ "umlsterm" ]
Age is a Person, = 18 years is a Value, undergoing is a Temporal, elective is a Qualifier, total knee or hip replacement is a Scope, at least one component is a Qualifier
NCT01884337_inc_task0
Sentence: Age =18 years Subjects undergoing elective total knee or hip replacement or a revision of at least one component of a total knee or hip replacement Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Qualifier, Value, Person, Scope
[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "B-Temporal", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O" ]
Age =18 years Subjects undergoing elective total knee or hip replacement or a revision of at least one component of a total knee or hip replacement
[ "Age", "=", "18", "years", "\n", "Subjects", "undergoing", "elective", "total", "knee", "or", "hip", "replacement", "or", "a", "revision", "of", "at", "least", "one", "component", "of", "a", "total", "knee", "or", "hip", "replacement", "\n" ]
[ "Scope", "Qualifier", "Procedure", "Temporal", "Value", "Person" ]
Age is a Person, = 18 years is a Value, undergoing is a Temporal, elective is a Qualifier, total knee or hip replacement is a Scope, at least one component is a Qualifier
NCT01884337_inc_task1
Sentence: Age =18 years Subjects undergoing elective total knee or hip replacement or a revision of at least one component of a total knee or hip replacement Instructions: please typing these entity words according to sentence: Age, = 18 years, undergoing, elective, total knee or hip replacement, at least one component Options: Temporal, Qualifier, Value, Person, Scope
[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "B-Temporal", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O" ]
Age =18 years Subjects undergoing elective total knee or hip replacement or a revision of at least one component of a total knee or hip replacement
[ "Age", "=", "18", "years", "\n", "Subjects", "undergoing", "elective", "total", "knee", "or", "hip", "replacement", "or", "a", "revision", "of", "at", "least", "one", "component", "of", "a", "total", "knee", "or", "hip", "replacement", "\n" ]
[ "Scope", "Qualifier", "Procedure", "Temporal", "Value", "Person" ]
Age, = 18 years, undergoing, elective, total knee or hip replacement, at least one component
NCT01884337_inc_task2
Sentence: Age =18 years Subjects undergoing elective total knee or hip replacement or a revision of at least one component of a total knee or hip replacement Instructions: please extract entity words from the input sentence
[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "O", "B-Temporal", "B-Qualifier", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "O", "O", "O", "O" ]
Age =18 years Subjects undergoing elective total knee or hip replacement or a revision of at least one component of a total knee or hip replacement
[ "Age", "=", "18", "years", "\n", "Subjects", "undergoing", "elective", "total", "knee", "or", "hip", "replacement", "or", "a", "revision", "of", "at", "least", "one", "component", "of", "a", "total", "knee", "or", "hip", "replacement", "\n" ]
[ "Scope", "Qualifier", "Procedure", "Temporal", "Value", "Person" ]
glycoprotein - binding activity is a Phenotype, Streptococcus pyogenes is a Microorganism, Streptococcus pyogenes is a Microorganism, host cell is a Habitat, adhesion mechanisms is a Phenotype, host cell is a Habitat, vaccines is a Habitat, glycoprotein - binding activities is a Phenotype, streptococcal is a Microorganism, activity binding to thyroglobulin is a Phenotype, S. pyogenes is a Microorganism, glycoprotein - binding activity is a Phenotype, adherence is a Phenotype, S. pyogenes is a Microorganism, virulence is a Phenotype
2_task0
Sentence: Identification of a novel glycoprotein-binding activity in Streptococcus pyogenes regulated by the mga gene. The interaction between Streptococcus pyogenes and the host cell surface is not completely understood. Characterization of the adhesion mechanisms of the bacterium to the host cell surface is needed in order to develop new vaccines and anti-adhesion drugs. The presence of glycoprotein-binding activities among streptococcal strains was investigated. An activity binding to thyroglobulin, fetuin, asialofetuin and mucin but not non-glycosylated proteins was found to be present in the majority of the S. pyogenes strains studied. Cross-inhibition experiments suggested that the glycoproteins share a common structure recognized by the bacteria. The glycoprotein-binding activity was found to be proteinaceous, tightly attached to the bacterial surface and it also mediated the adherence of bacteria to solid surfaces coated with glycoproteins. The activity was found by transposon mutagenesis and complementation to be regulated by the multiple-gene regulator Mga, which has been implicated as a regulator of S. pyogenes virulence factors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Phenotype, Habitat
[ "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "B-Phenotype", "O", "O", "O" ]
Identification of a novel glycoprotein-binding activity in Streptococcus pyogenes regulated by the mga gene. The interaction between Streptococcus pyogenes and the host cell surface is not completely understood. Characterization of the adhesion mechanisms of the bacterium to the host cell surface is needed in order to develop new vaccines and anti-adhesion drugs. The presence of glycoprotein-binding activities among streptococcal strains was investigated. An activity binding to thyroglobulin, fetuin, asialofetuin and mucin but not non-glycosylated proteins was found to be present in the majority of the S. pyogenes strains studied. Cross-inhibition experiments suggested that the glycoproteins share a common structure recognized by the bacteria. The glycoprotein-binding activity was found to be proteinaceous, tightly attached to the bacterial surface and it also mediated the adherence of bacteria to solid surfaces coated with glycoproteins. The activity was found by transposon mutagenesis and complementation to be regulated by the multiple-gene regulator Mga, which has been implicated as a regulator of S. pyogenes virulence factors.
[ "Identification", "of", "a", "novel", "glycoprotein", "-", "binding", "activity", "in", "Streptococcus", "pyogenes", "regulated", "by", "the", "mga", "gene", ".", "The", "interaction", "between", "Streptococcus", "pyogenes", "and", "the", "host", "cell", "surface", "is", "not", "completely", "understood", ".", "Characterization", "of", "the", "adhesion", "mechanisms", "of", "the", "bacterium", "to", "the", "host", "cell", "surface", "is", "needed", "in", "order", "to", "develop", "new", "vaccines", "and", "anti", "-", "adhesion", "drugs", ".", "The", "presence", "of", "glycoprotein", "-", "binding", "activities", "among", "streptococcal", "strains", "was", "investigated", ".", "An", "activity", "binding", "to", "thyroglobulin", ",", "fetuin", ",", "asialofetuin", "and", "mucin", "but", "not", "non", "-", "glycosylated", "proteins", "was", "found", "to", "be", "present", "in", "the", "majority", "of", "the", "S.", "pyogenes", "strains", "studied", ".", "Cross", "-", "inhibition", "experiments", "suggested", "that", "the", "glycoproteins", "share", "a", "common", "structure", "recognized", "by", "the", "bacteria", ".", "The", "glycoprotein", "-", "binding", "activity", "was", "found", "to", "be", "proteinaceous", ",", "tightly", "attached", "to", "the", "bacterial", "surface", "and", "it", "also", "mediated", "the", "adherence", "of", "bacteria", "to", "solid", "surfaces", "coated", "with", "glycoproteins", ".", "The", "activity", "was", "found", "by", "transposon", "mutagenesis", "and", "complementation", "to", "be", "regulated", "by", "the", "multiple", "-", "gene", "regulator", "Mga", ",", "which", "has", "been", "implicated", "as", "a", "regulator", "of", "S.", "pyogenes", "virulence", "factors", ".", " " ]
[ "Phenotype", "Microorganism", "Habitat" ]
glycoprotein - binding activity is a Phenotype, Streptococcus pyogenes is a Microorganism, Streptococcus pyogenes is a Microorganism, host cell is a Habitat, adhesion mechanisms is a Phenotype, host cell is a Habitat, vaccines is a Habitat, glycoprotein - binding activities is a Phenotype, streptococcal is a Microorganism, activity binding to thyroglobulin is a Phenotype, S. pyogenes is a Microorganism, glycoprotein - binding activity is a Phenotype, adherence is a Phenotype, S. pyogenes is a Microorganism, virulence is a Phenotype
2_task1
Sentence: Identification of a novel glycoprotein-binding activity in Streptococcus pyogenes regulated by the mga gene. The interaction between Streptococcus pyogenes and the host cell surface is not completely understood. Characterization of the adhesion mechanisms of the bacterium to the host cell surface is needed in order to develop new vaccines and anti-adhesion drugs. The presence of glycoprotein-binding activities among streptococcal strains was investigated. An activity binding to thyroglobulin, fetuin, asialofetuin and mucin but not non-glycosylated proteins was found to be present in the majority of the S. pyogenes strains studied. Cross-inhibition experiments suggested that the glycoproteins share a common structure recognized by the bacteria. The glycoprotein-binding activity was found to be proteinaceous, tightly attached to the bacterial surface and it also mediated the adherence of bacteria to solid surfaces coated with glycoproteins. The activity was found by transposon mutagenesis and complementation to be regulated by the multiple-gene regulator Mga, which has been implicated as a regulator of S. pyogenes virulence factors. Instructions: please typing these entity words according to sentence: glycoprotein - binding activity, Streptococcus pyogenes, Streptococcus pyogenes, host cell, adhesion mechanisms, host cell, vaccines, glycoprotein - binding activities, streptococcal, activity binding to thyroglobulin, S. pyogenes, glycoprotein - binding activity, adherence, S. pyogenes, virulence Options: Microorganism, Phenotype, Habitat
[ "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "B-Phenotype", "O", "O", "O" ]
Identification of a novel glycoprotein-binding activity in Streptococcus pyogenes regulated by the mga gene. The interaction between Streptococcus pyogenes and the host cell surface is not completely understood. Characterization of the adhesion mechanisms of the bacterium to the host cell surface is needed in order to develop new vaccines and anti-adhesion drugs. The presence of glycoprotein-binding activities among streptococcal strains was investigated. An activity binding to thyroglobulin, fetuin, asialofetuin and mucin but not non-glycosylated proteins was found to be present in the majority of the S. pyogenes strains studied. Cross-inhibition experiments suggested that the glycoproteins share a common structure recognized by the bacteria. The glycoprotein-binding activity was found to be proteinaceous, tightly attached to the bacterial surface and it also mediated the adherence of bacteria to solid surfaces coated with glycoproteins. The activity was found by transposon mutagenesis and complementation to be regulated by the multiple-gene regulator Mga, which has been implicated as a regulator of S. pyogenes virulence factors.
[ "Identification", "of", "a", "novel", "glycoprotein", "-", "binding", "activity", "in", "Streptococcus", "pyogenes", "regulated", "by", "the", "mga", "gene", ".", "The", "interaction", "between", "Streptococcus", "pyogenes", "and", "the", "host", "cell", "surface", "is", "not", "completely", "understood", ".", "Characterization", "of", "the", "adhesion", "mechanisms", "of", "the", "bacterium", "to", "the", "host", "cell", "surface", "is", "needed", "in", "order", "to", "develop", "new", "vaccines", "and", "anti", "-", "adhesion", "drugs", ".", "The", "presence", "of", "glycoprotein", "-", "binding", "activities", "among", "streptococcal", "strains", "was", "investigated", ".", "An", "activity", "binding", "to", "thyroglobulin", ",", "fetuin", ",", "asialofetuin", "and", "mucin", "but", "not", "non", "-", "glycosylated", "proteins", "was", "found", "to", "be", "present", "in", "the", "majority", "of", "the", "S.", "pyogenes", "strains", "studied", ".", "Cross", "-", "inhibition", "experiments", "suggested", "that", "the", "glycoproteins", "share", "a", "common", "structure", "recognized", "by", "the", "bacteria", ".", "The", "glycoprotein", "-", "binding", "activity", "was", "found", "to", "be", "proteinaceous", ",", "tightly", "attached", "to", "the", "bacterial", "surface", "and", "it", "also", "mediated", "the", "adherence", "of", "bacteria", "to", "solid", "surfaces", "coated", "with", "glycoproteins", ".", "The", "activity", "was", "found", "by", "transposon", "mutagenesis", "and", "complementation", "to", "be", "regulated", "by", "the", "multiple", "-", "gene", "regulator", "Mga", ",", "which", "has", "been", "implicated", "as", "a", "regulator", "of", "S.", "pyogenes", "virulence", "factors", ".", " " ]
[ "Phenotype", "Microorganism", "Habitat" ]
glycoprotein - binding activity, Streptococcus pyogenes, Streptococcus pyogenes, host cell, adhesion mechanisms, host cell, vaccines, glycoprotein - binding activities, streptococcal, activity binding to thyroglobulin, S. pyogenes, glycoprotein - binding activity, adherence, S. pyogenes, virulence
2_task2
Sentence: Identification of a novel glycoprotein-binding activity in Streptococcus pyogenes regulated by the mga gene. The interaction between Streptococcus pyogenes and the host cell surface is not completely understood. Characterization of the adhesion mechanisms of the bacterium to the host cell surface is needed in order to develop new vaccines and anti-adhesion drugs. The presence of glycoprotein-binding activities among streptococcal strains was investigated. An activity binding to thyroglobulin, fetuin, asialofetuin and mucin but not non-glycosylated proteins was found to be present in the majority of the S. pyogenes strains studied. Cross-inhibition experiments suggested that the glycoproteins share a common structure recognized by the bacteria. The glycoprotein-binding activity was found to be proteinaceous, tightly attached to the bacterial surface and it also mediated the adherence of bacteria to solid surfaces coated with glycoproteins. The activity was found by transposon mutagenesis and complementation to be regulated by the multiple-gene regulator Mga, which has been implicated as a regulator of S. pyogenes virulence factors. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "B-Phenotype", "O", "O", "O" ]
Identification of a novel glycoprotein-binding activity in Streptococcus pyogenes regulated by the mga gene. The interaction between Streptococcus pyogenes and the host cell surface is not completely understood. Characterization of the adhesion mechanisms of the bacterium to the host cell surface is needed in order to develop new vaccines and anti-adhesion drugs. The presence of glycoprotein-binding activities among streptococcal strains was investigated. An activity binding to thyroglobulin, fetuin, asialofetuin and mucin but not non-glycosylated proteins was found to be present in the majority of the S. pyogenes strains studied. Cross-inhibition experiments suggested that the glycoproteins share a common structure recognized by the bacteria. The glycoprotein-binding activity was found to be proteinaceous, tightly attached to the bacterial surface and it also mediated the adherence of bacteria to solid surfaces coated with glycoproteins. The activity was found by transposon mutagenesis and complementation to be regulated by the multiple-gene regulator Mga, which has been implicated as a regulator of S. pyogenes virulence factors.
[ "Identification", "of", "a", "novel", "glycoprotein", "-", "binding", "activity", "in", "Streptococcus", "pyogenes", "regulated", "by", "the", "mga", "gene", ".", "The", "interaction", "between", "Streptococcus", "pyogenes", "and", "the", "host", "cell", "surface", "is", "not", "completely", "understood", ".", "Characterization", "of", "the", "adhesion", "mechanisms", "of", "the", "bacterium", "to", "the", "host", "cell", "surface", "is", "needed", "in", "order", "to", "develop", "new", "vaccines", "and", "anti", "-", "adhesion", "drugs", ".", "The", "presence", "of", "glycoprotein", "-", "binding", "activities", "among", "streptococcal", "strains", "was", "investigated", ".", "An", "activity", "binding", "to", "thyroglobulin", ",", "fetuin", ",", "asialofetuin", "and", "mucin", "but", "not", "non", "-", "glycosylated", "proteins", "was", "found", "to", "be", "present", "in", "the", "majority", "of", "the", "S.", "pyogenes", "strains", "studied", ".", "Cross", "-", "inhibition", "experiments", "suggested", "that", "the", "glycoproteins", "share", "a", "common", "structure", "recognized", "by", "the", "bacteria", ".", "The", "glycoprotein", "-", "binding", "activity", "was", "found", "to", "be", "proteinaceous", ",", "tightly", "attached", "to", "the", "bacterial", "surface", "and", "it", "also", "mediated", "the", "adherence", "of", "bacteria", "to", "solid", "surfaces", "coated", "with", "glycoproteins", ".", "The", "activity", "was", "found", "by", "transposon", "mutagenesis", "and", "complementation", "to", "be", "regulated", "by", "the", "multiple", "-", "gene", "regulator", "Mga", ",", "which", "has", "been", "implicated", "as", "a", "regulator", "of", "S.", "pyogenes", "virulence", "factors", ".", " " ]
[ "Phenotype", "Microorganism", "Habitat" ]
telemedicine is an umlsterm, time is an umlsterm, time is an umlsterm, economic is an umlsterm, need is an umlsterm, all is an umlsterm
DerRadiologe.70370294.eng.abstr_task0
Sentence: The discussion about the implementation of telemedicine and teleresourcing and its consequences has been under way for some time now . The rate at which telemedical applications are being developed , leaves little time for consideration of the economic , scientific and social aspects . There is a need for integration of all the existing fragments into one coherent telemedical concept . Different aspects of telemedical concepts are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The discussion about the implementation of telemedicine and teleresourcing and its consequences has been under way for some time now . The rate at which telemedical applications are being developed , leaves little time for consideration of the economic , scientific and social aspects . There is a need for integration of all the existing fragments into one coherent telemedical concept . Different aspects of telemedical concepts are discussed .
[ "The", "discussion", "about", "the", "implementation", "of", "telemedicine", "and", "teleresourcing", "and", "its", "consequences", "has", "been", "under", "way", "for", "some", "time", "now", ".", "The", "rate", "at", "which", "telemedical", "applications", "are", "being", "developed", ",", "leaves", "little", "time", "for", "consideration", "of", "the", "economic", ",", "scientific", "and", "social", "aspects", ".", "There", "is", "a", "need", "for", "integration", "of", "all", "the", "existing", "fragments", "into", "one", "coherent", "telemedical", "concept", ".", "Different", "aspects", "of", "telemedical", "concepts", "are", "discussed", "." ]
[ "umlsterm" ]